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Human parainfluenza virus type 1 (HPIV1) is an important pediatric respiratory 
pathogen, and its virulence in vivo can be attenuated by introducing mutations into the C 
gene, a strategy that has been used to design live attenuated candidate vaccines.  By 
tracking gene expression over time, we found that a HPIV1 mutant with a single point 
mutation in the C gene, referred to as CF170S, and a HPIV1 mutant with complete deletion 
of the C gene, referred to as P(C-), altered the expression of over 1000 genes, in sharp 
contrast to wild-type (WT) HPIV1.  Using functional bioinformatics, we found that 
binding sites for the IRF and NF-κB family of transcription factors were over-represented 
in many of the C protein targeted pathways.  By examining the activation of the major 
components of the type I interferon (IFN) enhanceosome, we found that the C mutant 
viruses, but not WT HPIV1, activated IRF3 phosphorylation and IκBβ degradation, steps 
integral to the formation of the interferon enhanceosome.  To investigate the basis for the 
observed antagonism of the host response by the WT C proteins, which are expressed 
from the C open reading frame as a nested set of carboxy-coterminal proteins, we 
 
searched for but were unable to identify C-interacting proteins among members of the 
RIG-I/MDA5 pathway.  Furthermore, we also found that the WT C proteins supplied in 
trans could block IFNβ induced by P(C-) HPIV1 infection but not by heterologous 
inducers of RIG-I and MDA5, namely RSV and poly I:C, respectively. These two lines of 
evidence suggested that the HPIV1 C proteins do not directly block type I IFN 
production, such as by interacting with a host factor of the RIG-I/MDA5 pathway.  Using 
knockout mouse embryonic fibroblasts, we found that HPIV1-induced IFNβ production 
relied mainly on MDA5.  Consistent with this observation, a striking amount of 
intracellular dsRNA was detected during infection with the C mutant HPIV1 viruses but 
not with WT HPIV1.  A marked increase in viral genome, antigenome, and mRNA as 
well as a decrease in viral protein accumulation provided compelling evidence for 
dysregulated viral RNA synthesis and an inhibition of viral protein synthesis in the 
absence of WT C proteins.  We suggest that this resulted in an imbalance in the N 
protein-to-genomic RNA ratio, leading to incomplete encapsidation and an intracellular 
environment permissive for the generation of dsRNA.  PKR activation followed the 
kinetics of dsRNA accumulation and contributed to both IFNβ induction and the 
reduction in viral protein levels.  This study establishes the profound effects that the C 
proteins of wild-type HPIV1 play in evading the host response to HPIV1 infection, and it 
extends our current understanding of the innate immune response to HPIV1 infection. 
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Chapter 1: General Introduction 
 
Background and Rationale 
Human parainfluenza virus type 1 (HPIV1) is an important and uncontrolled pediatric 
respiratory pathogen that causes a significant burden of disease, mainly in young 
children, the immunocompromised, and the elderly (30, 42, 58, 79, 134, 154).  HPIV1 is 
the single most common cause of laryngotracheobronchitis or croup.  Other clinical 
manifestations of HPIV1 range from mild disease, including rhinitis, pharyngitis, and 
otitis media, to severe lower respiratory disease, including bronchitis, bronchiolitis, and 
pneumonia (Figure 1) (30).  In all, 4 major serotypes of human parainfluenza virus have 
been described, including HPIV1, 2, and 3 which, collectively, are the second most 
common cause of pediatric respiratory hospitalizations, only surpassed by respiratory 
syncytial virus (RSV) (42, 134).  Disease caused by HPIV4 is less frequently diagnosed 
and typically less severe (13).  Licensed vaccines are currently not available against any 
of the HPIVs but ongoing vaccine development efforts that employ cDNA derived live 









Figure 1. The clinical manifestations of HPIV1 infection. 
 
 
Viral Tropism, Animal Models, and Cell Culture 
HPIV1 was first isolated from infants and children with lower respiratory tract disease 
(23).  The virus infects and replicates in the epithelial cells that line the respiratory tract, 
including the mucus membranes of the nose and throat, larynx, trachea, bronchi, and 
lower airways (143).  In vivo, HPIV1 is generally considered a pneumotropic virus since 
it buds from the apical surface instead of the basolateral surface (10, 136).  The virus 
replicates well in the respiratory tract of hamsters, guinea pigs, cotton rats, ferrets, and 
non-human primates but infection is typically self-limited and asymptomatic with 
minimal pulmonary pathology (26, 37).  In cell culture, HPIV1 replicates well in both 
simian and human kidney cells and human respiratory cells but trypsin must be supplied 




Viral Attachment and Entry 
The hemagglutinin-neuraminidase (HN) transmembrane surface glycoprotein mediates 
attachment by binding sialic acid on cell surfaces.  The HN protein also triggers fusion by 
interacting with the F protein (130, 151).  The F protein promotes viral entry by 
mediating fusion between the viral envelope and the cell membrane.  The inactive 
precursor F0 protein is converted to the fusogenic F1 and F2 polypeptides after cleavage 
by a secretory protease, and a hydrophobic fusion peptide in F1 initiates fusion (211).  
Together, the two surface glycoproteins HN and F constitute the major protective and the 
sole neutralizing antigens against infection (94, 153, 175).              
 
Viral Replication and Transcription 
HPIV1 is an enveloped, single stranded, negative sense, nonsegmented RNA virus in the 
Paramyxoviridae family (Figure 2).  Upon attachment and fusion, the viral genome 
enters, replicates in the cytoplasm, and buds as pleomorphic, spherical virions through 
the plasma membrane (191).  The viral genome, 15.6 kb in length, consists of 6 genes (3’ 
– N-P/C-M-F-HN-L – 5’) that encode the nucleoprotein (N), phosphoprotein (P), C 
proteins (C), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase protein 
(HN), and the large polymerase protein (L).  Replication of the parainfluenza viral 
genome proceeds through an intermediate positive sense antigenome.  Viral replication 
occurs in a nucleocapsid that consists of viral RNA-dependent RNA polymerase and P 
protein in association with N-bound genome and antigenomes.  The L polymerase 
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catalyzes both RNA replication and transcription.  The P protein binds to both the N and 
L proteins and serves as a polymerase cofactor that links the L protein to the N-RNA 
template (74).  The N protein has traditionally been thought to function as a highly stable 
and ribonuclease resistant coat that protects the viral genome and antigenome from 
nuclease digestion (100).  N encapsidation also leads to the formation of a helical 
structure that may align the major promoter at the 3’ end of the viral genome and that 
may provide interaction sites for the assembly of nucleocapsids during viral budding 
(112, 186).  The nucleotide length of the viral genome and antigenome must be an even 
multiple of six for efficient replication to occur.  This “rule of six” is thought to arise 
from the need to fully encapsidate the entire length of the genome with a chain of N 
protein monomers that span exactly six nucleotides so that the phase or position of the 
nucleotides of the major promoter relative to each N monomer, i.e. positions 1 through 6, 
is conserved (102, 170, 194).              
 
A single promoter at the 3’ end of the genome promotes replication and leads to 
sequential transcription.  Each gene is flanked by an upstream gene start region that 
directs viral polymerase initiation and mRNA capping and a downstream gene end that 
directs transcriptional termination and polyadenylation (138).  Since polymerase 
reinitiation is imperfect, polymerase drop-off leads to a gradient of mRNA transcription 
that decreases with increasing distance from the 3’ major promoter, i.e. N mRNA is more 





Each gene of the HPIV1 genome encodes a single major protein with the exception of the 
P/C gene, which encodes the P protein in one open reading frame and a nested set of four 
carboxy-coterminal C proteins (C', C, Y1, and Y2) expressed from individual start sites 
in a second open reading frame.  An unconventional GUG start codon for C' reduces 
translation initiation efficiency and thereby allows leaky scanning by the ribosome to 
initiate at the next downstream start codon for C.  In contrast, the ribosome accesses the 
Y1 and Y2 start codons by discontinuous scanning-independent shunting from the 5’ cap 
(32, 34).  Recent studies, including the findings from this dissertation and from others in 
the lab, have shown that the C proteins play a critical role in HPIV1 virulence by 
inhibiting apoptosis, regulating type I interferon (IFN) production and signaling, and 
















Figure 2. Diagrammatic representation of the HPIV1 virion (top) and its genome 
organization (bottom).  The N gene and the N proteins encapsidating the viral genome are 
colored in green.  The P gene and the P proteins associated with the viral polymerase are 
colored in yellow.  The C ORF is colored in orange.  The M gene and the M proteins 
located on the inner face of the viral envelope are colored in blue.  The F gene and the F 
surface glycoproteins are colored in aqua.  The HN gene and HN suface glycoproteins are 
colored in red.  The L gene and the L polymerase are colored in purple.     
 
  
The Innate Immune Response and Type I IFN 
Innate immunity, considered the front-line of host defense, comprises the early phases of 
the host response to infection and generally discriminates between groups of related 
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pathogens.  The innate immune response also contributes, by antigen presentation and the 
secretion of cytokines, to the induction of effectors in the adaptive immune response, 
including cytotoxic T lymphocytes and secretory and serum neutralizing antibodies (77, 
172, 184).  An important component of the innate immune response to viral infection is 
the production of type I IFN, signaling through its receptor, and the subsequent 
establishment of an antiviral state.  The induction of IFN synthesis following virus 
infection depends on a number of pattern-recognition receptors that recognize conserved 
pathogen-associated molecular patterns and initiate downstream signaling cascades 
(Figure 3).  The presence of dsRNA, an intermediate of RNA viral replication, is 
recognized as a pathogen-associated molecular pattern by Toll-like receptor 3 (TLR3) 
and two caspase recruitment domain (CARD)-containing RNA helicases, retinoic acid-
inducible gene I (RIG-I) and melanoma associated-differentiation gene 5 (MDA5), which 
act as intracytoplasmic sensors of dsRNA (2, 76, 147, 180, 212, 214).  Whereas TLR3 
mainly senses extracellular dsRNA on the surface and in the endosomal compartment of 
antigen-presenting cells, RIG-I and MDA5 are constitutively present and detect 
intracellular dsRNA (2, 214).  RIG-I activation by dsRNA requires ubiquitination of its 
CARD domain by the ubiquitin ligase TRIM25 (45).  The exact nature of the dsRNA 
ligands recognized by RIG-I and MDA5 is still controversial (203).  Currently, it is 
thought that RIG-I binds to 5’ triphosphorylated dsRNA, whereas MDA5 binds higher-
order webs of dsRNA and ssRNA (148, 165).  TLR3 signals through an adaptor called 
TIR domain-containing adaptor inducing IFNβ (TRIF), while RIG-I and MDA5 recruit 
another CARD-containing adaptor called mitochondrial antiviral signaling protein 
(MAVS, also referred to as IPS-1, Cardif, or VISA).  MAVS contains a transmembrane 
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domain that targets the protein to the mitochondria, implicating a role for the 
mitochondria as a signaling platform for the innate immune response (167).  MAVS 
relays the signal to two ubiquitin ligases TRAF3 and TRAF6.  The deubiquitinases 
DUBA and A20 negatively regulate IFNβ induction by removing ubiquitin from TRAF3 
and TRAF6, respectively.  TRAF3 activates the kinases TBK1 and IKKε, which 
phosphorylate IRF3 (interferon regulatory factor 3) (41, 99, 140, 167, 207).  Once 
activated, IRF3 translocates into the nucleus and binds the positive regulatory domain III 
(PRDIII) of the IFNβ promoter.  TRAF6 activates IKKβ and induces the proteasome-
mediated degradation of IκB which allows NF-κB to translocate into the nucleus and 
bind PRDII (167, 207).  After the host cell recognizes and signals the presence of foreign 
RNA, IRF-3 and NF-κB, together with ATF-2/c-Jun (AP-1), form an enhanceosome that 
binds to the IFNβ promoter, inducing transcription of the IFNβ gene.  Although crystal 
structures of ATF-2 and c-Jun bound to PRDIV of the IFNβ promoter are known, the 
viral triggers that activate the MAPK pathway leading to ATF-2 and c-Jun 
phosphorylation and dimerization are less well understood (142).  Once type I IFN is 
produced and secreted, it binds to the type I IFN receptor on the surface of the infected 









Figure 3. Diagrammatic representation of the cellular signal transduction pathways that 
can be activated by RNA virus infection and lead to IFNβ production.  IFNβ expression 
relies on the activation of three transcription factors IRF3, NF-κB, and AP-1 that bind the 
IFNβ enhanceosome.  Dotted lines represent protein-protein interactions.  The dotted line 
with an arrowhead signifies binding of the AP-1 transcription factor to PRDIV.  The 
dashed lines signify that the viral triggers that activate MEKK1 and the MAPK signal 




The transcriptional activation of type I IFN is biphasic.  One gene encodes the 
prototypical IFNβ, while more than a dozen IFN species comprise the IFNα family (183).  
In humans, at least 23 gene loci on chromosome 9 correspond to the IFNα family, and at 
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least 14 are known to encode functional proteins (144).  Recognition of viral infection 
results in phosphorylation of constitutively expressed IRF3 to induce IFNβ and IFNα1 
expression in human cells as part of the early response to virus infection.  Once early type 
I IFN is produced and secreted, it binds to the type I IFN receptor on the surface of the 
infected and neighboring cells and activates the JAK-STAT signal transduction cascade.  
The JAK1 and TYK2 kinases are activated by autophosphorylation and phosphorylate 
STAT1 and STAT2, inducing the formation of IFN-stimulated gene factor 3 (ISGF3) 
which consists of a heterotrimeric complex of STAT1, STAT2, and IRF9 (Figure 4).  
ISGF3 binds to the IFN-stimulated response elements (ISRE) within the promoter regions 
of several hundred IFN-inducible genes, including 2’-5’-oligoadenylate synthetase 
(OAS), dsRNA dependent protein kinase (PKR), and IRF7.  The de novo produced IRF7, 
which is highly homologous to IRF3, can also undergo phosphorylation by TBK1, 
dimerize, translocate into the nucleus, and then activate production of additional type I 
IFNs.  Unlike IRF3 though, IRF7 can form a homodimer or heterodimerize with IRF3 to 
efficienty activate the expression of both the IFNβ gene and the full set of IFNα genes 
(73, 163).  Thus, immediate-early expression of IFNβ and IFNα1 occurs soon after viral 
infection is detected, while delayed expression of the entire type I IFN family, induced by 
IRF7, occurs only after IFNβ and IFNα1 secretion, receptor binding, and signaling to 







Figure 4. Diagrammatic representation of the type 1 IFN signaling pathway from IFN 
receptor activation to the formation of the STAT1, STAT2, and IRF9 transcription 




Many viruses have evolved strategies to regulate host cell apoptotic responses to virus 
infection (reviewed in (127)).  Apoptosis, a process of programmed cell death mediated 
by the activation of a group of caspases, results in systematic cellular self-destruction in 
response to a variety of stimuli (reviewed in (40)).  There are two major apoptotic 
pathways, the extrinsic and intrinsic pathways, which converge at a step involving the 
activation of the effector caspase 3.  The activation of effector caspases, nuclear 
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condensation and fragmentation, and cell death are the final steps in the apoptosis 
pathway.  Viral proteins that are able to modulate the host apoptotic response include 
pro-apoptotic viral proteins such as West Nile virus capsid protein (208) and bunyavirus 
NSs proteins (28), and anti-apoptotic viral proteins such as RSV NS proteins (14), 
Bunyamwera virus NSs (101) and Rift Valley fever NSm protein (204).  However, these 
studies are complex and some viral proteins such as influenza A virus NS1 have been 
reported to have both pro- and anti-apoptotic functions (166, 220).  SeV C proteins have 
been implicated in the regulation of apoptosis but their role in this process remains 
incompletely defined (15, 71, 83, 105, 145).  A role for HPIV1 proteins in apoptosis had 
not been investigated to date (9). 
 
The HPIV1 C Proteins 
The C proteins of SeV have been shown to have multiple functions that include inhibition 
of host innate immunity through antagonism of interferon (IFN) induction and/or 
signaling (51, 56, 104), regulation of viral mRNA synthesis by binding to the L 
polymerase protein (21, 33, 75, 110, 185), participation in virion assembly and budding 
via an interaction with AIP1/Alix, a cellular protein involved in apoptosis and endosomal 
membrane trafficking (66, 82, 156), and regulation of apoptosis.  SeV mutants containing 
deletions of all four C proteins are viable, but are highly attenuated in vitro and in mice 
(55, 109, 110).  To date, the HPIV1 C proteins have not been as extensively studied as 
those of SeV.  However, the HPIV1 C proteins, like the SeV C proteins, are nonessential, 
play a role in evasion of host innate immunity through inhibition of type I IFN production 





Our laboratory has established a reverse genetics system for HPIV1 that allows the 
generation of infectious virus from cDNA (85, 137).  In the reverse genetics system for 
HPIV1, a full length HPIV1 antigenomic cDNA, under the control of a T7 promoter, is 
transfected with support plasmids encoding the N, P, and L proteins into cells that 
constitutively express the T7 RNA polymerase, i.e. BHK-T7 cells, or into cells infected 
with the replication-deficient vaccinia virus MVA-T7 that encodes the T7 polymerase 
(206).  HPIV1 can then be recovered from the supernatant.  Using this system, we 
generated a number of HPIV1 mutants to investigate C protein function as well as to 
generate novel live virus vaccines that would be attenuated by disturbing the IFN 
antagonistic function of the C proteins, a strategy that has been shown to result in 
attenuation of replication in vivo (5, 6, 192).  Previously, a phenylalanine to serine 
substitution of amino acid 170 of Sendai Virus (SeV, also referred to as murine PIV1) 
was shown to significantly attenuate a highly virulent SeV strain, increasing the lethal 
dose 50% (LD50) 20,000-fold in mice (50).  This CF170S mutation was introduced into the 
P/C gene of recombinant HPIV1 by reverse genetics (85, 137).  Whereas WT HPIV1 
infection prevented IRF3 dimerization, its nuclear translocation, and IFNβ production, 
infection with HPIV1 containing the CF170S mutation (F170S virus) led to IRF3 activation 
and IFNβ production (192).  WT HPIV1, but not the F170S mutant virus, also inhibited 
the antiviral state induced by type I IFN, most likely due to inhibition of STAT1 nuclear 
translocation in human lung cells (18, 192).  Not unexpectedly, the F170S mutant was 
attenuated for replication in the respiratory tract of hamsters and African green monkeys 
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(AGMs) (5, 192).  We also constructed a HPIV1 mutant referred to as P(C-) that does not 
express any of the four C proteins due to point mutations that silence the C ORF, and this 
mutant was even more attenuated than F170S HPIV1 in vivo (9).  
 
Current strategies to develop live attenuated vaccine candidates against this important 
pediatric pathogen include the introduction of attenuating mutations within the viral 
genome so that the vaccine strain causes little or no disease while, at the same time, 
confers protection from subsequent infections.  The induction of IFN production, IFN 
signaling, and apoptosis that results from mutating or silencing the C gene may augment 
the establisment of an antiviral state, enhance antigen presentation and the adaptive 
immune response, and limit the spread of virus from infected cells.  Interferon has been 
detected in the nasal washes of children infected with HPIV1 and likely contributes to 
host defense (63).  The attenuation achieved by mutating or silencing the C gene 
underscores the importance of the HPIV1 C proteins as virulence factors during infection 
and as targets for developing candidate live attenuated virus vaccines.  
 
Study Aims and Outline 
This study addresses seven major aims: first, to create by reverse genetics a virus named 
P(C-) HPIV1 in which expression of the C proteins is silenced (this mutant virus was 
recovered by E. Bartlett); second, to compare the level of replication and of type I IFN 
induced in vitro during infection with P(C-) and WT HPIV1;  third, to characterize the 
transcriptional response of human respiratory epithelial cells to infection with WT HPIV1 
or HPIV1 in which the C gene is mutated or ablated; fourth, to examine the contribution 
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of IFNβ to this response; fifth, to determine the components of the type I interferon (IFN) 
response that are activated upon infection with C mutant HPIV1 viruses; sixth, to identify 
the stimuli that trigger host IFNβ production in response to these HPIV1 C mutants; and 
seventh, to examine the mechanisms by which the wild-type C proteins hold in check the 
induction of a potent host innate immune response.  Aims one and two are described in 
chapter 2, aims three and four are described in chapter 3, and aims five through seven are 
described in chapter 4.  Supplementary tables and figures are provided in the appendix.      
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Chapter 2: Human parainfluenza virus type 1 C proteins are 
nonessential proteins that inhibit the host interferon and 
apoptotic responses 
 
Adapted from Journal of Virology 2008 Sep; 82(18): 8965–8977 
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Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to create 
rHPIV1-P(C-), a virus in which expression of the C proteins (C’ , C, Y1, and Y2) was 
silenced without affecting the amino acid sequence of the P protein.  Infectious rHPIV1-
P(C-) was readily recovered from cDNA, indicating that the four C proteins were not 
essential for virus replication.  Early during infection in vitro, rHPIV1-P(C-) replicated as 
efficiently as wild-type (wt) HPIV1, but its titer subsequently decreased coincident with 
the onset of an extensive cytopathic effect not observed with wt rHPIV1.  rHPIV1-P(C-) 
infection, but not wt rHPIV1 infection, induced caspase 3 activation and nuclear 
fragmentation in LLC-MK2 cells, identifying the HPIV1 C proteins as inhibitors of 
apoptosis.  In contrast to wt rHPIV1, rHPIV1-P(C-) and rHPIV1-CF170S, a mutant 
encoding an F170S substitution in C, induced interferon (IFN) and did not inhibit IFN 
signaling in vitro.  However, only rHPIV1-P(C-) induced apoptosis.  Thus, the anti-IFN 
and antiapoptosis activities of HPIV1 were separable: both activities are disabled in 
rHPIV1-P(C-), whereas only the anti-IFN activity is disabled in rHPIV1-CF170S.   In 
primary human airway epithelial cell cultures, rHPIV1-P(C-) was considerably 
attenuated, suggesting that disabling the anti-IFN and antiapoptotic activities of HPIV1 
had additive effects on attenuation.  Its highly restricted replication in primary human 
airway epithelial cell cultures suggests that it might be overattenuated for use as a 
vaccine.  Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and 





Human parainfluenza virus type 1 (HPIV1) is a member of the Paramyxoviridae family, 
which includes a number of other medically important human pathogens such as HPIV2 
and 3, respiratory syncytial virus (RSV), measles virus, mumps virus, and human 
metapneumovirus (90).  The HPIVs are enveloped, non-segmented, single-stranded, 
negative-sense RNA viruses that are classified in the genera Respirovirus (HPIV1 and 
HPIV3) and Rubulavirus (HPIV2).  HPIV1, 2 and 3 are significant respiratory pathogens 
for infants and young children, with clinical manifestations ranging from mild disease, 
including rhinitis and pharyngitis, to more severe disease, including croup, bronchiolitis, 
and pneumonia (31, 68, 69, 90, 122, 154).  The contribution of HPIV infections to 
pediatric respiratory hospitalizations varies between studies and ranges from 7-21% 
overall for HPIV1, 2 and 3.  The HPIVs collectively are the second leading cause of 
pediatric hospitalizations for viral respiratory disease behind RSV and ahead of influenza 
(86, 90, 134).  A licensed vaccine is currently not available for the prevention of HPIV 
disease, but experimental live attenuated candidate vaccines are under development for 
HPIV1, 2 and 3, with those for HPIV3 in clinical trials (8, 12, 61, 89, 92, 139). 
 
The HPIV1 genome is 15,600 nucleotides in length and contains six genes in the order 
3´-N-P/C-M-F-HN-L-5´ (138).  Each gene encodes a single protein with the exception of 
the P/C gene that encodes the phosphoprotein P in one open reading frame (ORF) and up 
to four accessory C proteins, C', C, Y1 and Y2, in a second, overlapping ORF.  The 
synthesis of the C proteins initiates at four separate translational start codons in the C 
ORF in the order C', C, Y1, and Y2, and the four proteins are carboxy co-terminal (90).  
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However, it is unclear whether the Y2 protein is actually expressed during HPIV1 
infection (152).  C proteins are expressed by members of the Respirovirus, Morbillivirus 
and Henipavirus genera but not by viruses that belong to the Rubulavirus and Avulavirus 
genera.  The paramyxovirus C proteins studied to date are non-essential accessory 
proteins that contribute significantly to virus replication and virulence in vivo (5, 84, 109, 
110).  The C proteins of Sendai virus (SeV), a member of the Respirovirus genus and the 
closest homolog of HPIV1, are the most extensively characterized. 
 
The C proteins of SeV have been shown to have multiple functions that include inhibition 
of host innate immunity through antagonism of interferon (IFN) induction and/or 
signaling (51, 56, 104), regulation of viral mRNA synthesis by binding to the L 
polymerase protein (21, 33, 75, 110, 185), participation in virion assembly and budding 
via an interaction with AIP1/Alix, a cellular protein involved in apoptosis and endosomal 
membrane trafficking (66, 82, 156), and regulation of apoptosis (see below).  SeV 
mutants containing deletions of all four C proteins are viable, but are highly attenuated in 
vitro and in mice (55, 109, 110).  To date, the HPIV1 C proteins have not been as 
extensively studied as those of SeV.  However, the HPIV1 C proteins, like the SeV C 
proteins, play a role in evasion of host innate immunity through inhibition of type I IFN 
production and signaling (18, 192).  Type I IFN was not detected during infection with 
HPIV1 wild type (wt) in A549 cells, a human epithelial lung carcinoma cell line, but was 
induced during infection with a recombinant HPIV1 (rHPIV1) mutant bearing a F170S 
amino acid substitution in C, designated rHPIV1-CF170S (192).  HPIV1 wt virus, but not 
the rHPIV1-CF170S mutant virus, inhibited the antiviral state induced by type I IFN, most 
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likely due to inhibition of STAT1 nuclear translocation in human lung cells (18, 192).  
 
Many viruses have evolved strategies to regulate host cell apoptotic responses to virus 
infection (reviewed in (127)).  Apoptosis, a process of programmed cell death mediated 
by the activation of a group of caspases, results in systematic cellular self-destruction in 
response to a variety of stimuli (reviewed in (40)).  There are two major apoptotic 
pathways, the extrinsic and intrinsic pathways, which converge at a step involving the 
activation of the effector caspase 3.  The activation of effector caspases, nuclear 
condensation and fragmentation, and cell death are the final steps in the apoptosis 
pathway.  Viral proteins that are able to modulate the host apoptotic response include 
pro-apoptotic viral proteins such as West Nile virus capsid protein (208) and bunyavirus 
NSs proteins (28), and anti-apoptotic viral proteins such as RSV NS proteins (14), 
Bunyamwera virus NSs (101) and Rift Valley fever NSm protein (204).  However, these 
studies are complex and some viral proteins such as influenza A virus NS1 have been 
reported to have both pro- and anti-apoptotic functions (166, 220).  SeV C proteins have 
been implicated in the regulation of apoptosis but their role in this process remains 
incompletely defined (15, 71, 83, 105, 145).  A role for HPIV1 proteins in apoptosis has 
not been investigated to date. 
 
In the present study, a rHPIV1 mutant was generated in which the C protein ORF was 
modified using reverse genetics to preclude expression of any of the four C proteins 
while maintaining expression of a wt P protein.  This mutant, designated rHPIV1-P(C-), 
was evaluated for replication in vitro and in vivo in order to determine: i) whether C was 
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essential for HPIV1 replication; ii) what effect the deletion of C protein expression had 
on the host response to virus infection; and iii) whether a C protein deletion mutant had 
properties that warranted further development as a live attenuated HPIV1 candidate 
vaccine.  In contrast to HPIV1 wt (but similar to rHPIV1-CF170S), rHPIV1-P(C-) was 
found to induce a robust IFN response.  Additionally, in contrast to HPIV1 wt (and also 
in contrast to rHPIV1-CF170S), rHPIV1-P(C-) induced a potent apoptotic response.  Both 
phenotypes appeared to contribute to attenuation in cultures of human ciliated airway 
epithelium. 
 
Materials and Methods 
Cells and Viruses 
LLC–MK2 cells (ATCC CCL 7.1) and HEp–2 cells (ATCC CCL 23) were maintained in 
Opti–MEM I (Gibco–Invitrogen, Inc. Grand Island, NY) supplemented with 5% FBS and 
gentamicin sulfate (50 µg/ml).  A549 cells (ATCC CCL-185) were maintained in F-12 
nutrient mixture (HAM) (Gibco-Invitrogen, Inc.) supplemented with 10% FBS, 
gentamicin sulfate (50 µg/ml) and L-glutamine (4 mM).  Vero cells (ATCC CCL-81) 
were maintained in MEM (Gibco-Invitrogen, Inc.) supplemented with 10% FBS, 
gentamicin sulfate (50 µg/ml) and L-glutamine (4 mM).  BHK-T7 cells, which 
constitutively express T7 RNA polymerase (20), were kindly provided by Dr. Ursula 
Buchholz, NIAID, and were maintained in GMEM (Gibco-Invitrogen, Inc.) 
supplemented with 10% FBS, geneticin (1 mg/ml), MEM amino acids, and L-glutamine 
(2 mM).  Human airway tracheobronchial epithelial (HAE) cells were isolated from 
airway specimens of patients without underlying lung disease provided by the National 
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Disease Research Interchange (NDRI, Philadelphia, PA) or from excess tissue obtained 
during lung transplantation, provided by the UNC Cystic Fibrosis Center Tissue Culture 
Core under protocols approved by the University of North Carolina at Chapel Hill (UNC) 
Institutional Review Board.  Growth and differentiation of these cells on semi-permeable 
Transwell inserts at the air-liquid interface generated ciliated human airway epithelium, 
as previously described (149).  All infections were incubated at 32ºC except where 
indicated otherwise. 
 
Biologically-derived wt HPIV1 Washington/20993/1964, the parent of rHPIV1, was 
isolated from a clinical sample in primary AGM kidney (AGMK) cells, passaged 2 more 
times in primary AGMK cells (135) and once in LLC-MK2 cells (6).  This preparation 
has a wt phenotype in AGMs, and will be referred to here as HPIV1 wt, but it was 
previously referred to as HPIV1LLC1 (6).  The rHPIV1 wt referred to in this study also 
contains a mutation in the HN gene, HNT553A, that has previously been shown not to have 
an effect on virus replication (5) and is therefore considered the equivalent of wt virus.  
rHPIV1 wt was generated as previously described (6, 138, 192).  The rHPIV1 wt was 
used in all experiments, with the exception that the biological HPIV1 wt was used for the 
hamster challenge and in the AGM studies, as indicated.  The generation and 
characterization of the rHPIV1-CF170S mutant also was described previously (6); this virus 
contains a single nucleotide substitution in the P/C gene that creates a phenylalanine-to-
serine substitution at amino acid 170 (numbered relative to the C' protein) that affects all 
four C proteins and is silent in the P protein.  Media used for propagation and infection of 
HPIV1 wt and rHPIV1 mutants in LLC–MK2 cells did not contain FBS but contained 
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1.2% TrypLE Select, a recombinant trypsin (Gibco-Invitrogen, Inc.), in order to cleave 
and activate the HPIV1 fusion (F) protein, as described previously (138).  Purified virus 
stocks were obtained by infecting LLC-MK2 cells, followed by centrifugation and 
banding of virus containing supernatant in a discontinuous 30/60% (w/v) sucrose 
gradient, steps designed to minimize contamination with cellular factors, especially IFN.  
Recombinant vesicular stomatitis virus expressing the green fluorescent protein (VSV-
GFP) was originally obtained from John Hiscott (176).  Stocks of VSV were propagated 
in Vero cells and sucrose purified as indicated above. 
 
Virus titers in samples were determined by 10-fold serial dilution of virus in 96-well 
LLC-MK2 monolayer cultures, using two or four wells per dilution.  After 7 days of 
incubation, infected cultures were detected by hemadsorption with guinea pig 
erythrocytes, as described previously (169).  Virus titers are expressed as log10 50% 
tissue culture infectious dose per ml (log10 TCID50/ml).  VSV stock titers were 
determined by plaque assay on Vero cells under a 0.8% methyl cellulose overlay. 
 
Antibodies 
Polyclonal antisera directed against the HPIV1 C or P proteins were generated by 
repeated immunization of rabbits with the following KLH-conjugated peptides: (i) 
QMREDIRDQYLRMKTERW (amino acid (aa) residues 153-170 of HPIV1 C'; directed 
against the carboxyl terminal region of C', C, Y1 and Y2), for Skia-31; and (ii) 
RDPEAEGEAPRKQES (aa 10-24 of P), for Skia-2.  Antisera were generated at Spring 
Valley Labs (Woodbine, MD).  Two murine monoclonal antibodies directed against the 
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HPIV1 HN protein, designated 8.2.2.A and 4.5, were kindly provided by Dr. Yasuhiko 
Ito (103).  
 
Construction of mutant rHPIV1-P(C-) cDNA 
Nucleotide insertions, deletions and substitutions were introduced into the P/C gene of 
rHPIV1 wt (Figure 1A) (137) in order to silence the expression of the C', C, Y1, and Y2 
proteins without affecting the P protein (Figure 1B and C).  The 93 nucleotides between 
the P/C gene start signal and the P start codon, including the C' start codon, were deleted 
(Figure 1B and C, mutation 2) and replaced with a 6 nucleotide insertion to act as a 
“linker” (Figure 1B and C, mutation 1).  The sequence immediately upstream of the P 
start codon was modified by the addition of the “linker”: CGA(ATG) to AAC(ATG), 
making the P start site more efficient by Kozak’s rules (106) and reducing translational 
initiation at the downstream start codons (Figure 1B and C, mutation 1).  The C start 
codon was modified (ATG to ACG) (Figure 1B and C, mutation 3), and three codons 
were converted to stop codons, including one immediately downstream of the Y1 start 
codon (TCA to TGA), which will affect all of the C proteins except Y2, and two 
downstream of the Y2 start codon (TCG to TAG; TTG to TAG), which will affect all of 
the C proteins (Figure 1B and C, mutations 4, 5, and 6).  All of the introduced changes 
are silent in the P protein.  These changes were achieved using a modified PCR 
mutagenesis protocol described elsewhere (129) and the Advantage–HF PCR Kit 
(Clontech Laboratories, Palo Alto, CA).  The entire PCR amplified gene product was 
sequenced using a Perkin–Elmer ABI 3100 sequencer with the Big Dye sequencing kit 
(Perkin–Elmer Applied Biosystems, Warrington, UK) to confirm amplification of the 
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desired sequence containing the introduced changes.  Full–length antigenomic cDNA 
clones (FLCs) of HPIV1 containing the desired mutations were assembled in T7 
polymerase-driven plasmids using standard molecular cloning techniques (138), and the 
region containing the introduced mutation in each FLC was sequenced as described 
above to confirm the presence of the introduced mutation and absence of adventitious 
changes.  Each virus was designed to conform to the rule of six, i.e., the nucleotide length 
of each genome was designed to be an even multiple of six (102), a requirement for 
efficient replication of HPIV1. 
 
Figure 1.  Designing the HPIV1-P(C-) viral cDNA.  (A) The HPIV1 wt genome, shown 
3´ to 5´, includes the P/C gene that encodes the phosphoprotein P from one ORF and the 
four carboxy-coterminal C proteins, C', C, Y1 and Y2, from a second, overlapping ORF.  
The coding regions for these proteins are shown, with the initiation and termination 
codons numbered according to the P/C gene sequence.  (B) Various mutations were 
introduced into the HPIV1 P/C gene to silence expression of the four C proteins without 
affecting the amino acid sequence of the P protein.  Panel B shows the sequence of the 
upstream end of the P/C gene, with the transcription gene-start signal and the 
translational start signal for each protein boxed.  Nucleotide (nt) substitutions and an 
insertion in the rHPIV1-P(C-) sequence are indicated in boldface, and a deletion is 
indicated with a dotted line.  These mutations are identified with circled numbers that 
correspond with a description in panel (C) of the effect of each mutation.  Briefly, 93 nt 
were deleted between the gene-start signal and P start codon and replaced with a 6-nt 
spacer CCCAAC (mutations 1 and 2), thus eliminating the first 11 codons of C' including 
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its start codon.  The sequence immediately upstream of the P start codon was modified: 
CGA(ATG) to AAC(ATG), which will also optimize the Kozak sequence and reduce 
translational initiation at the downstream start codons (mutation 1).  The methionine start 
codon of the C protein was converted to threonine (mutation 3), and one stop codon was 
introduced downstream of the Y1 start codon (mutation 4) and two stop codons were 
introduced downstream of the Y2 start codon (mutations 5 and 6).  This cDNA was used 





Recovery of infectious rHPIV1-P(C-)  
rHPIV1-P(C-) was recovered using a reverse genetics system, similar to previously 
described methods (138), in BHK-T7 cells constitutively expressing T7 polymerase (20) 
that were grown to 90 to 95% confluence in six-well plates.  Cells were transfected with 
5 µg of the FLC, 0.8 µg each of the N and P, and 0.1 µg of the L support plasmids in a 
volume of 100 µl of Opti-MEM per well.  Transfection was carried out with 
Lipofectamine 2000 (Invitrogen, Inc., Carlsbad, CA), according to the manufacturer's 
directions.  The transfection mixture was removed after a 24 h incubation period at 37°C.  
Cells were then washed and maintained in GMEM supplemented with amino acids and 
1.2% TrypLE Select and transferred to 32°C.  On day 2 following transfection, the 
supernatant was harvested.  Virus was amplified by passage on LLC-MK2 cells and 
cloned biologically by two successive rounds of terminal dilution using LLC–MK2 
monolayers on 96–well plates (Corning Costar Inc., Acton, MA).  To confirm that 
rHPIV1-P(C-) contained the appropriate mutations and lacked adventitious mutations, 
viral RNA (vRNA) was isolated from infected cell supernatants using the QIAamp viral 
RNA mini kit (Qiagen Inc., Valencia, CA), reverse transcribed using the SuperScript 
First–Strand Synthesis System (Invitrogen, Inc., Carlsbad, CA), and amplified using the 
Advantage HF cDNA PCR Kit (Clontech Laboratories).  The viral genome was 





LLC-MK2 monolayers grown in 6 well plates (Costar) were mock-infected or infected at 
an input multiplicity of infection (MOI) of 5 TCID50/ml with sucrose-purified rHPIV1 wt 
or rHPIV1-P(C-).  Cell lysates were harvested 48 h post infection (p.i.) with 200 µl of 1X 
Loading Dye Solution sample buffer (Qiagen, Inc) and purified on QIAshredder (Qiagen, 
Inc.) spin columns.  Ten µl (for Skia-31 probing) or 6 µl (for Skia-2 probing) of each 
sample was reduced, denatured and loaded onto 10-well 10% Bis-Tris gels (Invitrogen, 
Inc.).  Gels were run in MOPS buffer (Invitrogen, Inc.), and protein was transferred onto 
PVDF membranes (Invitrogen, Inc.) and blocked overnight at 4°C in PBS/Tween (0.1%) 
containing 3% BSA.  PDVF membranes were incubated with 15 ml of a 1:1000 dilution 
of primary antibody in PBS/Tween with 1% BSA at room temperature (RT) for 2 h and 
then were washed 3 times for 10 min with PBS/Tween.  Membranes were incubated for 1 
h at RT with a 1:20,000 dilution of peroxidase labeled goat anti-rabbit IgG (KPL, 
Gaithersburg, MD) as the secondary antibody.  After washing 3 times for 10 min with 
PBS/Tween, SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) 
was added for 10 min at RT.  Membranes were developed on Kodak MR films (Kodak, 
Rochester, NY). 
 
Kinetics of replication of rHPIV1-P(C-) 
The rHPIV1 wt and rHPIV1-P(C-) viruses were compared in multi-cycle growth curves.  
Confluent monolayer cultures of LLC-MK2 cells in 6-well plates were infected in 
triplicate at a MOI of 0.01 TCID50/cell.  Virus adsorption was performed for 1 h in media 
containing trypsin.  The inoculum was then removed and cells were washed three times, 
after which fresh medium containing trypsin was added and then harvested as the day 0 
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sample and replaced with fresh media containing trypsin.  On days 1-7 p.i., the entire 
supernatant was removed for virus quantitation and was replaced with fresh medium 
containing trypsin.  Supernatants containing virus were frozen at -80°C, and virus titers 
(log10 TCID50/ml) were determined with endpoints identified by hemadsorption.  
Cytopathic effect (cpe) was visually monitored.  The amount of cpe observed under the 
microscope was given a score ranging from 1-5 based on the percentage of cells in the 
monolayer showing cpe.  Cpe of less than 20% of cells was scored as 1; 21-40% as 2; 
41%-60% as 3; 61-80% as 4; 81-100% as 5. 
 
Immunostaining and confocal microscopy 
LLC-MK2 cells were seeded onto 24 well plates containing 12 mm glass cover slips, 
were mock-infected or infected with rHPIV1-P(C-) or rHPIV1 wt at a MOI of 10 
TCID50/cell, and were incubated for 72 h.  Media was removed and cover slips were 
washed twice with PBS.  Cells were then fixed with 3% formaldehyde solution in PBS 
for 40 min at RT, washed once with PBS, permeabilized with 0.1% Triton X-100 in PBS 
for 4 min at RT, and washed twice with PBS prior to blocking with PBS containing 
0.25% BSA and 0.25% gelatin for 1 h at RT.  HPIV1 HN staining was performed using a 
1:4000 dilution of a mixture of HPIV1-HN 8.2.2.A and HPIV1-HN 4.5, two murine 
antibodies directed against the HPIV1 HN protein, kindly provided by Yasuhiko Ito, Mie 
University School of Medicine, as primary antibody.  After incubation at RT for 1 h, cells 
were washed twice with PBS and stained with a 1:1000 dilution of Texas Red conjugated 
donkey anti-mouse IgG (Jackson Immunochemicals, West Grove, PA), as secondary 
antibody, for 1 h at RT.  Activated caspase 3 was detected using a 1:25 dilution of a 
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FITC-conjugated rabbit anti-human activated caspase 3 antibody (BD Pharmingen, San 
Jose, CA).  Cells were washed twice with PBS and immediately mounted onto slides with 
the DAPI-containing antifade reagent, ProLong Gold (Invitrogen, Inc.).  Slides were 
covered with foil and left to dry overnight at RT, then stored at -20°C until microscopy 
was performed on a Leica SP5 confocal microscope. 
 
FACS analysis  
LLC-MK2, Vero, or A549 cells in 6-well plates were mock-infected or infected with 
rHPIV1 wt or rHPIV1-P(C-) at a MOI of 5 TCID50/cell.  Cells were harvested at 24, 48, 
and 72 h p.i. by scraping cells into 2 ml of fresh FACS buffer (PBS; 1% FBS) and 
pelleting at 1200 rpm for 10 min at 4°C.  Cells were resuspended in 1 ml of 3% 
paraformaldehyde (PFA) and fixed for 15 min on ice, then rinsed twice in 3 ml FACS 
buffer.  Cells were permeabilized and stained with the following antibodies diluted in 
FACS buffer containing 0.1% Triton-X-100: i) rabbit anti-human activated caspase 3 
FITC (1:100; BD Pharmingen); and ii) mouse anti-PIV1 HN (1:2000 of a 1:1 mix of 
HPIV1-HN 8.2.2.A and HPIV1-HN 4.5).  Staining was performed for 45 min at RT in a 
dark environment then cells were rinsed twice with 2 ml FACS buffer and stained with 
APC-conjugated goat anti-mouse IgG (1:1000; Jackson ImmunoResearch Laboratories, 
West Grove, PA), diluted in FACS buffer containing 0.1% Triton-X-100.  Staining was 
carried out for 30 min at RT.  Finally, cells were rinsed twice in FACS buffer and 
resuspended in 250 µl FACS buffer for analysis.  Sample analysis was carried out on a 
FACSCalibur (BD Biosciences, San Jose CA) using CellQuestPro software.  Further 




Type I IFN bioassay 
The amount of type I IFN produced by HPIV1-infected A549 cell cultures was 
determined by an IFN bioassay, as previously described (192).  Type I IFN 
concentrations were determined by measuring the ability of samples to restrict replication 
of VSV-GFP on HEp-2 cell monolayers in the samples in comparison to a known 
concentration of a human IFN-β standard (AVONEX; Biogen, Inc., Cambridge, MA).  
Briefly, samples were treated at pH 2.0 to inactivate virus and acid-labile type II IFN 
prior to being serially diluted 10-fold in duplicate in 96-well plates of HEp-2 cells along 
with the IFN-β standard (5000 pg/ml).  After 24 h, the cells were infected with VSV-GFP 
at 6.5x104 PFU/well.  After an additional 24 to 36 h, plates were read for GFP expression 
using a typhoon 8600 phosphorimager (Molecular Dynamics, Sunnyvale, CA).  The 
dilution at which the level of GFP expression was approximately 50% of that in untreated 
cultures was determined as the end-point.  The end-point of the AVONEX standard was 
compared to the end-point of the unknown samples, and IFN concentrations were 
determined and expressed as mean ± SE (pg/ml). 
 
Viral inoculation of HAE 
Apical surfaces of HAE were rinsed with PBS to remove apical surface secretions and 
fresh media was supplied to the basolateral compartments prior to inoculation.  The 
apical surfaces of HAE were inoculated with HPIV1s at a low input MOI (0.01 
TCID50/cell) in a 100 µl inoculum, and the cultures were incubated at 37°C.  The 
inoculum was removed 2 h p.i., and apical surfaces rinsed for 5 min with PBS and then 
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incubated at 37°C.  At days 0-7 p.i., apical samples were collected by incubating the 
apical surface with 300 µl of media for 30 min at 37°C, after which the media was 
recovered.  Samples were stored at -80°C prior to determination of virus titer. 
 
Statistical analysis 
The Prism 5 (GraphPad Software Inc., San Diego, CA) one-way ANOVA test (Student-
Newman-Keuls multiple comparison test) was used to assess statistically significant 
differences between data groups (P < 0.05). 
 
Results 
Construction and recovery of a rHPIV1 mutant not expressing any of the four C proteins  
The P/C gene of HPIV1 wt encodes the phosphoprotein, P, in one ORF and four carboxy 
co-terminal C proteins, C', C, Y1 and Y2, in a second, overlapping ORF (Figure 1A).  
We engineered rHPIV1 to silence expression of all four C proteins without affecting the 
P protein, creating the mutant virus rHPIV1-P(C-) (Figure 1B and C).  The changes 
introduced to silence expression of the C proteins included the deletion of the 3’ portion 
of the P/C gene containing the C' start, conversion of the C start to an ACG codon, and 
the introduction of three stop codons into the C ORF immediately downstream of the Y1 
and Y2 start codons (Figure 1B and C).  Importantly, all of the introduced changes were 
silent in the P protein (Figure 1B and C).  The Y1 and Y2 start codons were not 
modified since any changes introduced at these sites would have altered P protein amino 
acid assignments.  The AUG to ACG change at the start site of C would not necessarily 
silence its expression entirely, since ACG functions (inefficiently) as a start codon for the 
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C' protein of SeV, but other changes at this site could not be accommodated without 
affecting P coding, and in any event any residual expression of C would be ablated by the 
three stop codons that were introduced downstream.  The recombinant virus was 
recovered from this mutant cDNA in cell culture and the virus replicated to 8.0 log10 
TCID50/ml.  Sequence analysis of the entire virus genome revealed that rHPIV1-P(C-) 
contained all the intended mutations and no unintended changes (data not shown). 
 
Western blot analysis of infected LLC-MK2 cell lysates using an antibody directed 
against the carboxy terminus of the C proteins demonstrated the expression of the C' and 
C proteins in cells infected with HPIV1 wt, but not rHPIV1-P(C-) (Figure 2A).  C' was 
found to be the most abundant C protein, and Y1 and Y2 were not detected.  An 
additional unidentified species, indicated with an asterisk in Figure 2A, was detected in 
cells infected with rHPIV1-P(C-), but not in cells infected with rHPIV1 wt (Figure 2A).  
This species was not detected using an antibody directed against the amino terminus of 
the C' and C proteins (data not shown).  An ATG codon in the C ORF that is downstream 
of the last inserted stop codon in Y2 could potentially give rise to a truncated protein that 
would be carboxy-coterminal with the C proteins and would be 157 aa in length, 
compared to 204 aa for the C protein and 175 aa for Y2 (Figure 1A). This 47 aa 
difference in predicted size between C and the unknown protein in Figure 2A would 
correspond to an approximately 5 kDa difference in the proteins’ apparent molecular 
weights, consistent with the mobility difference observed in our Western blot (Figure 
2A).  The P protein could be detected in both rHPIV1 wt- and rHPIV1-P(C-)-infected 
cells (Figure 2B).  The ability to recover the rHPIV1-P(C-) mutant indicates that the four 
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wild type C proteins are not essential for replication in vitro, with the caveat that there 
was expression of a new species that may have been a truncated C protein. 
 
Figure 2.  Identification of HPIV1 C and P proteins in lysates from infected LLC-MK2 
cells.  Lysates were prepared 48 h p.i. from LLC-MK2 cells that were mock-infected or 
infected with sucrose-purified rHPIV1 wt or rHPIV1-P(C-) at an input MOI of 5 
TCID50/cell.  Reduced, denatured cell lysates were resolved by SDS-PAGE 
electrophoresis and Western blots were prepared and analyzed using rabbit anti-peptide 
antisera against (A) the HPIV1 C proteins and (B) the HPIV1 P protein.  The asterisk (*) 
in panel A indicates a new band of unknown identity, detected only in the rHPIV1-P(C-)-





The rHPIV1-P(C-) mutant replicates efficiently in vitro but causes increased cpe 
compared to rHPIV wt 
Multi-cycle replication of the rHPIV1-P(C-) mutant was assessed in LLC-MK2 cells 
infected at a MOI of 0.01 TCID50/cell (Figure 3A).  LLC-MK2 cells were chosen since 
HPIV1 wt replicates efficiently in this cell line.  rHPIV1-P(C-) and rHPIV1 wt replicated 
to similar titers until day 3 p.i., when rHPIV1 wt continued to increase in titer whereas 
rHPIV1-P(C-) decreased in titer.  Concomitantly, rHPIV1-P(C-)-infected LLC-MK2 cells 
developed extensive cpe while rHPIV1 wt-infected cells did not (Figure 3B).  This also 
is evident in photomicrographs of LLC-MK2 cells taken 72 h following infection at 
MOIs of 0.01 or 5 TCID50/cell (Figure 3A).  In LLC-MK2 cells infected at a MOI of 5 
TCID50/cell, increased cpe associated with rHPIV1-P(C-) but not rHPIV1 wt became 
evident at approximately 48 h p.i. (data not shown).  Similarly, enhanced cpe associated 
with infection by the rHPIV1-P(C-) mutant was observed in A549 cells (data not shown), 
which were evaluated since they are a human respiratory tract-derived continuous cell 
line and in vivo HPIV1 replicates preferentially, if not exclusively, in respiratory 
epithelial cells.  In summary, rHPIV1-P(C-) and rHPIV1 wt replicated with equal 
efficiency early in infection, but there was a subsequent decrease in rHPIV1-P(C-) titers 
that was temporally associated with development of extensive cpe, a phenomenon not 







Figure 3.  Comparison of the replication of rHPIV1 wt and rHPIV1-P(C-) viruses in 
vitro.  (A) Multi-cycle replication in LLC-MK2 cells infected at a MOI of 0.01 
TCID50/cell.  On days 0-7 p.i., the overlying medium was harvested for virus titration, 
shown as the means of 3 replicate cultures.  On days 1-7 p.i., the cell monolayers were 
monitored for cpe and assigned a score of 1-5 according to the extent of cpe (Materials 
and Methods), shown as the means of the 3 replicate cultures.  (B) LLC-MK2 cells were 
mock-infected or infected with rHPIV1 wt or rHPIV1-P(C-) at a MOI of 0.01 or 5 
TCID50/cell, as indicated in parentheses below the virus names.  Photomicrographs taken 






Infection with rHPIV1-P(C-) infection induces apoptosis 
To further explore the basis of the enhanced cpe associated with the rHPIV1-P(C-) 
mutant, we assayed virus-infected LLC-MK2 cells for activation of caspase 3, the major 
effector caspase in the apoptotic pathway.  Activated caspase 3 was visualized by 
immunofluorescence (Figure 4A) and by FACS analysis (Figure 4B) using an antibody 
that specifically recognizes the cleaved, activated form of the enzyme.  Replicate LLC-
MK2 monolayers were infected at a MOI of 10 TCID50/cell, incubated for 24, 48 and 72 
h, fixed, permeabilized, and stained with antibodies for HPIV1 HN (Texas-Red) and for 
activated caspase 3 (FITC).  The HPIV1 HN antigen was detected in the vast majority of 
cells infected with either virus (Figure 4A).  By 72 h p.i., activated caspase 3 was 
detected in the majority of the rHPIV1-P(C-)-infected cells but not rHPIV1 wt-infected 
cells (Figure 4A).  In addition, cell rounding and nuclear condensation was seen in the 
majority of rHPIV1-P(C-)-infected cells but not in rHPIV1 wt-infected cells (Figure 4A, 
asterisk), consistent with the interpretation that the rHPIV1-P(C-)-induced cpe is the 
direct result of virus-induced apoptosis. 
 
We next determined the frequency of apoptosis in infected cells using flow cytometry.  
The rHPIV1-CF170S mutant, which encodes a F170S substitution in C, and which has 
previously been associated with type I IFN induction and effective type I IFN signaling, 
but not with cpe in vitro, was included here for comparison.  Replicate cultures of LLC-
MK2 cells were infected with rHPIV1 wt, rHPIV1-CF170S, or rHPIV1-P(C-) at a MOI of 5 
TCID50/cell and, at 24, 48, and 72 h p.i., were fixed, permeabilized, and immunostained 
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for HPIV1 HN protein and activated caspase 3 (Figure 4B).  More than 70% of cells in 
the rHPIV1-P(C-)-infected cultures were positive for activated caspase 3 by 72 h p.i., 
compared to approximately 5% and 7% in the rHPIV1 wt- and rHPIV1-CF170S-infected 
cell cultures respectively (Figure 4C).  Similar studies in Vero and A549 cells confirmed 
that rHPIV1-P(C-) was a potent activator of caspase 3 activation while rHPIV1 wt was 
not, although the level of caspase 3 activation in these cells was lower than in LLC-MK2 
cells (data not shown).  Vero cells were also evaluated here since vaccine viruses to be 
used in clinical trials are prepared in this cell line and therefore it is important to 
determine the growth characteristics of potential vaccine viruses in this cell line.  By 72 h 
p.i., approximately 12% and 18% of rHPIV1-P(C-)-infected Vero and A549 cell cultures, 
respectively, were positive for activated caspase 3, compared to approximately 4% of 
rHPIV1 wt-infected cell cultures for both cell types. 
 
Figure 4.  Infection with rHPIV1-P(C-) induces activation of caspase 3, indicative of 
apoptosis.  Caspase 3 activation was evaluated by immunostaining and FACS analysis.  
(A) Evaluation of caspase 3 activation by immunofluorescence.  LLC-MK2 cells were 
mock-infected or infected with rHPIV1 wt or rHIV1-P(C-) at a MOI of 10 TCID50/cell.  
At 72 h p.i., cells were fixed, permeabilized, and stained for HPIV1 HN protein (red) and 
activated caspase 3 (green), and nuclei were stained with DAPI (blue).  Cells were 
visualized by confocal microscopy and scale bars represent 10 µm.  (B) Evaluation of 
caspase 3 activation by FACS analysis.  LLC-MK2 cells were mock-infected or infected 
with rHPIV1 wt, rHPIV1-CF170S, or rHPIV1-P(C-) at a MOI of 5 TCID50/cell in triplicate.  
Cells were harvested at 24, 48, and 72 h p.i., fixed, permeabilized and stained for HPIV1 
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HN and activated caspase 3 in FACS buffer prior to analysis.  Sample analysis was 
carried out using a FACSCalibur flow cytometer and FlowJo software.  Dot plots of 
representative data for samples from the 48 h time point are shown.  (C) Percentage of 
cells positive for activated caspase 3 at 24, 48 and 72 h p.i., as determined by FACS 
analysis ± S.E. 
 
 
rHPIV1-P(C-), but not rHPIV1 wt, induces type I IFN production and signaling 
HPIV1 C proteins have been shown to inhibit production of and signaling by type I IFN 
(18, 192).  We have previously demonstrated that type I IFN was not detected during 
infection of A549 cells with HPIV1 wt but was efficiently produced in response to 
rHPIV1-CF170S (192).  To determine the relative effect of deleting all four C proteins on 
the ability of HPIV1 to inhibit the type I IFN response, we infected A549 cells at a MOI 
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of 5 TCID50/cell with rHPIV1-P(C-), rHPIV1 wt or rHPIV1-CF170S and subsequently 
quantified type I IFN in medium supernatants using a bioassay based on the inhibition of 
infection and GFP expression by VSV-GFP (Figure 5A).  As shown previously, rHPIV1 
wt inhibited the IFN response effectively (Figure 5A), with barely detectable levels of 
IFN-β appearing late in infection, at 72 h p.i.  In contrast, both rHPIV1-P(C-) and 
rHPIV1-CF170S induced a robust type I IFN response, with IFN detectable in the 
supernatant as early as 24 h p.i. and until 72 h p.i., achieving a peak concentration of 
approximately 300 pg/ml at 48 h p.i.  These data suggest that C proteins play a critical 
role in antagonism of type I IFN production but that IFN generation is unrelated to the 
apoptotic response seen with the C mutants since the F170S mutant generates similar 
levels of IFN with no observable cpe beyond wt HPIV1.  
 
We have previously demonstrated that type I IFN signaling leading to the establishment 
of an antiviral state is inhibited following infection with HPIV1 wt, but not with mutants 
that encode defective C proteins, e.g. rHPIV1-CF170S (192).  To determine the relative 
effect of deleting all four C proteins on the ability of HPIV1 to inhibit type I IFN 
signaling, Vero cells were mock-infected or infected with rHPIV1 wt, rHPIV1-CF170S, or 
rHPIV1-P(C-) at a MOI of 5 TCID50/cell for 24 h, treated with 0, 100 or 1000 IU of IFN-
β for 24 h, and infected with 200 PFU/well of VSV-GFP.  The number of VSV-GFP foci 
were counted 48 h later and the percent inhibition due to IFN-β treatment was calculated 
relative to cells that did not receive IFN-β (Figure 5B).  In control cells that were not 
infected with rHPIV1, VSV-GFP replication was completely inhibited by IFN-β 
treatment.  In contrast, infection with rHPIV1 wt ablated the ability of 100 IU/ml of IFN-
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β to inhibit VSV-GFP replication and blunted the inhibitory effect of 1000 IU/ml of IFN-
β, indicating that rHPIV1 wt can prevent IFN-β signaling and the induction of an 
antiviral state.  Infection with rHPIV1-P(C-) did not inhibit the antiviral effect of IFN-β 
at either concentration, an effect similar to that for rHPIV1-CF170S (Figure 5B).  In 
summary, unlike rHPIV1 wt, rHPIV1-P(C-) is unable to inhibit both the production of 
type I IFN and the induction of an antiviral state by IFN-β. 
 
Figure 5.  rHPIV1 wt, but not rHPIV1-P(C-), inhibits type I IFN induction and signaling. 
(A) Induction of type I IFN.  A549 cell monolayers were either mock-infected or infected 
with rHPIV1 wt, rHPIV1-CF170S, or rHPIV1-P(C-) at a MOI of 5 TCID50/cell.  Aliquots 
of the overlying medium were taken at 0, 24, 48 and 72 h p.i. and assayed on fresh cells 
for the ability to inhibit infection and GFP expression by VSV-GFP as measured with a 
phosphorimager.  IFN concentrations were determined by comparison with a standard 
curve prepared in parallel with an AVONEX® IFN-β standard and are expressed in 
pg/ml ± SE based on triplicate samples.  The lower limit of detection was 39.1 pg/ml 
(dashed line).  (B) Type I IFN signaling.  Vero cells in 6-well plates were infected with 
the indicated rHPIV1s at a MOI of 5 TCID50/cell and incubated for 24 h.  Cells were then 
left untreated or were treated with 100 or 1000 IU/ml IFN-β (1 well per treatment per 
virus) for 24 h.  The cells were then infected with VSV-GFP and incubated for 48 h.  The 
VSV-GFP foci were visualized using a phosphorimager and counted.  The graph 
represents the percent inhibition of VSV-GFP replication in IFN-β treated versus 






Replication of rHPIV1-P(C-) is restricted in human airway epithelial (HAE) cells in vitro 
HPIV1 wt has previously been shown to infect ciliated apical cells in an in vitro model of 
the human airway epithelium (11).  Here, we characterized the ability of the rHPIV1-
P(C-) to infect HAE in a multiple cycle growth curve.  Following apical inoculation at 
low input MOI (0.01 TCID50/cell), rHPIV1 wt replicated efficiently in HAE, reaching a 
peak titer of 7.4 log10 TCID50/ml in the apical wash fluid.  However, replication of the 
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rHPIV1-P(C-) was severely restricted in human ciliated cells, reaching a barely 
detectable peak of 1.8 log10 TCID50/ml (Figure 6). 
 
Figure 6.  rHPIV1-P(C-) replicates very poorly in primary human airway epithelial 
(HAE) cells compared to rHPIV1 wt.  HAE cultures were inoculated on the apical 
surface with either virus at a MOI of 0.01 TCID50/cell, and virus titers were determined 
in apical surface washes at days 0-7 p.i.  These are shown as the means of triplicate 




A recombinant HPIV1 mutant, rHPIV1-P(C-), that does not express any of the four wild 
type C proteins but does express a wild type P protein was generated and characterized in 
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vitro and in vivo.  rHPIV1-P(C-) was found to replicate efficiently in vitro, implying that 
the HPIV1 C proteins are non-essential accessory proteins.  However, rHPIV1-P(C-) 
expressed a novel protein not seen with rHPIV1 that may have been a truncated form of 
C, and thus we cannot yet conclude that C-related proteins are completely dispensable.  
rHPIV1-P(C-) replicated with the same efficiency as HPIV1 wt early after infection of 
human- and monkey-derived cell lines, but its replication subsequently decreased 
coincident with the onset of extensive cpe that was not observed with rHPIV1 wt.  The C 
proteins of SeV have been extensively characterized as non-essential gene products with 
multiple functions (105, 109, 110).  However, SeV and HPIV1 differ with regard to the 
genetic organization of their accessory proteins and the phenotypes specified by 
accessory protein mutations.  First, SeV encodes a V protein in addition to the C proteins, 
whereas HPIV1 does not (90).  Second, deletion of all four C proteins in SeV 
significantly restricted its replication in vitro (66, 105, 109), whereas loss of the wild type 
forms of all four HPIV1 C proteins did not appear to reduce the replication efficiency of 
rHPIV1-P(C-) apart from the indirect effect of its enhanced cpe.  Third, a six amino acid 
deletion in the N terminal region of the SeV C protein had a profound effect on 
replication in its natural host, i.e., rodents (47), whereas a similar mutation in HPIV1 C 
did not affect replication in non-human primates, the closest available animal model to its 
natural human host (5).  Fourth, the F170S mutation in SeV C induced apoptosis in 
primary mouse pulmonary epithelial cells (83), whereas the same mutation in HPIV1 
failed to specify this phenotype in the present study.  Since the genetic organization of the 
accessory proteins of SeV and HPIV1 differ and since the phenotypes of C protein 
mutants differ significantly in vitro and in vivo, the functions of the HPIV1 C proteins 
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cannot be reliably inferred from findings obtained with SeV C protein mutants, and 
therefore they must be determined directly.  An amino acid alignment of the HPIV1 and 
Sendai virus C proteins is provided in Figure 7.  In the case of HPIV1, this information 
has added importance since live attenuated vaccine candidates that are presently being 
prepared for clinical trials include mutations in the C protein. 
 
Figure 7.  CLUSTAL W alignment of the C protein amino acid sequences of Sendai 
virus and HPIV1 (Genbank accession numbers NP_056874 and NP_604436, 
respectively).  The alignment was generated using the MacVector software program 
(MacVector Inc., Cary, NC) using default parameters.  Conserved amino acids are 
indicated with asterisks. 
 
 
Replication of rHPIV1-P(C-) in cell culture peaked early and then decreased steadily 
coincident with the development of extensive cpe that was not observed with HPIV1 wt.  
This cpe was associated with caspase 3 activation, cell rounding, nuclear condensation 
and nuclear fragmentation, indicating that it was apoptotic in nature.  In this report, we 
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identified a novel protein expressed by rHPIV1-P(C-), therefore there is also the 
alternative possibility - albeit unlikely - that the observed apoptosis during infection with 
rHPIV1-P(C-) was a gain-of-function due to the novel protein.  However, in other work 
in progress, we have generated additional HPIV1 mutants that also express this novel 
protein but do not induce apoptosis and do not specify an attenuation phenotype (data not 
shown).  This indicates that the absence of the four C proteins, and not the presence of 
the additional protein, is associated with the apoptosis-inducing (and also the attenuation) 
phenotypes of rHPIV1-P(C-).  Taken together, our data indicate that one function of the 
HPIV1 C proteins is to delay or prevent the apoptotic response of the infected cell.  
Apoptosis has also previously been associated with Sendai virus C protein mutants.  SeV 
C deletion mutants have been shown to induce apoptosis in vitro, whereas SeV wt did not 
(83, 105), suggesting that both SeV C proteins and HPIV1 C proteins act as inhibitors of 
apoptosis.  In addition, the SeV mutant Ohita MVC11, containing the CF170S substitution, 
was observed to induce cell death in vitro while SeV wt did not (83).  Similar to our 
observations of rHPIV1-P(C-), Ohita MVC11 titers peaked early and decreased 
concomitant with the induction of apoptosis (83).  However, data we have presented 
suggests that despite the relatively high degree of amino acid conservation (70% identity) 
between HPIV1 and Sendai virus C proteins (Figure 7), the induction of apoptosis and/or 
virus-mediated inhibition of apoptosis may be mediated by different mechanisms for 
HPIV1 and SeV C proteins.  For example, although SeV Ohita MVC11 induces 
apoptosis, the HPIV1 mutant containing the homologous CF170S substitution, rHPIV1-
CF170S, does not induce apoptosis.  Furthermore, IRF-3 activation was recently shown to 
be required for apoptosis during SeV infection in human cell lines (145), but we have 
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previously shown that rHPIV1-CF170S, which does not induce apoptosis, stimulates IRF-3 
activation (192).  Studies to define the mechanism of apoptosis inhibition by HPIV1 have 
been initiated. 
 
The most extensively characterized function of paramyxovirus C proteins is their type I 
IFN antagonist activity.  HPIV1 C proteins have been shown to disrupt the host type I 
IFN response by (i) inhibiting IRF-3 activation and thereby inhibiting the production of 
type I IFN, and (ii) inhibiting STAT nuclear translocation (18) and thereby inhibiting the 
JAK-STAT signaling pathway (192).  Our results support these previous findings by 
demonstrating that, in the absence of C proteins, type I IFN is produced in response to 
HPIV1 infection and is able to successfully establish an antiviral state in respiratory 
epithelial cells.  In contrast, infection with HPIV1 wt inhibits type I IFN production as 
well as the establishment of an antiviral state that results from the activation of the 
JAK/STAT pathway (54, 60, 114, 158, 183, 198).  This pathway controls transcription of 
a group of more than 300 genes termed the IFN-stimulated genes, which have antiviral, 
antiproliferative, immunomodulatory, and apoptosis modulating functions (114).  
Therefore, it is not surprising that many viral proteins that have been characterized as 
IFN antagonists have also been identified to play a role in the regulation of apoptosis.  
Examples of such proteins include the Bunyamwera virus NSs proteins (101, 197), the 
RSV NS1 and NS2 proteins (14, 173) and the influenza A virus NS1 protein (166, 182, 
196, 220).  Our data demonstrate that the HPIV1 C proteins also act both as type I IFN 
antagonists and as apoptosis antagonists.  Interestingly, however, the anti-IFN and anti-
apoptosis activities of the HPIV1 C proteins were separable: while the rHPIV1-P(C-) and 
 
48 
rHPIV1-CF170S mutants were indistinguishable with regard to the induction of IFN 
production and signaling in cell culture, only rHPIV1-P(C-) induced apoptosis.  
 
Since the type I IFN response and apoptosis are both components of the host’s innate 
antiviral response, viruses that have lost the ability to inhibit these responses are often 
attenuated.  The attenuation phenotype of the rHPIV1-P(C-) virus was evaluated in an in 
vitro model of human ciliated airway epithelium (HAE).  In order to obtain an assessment 
of attenuation prior to the initiation of clinical trials, replication of rHPIV1-P(C-) was 
characterized in a HAE model, which uses primary human airway epithelial cells grown 
at an air-liquid interface to generate a differentiated, pseudo-stratified, ciliated epithelium 
that bears close structural and functional similarity to human airway epithelium in vivo 
(149, 219).  A similar model has been used previously to evaluate the attenuation of RSV 
vaccines (205).  We have also recently characterized the replication of HPIV1 wt and 
several HPIV1 vaccine candidates in the in vitro HAE model and observed a strong 
correlation between attenuation in AGMs and attenuation in HAE cells, indicating the 
potential usefulness of the HAE model for evaluating potential respiratory virus vaccine 
candidates (11).  In our current HPIV1 study, growth of rHPIV1-P(C-) in HAE cells was 
barely detectable, whereas rHPIV1 wt grew to high titer.  This suggests that this virus 
might be over-attenuated in humans, potentially limiting its efficacy as a vaccine.  
Therefore, we are currently proceeding to clinical trials with a previously characterized 
virus, rHPIV1-CR84G/Δ170HNT553ALY942A (8), that is less attenuated than rHPIV1-P(C-).  
Only if rHPIV1-CR84G/Δ170HNT553ALY942A proves to be insufficiently attenuated will we 




Previous studies of rHPIV1 C mutants demonstrated that in vivo attenuation correlated 
with the ability to stimulate an effective type I IFN response, including IFN production 
and IFN signaling (5, 192).  This was demonstrated in detail for rHPIV1-CF170S (192).  
The rHPIV1-P(C-) virus was indistinguishable from rHPIV1-CF170S with regard to the 
induction of type I IFN production and signaling to establish an antiviral state in vitro.  
However, rHPIV1-P(C-) was much more attenuated in AGMs than rHPIV1-CF170S.  This 
increased level of attenuation might be due to the induction of apoptosis by rHPIV1-P(C-
), a property not shared by rHPIV1-CF170S.  We did not determine whether apoptosis was 
induced in vivo following rHPIV1-P(C-) infection, however, a SeV mutant containing the 
CF170S mutation was shown to induce apoptosis both in vitro and in vivo, in the bronchial 
epithelium of mice, and this virus was also attenuated in its natural host (49, 83).  It is 
possible that the in vitro apoptosis phenotype of rHPIV1-P(C-) can translate to in vivo 
effects.  This would suggest that the greater level of attenuation of rHPIV1-P(C-) versus 
rHPIV1-CF170S is based on two additive effects: i) the ability (of both viruses) to activate 
the type I IFN response; and ii) the ability of rHPIV1-P(C-) (but not PIV1-CF170S) to 
induce apoptosis.  However, it is also possible that a C protein function other than 
inhibition of the IFN response and apoptosis contributed to the high level of attenuation 
of rHPIV1-P(C-). 
 
In summary, we have demonstrated that the HPIV1 C proteins are non-essential viral 
proteins that play an important role in viral replication in vitro and in vivo and act as 
antagonists of the type I IFN response and of apoptosis.  Our HPIV1 C protein deletion 
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mutant is highly attenuated in primary human airway epithelium.  It remains to be 
determined whether such a highly attenuated virus would be useful as a vaccine candidate 
against PIV1 in humans. 
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Chapter 3: The C proteins of human parainfluenza virus type I 
(HPIV1) control the transcription of a broad array of cellular 
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HPIV1 is an important respiratory pathogen in children and the most common cause of 
viral croup. We performed a microarray-based analysis of gene expression kinetics to 
examine how wild-type (wt) HPIV1 infection altered gene expression in human 
respiratory epithelial cells and what role IFNβ played in this response. We similarly 
evaluated HPIV1-P(C-), a highly attenuated and apoptosis-inducing virus that does not 
express any of the four C proteins, and HPIV1-CF170S, a less attenuated mutant that 
contains a single point mutation in C and, like wt HPIV1, does not efficiently induce 
apoptosis, to examine the role of the C proteins in controlling host gene expression. We 
also used this data to investigate whether the phenotypic differences between the two C 
mutants could be explained at the transcriptional level. Mutation or deletion of the C 
proteins of HPIV1 permitted the activation of over 2000 cellular genes that otherwise 
would be repressed by HPIV1 infection. Thus, the C proteins profoundly suppress the 
response of human respiratory cells to HPIV1 infection. Cellular pathways targeted by 
the HPIV1 C proteins were identified and their transcriptional control was analyzed using 
bioinformatics. Transcription factor binding sites for IRF and NF-κB were over-
represented in some of the C protein targeted pathways, but other pathways were 
dominated by less known factors such as forkhead transcription factor FOXD1. 
Surprisingly, the host response to the P(C-) and CF170S mutants was very similar, and only 
subtle differences in the expression kinetics of caspase 3 and the TRAIL receptor 2 were 
observed. Thus, changes in host cell transcription did not reflect the striking phenotypic 




Human parainfluenza virus type 1 (HPIV1) is the principal cause of 
laryngotracheobronchitis or croup, and HPIV1, 2, and 3 are collectively the second most 
common cause of pediatric respiratory hospitalizations, only surpassed by respiratory 
syncytial virus (42, 134). The clinical manifestations of HPIV1 range from mild disease, 
including rhinitis, pharyngitis, and otitis media, to severe disease, including croup, 
bronchiolitis, and pneumonia (30). Licensed vaccines are currently not available against 
any of the HPIVs but ongoing HPIV3 vaccine development efforts that employ cDNA 
derived live attenuated viruses have progressed to phase 1/2 clinical evaluation (89, 91, 
93).  
 
HPIV1 is an enveloped, negative sense, nonsegmented RNA virus. The viral genome, 
15.6 kb in length, consists of 6 genes (3’ – N-P/C-M-F-HN-L – 5’) that encode the 
nucleoprotein (N), phosphoprotein (P), C proteins (C), matrix protein (M), fusion protein 
(F), hemagglutinin-neuraminidase protein (HN), and the large polymerase protein (L). 
The C proteins comprise a nested set of four carboxy-coterminal proteins, designated C', 
C, Y1, and Y2, that are expressed from individual start sites in a second open reading 
frame (ORF) within the P/C gene and are thought to play an important role in HPIV1 
virulence (138). The C proteins of Sendai virus (SeV), or murine PIV1, are the best 
studied of the paramyxovirus C proteins, and there is considerable sequence conservation 
between the SeV and HPIV1 C proteins. However, the P/C gene organization of SeV 
differs from that of HPIV1 in that SeV expresses a second accessory protein, the V 
protein, in addition to the C proteins. There are also phenotypic differences between SeV 
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and HPIV1 C protein mutants. SeV mutants that do not express any of the C proteins 
(SeV C knockouts) could be recovered using reverse genetics which identified the C 
proteins as non-essential viral proteins (108). However, SeV C knockouts are restricted in 
replication in vitro and in vivo, which reflects the observation that the C proteins are 
multifunctional (48, 83, 123, 152). SeV C proteins have been shown to regulate viral 
replication (33), promote viral assembly (66), confer virulence in mice (85), suppress 
apoptosis in HEp-2 cells (105), and interfere with antiviral host defense through 
interferon (IFN) antagonism (57, 96). Recent studies evaluating the HPIV1 C proteins 
have also identified them as non-essential (9) and demonstrated an important role for the 
HPIV1 C proteins as IFN antagonists following infection of A549 and MRC-5 human 
respiratory epithelial cells (18, 192). Specifically, the HPIV1 C proteins inhibit the 
induction and signaling of IFN in the host cell. 
 
The induction of IFN synthesis following virus infection depends on a number of pattern-
recognition receptors that recognize conserved pathogen-associated molecular patterns 
and initiate downstream signaling cascades (87). The IFN antiviral pathway can be 
activated by double stranded RNA (dsRNA), 5'-triphosphate single stranded RNA or 
viral infection. The presence of dsRNA, an intermediate of viral replication, is recognized 
as a pathogen-associated molecular pattern by Toll-like receptor 3 (TLR3) and two 
caspase recruitment domain (CARD) containing RNA helicases, retinoic acid-inducible 
gene I (RIG-I) and melanoma associated-differentiation gene 5 (MDA-5), which are 
constitutively expressed and act as intracytoplasmic sensors of dsRNA (2, 180, 214). 
RIG-I also specifically binds single stranded RNA with 5’- triphosphate ends to 
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distinguish self from non-self RNA (76, 147, 180, 212). TLR3 uses the adaptor TIR 
domain-containing adaptor inducing IFNβ (TRIF) while RIG-I and MDA-5 recruit 
another CARD-containing adaptor mitochondrial antiviral signaling protein (MAVS, also 
referred to as IPS-1, Cardif or VISA) to relay the signal to the kinases TBK1 and IKK-i, 
which phosphorylate IRF3 (interferon regulatory factor 3), and to IKKβ, which activates 
the NF-κB pathway (41, 99, 140, 167, 207). Once activated, IRF3 translocates into the 
nucleus and binds the positive regulatory domain III (PRDIII) of the IFNβ promoter. 
RIG-I and MDA-5 can distinguish between different RNA viruses (98). IFN production 
in response to SeV infection is specifically dependent on RIG-I expression, whereas IFN 
production in response to picornavirus infection is dependent on MDA-5 expression (98). 
IRF-3 and NF-κB, together with ATF-2/c-Jun, form an enhanceosome that binds to the 
IFNβ promoter, inducing transcription of the IFNB gene. IFNβ, in turn, controls the 
expression of a broad array of antiviral genes (210). Transcriptional activation of type I 
IFN is biphasic. One gene encodes the prototypical IFNβ, while more than a dozen IFN 
species comprise the IFNα family (183). Recognition of viral infection results in 
phosphorylation of constitutively expressed IRF3 to induce IFNβ and IFNα1 expression 
in human cells as part of the early response to virus infection. Once early type I IFN is 
produced and secreted, it binds to the type 1 IFN receptor on the surface of the infected 
and neighboring cells, activates the JAK-STAT signal transduction cascade, and induces 
formation of IFN-stimulated gene factor 3 (ISGF3) which consists of a heterotrimeric 
complex of STAT1, STAT2, and IRF9. ISGF3 binds to the IFN-stimulated response 
elements (ISRE) within the promoter regions of several hundred IFN-inducible genes, 
including 2’-5’-oligoadenylate synthetase (OAS), dsRNA dependent protein kinase 
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(PKR), and IRF7. The de novo produced IRF7 is phosphorylated and can then activate 
production of additional type I IFNs, including IFNβ and the full set of IFNα’s (163). 
Thus, immediate-early expression of IFNβ and IFNα1, induced by IRF3, NF-κB, and 
ATF-2, occurs soon after viral infection is detected, while delayed expression of the 
entire type I IFN family, induced by IRF7, occurs only after IFNβ and IFNα1 secretion, 
receptor binding, and signaling to amplify a robust feed-forward antiviral response (121, 
183).               
 
Our laboratory has established a reverse genetics system for HPIV1 that allows the 
generation of infectious virus from cDNA (85, 137). Using this system, a number HPIV1 
mutants containing mutations in the C gene have been generated to investigate C protein 
function and to generate novel live attenuated experimental vaccines that are attenuated 
by disturbing the IFN antagonistic function of the C gene (192). Previously, a 
phenylalanine to serine substitution of amino acid 170 of SeV was shown to significantly 
attenuate a highly virulent SeV strain, increasing the lethal dose 50% (LD50) 20,000-fold 
in mice (50). This CF170S mutation, which affects all four C proteins without affecting the 
P protein, was introduced into the P/C gene of recombinant (r) HPIV1 by reverse genetics 
(85, 137). This mutant, designated as rHPIV1-CF170S and also referred to here as CF170S, 
was previously found to be defective in inhibiting IFNβ induction and signaling in vitro 
and to be attenuated for replication in the respiratory tract of hamsters and African green 
monkeys (AGMs) (5, 192). Whereas wild-type (wt) HPIV1 infection abrogated IRF3 
dimerization and nuclear translocation, infection with rHPIV1- CF170S resulted in IRF3 
activation and IFNβ production (192). The wt HPIV1 C proteins were also shown to 
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inhibit IFN signaling by blocking STAT1 and STAT2 nuclear translocation, and wt 
HPIV1 could overcome a pre-existing IFNβ-induced antiviral state in MRC-5 cells (18). 
In contrast to wt HPIV1, rHPIV1- CF170S did not inhibit the establishment of an antiviral 
state (192).  
 
More recently, we constructed a mutant HPIV1 that does not express any of the four C 
proteins, which is designated rHPIV1-P(C-) and also is referred to here as P(C-) (9). In 
this virus, the C' start codon was deleted, the C start codon was mutated, and several stop 
codons were inserted to ensure that the C', C, Y1, and Y2 proteins could not be 
expressed. All of the above mutations were designed to be silent in the P ORF. 
Interestingly, the P(C-) and CF170S mutant viruses differ in their in vitro and in vivo 
phenotypes. The P(C-) mutant is highly attenuated in vivo in AGMs whereas the CF170S 
mutant is only moderately attenuated. In addition, infection with the P(C-) mutant leads 
to early and significant induction of apoptosis while CF170S and wt HPIV1 are very weak 
inducers of apoptosis (9).  
 
Microarray-based analyses are increasingly being used in virology and have helped to 
elucidate virus-host interactions for a number of viruses (reviewed in (88)).  In the 
present study, we used a microarray-based analysis of the kinetics of gene expression to 
examine: 1) how wt HPIV1 infection altered human respiratory epithelial cell gene 
expression; 2) what role IFNβ played in this response; 3) how the response to infection 
with the C mutant viruses CF170S and P(C-) compared to the response to wt HPIV1; and 4) 
whether the phenotypic differences between the two C mutant viruses (level of 
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attenuation and apoptosis phenotype) could be explained on a transcriptional level. We 
compared the mRNA levels in A549 cells treated with IFNβ or infected with wt HPIV1, 
CF170S, or P(C-) using a microarray that represented the full complement of known human 
genes. To examine the function of the C proteins in the infected cell, the expression 
patterns of cells infected with HPIV1 C mutant viruses were compared to that of cells 
infected with wt HPIV1. We show that the C proteins of HPIV1 profoundly suppress the 
innate response of human respiratory cells to infection with this important pediatric 
respiratory virus.   
 
Materials and Methods 
Cell culture and viruses 
A549 human respiratory epithelial cells (ATCC catalog number CCL-185, Manassas, 
VA) were maintained in F-12 medium supplemented with 0.1mg/mL gentamicin sulfate, 
4 mM L-glutamine (Gibco-Invitrogen, Carlsbad, CA) and 5% fetal bovine serum 
(Hyclone, Logan, UT). LLC-MK2 cells (ATCC) were maintained in Opti-MEM I 
(Gibco-Invitrogen) supplemented with 0.1mg/mL gentamicin sulfate and 5% fetal bovine 
serum.  
 
Recombinant wt HPIV1 and mutant CF170S and P(C-) were each recovered from cDNA as 
previously described (9, 137, 138). All viral infections were carried out at 32°C in media 
containing 1.2% recombinant trypsin TrypLE Select (Gibco-Invitrogen) without fetal 
bovine serum. Virus stocks were generated by infecting LLC-MK2 cells at a multiplicity 
of infection (MOI) of 0.01 50% tissue culture infectious dose (TCID50) per cell and by 
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harvesting supernatant on day 7 post infection (p.i.). Virus particles in the supernatant 
were purified by centrifugation in a discontinuous 30%/60% sucrose gradient in 0.05M 
HEPES and 0.1M MgSO4 (Sigma-Aldrich, St. Louis, MO) at 120,000g for 90 minutes at 
4°C. This purification was performed to minimize contamination of virus suspensions 
used to infect cells with cellular proteins, including IFN. Virus titers were determined by 
infecting LLC-MK2 cell monolayers with serial 10-fold dilutions of virus, and infected 
cultures were detected 7 days p.i. by hemadsorption with guinea pig erythrocytes (168). 
The titer of sucrose purified wt HPIV1, CF170S, and P(C-) was determined at 8.9, 9.1, and 
8.5 log10TCID50 per mL, respectively.  
  
Viral genomic RNA was isolated from the sucrose purified stocks for sequence analysis 
using the QIAamp viral RNA Mini Kit (Qiagen, Valencia, CA), then reverse transcribed 
using the Superscript II First Strand Synthesis System (Invitrogen), amplified using the 
Advantage HF-PCR Kit (Clontech, Mountain View, CA), and purified using the High 
Pure PCR Purification Kit (Roche, Indianapolis, IN) per the manufacturers’ protocols and 
as previously described (138). The identity of each virus was confirmed by sequencing 
the entire viral genome using BigDye Terminator v1.1 on a DNA Analyzer 3730 
(Applied Biosystems, Foster City, CA) and analysis with Sequencher 4.7 (Gene Codes 
Corporation, Ann Arbor, MI).            
 
Microarray sample preparation and expression analysis 
A549 cells were mock infected or infected in triplicate at a MOI of 5 TCID50 per cell with 
wt HPIV1, CF170S, or P(C-) for 6, 12, 24, and 48 h. In an independent experiment, 
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additional A549 cell cultures were treated in triplicate with 300 pg/mL (60 IU/mL) of 
IFNβ (Avonex, Biogen Inc, Cambridge, MA) for 6 or 24 h. We chose this concentration 
because we previously found that infection of A549 cells with CF170S and P(C-) led to 
IFN secretion that resulted in an IFN concentration of approximately 300 pg/mL in the 
cell supernatant (9, 192). Thus, four treatment groups, i.e. IFNβ treatment, as well as 
infection with wt HPIV1, CF170S, or P(C-) were separately analyzed; IFN treatment at two 
time points and each of the three virus infections at 4 time points.  
 
Cellular RNA was extracted from infected/treated cells using the RNeasy Mini Kit and 
treated with the RNase-free DNase set (Qiagen). RNA from virus infected and IFNβ 
treated A549 cells was labeled with Cy5 while RNA from mock infected samples was 
labeled with Cy3 using the 2-Color Low RNA Input Linear Amp Kit PLUS (Agilent 
Technologies, Foster City, CA) as per the manufacturer’s protocol. Labeled RNA was 
hybridized onto Whole Human Genome 44K Oligo Microarrays (catalog number 
G4112F) and was scanned with a DNA Microarray Scanner (Agilent Technologies) per 
the manufacturer’s protocol. This microarray detects the expression of over 41,000 genes 
and expressed sequence tags, representing all known genes in the human genome. Spot 
detection, signal quantitation, dye normalization by Lowess regression, and quality 
control assessment of control RNA spike-ins was performed using Feature Extraction 
Software v9.5 (Agilent Technologies). Data was then loaded into GeneSpring GX 7.3.1 
(Agilent Technologies) for signal normalization, statistical tests, and hierarchical 
clustering. Relative gene expression ratios in virus infected and IFNβ treated cells 
compared to mock were calculated by dividing the intensity of the Cy5 signal by the Cy3 
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signal intensity. Each array was normalized to the median signal ratio of all probes on the 
array. Genes were defined as being differentially expressed between two samples if they 
were flagged as present in at least one sample and exhibited at least a 4-fold difference 
that was statistically significant after multiple testing correction with a Benjamini-
Hochberg false discovery rate of P < 0.01. The 4-fold cutoff was chosen to minimize 
false positives and increase confidence in our data interpretation. Wei, et al. give sample 
sizes required for detecting differential gene expression with 1.5-, 2-fold, and 4-fold 
change cutoffs.  Lower fold-change cutoffs lead to a greater rate of false positives and a 
requirement for much larger sample sizes to detect significant changes by statistical tests 
(200). The phenotypic differences between the C mutant viruses were striking and were 
expected to be associated with large changes in expression that could be detected above 
4-fold. 2,612 genes were identified as significantly differentially expressed compared to 
mock in at least one of the four infection/treatment groups. To identify differences in 
gene expression between wt HPIV1, CF170S, and P(C-), we selected 1,314 of the 2,612 
genes that demonstrated significant differential expression in at least one pair-wise 
comparison between virus infections at the same time point and/or between 
IFNβ treatment and mock. Hierarchical clustering was performed on individual samples 
based on the expression ratios at each time point using a Pearson correlation as a measure 
of similarity between expression profiles. These clusters are groups of genes that share 
similarities in the pattern with which their expression varies over all sampling time points 
(38). All of the microarray data was deposited according to the MIAME standards to the 





Functional genomic bioinformatics 
The clusters identified above were further examined for commonalities in functional 
characteristics including over-representation of biological pathways and over-
representation of transcription factor binding sites (TFBSs) within the respective cluster. 
Over-represented functional pathways within each cluster of genes were searched against 
the Agilent Whole Human Genome Reference Set using Ingenuity Pathway Analysis 
5.5.1 (Ingenuity Systems, Redwood City, CA). Statistically over-represented functional 
pathways (P < 0.05 using a right-tailed Fisher’s exact test) were retained for further 
analysis. A P value less than 0.05 in the Fisher exact test indicates that the proportion of 
probes in the cluster, compared to every other probe on the Agilent Whole Genome array, 
involved in a pathway is greater than would be expected by chance. TFBSs that were 
over-represented within each cluster were identified using oPOSSUM Single Site 
Analysis software to search the 2000 base pair (bp) upstream sequence of each gene in 
the cluster against the JASPAR database (72, 161, 193). JASPAR is an open-access, 
curated, non-redundant database of 123 sequence motif matrices of experimentally 
defined TFBSs. Genes with assigned Entrez Gene identifiers were loaded into oPOSSUM 
to examine upstream sequences in all of the genes within the respective cluster of genes. 
oPOSSUM retrieves upstream promoter sequences from Ensembl (www.ensembl.org), 
uses phylogenetic footprinting to identify conserved, functional, non-coding DNA, and 
aligns sequences to position specific scoring sequence matrices in JASPAR in order to 
identify high-quality, predicted, evolutionarily conserved TFBSs. We used an 85% 
matrix match threshold, a Z-score > 10, and a Fisher exact test P < 0.05 to select for 
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statistically over-represented TFBSs within each cluster compared to the background of 
all genes in oPOSSUM. These criteria have been shown by testing randomly generated 
gene lists to yield a specificity of 86% (72).  
 
Real-time quantitative PCR (RT-qPCR) expression analysis 
Total RNA was reverse transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) and amplified using the 
TaqMan Universal PCR Master Mix (Applied Biosystems). TaqMan Gene Expression 
Assays (Applied Biosystems) for IFNB1 (Hs01077958_s1), IRF7 (Hs00242190_g1), 
MX1 (Hs00182073_m1), NFKB1 (Hs00231653_m1), TRAF1 (Hs01090170_m1) and 
GAPDH (Hs99999905_m1) were chosen to validate microarray expression profiles, and 
samples were prepared for analysis as per the manufacturer’s protocol. The microarray 
analysis verified that GAPDH was an appropriate endogenous control since GAPDH 
expression was constant throughout all conditions and time points. Samples were run on 
the 7900HT Fast Real-time PCR System (Applied Biosystems). Quantitative PCR 
analysis was performed using SDS 2.3 and RQ Manager 1.2 (Applied Biosystems). All 
expression values were normalized against the GAPDH endogenous control and then 
normalized against mock infected samples to obtain relative gene expression ratios using 
the Pfaffl method (146). 
 
Results 
Differential gene expression following wt HPIV1 infection goes beyond modulation of the 
type 1 IFN response  
 
64 
In order to better understand the host cell response to HPIV1 infection, A549 human 
respiratory epithelial cells were infected with wt HPIV1 at a MOI of 5 TCID50 per cell or 
were mock infected, and total cellular RNA was extracted at 6, 12, 24, and 48 h p.i. RNA 
was reverse transcribed and changes in gene expression were compared to mock infected 
cells using a two-color 60-mer cDNA microarray platform representing more than 41,000 
human genes and expressed sequence tags. To directly identify IFN-inducible genes in 
A549 cells for comparison to the wt HPIV1 induced genes, additional A549 cells were 
treated with 300 pg/mL (60 IU/mL) of IFNβ or left untreated, and analyzed in the same 
way as the wt HPIV1 infected cells. This dose of IFNβ was chosen because it 
approximates the concentration previously shown to be induced in this cell line by 
infection with the CF170S and P(C-) viruses (9, 192). An overview of this data set is 
depicted in Figure 1, column I. Each treatment group (i.e. wt HPIV1 or IFNβ) at each 
time point consists of three replicates. A considerable number of known IFN-inducible 
genes, e.g. IRF7 and MX1, were up-regulated late in the course of wt HPIV1 infection, 
i.e., 48 h p.i., even though wt HPIV1 is known to inhibit type 1 IFN production and 
signaling in A549 cells (192). A total of 343 genes were differentially expressed (i.e. a 
four-fold or greater change compared to mock and P < 0.01) at one or more time points 
following infection with wt HPIV1 and/or IFNβ treatment; overall, 284 genes for HPIV1 






Figure 1. Comparison of A549 cellular genes responsive to infection with wt HPIV1 
(referred to here as WT) or treatment with IFNβ. Column I) Hierarchical clustering of 
the 343 genes that were differentially expressed (4-fold or greater change relative to 
mock, P < 0.01 with multiple testing correction) following wt HPIV1 infection and/or 
IFNβ treatment, with the fold-change indicated in color. Each colored row represents an 
individual transcript, with representative genes identified immediately to the right. Each 
colored column consists of three replicates, side by side, with the treatment 
condition/time point identified at the bottom. The genes were clustered into five groups 
(A through E, demarcated to the right) according to similarity of expression kinetics and 
magnitude of expression versus mock at each time point using a Pearson correlation as a 
measure of similarity. The number of genes in each cluster is given in parentheses. Three 
of the clusters (A, B, and D) contain genes that were predominantly responsive to IFNβ 
and/or wt HPIV1; one cluster (C) contains genes that were predominantly responsive to 
IFNβ but not wt HPIV1, and one cluster (E) contains genes were predominantly 
responsive to wt HPIV1 but not IFNβ (see the text). Column II) The gene expression 
profiles for clusters A through E are shown in panels A through E, respectively, with the 
geometric mean gene expression (y-axis) plotted against each treatment condition at the 
indicated time-points in h p.i. (x-axis). Column III) Functional pathways that are over-
represented in clusters A through E were determined using Ingenuity Pathway Analysis 
and are indicated on the left, next to the expression profile of the respective cluster. 
TFBSs that are over-represented among the genes within each cluster were identified 
using oPPOSUM to search the JASPAR core database, and are indicated to the right. The 
JASPAR database contains IRF1 and IRF2 but does not include an entry for other IRFs. 
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To identify potential binding sites for other IRFs and ISGF3, we also scanned all clusters 








Figure 2. Total number of genes differentially expressed during HPIV1 infection and 
IFNβ treatment compared to mock over time in h p.i. Specifically, the number of genes 
that were significantly differentially expressed, in comparison to mock infected cells, in 
cells infected with WT, CF170S, or P(C-) viruses at 6, 12, 24, and 48 h p.i., or in IFNβ 
treated A549 cells at 6 and 24 h is indicated. Total represents the cumulative number of 
genes differentially expressed taking all time points into consideration. Infection with 
CF170S or P(C-) viruses led to a significant alteration of gene expression in many more 
genes than did infection with WT or treatment with IFNβ.   
 
 
The 343 genes that were differentially expressed in response to wt HPIV1 and/or IFNβ 
treatment were grouped into clusters based on the kinetics and magnitude of gene 
expression. This was done using a hierarchical clustering analysis of the 343 genes across 
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both treatments and all of the time points (e.g. wt HPIV1 at 6, 12, 24 and 48 h p.i., and 
IFNβ at 6 and 24 h). Five different gene expression profile patterns were identified, 
including 3 clusters containing a combined total of 209 genes that were predominantly 
responsive to both IFN and wt HPIV1 (Fig. 1, clusters A, B and D), one cluster of 17 
genes that was predominantly responsive to IFNβ but not wt HPIV1 (cluster C), and one 
cluster of 117 genes that was predominantly responsive to wt HPIV1 but not IFNβ 
(cluster E). Although, in total, the 226 genes from clusters A, B, C, and D can be grouped 
together based on the predominant kinetics of gene expression after IFNβ treatment, only 
191 of the 226 genes satisfied the 4-fold change criteria for IFN-responsive genes (Fig. 
2). The remaining 34 genes were up-regulated less than 4-fold with IFNβ treatment but 
greater than 4-fold with wt HPIV1 infection. Some representative members of each 
cluster are indicated in Fig. 1, column I; a complete list of the genes and their expression 
levels is provided in supplementary Table S1 of the appendix. The graphs in Fig. 1, 
column II represent the geometric mean value for the fold change over time compared to 
mock for all genes within each cluster and indicate a signature profile for the genes in 
that cluster.  
 
Nearly all of the 170 genes in cluster A were responsive to IFNβ treatment, and a 
majority also were responsive to wt HPIV1 infection, although the response to wt HPIV1 
infection was delayed by approximately 24 h (Fig. 1, column II, cluster A). In both 
treatment groups, the fold change increased with time. We next analyzed cluster A (and 
each succeeding cluster) for over-representation of functional pathways within each 
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cluster of genes using a software tool that determines the likelihood of a given number of 
genes being represented within a defined pathway (Ingenuity Pathway Analysis). The P 
value (Fisher’s exact test) for that likelihood is indicated next to the pathways in Fig. 1, 
column III. Genes involved in the Toll-like receptor and NF-κB pathways were over-
represented in cluster A, which is not surprising given the observed up-regulation in 
response to IFNβ and wt HPIV1 (Fig. 1, column III and Table S1). Aiming to understand 
the regulation of gene expression within a given cluster, the JASPAR database of TFBSs 
was searched for over-representation of specific TFBSs within the genes contained in 
each cluster. In cluster A, IRF1 and IRF3/ISGF3 TFBSs, which all share the same 
conserved consensus sequence, were found to be significantly over-represented (Fig. 1, 
column III). Since ISGF3, a heterotrimeric complex of STAT1, STAT2, and IRF9, is 
induced by binding of IFNβ to the IFN receptor, this finding was not unexpected. 
Translocation of ISGF3 into the nucleus activates the transcription of genes with ISREs. 
IRF1 similarly binds to and activates upstream cis-acting elements of the IFNA and IFNB 
genes.  
 
Cluster B contained 27 genes that were predominantly up-regulated by IFNβ and wt 
HPIV1. The mRNAs in cluster B were rapidly induced at 6 h post IFNβ treatment but, on 
average, failed to increase further at 24 h, whereas HPIV1 infection led to a steady 
increase in the expression of the cluster B genes (Fig. 1 column II, cluster B). Genes 
within this cluster seem to be functionally involved in IFN signaling and IL6 signaling. 
Analysis of upstream cis-acting elements reveals that the family of NF−κB binding sites 
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was significantly over-represented amongst these genes. IFIT2 (IFN-induced protein with 
tetratricopeptide repeats-2/ISG-54) was one of the most strongly expressed genes in 
cluster B and was up-regulated 85-fold by IFNβ treatment and more than 500-fold 
following wt HPIV1 infection (Table S1). 
 
The 17 genes in cluster C were up-regulated by IFNβ but not by wt HPIV1. Up-
regulation was rapid, occurring by 6 h with continued increase at 24 h (Fig. 1, column II, 
cluster C). The genes in cluster C formed a relatively heterogeneous group that contained 
no significantly over-represented functional pathways or TFBSs, and contained only a 
few genes with known antiviral function such as the tripartite motif protein 34 (TRIM34) 
(115). It is significant that infection with wt HPIV1 did not induce or activate expression 
of the subset of IFNβ-responsive genes that are represented in cluster C, suggesting that 
HPIV1 might activate a selective negative feedback mechanism that inhibits transcription 
of a subset of IFNβ-responsive genes.  
 
Cluster D is comprised of 12 genes that as a group were strongly induced by wt HPIV1 
infection but weakly induced with IFNβ treatment. Only 2 genes were significantly 
induced by IFNβ beyond 4-fold. Genes involved in IFNβ and chemokine signaling, such 
as CCL3, CCL5, CXCL10 and IL28A/IFNλ, were over-represented in this cluster, and 
both IRF1 and c-REL binding sites dominated in the promoter regions of cluster D genes  




Cluster E contained 117 genes that were predominantly induced by wt HPIV1 but not by 
IFNβ. Induction of the genes in cluster E was significantly delayed, i.e., it was not 
observed until 48 h p.i. This cluster notably included the cytokines IL6, IL8, TNF (tumor 
necrosis factor α), and CXCL3, and, as a result, pathways involved in apoptosis, NF-κB, 
and death receptor pathways as well as in IL6 signaling were significantly over-
represented in cluster E. The family of NF-κB TFBSs, but not ISRE or IRF, were 
statistically over-represented in the promoters of these genes. The five species of NF-κB 
transcription factors, RELA (p65), RELB, c-REL, NF-κB1 (p105/p50), and NF-κB2 
(p100/p52), are present in homo- and heterodimers that are bound by IκB proteins and 
localized in the cytoplasm until IκB is phosphorylated by the IκB kinase, leading to its 
ubiquitination and proteasome-mediated degradation. This releases the various NF-κB 
dimers for nuclear translocation and binding to NF-κΒ TFBS in target genes. RELA, 
RELB, and c-REL each contain a transactivator domain that strongly activates 
transcription whereas NF-κB1 and NF-κB2 lack this domain and, when binding as 
homodimers, can function as transcription repressors (188). Taken together, two key 
signaling pathways, the NF-κB and the IFN pathway, are central to regulating the cellular 
antiviral and inflammatory response to wt HPIV1 infection.      
 
The HPIV1 C proteins inhibit the induction of gene expression in A549 cells     
The HPIV1 C proteins play an important role in the inhibition of IFNβ production and 
signaling (18, 192). The recently generated rHPIV1 mutant that does not express any of 
the C proteins, designated P(C-), is similar to CF170S with regard to its IFN phenotype in 
A549 cells but differs from CF170S in that P(C-) is a strong inducer of apoptosis in LLC-
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MK2 and A549 cells whereas CF170S more closely resembles wt HPIV1 in that it is a 
weak inducer of apoptosis (9, 192). In addition, P(C-) is more attenuated than CF170S in 
the respiratory tracts of hamsters and AGMs (9). We first sought to compare the number 
of genes that were differentially expressed by infection with wt HPIV1 or HPIV1 C 
mutant viruses to assess the role of the C proteins in controlling the host response to viral 
infection. Therefore, the number of significantly differentially regulated genes (4-fold 
cutoff, P < 0.01) in A549 cells infected with either the CF170S or the P(C-) mutant was 
compared to that with wt HPIV1 infection or IFNβ treatment. Surprisingly, infection with 
CF170S or P(C-) altered the expression of a substantially greater number of genes than wt 
HPIV1 infection or IFNβ treatment. Specifically, taking all of the time points into 
consideration, the CF170S mutant significantly induced 1,734 genes and suppressed 690 
genes, whereas P(C-) induced 1,430 genes and suppressed 170 genes by 48 h p.i.  In 
contrast, wt HPIV1 significantly induced 281 genes and suppressed 3 genes (Fig. 2). This 
indicates the profound effect the C proteins have on suppression of the host cell response 
to HPIV1 infection. 
 
Treatment with IFNβ differentially induced 190 genes and suppressed only 1 expressed 
sequence tag at 6 h and/or 24 h post-treatment, based on a four-fold or greater change 
compared to mock-treatment, for a total of 191 IFNβ-responsive genes (Fig. 2). For 
comparison, previous microarray-based studies that surveyed only a fraction of the 
human genome identified 14, 56, and 268 genes whose expression changed 10-fold, 4-
fold, and 2-fold, respectively, in IFNβ treated HT1080 human fibrosarcoma cells by 6 h 
and 42 genes whose expression changed 5-fold in IFNα treated A549 cells by 24 h (36, 
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59, 160). Interestingly, to the best of our knowledge, 66 of the 190 induced genes whose 
expression changed 4-fold or greater in the present study have not been previously 
described as IFN-regulated (Table S1) (36, 59, 160).  
 
Pair-wise comparisons of the fold change in the global gene expression (i.e., the entire 
microarray) was conducted for CF170S versus wt HPIV1, P(C-) versus wt HPIV1, and 
CF170S versus P(C-) at 6, 12, 24, and 48 h p.i. (Fig. 3). In this comparison, each gene is 
represented by a single dot, and the accumulation of dots along the center diagonal line in 
each plot in Fig. 3 indicates a similar fold change between the viruses represented on the 
x- and y-axes, whereas the two outer lines indicate a four-fold difference. This 
comparison of the kinetics of the cellular response to infection showed that global gene 
expression in cells infected with CF170S or P(C-) at 6 and 12 h p.i. did not differ 
significantly from that of wt HPIV1 infected cells (Fig. 3, 6 h and 12 h panels). Points 
deviate from the central diagonal only at 24 h and/or 48 h p.i., especially when either of 
the C mutant viruses are compared to WT due to the potent effects of infection with 
mutant viruses that are unable to suppress the cellular response to viral infection. By 24 h 
p.i., a significant proportion of genes were either up- or down-regulated more than four-
fold in both the CF170S and P(C-) groups, as indicated by the number of dots outside the 
two outer boundaries that run parallel to the diagonal, while wt HPIV1 virus did not have 
this effect (Fig. 3, 24 h). At 48 h p.i., this difference in gene expression between each of 
the C mutants versus wt HPIV1 was even more pronounced. It was also important to 
compare transcriptional patterns between the two C mutant viruses in order to investigate 
why complete deletion of the C gene conferred a greater level of attenuation and an 
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apoptotic phenotype, in contrast to CF170S. Surprisingly, there was no apparent difference 
in global gene expression between the CF170S and P(C-) infected cells with the exception 
of a slightly more pronounced gene induction in P(C-) infected cells at 24 h p.i. (Fig. 3, 
right column). However, none of the genes differed four-fold or more in expression 
between these two C mutant viruses. Because of the remarkable lack of obvious 
differential gene expression between CF170S and P(C-) infected cells, the sequence 
identity of CF170S and P(C-) was confirmed in the supernatant of the respective cell 



















Figure 3. Pair-wise comparisons of global gene expression in A549 cells indicates that 
the CF170S and P(C-) viruses induce a highly similar host cell response that differs greatly 
from the wt HPIV1 (WT) -induced response. Each plot depicts the geometric mean 
difference for individual transcripts (represented by dots) from triplicate samples in pair-
wise comparisons between cells infected with CF170S versus WT (left panels), P(C-) 
versus WT (middle panels), and CF170S versus P(C-) (right panels) at 6, 12, 24, and 48 h 
p.i. (rows 1, 2, 3, and 4, respectively). The central diagonal line indicates equal fold 






The observation that there was not a single gene that differed with statistical significance 
by four-fold or more between the two C mutant viruses at any time point might seem 
inconsistent with the data in Fig. 2 where, for example, the overall number of genes that 
were differentially regulated for each C mutant virus versus the mock-treated control was 
1,600 for the P(C-) virus and 2421 for the CF170S mutant, an apparent difference of  821 
genes. This apparent discrepancy can be reconciled by constructing a Venn diagram and 
inspecting the genes that are differentially expressed only by P(C-) infection compared to 
mock or only by CF170S infection compared to mock (Fig. S1). The difference in the 
number of differentially regulated genes, i.e. 821, between the P(C-) and CF170S groups 
compared to mock does not accurately represent the total number of genes that were 
differentially expressed between the two C mutant viruses because not every one of the 
1600 genes that was differentially expressed by P(C-) infection was also differentially 
expressed by CF170S infection. The number of genes that are differentially expressed 
compared to mock during P(C-) or CF170S infection can be grouped into three sets: 169 
genes that were altered by P(C-) infection only, 990 genes that were altered by CF170S 
infection only, and 1,431 genes that were altered by both C mutant infections (Fig. S1). 
Thus, in total, there were 1159 genes that were identified as differentially expressed 
compared to mock during infection with one C mutant but not the other. Of these 1159 
genes, none was significantly diffesrentially expressed by 4-fold or more between the two 
viruses, suggesting that the differences were small and generally in the same direction, as 
indicated in the examples given in Table 1. Thus, fold-change and statistical filters that 
compared the two mutant viruses directly were needed to identify genes that differed 
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significantly so that subsequent functional bioinformatics analyses could be performed 
(Table 2 and Fig. S3). 
 
  
Organization of genes that are differentially regulated in wt and mutant HPIV1and in 
IFNβ treatment groups into hierarchical clusters 
We further analyzed those genes that were differentially regulated (four-fold or greater 
difference, P < 0.01 with multiple testing correction) in any of the four treatment groups 
(wt HPIV1, CF170S, P(C-), and IFNβ) versus the mock-treated control at any time point. 
These genes, which numbered 2,612, were subjected to pair-wise comparisons among the 
three virus treatment groups, analyzing each time point separately, in order to identify 
virus-to-virus differences that might account for phenotypic differences. Of the 2,612 
genes, 1,238 were differentially regulated in at least one pair-wise comparison between 
any two virus groups at the same time point. Consistent with the analysis in Fig. 3, we 
did not identify a single gene that was significantly differentially expressed between 
CF170S and P(C-) infection when using a four-fold cutoff and multiple testing correction. 
The 1,238 genes included all but 76 of the 191 IFNβ-responsive genes detected in this 
study; therefore, these additional 76 genes were added to the comparison so that the full 
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complement of IFNβ-responsive genes could serve as a benchmark for analysis of a 
possible transcriptional basis for the phenotypic differences seen between wt HPIV1, 
CF170S and P(C-) infection, and also to permit an analysis of the behavior of IFN-
responsive genes during infection with the HPIV1 C protein mutants. The total of 1,314 
genes were hierarchically clustered into groups A-H based on similarities in the gene 
expression kinetics and magnitude, as described for Fig. 1 (Fig. 4 columns I and II; 
Table S2).  
 
Figure 4. Infection of A549 cells with CF170S or P(C-)  drastically alters the expression of 
a large number of genes involved in diverse cellular functions. A total of 1,238 genes that 
were differentially expressed at 6, 12, 24, and 48 h p.i. following infection with CF170S, 
P(C-), or WT viruses were combined with 76 genes that were differentially regulated at 6 
or 24 h after IFNβ treatment and subjected to hierarchical clustering based on similarity 
of expression kinetics and magnitude of expression as described in the legend to Fig. 1, 
yielding eight clusters (A through H). Column I) As in Fig. 1, the clusters are depicted 
by a hierarchical clustering matrix with the columns representing treatment and time 
point and the rows indicating individual transcripts, with representative transcripts 
identified to the right. The number of genes in each cluster is given in parentheses. 
Column II) The geometric mean gene expression profiles for clusters A through H are 
shown in panels A through H, respectively, with the geometric mean gene expression (y-
axis) plotted against each treatment condition at the indicated time-points in h p.i. (x-
axis). Column III) Functional pathways that are over-represented in clusters A through 
H were determined using Ingenuity Pathway Analysis and are indicated on the left, next 
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to the expression profile of the respective cluster. TFBSs that are over-represented among 




Cluster F represented a distinct group of 223 mRNAs that individually were responsive to 
most or all of the four treatments (IFNβ, CF170S, P(C-), or wt HPIV1) (Fig. 4, column I; 
Table S2). Cluster F included most of the 191 IFNβ-responsive genes detected in this 
study. Cluster F is similar, but not identical, to cluster A in Fig. 1. In addition, the 
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majority of genes in cluster C of Fig. 1, which were up-regulated predominantly by IFNβ 
treatment and not at all by wt HPIV1 infection, are found in cluster F of Fig. 4. The 
expression of 16 of these 17 genes was significantly more highly induced by infection 
with the C mutant viruses beginning at 24 h p.i. (Table S1 vs Table S2). Paradoxically, 
the remaining gene, namely angiotensinogen (AGT), in this group of 17 was down-
regulated by the C mutant viruses even though it was induced by IFNβ. This is an 
indication that the effects of the C proteins are more complex than a general inhibition of 
IFN production and signaling. For the genes in cluster F as a whole, the mean fold change 
induced by IFNβ was approximately 3-fold at 6 h and approximately 8-fold at 24 h (Fig. 
4, column II, cluster F). Infection with wt HPIV1 induced a delayed response that, at 48 h 
p.i., was similar in magnitude to the IFNβ induced response at 24 h, whereas CF170S and 
P(C-) induced a far earlier and greater response than wt HPIV1 that equaled or exceeded 
that of IFNβ. By 24 h p.i., CF170S and P(C-) induced on average a greater than 10-fold up-
regulation of cluster F gene expression, exceeding the response induced by IFNβ 
treatment for 24 h (Fig. 4 column II, cluster F). Amongst the genes within cluster F, 
genes involved in IFN signaling, antigen presentation, ubiquitination, and Toll-like 
receptor signaling were over-represented. As expected, ISGF3, IRF1, and IRF3 TFBSs 
were over-represented within the upstream promoter sequences of cluster F genes (Fig. 4, 
column III, cluster F). Virtually every member of cluster F was induced much earlier and 
to a greater extent by the CF170S and P(C-) mutants compared to wt HPIV1, suggesting 
that functional C proteins are crucial in suppressing the transcription of antiviral genes 




The remaining 7 gene clusters (Fig. 4, column ΙΙ) contained only a few IFNβ–responsive 
genes and consisted mainly of genes that were differentially expressed between virus 
groups. Genes in clusters A, B, and C shared three features: 1) they were not significantly 
up-regulated by IFNβ; 2) they were up-regulated by all three viruses; and 3) the fold 
increase in up-regulation was much greater for the C mutant viruses than for wt HPIV1. 
Nonetheless, each cluster exhibited a clear difference in the kinetics or magnitude of the 
up-regulation of expression. The 337 genes in cluster A, on average, were induced 
strongly following infection with either C mutant within 12 h and to a much more limited 
and delayed degree following wt HPIV1 infection (Fig. 4 columns I and II, cluster A). 
The 102 genes in cluster B shared a similar expression profile. However, infection with 
P(C-) up-regulated cluster B gene expression at 24 h p.i. to an even higher level than in 
cluster A, and expression was maintained at that level through 48 h p.i. In cluster B, wt 
HPIV1 infection led to a slightly more pronounced average gene induction at 48 h than in 
cluster A (Fig. 4 column II, cluster B). Cluster A included genes involved in the p38 
MAPK, NF-κB, p53, and death receptor pathways, while genes involved in death 
receptor, IL6, and apoptosis pathways were over-represented in cluster B (Fig. 4 column 
III, clusters A and B). Over-representation of TFBSs suggested a role for forkhead 
transcription factors FOXD1 and FOXD3 in the regulation of cluster A genes and for c-
REL, RELA, and NF-κB1 in the regulation of cluster B genes (Fig. 4, column III, panels 
A and B). The specific function FOXD1 and FOXD3 have not yet been well defined, but 
the family of forkhead transcription factors are best known for their role in regulating 
cellular development and differentiation (150). The 334 genes in cluster C behaved 
similarly to those in clusters A and B, but the magnitude of expression was less than that 
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in clusters A and B, and over-representation of only one functional pathway (lipid 
metabolism) was found in this large cluster of genes (Fig. 4, column III, cluster C). 
Clearly, functional C proteins partially suppress the activation of genes in clusters A, B, 
and C. 
 
Cluster D stood out because of its small size  (only 9 genes were assigned to this cluster) 
and because these genes were up-regulated rapidly and to a very high level following wt 
or mutant HPIV1 infection. These findings indicate that wt C proteins permit the 
activation of these 9 genes.  However, since the level of expression of these genes is 
slightly lower in the wt versus mutant HPIV1 infected groups, this indicates that the C 
proteins can have a quantitative effect on modulating the overall level of gene induction 
in response to viral infection (Fig. 4, column II, cluster D).  Cluster D included mRNAs 
encoding IL6, IFNβ and IL28A/ IFNλ2, and the chemokines CX3CL1, CCL2, and CCL5 
(Fig. 4, columns I-III, cluster D). c-REL TFBSs were over-represented in this set of 
genes. Cluster D genes contrast with those in clusters E and G which fail to activate 
during wt HPIV1 infection.     
 
The 25 genes in cluster E and the 48 genes in cluster G were induced at a relatively low 
level and only late following infection with CF170S or P(C-) but not at all following either 
wt HPIV1 infection or IFNβ treatment (Fig. 4, column II, clusters E and G). The two 
clusters differed in the magnitude of expression between 24 h and 48 h p.i. since, after 
infection with the C mutant viruses, average gene expression increased substantially for 
cluster E but remained flat or decreased for cluster G. The genes in cluster E were only 
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marginally over-represented in the lipid metabolism pathway, and none of the TFBSs 
were over-represented in this cluster (Fig. 4, column II, cluster E). The 48 genes in 
cluster G, however, including pro-inflammatory genes (e.g. IL1B) as well as inhibitors of 
inflammation (e.g. SOCS3), were over-represented in the acute phase response and the 
IL10 pathway, with complex transcriptional regulation (Fig. 4, column III, cluster G). 
The transcription factors over-represented in this cluster included FOXI1, zinc finger 
protein 42 (ZNF42), and FOXD1. ZNF42 and both forkhead transcription factors FOXI1 
and FOXD1 are best known for regulating cellular development and differentiation (78, 
150). 
 
Lastly, cluster H included all of the genes down-regulated by infection with CF170S or 
P(C-) (Fig. 4, column II, cluster H). Infection with either C mutant virus significantly 
suppressed the expression of the 234 genes in this cluster. Genes involved in xenobiotic, 
hydrocarbon, and cellular stress / protein metabolism pathways were over-represented in 
this cluster, including members of the cytochrome P450 superfamily, glutathione 
transferases, and UDP-glucuronosyltransferase. Wt HPIV1 infection and IFNβ treatment 
had no effect on these genes. The only transcription factor statistically over-represented 
was TCF1, also known as IFN production regulator factor, a protein that initially became 
known to control important liver specific genes involved in metabolism but more recently 
was found to be expressed in lung tissue as well (164) (Fig. 4, column III, cluster H). The 
gene expression profile of cluster H suggests that the C proteins expressed by wt HPIV1 




Taken together, the analysis of global gene expression in A549 cells infected with wt 
HPIV1, CF170S, or P(C-) suggests that wt HPIV1 is able to control a large and diverse 
array of host genes involved in the recognition of non-self and the initiation of an 
antiviral response. Ablation of HPIV1 C protein function, by mutation or deletion, allows 
for an innate response of epithelial cells that encompasses a multitude of biological 
processes, including IFN signaling, cell death, inflammation, and metabolic regulation. 
We have observed that infection with P(C-) rapidly induces apoptosis, which is not seen 
during infection with CF170S or wt HPIV1. The similarity of the host transcriptional 
response to infection with CF170S and P(C-) was unexpected (Figs. 2, 3, and 4 column I) 
since the C proteins are multifunctional. We applied a principal component analysis, 
using all genes on the microarrays to examine the level of similarity between treatments, 
and found that overall gene expression during P(C-) and CF170S infection was highly 
similar (Fig. S2). Furthermore, both C mutant viruses induced gene expression patterns 
that were significantly different from WT infection. This identifies a high degree of 
similarity between the global gene expression profiles of the two mutants, but it does not 
rule out the possibility that small, specific differences exist between the two mutants, as 
addressed below. One might have expected that the host cell response to infection with 
CF170S, the virus containing only a single point mutation in each of the four C proteins, 
would not be as dramatic as the response to infection with P(C-), the virus not encoding 
any of the C proteins.   
 
Real-time quantitative PCR confirms microarray-based observations regarding 
differential gene expression  
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In order to validate the kinetics of gene expression observed in the microarray study, five 
differentially expressed genes that encompassed a range of expression levels, kinetic 
patterns, and pathways representing all four treatment groups were selected for RT-qPCR 
analysis (Fig. 5). For all five mRNAs, the gene expression profiles determined by 
microarray analysis were generally confirmed by the RT-qPCR analysis, indicating that 
this microarray platform yielded reliable semiquantitative results when using triplicate 
samples. However, the microarray-generated data underestimated the magnitude of 
expression compared to RT-qPCR by a factor of 10 to 1000. This probably reflected the 
more limited dynamic range in microarray analyses and probe saturation with high 
mRNA levels, as reported previously in a comparison of expression levels determined by 
Northern blot versus microarray (52). However, the expression profiles derived from 
microarray data and RT-qPCR data, in general, followed the same trend over time. This 
confirmed that IRF7 and MX1 mRNAs were strongly induced by IFNβ treatment, 
whereas IFNΒ mRNA was only weakly induced, and NFKB1 (transcription factor NF-κB 
p100/p52) and TRAF1 (tumor necrosis factor receptor-associated factor 1, involved in 
signal transduction) mRNAs were not induced at all by this treatment (Fig. 5). In 
addition, IRF7, NFKB1, and TRAF1 mRNAs were barely induced by wt HPIV1 
infection but strongly induced by infection with either C mutant (Fig. 5). IFNΒ and MX1 
mRNAs were also induced by wt HPIV1 infection, but not as strongly as following CF170S 
or P(C-) infection, confirming the previous expression pattern observed for cluster D 




Figure 5. Comparison of the kinetics and magnitude of expression of representative 
genes quantified by microarrays versus RT-qPCR. An aliquot of the total RNA that was 
used for microarray analysis was reverse transcribed and amplified using TaqMan probes 
for A) IFNB, B) IRF7, C) MX1, D) NFKB1, and E) TRAF1. These include both IFN-
responsive (A, B, and C) and IFN-independent (D, E) genes. Values were normalized to 
the endogenous control gene GAPDH and expressed as fold-increase relative to mock 
infection. Microarray expression values are indicated with a continuous line, while the 
dotted line represents qPCR expression values. Note, both axes are in logarithmic scale, 
and the qPCR data (left-sided axes) spans a much larger dynamic range than the 





A more detailed examination of the IFN pathway 
Since ablation of the function of IFN antagonist proteins results in restriction of 
replication of many viruses in vivo (46, 192, 216) and since CF170S and P(C-) are 
attenuated in vivo but differ in their level of replication, we took a closer look at 
individual genes in the IFN pathway to examine whether subtle differences in their 
expression level in CF170S and P(C-) infected cells could explain the greater level of 
attenuation of P(C-). We examined the kinetics and magnitude of expression of genes 
encoding type 1 IFNs and their receptors (Fig. 6A), as well as that of genes involved in 
IRF3 and IFN signaling (Fig. 6B). Since the number of genes in these pathways is large, 
only selected genes representative of most pathway members are presented. Interestingly, 
CF170S and P(C-) infection, but not wt HPIV1 infection or IFNβ treatment, induced 
transcription of members of the family of IFNA genes such as IFNA4, 5, 8, 10, and 14, 
but the expression of the type 1 IFN receptors IFNAR1 and IFNAR2 was not affected by 
any of the treatments (Fig. 6A).  
 
IRF3 can induce a subset of antiviral effector molecules in the absence of IFNβ, such as 
IFIT1 (IFN-induced protein with tetratricopeptide repeats-1/ISG60), ISG15, and IFI44. A 
hierarchical clustering matrix for these three genes is shown in Fig. 6B, top panel. These 
IRF3-regulated genes were more strongly induced in C mutant virus infected cells 
compared to wt HPIV1 infected or IFNβ treated cells (see expression profile in Fig. 6B). 
Since IRF3 dimerization and activation occurs upstream of IFNβ and ISGF3 signaling 
during viral infection, these genes would be induced more rapidly than genes that are 
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only ISGF3-stimulated, but, later in infection, IFN-stimulation would contribute to 
expression of both sets of genes. A selection of genes that are only ISGF3-stimulated is 
shown in the lower panel of Fig. 6B, and indeed appears to be induced less rapidly than 
the IRF3-stimulated genes. For all of these genes, the expression profiles were highly 
similar in CF170S and P(C-) infected cells. 
 
Throughout the time course, wt HPIV1 failed to induce ISGF3-responsive genes to a 
level comparable to that induced by CF170S or P(C-), consistent with the reduced 
expression of IFN (Fig. 6B). MX2 expression was completely suppressed for 24 h in the 
presence of wt C protein whereas CF170S or P(C-) induced high levels of MX2 mRNAs by 
24 h p.i. (Fig. 6B). Importantly, wt HPIV1-induced expression of IFNβ- and IRF3-
responsive genes, including IRF7, ADAR, and PKR, was delayed, diminished, or 
completely absent even at 48 h p.i. compared to CF170S or P(C-) induced up-regulation 
(Fig. 6B). Interestingly, CF170S or P(C-) infection up-regulated these IFNβ- or IRF3-











Figure 6. The CF170S and P(C-) mutant viruses are similar with regard to the expression 
of IFNs, IFN receptors, and IRF3-responsive genes. A) Hierarchical clustering matrix of 
genes encoding IFNs and IFN receptors and B) Hierarchical clustering matrix of genes 
encoding IRF3-responsive (first three entries) and ISGF3-responsive (all of the entries) 
genes. Treatment conditions and time points are indicated below the hierarchical 
clustering matrix. On the right, expression kinetics are shown for four representative 
genes of each group, with the geometric mean gene expression (y-axis) plotted against 
each treatment condition at the indicated time-points in h p.i. (x-axis), to illustrate the full 





Changes in host cell transcription do not reflect the striking cytopathic effect induced by 
P(C-) infection 
P(C-) is a potent inducer of apoptosis in A549 cells while CF170S and wt HPIV1 are not 
(9). We sought to examine individual genes in the apoptosis pathway to see if subtle 
differences in their expression level in CF170S, P(C-), and wt HPIV1 infected cells could 
be detected that might explain the apoptosis phenotype seen in cells infected with P(C-). 
To do this, we looked at the kinetics and magnitude of expression of individual genes in 
the extrinsic and intrinsic apoptosis pathways. Despite this prominent phenotypic 
difference, CF170S and P(C-) induced remarkably similar transcriptional profiles (Fig. 7). 
Both C mutant viruses up-regulated the expression of the same death ligands and death 
receptors examined with highly similar kinetics and magnitude (Fig. 7A and B). In 
addition, no difference was found in the regulation of apoptosis inhibitors such as BIRC3 
and BIRC5 (Baculoviral IAP Repeat-Containing Protein 3 and 5), BCL2A1 (BCL2-
Related Protein A1) and MCL1 (Myeloid Cell Leukemia I) (Fig. 7C; Table S4). We also 
compared gene expression in the intrinsic apoptosis pathway, for instance CASP9, 
DIABLO, and BAX, and, again, found no difference in gene expression induced by the C 
mutant viruses (Table S5). As already noted, direct comparison between CF170S and P(C-) 
at 6, 12, 24, or 48 h did not detect a single gene that differed by 4-fold or more between 
the two mutants with a P < 0.01 after multiple testing correction. We appreciate that the 
statistical criteria chosen are somewhat arbitrary and that we may have missed genes that 
differed between infection with the C mutant viruses due to the stringency of our original 
selection criteria. To detect subtle differences in gene expression profiles that could 
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explain the marked cytopathic effect seen during P(C-) infection but not during CF170S 
infection, we tested several fold change cutoffs below the 4-fold level (Table 2).  While 
we were unable to find any genes that were differentially expressed between CF170S and 
P(C-) infection using a 4-fold cutoff, we found 28 genes that differed significantly (P < 
0.01) between the two C mutants by 2-fold if multiple testing correction was performed 
sequentially and not simultaneously with the fold change cutoff (Fig. S3 and Table S6). 
Functional analysis revealed that 2 of these 28 genes are known mediators of cell death.  
Notably, caspase 3 was up-regulated 6.5-fold with P(C-) infection at 24 hours post 
infection, 2.8-fold greater than with CF170S infection.  However, by 48 hours post-
infection, caspase 3 expression during CF170S infection increased to 6.3-fold above mock, 
whereas the up-regulation of caspase 3 induced by P(C-) diminished to 4.1-fold. The 
second apoptosis-related gene, TNFRSF10B or TRAIL receptor 2 (TRAIL-R2), is 
responsible for signaling through the extrinsic apoptosis pathway.  Similar to caspase 3, 
TNFRSF10B was up-regulated 4.8-fold with P(C-) infection at 24 hours post-infection, 
2.1-fold greater than that seen with CF170S infection.  However, at 48 hours post-infection, 
TNFRSF10B expression during CF170S and P(C-) infection were comparable. At 24 h p.i., 
TNFSF10 (TRAIL) itself was upregulated 50.9-fold by CF170S infection, 1.95-fold greater 
than that seen with P(C-) infection, although apoptosis was induced only during P(C-) 
infection (Fig. 7A). The earlier expression of TNFRSF10B and caspase 3 may contribute 
to the significant cytopathic effect observed during P(C-) infection at 48 hours post-
infection although the induction of TNFSF10 (TRAIL) itself was more pronounced in 




Figure 7. The CF170S and P(C-) mutant viruses share remarkably similar expression 
profiles for genes encoding death ligands, death receptors, and apoptosis inhibitors 
despite distinct cytopathic phenotypes. Hierarchical clustering matrices and gene 
expression profiles comparing the gene expression of A) death ligands, B) death 
receptors, and C) apoptosis inhibitors following infection with wt HPIV1 (WT) or the 
indicated mutant HPIV1 or following IFNβ treatment. A significant difference was not 











Microarray-based analyses are increasingly being used in virology and have helped to 
elucidate virus-host interactions for a number of viruses (reviewed in (88)). Here, we 
performed a comprehensive analysis of the response of a human respiratory epithelial cell 
line to HPIV1 infection and to IFNβ treatment. Microarray analyses have been previously 
applied to study infection by murine PIV1 (SeV) (39, 178). However, these studies had 
methodological issues that limited the ability to interpret the results, including: 1) human 
cells were infected with a murine virus; 2) non-respiratory cells were infected with a 
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respiratory virus; 3) mRNA levels were determined only at a single time point; 4) 
customized arrays were used that included fewer than 1000 genes that focused on the IFN 
and antiviral pathways; and 5) the response to viral infection was not compared with the 
response to IFN treatment (39, 178). In the present study, gene expression kinetics 
following infection with a human respiratory virus or administration of IFNβ were 
determined across multiple time points in human respiratory epithelial cells, the natural 
target of HPIV1, using a microarray representing the entire human genome. We chose to 
analyze only genes whose expression was at least four-fold up- or down-regulated, 
thereby excluding genes that were more modestly induced or suppressed by viral 
infection or IFN treatment. In order to avoid a subjective or biased analysis, functional 
bioinformatics tools were used to group thousands of differentially expressed genes into 
distinct hierarchical clusters and to identify functional pathways over-represented in each 
cluster. oPOSSUM Single Site Analysis software was used to examine upstream 
sequences for predicted transcription factor binding sites within each hierarchical cluster 
(72, 161, 193), resulting in the identification of several key transcriptional regulatory 
pathways that are likely involved in the cellular response to HPIV1 infection.  
 
As a first step in our analysis, we sought to identify genes that were differentially 
expressed as a result of wt HPIV1 infection. This set of genes was subsequently 
compared to the set of genes whose expression was altered by treatment with a 
physiological concentration of IFNβ, allowing us to segregate and separately analyze 
IFN-responsive from IFN-independent genes in the wt HPIV1 microarray data set. IFNβ 
treatment was chosen for comparison because A549 cells and human airway epithelial 
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cells produce this IFN in response to HPIV1, whereas IFNα is not secreted at all or is 
barely detectable. In agreement with previous reports that established the central role of 
the type I IFN response in innate antiviral immunity (35, 159), our clustering analysis 
indicated that approximately 60% of all genes induced late in infection with wt HPIV1 
were also induced by IFNβ treatment. Specifically, 209 of the 343 genes were up-
regulated by both wt HPIV1 infection and IFNβ treatment (Fig. 1, clusters A, B, and D). 
These 209 genes were over-represented in the IFN signaling, antigen presentation and 
ubiquitination pathways, as well as in the Toll-like receptor and NF-κB pathways. 
However, wt HPIV1 up-regulated an additional 129 genes that were not up-regulated by 
IFNβ (Fig. 1, column I, cluster E). Many of these genes were also under the control of 
the family of IRF and NF-κB transcription factors and were involved in apoptosis 
signaling and inflammation. This data is in agreement with and expands on a previous 
report on the dominant role of IRF3 and NF-κB regulated genes in the response of human 
embryonic kidney cells to SeV infection at 6 h (39). It can be concluded by inspection of 
the kinetic data that wt HPIV1 is able to silence the innate antiviral response for at least 6 
to 12 h p.i., but IFN dependent and IFN independent antiviral pathways are activated at 
later time points as part of the innate response to infection.    
 
Next, we sought to determine the role of the HPIV1 C proteins in suppressing the 
antiviral response of respiratory epithelial cells by analyzing gene expression patterns 
following infection of A549 cells with two C mutant viruses. Previous studies had 
established a role for the HPIV1 C proteins and SeV C proteins as inhibitors of IFN 
induction and signaling, as well as inhibitors of apoptosis (57, 96, 105). Two mutant 
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viruses with a single point mutation in C or a deletion of all four C proteins, CF170S and 
P(C-) respectively, were selected for this analysis. Wt HPIV1 inhibits the induction of 
IFN and signaling of IFN through its receptor, but CF170S and P(C-) each fail to inhibit 
these two activities. In addition, P(C-) infection induces apoptosis, whereas CF170S  and 
wt HPIV1 do not, and P(C-) is much more restricted in replication in AGMs than CF170S 
(5, 9, 192). Using the CF170S and P(C-) viruses, we sought to compare the host response 
following infection with these mutants to that following wt HPIV1 infection. We found 
that, following infection with either C mutant virus, the number of differentially 
expressed genes expanded dramatically, implicating a critical role for the HPIV1 C 
proteins in blunting the host’s antiviral response. Using whole genome microarrays, we 
found that with CF170S infection, 392 and 2,322 genes were differentially regulated more 
than 4-fold at 24 and 48 h p.i., respectively, while with wt HPIV1 infection, only 54 and 
277 genes were differentially expressed at the same time points. Thus, approximately 1% 
of the over 41,000 unique probes analyzed in our study were altered by HPIV1-CF170S at 
24 h p.i., and only 14% of that subset of genes were altered by wt HPIV1, indicating that 
the wt HPIV1 C proteins inhibited modulation of the majority of antiviral genes that 
would otherwise be up-regulated or down-regulated as a result of HPIV1 infection. 
Importantly, this striking suppression of gene expression was associated with mutation in 
the C proteins but not with differences in virus replication. CF170S and wt HPIV1 
exhibited identical kinetics of replication in vitro, and although P(C-) was approximately 
100-fold restricted in replication at 24 and 48 h p.i. compared to wt HPIV1 and CF170S 
(Fig. S5), P(C-) infection was capable of suppressing gene expression just as well as 
CF170S. Strähle et al. examined gene expression in human fibrosarcoma cells 24 h p.i. in 
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response to SeV-wt or SeV-CF170S infection using a customized array designed to probe 
approximately 150 genes with over-representation of the IFN pathway (178). In their 
study, infection with SeV-CF170S at a MOI of 20 induced 15 of 150 genes (10%) more 
than 2-fold at 24 h p.i. while SeV-wt (Ohita M strain) failed to induce the expression of 
any gene. We also found that the expression of IFNβ-inducible genes was greater 
following infection with CF170S or P(C-) than following treatment with 300 pg/mL of 
IFNβ, the concentration of IFN induced by CF170S infection of A549 cells (192). The 
greater induction seen with C mutant infection is due in part to direct viral recognition by 
RIG-I-like receptors (RLR) and subsequent activation of IRFs and NF-κB. Activated 
IRF3 not only stimulates the IFNB promoter to produce IFNβ but also can independently 
activate IFN stimulated response elements to augment the production of IFN stimulated 
genes (ISGs). In contrast, the effect of exogenous IFN is limited to signaling through the 
IFN receptor and activation of the ISGF3 transcription factor complex to up-regulate the 
expression of antiviral effectors and other ISGs. The wt C proteins likely block the RLR 
and IFN signaling pathways as evidenced by the lack of IRF3 and STAT activation and 
IFN production during infection with wt HPIV1, and this antagonism is ablated as a 
result of mutation or deletion of the HPIV1 C proteins (18, 192). In another similarly 
designed microarray study, Hartman et al. compared the host response to wt Ebola virus 
with a highly attenuated Ebola virus containing a single amino acid change, namely, 
R312A in the IRF3-inhibitory domain of VP35 (65). Like wt HPIV1, wt Ebola was 
remarkably effective in suppressing the activation of cellular antiviral and IFN-
responsive genes. The single VP35R312A mutation in Ebola, however, reversed the 
inhibition of only 39 genes, whereas the single CF170S mutation in HPIV1 reversed the 
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inhibition of over 2000 genes (Fig. 2). The Ebola VP35 protein confers virulence during 
infection by inhibiting IRF3 activation and IFNβ production, whereas the VP24 protein 
inhibits STAT1 nuclear translocation and IFN signaling (64, 155). Unlike Ebola which 
utilizes two separate viral proteins to antagonize IFN production and signaling, HPIV1 
encodes the C proteins from a single gene segment that blocks both arms of the viral 
recognition and IFN pathways and probably suppresses the expression of many more 
genes compared to VP35 alone.  
 
Following comparison of gene expression between wt HPIV1 and the two C mutant 
viruses, we next compared the cellular response to CF170S versus P(C-) infection to 
determine whether differences in gene expression profiles were associated with the 
observed differences in the mutants’ apoptosis and attenuation phenotypes. Surprisingly, 
the cellular response to CF170S infection was comparable to the response to P(C-) 
infection, both qualitatively and quantitatively (Figure 4). Although the microarray-
based analysis may have missed differences between CF170S and P(C-) due to decreased 
sensitivity compared to RT-qPCR, this limitation occurred only with very highly up-
regulated genes where gene induction is already qualitatively clear. For example, IFNB, 
which was induced 853,062-fold as measured by RT-qPCR and 628-fold by microarray 
analysis, showed 1358-fold greater sensitivity by qPCR due to saturation of the IFNB 
probe on the microarray. However, less strongly up-regulated genes such as NFKB1, 
which was induced 68-fold as measured by RT-qPCR and 11-fold by microarray 
analysis, showed only 6-fold greater sensitivity in detecting differential expression. The 
difference is significantly less pronounced since genes that are up-regulated less do not 
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suffer as much from microarray probe saturation. Thus, although the microarray-based 
analysis may have missed small differences in gene expression between viruses, we have 
shown that both technologies have comparable sensitivity at lower expression levels. 
Based on the phenotypic differences between the two mutants, with P(C-) being the more 
attenuated in vivo and a strong inducer of apoptosis in vitro, we expected to find 
transcriptional differences in at least the apoptosis pathway. However, not a single 
mRNA was differentially expressed using our predefined criteria, i.e. 4-fold and P < 0.01. 
To detect any subtle differences between infection with the two C mutant viruses, we 
tested several fold-change cutoffs. After relaxing our fold-change cutoff to two-fold and 
subsequently performing a t-test with multiple testing correction, we identified two 
genes, caspase 3 and the TRAIL receptor 2 (TNFRSF10B), that could potentially 
contribute to P(C-)-induced apoptosis.  P(C-) infection up-regulated both genes earlier, at 
24 h p.i., compared to CF170S infection.  However, in both cases, the magnitude of up-
regulation during CF170S infection caught up by 48 h p.i., and the TRAIL ligand 
(TNFSF10) itself was comparably induced by both viruses at 24 h p.i.  
 
It was surprising that the CF170S mutant, that contains a single point mutation at amino 
acid 170 of the C protein, induced a transcriptional profile that was almost 
indistinguishable from that induced by the P(C-) mutant, a virus that does not express any 
of the C genes. Although P(C-) infection induces apoptosis much more rapidly and 
extensively than CF170S (9), the expression kinetics of death ligands, death receptors, or 
antiapoptotic factors that could account for P(C-) induced cell death did not differ 
significantly by 4-fold from CF170S at any time (Fig. 7a, b, and c). Since knockout of the 
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C gene causes cell death whereas expression of the wt C gene does not, we hypothesized 
that the wt HPIV1 and CF170S C proteins prevented cell death through apoptosis 
inhibition, i.e., either through inhibition of proapoptotic pathways or activation of 
antiapoptotic pathways. Previous studies on SeV suggested that a delicate balance exists 
between proapoptotic and antiapoptotic pathways during viral infection. SeV infection 
activates the cellular phosphatidylinositol 3-kinase (PI3K) pathway and, through AKT 
activation, prevents apoptosis (145). Thus, the differences in the apoptosis phenotype 
between the two C mutants likely lies in the interaction of one or more of the C proteins 
of CF170S and wt HPIV1 with one or more constitutively expressed factors, which results 
in the suppression of the apoptosis response. Both wt C proteins and point mutated C 
proteins could potentially activate apoptosis inhibitory proteins or antagonize 
proapoptotic proteins that would otherwise be triggered during HPIV1 infection. These 
two possibilities can be tested once the mechanism of interaction with the host apoptosis 
machinery has been defined. The greater level of attenuation of P(C-) versus CF170S likely 
reflects a contribution of apoptosis to the decreased replication of P(C-), but the loss of a 
yet undefined function of C required for replication in vivo may contribute as well. 
 
Although wt HPIV1 suppressed the up-regulation of a broad array of cellular genes that 
were induced by P(C-) and CF170S infection, global shutoff of host transcription did not 
occur. In fact, only 234 of 2612 differentially expressed genes were down-regulated (Fig. 
4, panel II, cluster H). Interestingly, both C mutant viruses down-regulated these genes to 
a greater extent than wt HPIV1 (Table S2). Thus, the wt C proteins blunted both 
induction and suppression of a specific set of host genes that would otherwise react to 
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viral infection. This is in stark contrast to what has been described for vesicular stomatitis 
virus which shuts down transcription globally through M protein-mediated inhibition of 
the three cellular RNA polymerases I, II, and III (1, 202), or for Rift Valley fever virus 
which, through inhibition of TFIIH transcription factor complex assembly via its NSs 
protein, leads to the rapid destabilization of host cellular RNA synthesis (111). However, 
other members of the order Mononegavirales, such as the Marburg and Ebola filoviruses, 
suppress the antiviral and type I IFN responses without shutting down host cell functions 
globally, and the degree of antiviral suppression by these viruses seems to correlate with 
virulence in vivo (95).  Similarly, our data indicate that wt HPIV1 C protein function, i.e., 
suppression of antiviral pathways early in infection, is an important virulence factor and 
that the loss of this activity in both CF170S and P(C-) leads to attenuation in vivo.             
 
Following global analysis of virus modulated pathways, we attempted a more detailed 
analysis of the IFN and apoptotic pathways in order to understand the different in vivo 
and in vitro phenotypes of wt HPIV1, P(C-) and CF170S. We found that by 48 h p.i., wt 
HPIV1 induced IFNB expression 180-fold, as measured by microarray, and 1200-fold, as 
measured by qPCR (Fig. 5A). Previously, we reported that IFNB mRNA was not 
detectable at any time point in response to HPIV1 infection (192). Re-examination of that 
data identified a 5600-fold induction of IFNB mRNA following CF170S infection versus a 
12-fold induction following wt HPIV1 infection at 48 h p.i., i.e., a 458-fold reduction in 
IFNB transcription following wt HPIV1 infection, as compared to CF170S infection (192). 
In the present study, CF170S induced 695 times more IFNB mRNA than wt HPIV1 at 48 h 
p.i., confirming that IFNB mRNA is strongly induced by CF170S but not by wt HPIV1 
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(Table S3). At the protein level, we previously were unable to detect IFNβ in the 
supernatant of wt HPIV1 infected A549 cells by IFN bioassay, not even after 96 h p.i. 
(192). In contrast, Bousse et al. detected 380 IU/mL of IFNβ  by ELISA in MRC-5 cells 
48 h p.i. with wt HPIV1 strain C-35 (Genbank M74081) (18). This difference in 
IFNβ secretion could be due to the use of different cell lines (MRC-5 versus A549) 
and/or different virus strains. Protein sequence alignment of the C protein of the C-35 
strain of HPIV1 used by Bousse et al. with our Washington 1964 wt HPIV1 strain 
revealed a CQ38P substitution in the C gene that could potentially be responsible for a 
distinct IFN phenotype. The CF170S virus serves as an example for the role a single amino 
acid substitution in the C protein can potentially have on the IFN phenotype. Importantly, 
the deficient IFNβ response of A549 cells to wt HPIV1 infection was also seen in 
primary human airway epithelial cell cultures, confirming the IFN production deficiency 
of respiratory epithelial cells infected with wt HPIV1 (11). 
 
One aim of this project was to identify cellular pathways that are targeted by the HPIV1 
C proteins and to define how the C proteins exert such impressive transcriptional control 
of the host’s innate immune system. We analyzed the gene expression profiles for all 14 
transcription factors identified by bioinformatics analysis (Fig. S6) and found that the 
expression of 4 genes IRF1, ISGF3G, NF-κB1, and c-Rel were significantly up-regulated 
increasingly over time, confirming the importance of the IRF3 and NF-κB signaling 
pathways during parainfluenza infection and furthermore providing a feed-forward 
mechanism to amplify the host transcriptional response to viral infection. We expected to 
identify IRF and NF-κB TFBSs over-represented in genes induced by IFN treatment and 
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HPIV1 infection, but other unexpected TFBSs were also identified. For example, FOXD1 
and FOXD3 TFBS were identified in genes up-regulated by the HPIV1 C mutant viruses. 
Only recently has an important role for FoxD1 been identified in the regulation of 
immune activation through the NF-κB pathway (117). FoxD3 is well known for 
controlling cellular differentiation but no role has yet been defined for FoxD3 in the 
regulation of the immune response or the response to viral infection. In future work, it 
will be important to define how the HPIV1 C proteins modify the activity of FOXD1, 
FOXD3, and other transcription factors and how C', C, Y1, and Y2 differ in their ability 
to alter transcriptional activity. 
 
In summary, the HPIV1 C proteins exert remarkable control over the cellular 
transcriptional response to viral infection, indicating that the C proteins are important 
virulence factors for HPIV1. Mutations within the C gene permit the activation of a broad 
array of cellular genes involved in the type I IFN, IRF3 and NF-κB pathways that would 
otherwise be repressed by HPIV1 infection, and these mutations specify an attenuation 
phenotype in vivo. However, the lack of a clear differential regulation of antiapoptotic 
and proapoptotic genes in P(C-) and CF170S infected cells allows for two models of P(C-) 
induced apoptosis that could individually, or in combination, play a key role in 
determining the apoptosis phenotype of HPIV1 infection: 1) earlier expression of 
TNFRSF10B and caspase 3 or 2) alterations in post-translational events involving 
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Human parainfluenza virus type I (HPIV1) is an important respiratory pathogen in young 
children, the immunocompromised, and the elderly.  We found that infection with wild-
type (WT) HPIV1 suppressed the innate immune response in human airway epithelial 
cells by preventing not only phosphorylation of IRF3 but also degradation of IκBβ, 
thereby inhibiting IRF3 and NF-κB activation, respectively.  Both of these effects were 
ablated by a F170S substitution in the HPIV1 C proteins (F170S) or by silencing the C 
open reading frame (P(C-)), resulting in a potent IFNβ response.  Using murine knockout 
cells, we found that IFNβ induction following infection with either mutant relied mainly 
on MDA5 rather than RIG-I.  Infection with either mutant, but not WT HPIV1, induced a 
significant accumulation of intracellular dsRNA.  These mutant viruses directed a marked 
increase in the accumulation of viral genome, antigenome, and mRNA that was 
coincident with the accumulation of dsRNA.  In addition, the amount of viral proteins 
was reduced compared to WT HPIV1.  Thus, the accumulation of dsRNA might be a 
result of an imbalance in the N protein-to-genomic RNA ratio leading to incomplete 
encapsidation.  PKR activation and IFNβ induction followed the kinetics of dsRNA 
accumulation.  Interestingly, the C proteins did not appear to directly inhibit intracellular 
signaling involved in IFNβ induction; instead, its role in preventing IFNβ induction 
appeared to be in suppressing the formation of dsRNA.  PKR activation contributed to 
IFNβ induction and also was associated with the reduction in the amount of viral 
proteins.  Thus, the HPIV1 C proteins normally limit the accumulation of dsRNA and 
thereby limit activation of IRF3, NF-κB, and PKR.  If C protein function is 
compromised, as in the case of F170S HPIV1, the resulting PKR activation and reduction 
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in viral protein levels enables the host to further reduce C protein levels and to mount a 
potent antiviral type I IFN response.    
Introduction 
Human parainfluenza virus type 1 (HPIV1) is an important and uncontrolled respiratory 
pathogen that causes a significant burden of disease, mainly in young children, the 
immunocompromised, and the elderly (30, 42, 58, 79, 134, 154).  HPIV1 is a single 
stranded, negative sense, nonsegmented RNA virus in the Paramyxoviridae family.  The 
viral genome, 15.6 kb in length, consists of 6 genes (3’ – N-P/C-M-F-HN-L – 5’) that 
encode the nucleoprotein (N), phosphoprotein (P), C proteins (C), matrix protein (M), 
fusion protein (F), hemagglutinin-neuraminidase protein (HN), and the large polymerase 
protein (L).  Each gene encodes a single major protein with the exception of the P/C 
gene, which encodes the P protein in one open reading frame and a nested set of four 
carboxy-coterminal C proteins (C', C, Y1, and Y2) expressed from individual start sites 
in a second open reading frame.  The C proteins play a critical role in HPIV1 virulence 
by inhibiting apoptosis, regulating type I interferon (IFN) production and signaling, and 
controlling the transcription of a large number of host genes (9, 17, 18, 192).  The C 
proteins of Sendai virus (SeV), or murine PIV1, have considerable sequence conservation 
with the HPIV1 C proteins.  However, the P/C gene organization of SeV differs from that 
of HPIV1 in that SeV expresses, in addition to the C proteins, a second accessory protein, 
the V protein, that also exerts an inhibitory role on the host innate antiviral response (3).  
In addition, some of the immune evasion activities of SeV and HPIV1 are species-
specific (18, 22), indicating that a careful examination of the innate immune response to 
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HPIV1 may yield important clues about the pathogenesis of this human respiratory virus 
that differ from the murine SeV. 
  
Type I IFN is a central mediator of antiviral innate immunity.  The induction of IFN 
synthesis following virus infection depends on a number of pattern-recognition receptors 
that recognize conserved pathogen-associated molecular patterns and initiate downstream 
signaling cascades (87).  The presence of dsRNA, an intermediate of RNA viral 
replication, is recognized as a pathogen-associated molecular pattern by Toll-like 
receptor 3 (TLR3) and two caspase recruitment domain (CARD)-containing RNA 
helicases, retinoic acid-inducible gene I (RIG-I) and melanoma associated-differentiation 
gene 5 (MDA5), which act as intracytoplasmic sensors of dsRNA (2, 76, 147, 180, 212, 
214).  Whereas TLR3 mainly senses extracellular dsRNA on antigen-presenting cells, 
RIG-I and MDA5 are constitutively present and detect intracellular dsRNA (2, 214).  
TLR3 signals through an adaptor called TIR domain-containing adaptor inducing IFNβ 
(TRIF), while RIG-I and MDA5 recruit another CARD-containing adaptor called 
mitochondrial antiviral signaling protein (MAVS, also referred to as IPS-1, Cardif, or 
VISA) to relay the signal to the kinases TBK1 and IKKε, which phosphorylate IRF3 
(interferon regulatory factor 3), and to IKKβ, which activates the NF-κB pathway (41, 
99, 140, 167, 207).  Once activated, IRF3 translocates into the nucleus and binds the 
positive regulatory domain III (PRDIII) of the IFNβ promoter.  RIG-I and MDA5 can 
distinguish between different RNA viruses (98).  It was originally reported that IFN 
production in response to infection with negative-sense RNA viruses, including SeV, was 
dependent on RIG-I expression whereas the response to infection with positive-sense 
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RNA viruses was dependent on MDA5 expression (98, 195).  This model was in 
agreement with earlier reports that found a substantial accumulation of cytoplasmic 
dsRNA during infection with positive-sense RNA viruses but not with negative-sense 
RNA viruses (199).  However, a more recent study suggested that MDA5 does contribute 
in vivo to sustaining the IFN response and restricting SeV infection (53).  After the host 
cell recognizes and signals the presence of foreign RNA, IRF-3 and NF-κB, together with 
ATF-2/c-Jun (AP-1), form an enhanceosome that binds to the IFNβ promoter, inducing 
transcription of the IFNβ gene.  Once type I IFN is produced and secreted, it binds to the 
type 1 IFN receptor on the surface of the infected and neighboring cells to amplify a 
robust antiviral response (121, 183).  One IFN-inducible gene, PKR, is best known for its 
ability to bind dsRNA and subsequently phosphorylate EIF2A thereby inhibiting 
translation initiation during viral infection (70).  PKR has also been implicated in 
contributing to NF-κB activation, IRF1 activation, and IFN induction by poly I:C, 
independent of its kinase activity, as another mechanism of innate antiviral host defense 
(4, 16, 25, 107, 209, 218).   
 
We generated a number of HPIV1 mutants to investigate C protein function as well as to 
generate novel live vaccines that would be attenuated by disturbing the IFN antagonistic 
function of the C proteins, a strategy that has been shown to result in attenuation of 
replication in vivo (5, 6, 192).  Previously, a phenylalanine to serine substitution of amino 
acid 170 of SeV was shown to significantly attenuate a highly virulent SeV strain, 
increasing the lethal dose 50% (LD50) 20,000-fold in mice (50).  This CF170S mutation 
was introduced into the P/C gene of recombinant HPIV1 by reverse genetics (85, 137).  
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Whereas WT HPIV1 infection prevented IRF3 dimerization, its nuclear translocation, and 
IFNβ production, infection with HPIV1 containing the CF170S mutation (F170S virus) led 
to IRF3 activation and IFNβ production (192).  Not unexpectedly, the F170S mutant was 
attenuated for replication in the respiratory tract of hamsters and African green monkeys 
(AGMs)  (5, 192).  We also constructed a HPIV1 mutant, referred to as P(C-), that does 
not express any of the four C proteins due to point mutations that silence the C ORF, and 
which was even more attenuated than F170S in vivo (9).  
 
In the present study, we found that the C proteins of HPIV1 profoundly suppress the 
innate immune response in epithelial cells by preventing the activation of both IRF3 and 
NF-κB.  We found that mutation or silencing of the C gene ablated both of these 
inhibitory effects.  In contrast to WT, infection with both F170S and P(C-) HPIV1 
resulted in the accumulation of significant amounts of cytoplasmic dsRNA with kinetics 
that were more rapid for the P(C-) virus.  The accumulation of dsRNA coincided with an 
increase in the accumulation of viral genomic/anti-genomic RNA or mRNA and a 
decrease in N protein levels, and thus appeared to result from incomplete encapsidation. 
The enhanced induction of IFNβ observed with these mutants relied mainly on MDA5 
rather than on RIG-I.  PKR activation coincided with dsRNA accumulation, contributed 
to IFNβ induction, and restricted viral C protein expression.  Thus, PKR activation 
provides a mechanism that allows the host cell to eliminate the very protein responsible 




Materials and Methods 
Cells, viruses, and DNA transfection 
A549 human respiratory epithelial cells were maintained in F-12 medium supplemented 
with 0.1 mg/mL gentamicin sulfate, 4 mM L-glutamine, and 10% fetal bovine serum 
(FBS).  Human embryonic kidney 293T cells were maintained in DMEM medium 
supplemented with 10% FBS and gentamicin sulfate.  Mouse embryonic fibroblasts were 
prepared from RIGI MDA5 +/- +/-, RIGI -/-, and MDA5 -/- mice and maintained in 
DMEM with 10% FBS and gentamicin sulfate as described (98).  Stable shPKR 
knockdown and shCON control 293A cells were maintained in DMEM with 10% FBS 
and gentamicin sulfate supplemented with 1 µg/mL puromycin as described (215).  
Doxycycline-inducible, stable cells that express WT C´ protein tagged at the C-terminus 
with a c-Myc epitope were generated using Flp-In T-REx 293 cells grown in 100 µg/mL 
Hygromycin and 15 µg/mL Blasticidin (Invitrogen).   C expression was induced by 
incubation for 24 h with 1 µg/mL Doxycycline (Sigma).  Sucrose gradient-purified 
recombinant WT, F170S, and P(C-) HPIV1 were prepared and titered by limiting dilution 
assay as reported (17).  All viral infections were carried out using a multiplicity of 
infection (MOI) of 5 TCID50/mL at 32°C in medium containing 1.2% trypsin TrypLE 
Select (Invitrogen).  For type I IFN neutralization, 5000 NU/mL anti-IFNα and 2000 
NU/mL anti-IFNβ antibodies (PBL InterferonSource) were added at 12 h p.i.  For 
transient transfections, 3 µL Lipofectamine 2000 (Invitrogen) per 1 µg total DNA was 
added for every 400,000 293T cells for 48 h at 37°C.  For poly I:C-induced IFNβ 
expression, 3 µL Lipofectamine 2000 per 1 µg of poly I:C (Sigma) was added for every 
400,000 293T cells for 6 h at 37 °C.  For the preparation of cellular extracts, cells were 
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suspended in lysis buffer (1% Triton X-100, 50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 
mM EDTA) with protease inhibitor cocktail (Sigma) at a concentration of 2000 cells/µL 
for 30 min at 4°C and centrifuged at 15,000 g for 10 min.  Halt protease and phosphatase 
inhibitor cocktail (Pierce) was added to the lysis buffer whenever phosphorylation states 
were examined.  After centrifugation, the supernatant was used for Western blotting and 
immunoprecipitation.           
 
Real-time RT-PCR   
Intracellular RNA or virion-associated RNA was extracted and analyzed by real-time RT-
PCR as described previously (17).  The relative levels of expression of mRNA for human 
and murine IFNβ and GAPDH were determined using TaqMan Gene Expression Assays 
(Applied Biosystems) for human IFNβ (Hs01077958_s1), human GAPDH 
(Hs99999905_m1), mouse IFNβ (Mm00439546_s1), and mouse GAPDH 
(Mm99999915_g1), with the RT performed on intracellular RNA using random 
hexamers.  Experiments were performed in triplicate.  Combined genomic/anti-genomic 
RNA, genomic RNA, anti-genomic RNA, and IFNβ expression in shPKR 293 cells was 
measured in triplicate and confirmed in two independent experiments.  Student’s t-test 
was used to determine statistical significance.  To measure the relative copy numbers of 
HPIV1 genome plus antigenome in sucrose-purified virus stocks, RT was performed on 
extracted virion RNA with random hexamers and PCR was performed to amplify genome 
nucleotides 15,502-15,600, corresponding to the downstream end of the L gene and the 
adjoining trailer region (forward primer ACCAGACAAGAGTTTAAGAAATATCGA, 
reverse primer AGAAATCCCTTTAACTGACTCATAAAAACATAGT, probe 
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CAACAGACAAGAGTATTAATAAT).  To distinguish between genomic and 
antigenomic RNA in intracellular RNA, RT was performed with a positive-sense primer 
representing genome nucleotides 15502-15519 (AGAAATCCCTTTAACTGA) to 
measure genome or with a negative-sense primer representing genome nucleotides 
15583-15600 (CTTAAACTCTTGTCTGGT) to measure antigenome.  PCR was then 
performed to amplify nucleotides 15,502-15,600 of the genome or its complement, using 
the primer/probe set described above.  To measure the relative copy numbers of the N 
and P mRNAs in intracellular RNA, RT was performed with oligo-dT primer and PCR 
was performed to amplify, in the case of N, genome nucleotides 917-1014 (forward 
primer  AGCATCTTTCATGAACACCATCAAGT, reverse primer 
GGCTTCTCAATTTGTTTATATCTGGTCTCA, probe CCGCCCTGACACTAT) and, 
in the case of P, genome nucleotides 2624-2685 (forward 
GAAGACCACAACACCAAAACCA, reverse primer 
GCTGCTGACTCTTCGTTCTTTG, probe ACGGTGGAACTTTTG).  
 
Western blotting and antibodies 
Cells were lysed and clarified as described above for the preparation of cellular extracts, 
and the resulting extracts (15 µL) were denatured and reduced in sample loading buffer 
(0.3M Tris HCl, 5% SDS, 50% glycerol, 0.1M DTT) at 95 °C for 5 min, separated by 
SDS-PAGE on 4-20% Tris-Glycine gels (Invitrogen), and transferred to 0.45 µm PVDF 
membranes (Invitrogen).  Membranes were blocked overnight with 5% milk powder and 
1% BSA or, whenever probing with phospho-specific antibodies, with 5% BSA in 0.1% 
Tween-PBS.  Rabbit polyclonal anti-serum was raised against a synthetic peptide 
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corresponding to an internal sequence (amino acids 78–92, TITTKTEQSQRRPK) in the 
HPIV1 C proteins shared by C’, C Y1, and Y2 by ProSci (Poway, CA), against a 
synthetic peptide corresponding to an internal sequence (amino acid residues 485–499, 
RRLADRKQRLSQANN) in the HPIV1 N protein by ProSci, and against a synthetic 
peptide corresponding to a N-terminal sequence (amino acids 10-24, 
RDPEAEGEAPRKQES) in the HPIV1 P protein by Spring Valley Laboratories 
(Woodbine, MD).  Membranes were probed with rabbit anti-serum at a 1:1000 dilution 
with 5% milk and 1% BSA in 0.1% Tween-PBS for 1 hour.  Antibodies used included 
rabbit polyclonal antibodies to human pIRF3 (S396) (Millipore; #07-582), IRF3 (Santa 
Cruz Biotechnology; sc-9082), IκB-β (Santa Cruz; sc-945), ATF2 (Santa Cruz; sc-187), 
pP38 (T180/Y182) (Santa Cruz; sc-101759), P38 (Santa Cruz; sc-7149), PKR (Santa 
Cruz; sc-707), pEIF2α (S51) (Enzo Life Sciences; BML-SA405), EIF2α (Sigma; 
E0157), MDA5 (Alexis Biochemicals; ALX-210-935), Flag epitope tag (Sigma; F7425), 
HA epitope tag (Sigma; H6908), Myc epitope tag (Sigma; C3956), rabbit monoclonal 
antibody to human pPKR (T451) (Epitomics; #2283-1), or mouse monoclonal antibodies 
to human pATF2 (T71) (Santa Cruz; sc-8398), GAPDH (Sigma; G9295) and V5 epitope 
tag (Invitrogen; R960-25).  Horseradish peroxidase-conjugated goat anti-rabbit secondary 
antibody (Santa Cruz) was used at a dilution of 1:5000 and horseradish peroxidase-
conjugated goat anti-mouse secondary antibody (Kirkegaard & Perry Laboratories) was 
used at a dilution of 1:2400 for 1 hour.  Membranes were washed 3 times for 5 minutes 
with 0.1% Tween-PBS after primary and secondary antibody incubations.  Enhanced 
chemiluminescent substrate (Pierce) was used to visualize proteins on BIOMAX MR film 





Cell lysates extracted from transfected 293T cells were mixed for 16 h at 4°C with anti-
Myc agarose (Pierce), washed extensively with wash buffer (50 mM Tris HCl pH 7.4, 
150 mM NaCl), eluted with 0.1 M glycine pH 2.8, and separated by SDS-PAGE.   
 
Immunofluorescence 
A549 cells were fixed with 2% paraformaldehyde, permeabilized with 0.2% Triton X-
100, and blocked with 10% goat serum and 0.02% BSA for 2 h.  Mouse monoclonal J2 
anti-dsRNA antibody (English and Scientific Consulting) at a 1:200 dilution or rabbit 
polyclonal anti-HPIV1 P antibody at a dilution of 1:100 was added in 1% goat serum and 
0.002% BSA for 1 h at 37°C.  Texas Red-conjugated goat anti-rabbit and FITC-
conjugated goat anti-mouse secondary antibodies (Jackson ImmunoResearch) were added 
at a dilution of 1:250 for 45 min at 37°C.  Cells were mounted in ProLong Gold reagent 
with DAPI (Invitrogen) and visualized on a Leica SP5 confocal microscope.          
 
Plasmid constructs 
A cDNA for HPIV1 C was generated by PCR (forward primer 
CATCGGTACCGTGGATACCTCAGCATCCAAAACTCTCCTTCCC and reverse 
primer 
ATCACATGCGGCCGCTTACAGATCTTCTTCAGAAATAAGTTTTTGTTCTTCTTG
TACTATGTGTGCTGCTAGTTTCC) of the full-length antigenomic cDNA for WT 
HPIV1 and constructed with the insertion of a C-terminal c-Myc tag and KpnI and EagI 
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restriction sequences to allow cloning into pcDNA3.1 (Invitrogen).  The nucleotide 
sequence was confirmed using BigDye Terminator and a DNA Analyzer 3730 (Applied 
Biosystems).  pEF-IRES V5-TRIM25 was kindly provided by Michaela Gack and Jae 
Jung (45).  pEF-BOS HA-Riplet was kindly provided by Hiroyuki Oshiumi and Tsukasa 
Seya (141).  pRK5 Flag-TRAF3 and Myc-TRADD3 were kindly provided by Jurg 
Tschopp (128).  pCMV2 Flag-TRAF6 was kindly provided by Masashi Muroi and Ken-
ichi Tanamoto (132).  pEF-BOS Flag-RIGI and Flag-MDA5 were kindly provided by 
Takashi Fujita (213, 214).  pcDNA3 Flag-TBK1 was kindly provided by Katherine 
Fitzgerald and Makoto Nakanishi (41, 190).  pCMV2 Flag-IPS1 has been previously 
described (99).  pcDNA3 Flag-BIRC2 and Flag-BIRC4 were kindly provided by 




HPIV1 activation of the interferon induction pathway  
We found previously that, in stark contrast to WT HPIV1, HPIV1 with a F170S point 
mutation in the C proteins or in which the C gene was silenced by point mutations 
induced the transcription of a broad array of cellular genes, in particular genes involved 
in type I IFN production and the subsequent antiviral response (17, 192).  To investigate 
the mechanism of C-mediated antagonism of the host innate immune response, we used 
three cell types.  A549 cells were used to model infection in human respiratory epithelial 
cells, 293 human kidney cells were used for transfection and knockdown experiments, 
and mouse embryonic fibroblasts were used for knockout experiments.  We found that 
 
117 
the HPIV1-induced IFN phenotype was comparable between the three cell types: 
specifically, in each cell type, F170S and P(C-) HPIV1 induced similar, abundant levels 
of IFNβ expression mRNA expression, whereas WT HPIV1 did not induce significant 
IFNβ (not shown).   
 
IFNβ induction is transcriptionally controlled by the coordinate assembly of an 
enhanceosome consisting of IRF3, NF-κB, and AP-1 at the IFNβ promoter (120, 210).  
We examined the activation of the three components of the IFNβ enhanceosome during 
HPIV1 infection and found that both F170S and P(C-) HPIV1 induced IRF3 
phosphorylation and IκBβ degradation, which would permit nuclear translocation of 
IRF3 and NF-κB, respectively, whereas WT HPIV1 effectively blocked IRF3 
phosphorylation and IκBβ degradation (Fig. 1).  On the other hand, WT, F170S, and 
P(C-) HPIV1 did not induce detectable phosphorylation of P38 or ATF2 












Figure 1. Activation of the IRF3 and NF-κB components of the IFNβ enhanceosome by 
infection with WT and mutant HPIV1.  A549 cells were infected with WT, F170S, or 
P(C-) HPIV1 at a MOI of 5 for 6 or 48 h.  Phosphorylated IRF3 (Ser 396), total IRF3, 
and total IκBβ were detected by Western blot.   
 
 
To investigate the basis for the observed antagonism of the host response by the WT 
HPIV1 C proteins, a selective search for cellular C-interacting proteins was performed 
among RIG-I/MDA5 pathway components.  Cells transfected with expression plasmids 
expressing a tagged C’ protein and various tagged proteins of the RIG-I/MDA5 pathway 
were lysed and analyzed in co-immunoprecipitation experiments using various conditions 
in an attempt to sensitively detect any interactions.  However, we were unable to detect 
any cellular C-interacting proteins among those tested, including TRIM25, Riplet, RIGI, 
MDA5, IPS1, TBK1, TRAF3, TRAF6, BIRC2, BIRC4, TRADD, and FADD, even 
though, under these same conditions, TRAF3 was immunoprecipitated with TRADD, a 
known binding partner of TRAF3  (Supplementary Fig. 2).  Since we could not identify 
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any cellular C-interacting proteins, we investigated whether supplying the HPIV1 C 
proteins in trans could block the IFNβ induction pathway triggered by infection with 
respiratory syncytial virus (RSV) or by transfection with poly I:C, which mainly involves 
activation of RIG-I and MDA5, respectively (118, 174).  Infection with WT HPIV1, as a 
source of C proteins, strongly suppressed IFNβ induction in response to super-infection 
with P(C-) HPIV1, but failed to block IFNβ induction in response to super-infection with 
a RSV mutant that expresses GFP from an added gene and lacks the NS1 and NS2 RSV 
IFN antagonist genes (ΔNS1/NS2 RSV) (Fig. 2a).  As a control, analysis of GFP 
expression showed that the efficiency of infection by ΔNS1/NS2 RSV was not affected 
by pre-infection with WT HPIV1 (not shown).  To test whether the HPIV1 C proteins 
could interfere with IFN production triggered through MDA5, a doxycycline-inducible 
stable human cell line that expresses the HPIV1 C proteins was generated.  In this 
system, expression of the HPIV1 C proteins in trans strongly suppressed IFNβ induction 
by infection with P(C-) HPIV1 (Fig. 2b), confirming the efficient expression of 
functional C protein.  In contrast, expression of the HPIV1 C proteins had no effect on 
IFNβ induction in response to transfection with poly I:C (Fig. 2c).  In this last 
experiment, the cells had also been transfected with a plasmid expressing human MDA5 
to provide the homologous sensor for dsRNA prior to the transfection of poly I:C.  Taken 
together, these results indicate that the HPIV1 C proteins supplied in trans can efficiently 






Figure 2. IFNβ induction in A549 cells by heterologous RIG-I and MDA5 stimuli is not 
affected by expression of the HPIV1 C proteins in trans.  (A) A549 cells were pre-
infected with WT HPIV1 at a MOI of 5 for 24 h and then super-infected with either P(C-) 
HPIV1 or GFP-expressing ΔNS1/NS2 RSV at a MOI of 5 for another 24 h.  IFNβ 
expression was measured by real-time PCR and was normalized to the mock pre-infected, 
mock super-infected sample.  * denotes P < 0.01 compared to mock pre-infected samples.  
(B) C protein expression was induced in stable C-expressing 293 cells with 1 µg/mL 
doxycycline for 24 h.  Cells were then mock-infected or infected with P(C-) HPIV1 at a 
MOI of 5 for another 24 h. IFNβ expression was measured by real-time PCR and was 
normalized to the control treated, mock infected sample.   * denotes P < 0.01 compared 
to control treated cells.  (C) C protein expression was induced in stable C-expressing 293 
cells with 1 µg/mL doxycycline for 24 h, then transfected with 2.5 µg MDA5 expression 
plasmid for another 18 h, and then transfected with 10 µg poly I:C for 6 h.  IFNβ 
expression was measured by real-time PCR and was normalized to the control treated, 






HPIV1-induced IFNβ expression is mediated mostly by MDA5 
Since we were unable to obtain either direct or indirect evidence that the C proteins 
blocked IFN production by interacting with a host factor of the RIG-I/MDA5 pathway, 
we evaluated the involvement of this pathway in IFNβ induction by HPIV1 using 
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knockout MEFs.  In contrast to WT HPIV1, F170S and P(C-) HPIV1 strongly induced 
IFNβ expression in control MEFs (Fig. 3a, black bars).  RIG-I knockout led to a slight 
decrease (2.3-fold) in IFNβ expression in F170S-infected cells, but no effect was 
observed in P(C-)-infected cells (Fig. 3a).  MDA5 knockout led to a greater reduction in 
IFNβ expression in both F170S- and P(C-)-infected cells (4.5-fold and 8.0-fold, 
respectively) (Fig. 3a).  TBK1 and IKKε double knockout led to a dramatic reduction in 
IFNβ expression in both F170S- and P(C-)-infected cells, confirming the requirement for 
TBK1 and IKKε in IFN induction due to infection with F170S or P(C-) HPIV1 (Fig. 3b).  
The observation that knock-outs of TBK1 and IKKε led to almost complete inhibition of 
IFNβ mRNA synthesis, whereas knock-out of MDA5 led to only a partial inhibition, 
raised the possibility that factors in addition to MDA5 are contributing to the induction of 














Figure 3. IFNβ expression in RIG-I/MDA5 pathway knockout MEFs infected with WT 
or mutant HPIV1.  (A) RIG-I and MDA5 knockout MEFs and (B) TBK1 and IKKε 
double knockout MEFs were infected with WT, F170S, or P(C-) HPIV1 at a MOI of 5 for 
48 h.  IFNβ expression was measured by real-time PCR and normalized to mock infected 








Intracellular dsRNA accumulates in cells infected with C mutant HPIV1 viruses 
Since knockout of the dsRNA sensor MDA5 strongly reduced IFNβ expression during 
infection with F170S or P(C-) HPIV1, we looked for the presence of dsRNA in HPIV1-
infected cells by immunofluorescence using a monoclonal antibody against dsRNA. 
Transfection of poly I:C was used as a positive control, demonstrating the ability of the 
dsRNA-specific monoclonal antibody to detect intracellular dsRNA (Fig. 4a).  dsRNA 
was not detected in WT-infected cells at either 24 or 48 h (Fig. 4b, e), similar to 
observations previously reported for a number of negative sense RNA viruses, including 
influenza, La Crosse, Sendai, and Newcastle disease viruses (199).  In contrast, dsRNA 
was readily detected in cells infected with either the F170S or P(C-) virus; however, the 
kinetics of accumulation differed.  In the case of F170S HPIV1, less than 10% of infected 
cells were positive for dsRNA at 24 h, whereas over 60% of infected cells were positive 
at 48 h (Fig. 4c, e, f).  In contrast to F170S HPIV1, the accumulation of dsRNA in 
response to P(C-) HPIV1 occurred more rapidly, with approximately 70% of infected 
cells containing detectable dsRNA at 24 h.  However, the accumulation of dsRNA in 
response to the P(C-) virus was also transient: by 48 h, less than 10% of P(C-)-infected 
cells contained dsRNA (Fig. 4d-f).  This difference did not appear to be due to 
differences in the kinetics or efficiencies of infection: the percent of cells infected with 
WT, F170S, and P(C-) HPIV1 was similar at 24 and 48 h, as assessed by 
immunofluorescence using polyclonal antibodies specific to the HPIV1 P protein (Fig. 




Figure 4. Immunofluorescence of dsRNA in A549 cells infected with WT or mutant 
HPIV1.  A549 cells were transfected with (A) poly I:C (0.02 µg/µL) or infected with (B) 
WT, (C) F170S, or (D) P(C-) HPIV1 at a MOI of 5 for 24 h.  HPIV1 P protein (red) was 
detected using a rabbit polyclonal anti-P antibody and a Texas-Red conjugated secondary 
anti-rabbit antibody.  dsRNA (green) was detected using a mouse monoclonal anti-
dsRNA antibody and a FITC conjugated secondary anti-mouse antibody.  (E) dsRNA and 
the HPIV1 P protein was examined as in A-D in A549 cells infected with WT, F170S, or 
P(C-) HPIV1 at a MOI of 5 for 24 and 48 h.  (F, G) Quantitation of the number of cells in 
D with and without detectable dsRNA (F) or HPIV1 P protein (G) at 24 and 48 h.  









One possible explanation for the increased accumulation of intracellular dsRNA in cells 
infected with the F170S and P(C-) viruses was that these virus preparations contained 
disproportionately high levels of defective interfering particles, which, for nonsegmented 
negative strand RNA viruses, usually have copy-back genomes that can form base-paired 
panhandles.  To investigate this possibility, we assayed a sucrose gradient-purified 
preparation of each virus for (i) the number of infectious particles, measured by limiting 
dilution assay, and (ii) the relative copy number of genomic plus antigenomic RNA, 
measured by real time RT-PCR with primers specific to the trailer region that would be 
present in both standard and defective genomes.  We then calculated the ratio of 
infectious particles to genome/antigenome copies for each virus, and then normalized 
these ratios to that of the F170S virus, which was assigned the value of 1.0.  The resulting 
values were: F170S, 1.0; WT, 0.28; and P(C-), 0.09.  In other words, F170S HPIV1 had 
the highest ratio of infectious particles to genome copies, and P(C-) had the lowest, with 
WT HPIV1 being intermediate.  This lack of a consistent trend, i.e. the F170S virus had a 
higher ratio of infectious particles to genome/antigenome copies than the WT virus and 
yet the F170S virus led to dsRNA accumulation whereas the WT virus did not,  suggests 
that the dsRNA produced during infection with the F170S and P(C-) viruses probably 
cannot be attributed to the presence of  a disproportionately high content of defective-








Mutation or deletion of the HPIV1 C proteins results in increased viral RNA synthesis 
and decreased accumulation of viral proteins 
Another potential source for intracellular dsRNA could arise from annealing between 
incompletely encapsidated negative sense genomic RNA and either positive sense 
antigenomic RNA or mRNA, which might occur if mutation or deletion of the C proteins 
perturbed viral RNA production.  We therefore used real-time RT-PCR to monitor viral 
RNA accumulation in A549 cells infected with the WT, F170S and P(C-) viruses.  The 
combined amount of genomic plus antigenomic RNA was quantified using primer/probes 
specific for the trailer region (Fig. 5a), whereas the N and P mRNAs (Fig. 5b and c, 
respectively) were quantified using oligo-dT for reverse transcription followed by gene-
specific primer/probes for PCR.  In cells infected with WT HPIV1, the levels of 
genome/antigenome, N mRNA, and P mRNA rose gradually over the time-course of the 
experiment (Fig. 5a-c).  For the F170S mutant, the levels of these RNAs were similar to 
those of WT HPIV1 at 24 h, but then increased substantially by 48 h.  A very different 
pattern was observed during infection with P(C-) virus.  The amount of 
genome/antigenome was higher than for the other two viruses at 24 h, and continued to 
increase to a very high level at 48 h (Fig. 5a).  In contrast, the levels of N and P mRNAs 
were extremely high at 24 h, but thereafter dropped sharply (Fig. 5b).  In addition, the 
relative levels of intracellular genomic versus antigenomic HPIV1 RNA were measured 
by reverse transcription with positive- or negative-sense primers, to prime genomic or 
antigenomic RNA, respectively, followed by real-time PCR (Supplementary Fig. 3).  
This showed that the ratio of genomic RNA to antigenomic RNA (average ratio 17:1) 
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was similar for each virus at each time point (Supplementary Fig. 3) and, thus, was not 
detectably perturbed by mutation/deletion of the C protein.  
 
Figure 5. Viral RNA and protein expression over time during infection with WT and 
mutant HPIV1.  A549 cells were infected with WT, F170S, or P(C-) HPIV1 at a MOI of 
5 for 12, 24, or 48 h.  Relative amounts of HPIV1 (A) combined genomic and anti-
genomic RNA, (B) N mRNA, and (C) P mRNA were measured by real-time PCR.  The 
values were normalized to the 12 h time point for WT HPIV1, which was assigned the 
value of 1.0.  (D) HPIV1 N, C, and P proteins were detected by Western blot from 
samples collected in parallel to the samples in A-C.  Shown is a representative of two 
independent experiments with similar results.  (E) A549 cells were infected with F170S 
HPIV1 at a MOI of 5 for 24, 30, 36, 42, or 48 h.  The C and P proteins were detected by 
Western blot.  P denotes the position of the P protein, n.s. indicates a non-specific band, 






We also monitored the accumulation of cell-associated viral proteins in the time-course 
experiment described above by Western blot analysis (Fig. 5d).  WT-infected cells 
contained higher levels of N and P protein at both 24 and 48 h compared to the mutant 
viruses, which was surprising since WT-infected cells contained the lowest levels of N 
and P mRNA (Fig. 5d).  In contrast, although P(C-)-infected cells contained the highest 
levels of genomic/anti-genomic RNA at both time points and very high levels of N and P 
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mRNAs at 24 h, they contained the lowest levels of N and P protein at both time points 
(Fig. 5a-d).  Similarly, F170S-infected cells contained much less N and P protein than 
WT-infected cells despite higher levels of N and P mRNA.  Lysates from WT-infected 
A549 cells also contained a major band of C´ protein, which is the most abundant of the 
HPIV1 C proteins.  As expected, no C proteins were detected with P(C-) HPIV1 
infection.  The C´ protein also was detected in lysates from F170S-infected cells at 24 h 
but, as with the N and P proteins, in lower abundance compared to WT HPIV1.  
Interestingly, however, the C’F170S protein was not detected at 48 h.  We further 
investigated the kinetics of accumulation of the C’F170S protein in additional time course 
experiments.  This showed that the C’F170S protein was present at 12 and 24 h post-
infection (not shown).  However, beginning at 30 h post-infection, the level of C’F170S 
protein began to decline until it was no longer detectable by 42 h (Fig. 5e).  In this 
experiment, the level of the P protein expressed by F170S HPIV1 also decreased with 
time coincident with the appearance of a smaller P-specific band that might be a 
degradation product (Fig. 5e).  
 
These observations indicated that HPIV1 RNA synthesis indeed was perturbed by 
mutation and, in particular, deletion of the C protein.  These observations also indicate 
that viral protein synthesis was inhibited in cells infected with F170S and P(C-) HPIV1. 
The increased production of viral RNA by F170S and P(C-) HPIV1, in the context of 
reduced levels of N and P protein necessary for encapsidation, could provide for the 
accumulation of incompletely encapsidated genome capable of annealing with positive 




HPIV1 infection and dsRNA accumulation induce PKR activation 
Since dsRNA was highly abundant during infection with P(C-) and F170S HPIV1 at 24 
and 48 h respectively, we examined PKR activation at these same time points.  When 
bound to dsRNA, PKR is activated by autophosphorylation.  Activated PKR can 
phosphorylate EIF2A, resulting in an inhibition of translational initiation (70) that 
potentially could contribute to the reduced accumulation of viral proteins in cells infected 
with F170S and P(C-) HPIV1.  Consistent with this idea, we found that both F170S and 
P(C-) HPIV1 induced PKR autophosphorylation and EIF2A phosphorylation, with 
kinetics mirroring those of dsRNA accumulation (Fig. 4e, f and Fig. 6).  Specifically, 
P(C-) HPIV1 infection induced activation of PKR by 24 h, and F170S HPIV1 infection 
induced activation of PKR by 48 h.  In addition, infection with either mutant strongly 
induced the expression of MDA5, a highly IRF and IFN-inducible gene (Fig. 6).  The 
expression of the C´ and C proteins was observed at 24 and 48 h in cells infected with 
WT HPIV1, and were not expressed by P(C-) HPIV1, as expected.  Consistent with the 
results in Fig. 5d, both species were present in F170S-infected cells at 24h, and their 
accumulation greatly decreased by 48 h (Fig. 6).  Thus, infection with F170S and P(C-) 
HPIV1 activated PKR and phosphorylated EIF2A, which might contribute to the reduced 
accumulation of viral proteins.  However, this may not be a complete explanation for the 
reduced accumulation of viral proteins in the case of F170S HPIV1, since there was little 
activation of PKR and EIF2A at 24 h (Fig. 6), a time when the reduction in protein 
accumulation was already evident (Fig. 5d and 6).  
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Figure 6. PKR activation during infection with WT and mutant HPIV1.  A549 cells were 
infected with WT, F170S, or P(C-) HPIV1 at a MOI of 5 for 24 or 48 h.  PKR 
phosphorylation, total PKR, EIF2A phosphorylation, total EIF2A, total MDA5, and C 
proteins were detected by Western blot.   
 
 
PKR contributes to HPIV1-induced IFN induction as well as the reduced accumulation of 
viral proteins 
We examined the effects of PKR activation using stable PKR knockdown 293 cells, in 
which expression of PKR expression was strongly reduced, although not completely 
blocked, due to the constitutive expression of a shRNA specific to PKR.  PKR 
knockdown significantly reduced IFNβ expression in F170S- and P(C-)-infected cells by 
6.2 and 10.1-fold, respectively (Fig. 7).  This reduction in IFNβ expression corresponded 
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with a reduction in IRF3 phosphorylation (3.1 and 3.4-fold, respectively) (Fig. 8a; see 
Supplementary Fig. 4a for quantitation).  IκBβ degradation was only slightly reduced 
(1.3 and 1.6-fold, respectively) in PKR knockdown cells (Fig. 8a; see Supplementary 
Fig. 4b for quantitation).  P38 phosphorylation was similar in control and PKR 
knockdown cells (Fig. 8a; see Supplementary Fig. 4c for quantitation).  In the mock-
infected cells, the expression of PKR in the knockdown cells was 25% that of the control 
knockdown cells (Fig. 8a; see Supplementary Fig. 4d for quantitation).  Interestingly, 
PKR knockdown also reversed the decrease in the accumulation of C’F170S between 24 
and 48 h, an effect that was not observed with the wild-type C' protein (Fig. 8a; see 
Supplementary Fig. 4e for quantitation).  These findings indicated that the reduction in 
viral protein synthesis in normal cells infected with the C mutant viruses (e.g., Fig 5d, e, 
and Fig. 6) indeed is linked to PKR activity.  Since PKR is an IFN-inducible gene 
product, the induction of additional PKR due to IFN-mediated signaling could contribute 
to the loss of viral protein expression during infection with the mutant HPIV1 viruses.  
Indeed, we found that the decrease in C’F170S protein expression could be partially 










Figure 7. IFNβ expression induced by infection with WT and mutant HPIV1 during PKR 
knockdown. Stable 293 cells expressing small hairpin RNAs shPKR and control shCON 
were infected with WT, F170S, or P(C-) HPIV1 at a MOI of 5 for 48 h.  IFNβ expression 
was measured by real-time PCR and normalized to mock infected shCON cells.  * 














Figure 8. Effect of PKR on activation of the components of the IFNβ enhanceosome and 
accumulation of the C protein in HPIV1 WT and mutant virus-infected cells.  (A) Stable 
shPKR-expressing and control shCON 293A cells were infected with WT, F170S, or 
P(C-) HPIV1 at a MOI of 5 for 48 h.  Phosphorylated IRF3, total IRF3, total IκBβ, 
phosphorylated P38, total P38, total PKR, and C proteins were detected by Western blot.  
(B) Type I IFN affects C’ protein expression during HPIV1 infection.  A549 cells were 
infected with F170S HPIV1 at a MOI of 5.  At 12 h post-infection, neutralizing 
antibodies against IFNα (5000 NU/mL) and IFNβ (2000 NU/mL) were added.  C protein 






We had previously demonstrated that infection with C mutant HPIV1s (F170S and P(C-
)), but not WT HPIV1, effectively stimulated IFNβ production in epithelial cells (192).  
F170S, but not WT, HPIV1 triggered IRF3 dimerization and nuclear translocation, 
indicating that the wild-type C proteins block the activation of IRF3 (192).  In the present 
study, the mechanisms by which the C proteins prevent IFNβ induction were explored in 
more detail.  Since IFNβ production is induced optimally by the assembly of an 
enhanceosome comprised of IRF3, NF-κB, and AP-1 at the IFNβ promoter, the 
activation of these transcription factors during HPIV1 infection was examined first.  
Infection with HPIV1 containing a single point mutation in C (F170S) or lacking 
expression of the C proteins (P(C-)) triggered IRF3 and NF-κB activation, whereas WT 
HPIV1 inhibited activation of these two critical components of the IFNβ enhanceosome.  
Although crystal structures of ATF-2 and c-Jun bound to PRD IV of the IFNβ promoter 
are known, their contribution to the induction of a type I IFN response is less well 
understood (142).  ATF-2 and c-Jun can be phosphorylated and activated by P38 and 
JNK; however, we found that WT, F170S, and P(C-) HPIV1 did not induce P38 
phosphorylation or ATF-2 phosphorylation.   
 
Numerous examples of viral proteins that antagonize IFNβ production by interacting with 
various proteins in the RIG-I/MDA5 pathway have been described (19).  For instance, the 
influenza NS1 protein inhibits RIG-I activation by binding to TRIM25 and the hepatitis C 
NS3/4A protease cleaves and inactivates MAVS (44, 116).  In this context, we initially 
hypothesized that the HPIV1 C proteins acted to inhibit IFNβ production by binding or 
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otherwise interfering with one or more components of the RIG-I/MDA5 pathway.  
Surprisingly, however, several observations made during the present study speak against 
this hypothesis.  First, we were unable to immunoprecipitate the HPIV1 C proteins with 
any of the known members of the RIG-I/MDA5 pathway that we examined.  In addition, 
we did not observe a significant decrease in abundance or a shift in the gel mobility of 
any of these host proteins, suggesting that the C proteins do not promote their 
modification or degradation.  Finally, the HPIV1 C proteins, supplied in trans, failed to 
block IFNβ induction by two heterologous inducers, RSV and poly I:C, which are known 
to signal through RIG-I and MDA5, respectively.  Specifically, while infection with WT 
HPIV1 was able to efficiently block IFNβ induction in response to a super-infection with 
P(C-) HPIV1, it was unable to do so against super-infection with a RSV mutant that does 
not express the RSV NS1 and NS2 IFN antagonist proteins (Fig. 2a).  Similarly, 
expression of the C proteins in an inducible cell line was able to efficiently block IFNβ 
induction in response to super-infection with P(C-) HPIV1, but failed to prevent poly I:C-
induced MDA5-mediated IFNβ expression (Fig. 2b, c).  The inability of the HPIV1 C 
proteins to prevent induction in response to these heterologous inducers suggested that 
they do not antagonize the components of the IFN production pathway at or downstream 
of RIG-I and MDA5.  On the other hand, the ability of the C proteins to inhibit IFNβ 
induction in the context of an HPIV1 infection suggested that their effect is specific to 
HPIV1.  
 
Because the C proteins appeared to disrupt type I IFN production without interacting with 
key members of the RIG-I/MDA5 pathway, we wanted to confirm that IFNβ induction by 
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C mutant HPIV1 viruses did indeed depend on this pathway.  Using murine knockout 
cells, we found that knockout of TBK1 and IKKε completely ablated the IFNβ response 
to F170S and P(C-) HPIV1 infection, confirming that the RIG-I/MDA5 pathway 
mediates IFNβ production for these two viruses.  In addition, it was found that IFNβ 
induction relied more strongly on MDA5 than on RIG-I.  This is in contrast to the 
original suggestion that recognition of paramyxovirus infection depends mainly on RIG-I 
whereas MDA5 is dispensable (67, 98, 119, 179).  Several more recent studies with SeV 
indicated that both RIG-I and MDA5 can contribute to IFNβ production in vitro or to 
resistance in vivo (53, 217).  However, these previous findings cannot be readily 
extrapolated to HPIV1, because SeV, but not HPIV1, also expresses a V protein, a known 
inhibitor of MDA5 (3, 22, 53, 179, 217).  Since MDA5 primarily recognizes long dsRNA 
molecules (or, more specifically, webs of dsRNA and ssRNA (148)), its involvement in 
IFNβ expression during infection with F170S and P(C-) HPIV1 implied that dsRNA was 
involved.  
 
A striking abundance of cytoplasmic dsRNA was observed in both F170S- and P(C-)-, 
but not WT-, infected cells.  Earlier studies had reported large amounts of dsRNA after 
infection with positive-strand RNA viruses, double-strand RNA viruses, and DNA 
viruses but not with negative-strand RNA viruses (113, 177, 199, 201).  However, more 
recently, dsRNA accumulation was detected in cells infected with a C deletion mutant of 
SeV (181).  We did not detect appreciable amounts of dsRNA after infection with WT 
HPIV1, consistent with expectations (62).  In contrast, infection with the P(C-) mutant 
that completely lacks C expression led to a relatively rapid accumulation of cytoplasmic 
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dsRNA that was readily detected by 24 h but subsequently decreased, and infection with 
the F170S virus that makes a mutated C protein led to a relatively slower accumulation of 
dsRNA that was detected in only a few cells at 24 h but increased substantially by 48 h.  
Thus, HPIV1, a negative-strand RNA virus, does indeed have the capacity to produce 
dsRNA, and functional C proteins are required during infection to prevent the 
accumulation of dsRNA that would otherwise trigger a potent host innate antiviral 
response.   
 
The appearance of dsRNA was temporally associated with the activation of PKR, which 
in turn was associated with a reduction in viral protein accumulation.  Infection by P(C-) 
and F170S HPIV1 was accompanied by autophosphorylation of PKR, phosphorylation of 
EIF2A, and decreased accumulation of the N, P, and C (in F170S-infected cells) proteins.   
C protein expression in F170S-infected cells was robust at 24 h but diminished at 30 h 
and was difficult to detect from 36 h onwards.  PKR knockdown studies indicated that 
PKR is a major contributor to the loss of CF170S from 24 h post-infection onwards.  The 
decrease in C protein synthesis late during infection would render the F170S HPIV1 
infection functionally similar to a P(C-) HPIV1 infection, i.e. yield a virus unable to 
accumulate needed amounts of C protein, and this gradual loss of C proteins in F170S 
HPIV1 infection accounts for the difference in the kinetics of dsRNA formation between 
these two mutants.  In addition to its role in inhibiting translation during viral infection, 
PKR has also been implicated in NF-κB activation, IRF1 activation, and IFN induction 
by poly I:C via MAVS, effects that are independent of its kinase activity and that provide 
another mechanism of innate antiviral host defense mediated by PKR (4, 16, 25, 107, 
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124, 209, 218).  Infection with SeV lacking the entire C gene led to the generation of a 
large amount of dsRNA with subsequent PKR activation and inhibition of translation 
(181).  In addition, infection with a measles virus mutant lacking the C gene required 
PKR for maximal IFNβ induction (125).  Our data indicated that PKR contributed 
significantly to the induction of IFNβ and, more specifically, IRF3 phosphorylation 
following infection with HPIV1 mutants that generated dsRNA.  Thus, MDA5 and PKR 
each contribute to the generation of IFNβ during infection with C mutant HPIV1s, and 
the generation of dsRNA in F170S- and P(C-)-infected cells is the likely trigger for these 
two RNA sensors.  
 
To investigate the mechanisms underlying the generation of dsRNA during infection with 
the HPIV1 mutants, we monitored viral RNA levels in infected A549 cells.  Compared 
with WT-infected cells at 24 h post-infection, cells infected with the P(C-) mutant had 
greatly increased accumulation of genomic and anti-genomic RNA and viral mRNA.  
Similar findings were made for the F170S mutant, although the increases in viral RNA 
accumulation were delayed, consistent with the observed delay in dsRNA accumulation 
compared to the P(C-) mutant.  These results indicate that deletion or mutation of the 
HPIV1 C proteins resulted in a substantial perturbation of viral RNA synthesis.  We 
suggest that the increased accumulation of genomic and anti-genomic RNA in the context 
of reduced availability of N and P protein led to unencapsidated RNAs that could anneal 
with each other or with excess viral mRNA to form dsRNA.  The C proteins of SeV have 
been previously implicated in inhibiting viral RNA synthesis and regulating the balance 
between genome and anti-genome levels (33, 80, 81).  Interestingly, one study reported 
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that infection of primate LLC-MK2 and Vero cells with a C deletion SeV led to a 
predominance of anti-genomic RNA compared to genomic RNA and to an increase in 
viral protein synthesis (81).  In contrast, our results differ in two ways: first, the 
accumulation of viral proteins was decreased rather than increased, and, second, deletion 
of the HPIV1 C proteins did not alter the ratio of viral genomic RNA to anti-genomic 
RNA.  These findings suggest that the HPIV1 C proteins prevent the host innate response 
by modulating the production of viral RNA rather than directly inhibiting the RIG-
I/MDA5 pathway.  These results also may provide an alternative explanation for the 
observation that a recombinant SeV expressing HPIV1 C in place of SeV C failed to 
block IRF3 activation in murine cells (22).  This originally was interpreted to indicate 
that the respirovirus C proteins, like the rubulavirus V protein, is a determinant of host 
range (22).  However, it may be that the HPIV1 C proteins do not function efficiently in 
the context of the heterologous SeV N, P, and L proteins to prevent the accumulation of 
dsRNA and subsequent IRF3 activation.  
  
It is not clear whether PKR- and IFNβ-induced inhibition of protein synthesis can fully 
account for the reduced accumulation of viral proteins during infection with the HPIV1 
mutants.  For example, in cells infected with the F170S mutant, the levels of N and P 
protein were reduced compared to WT-infected cells even at 24 h, a time point before the 
activation of PKR was detected.  Also, while the extremely high accumulation of 
genomic and anti-genomic RNA with the P(C-) mutant could be imagined to outpace the 
synthesis of N and P protein and thus initiate the dsRNA formation resulting in PKR 
activation and IFNβ induction, this seemed less likely for the F170S mutant, since the 
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increase in RNA accumulation was more gradual.  Thus, there may be an additional host 
inhibitory effect on viral protein accumulation that is unleashed by deletion/mutation of 
the C proteins or, alternatively, the C proteins may have a positive effect on viral protein 
synthesis.  Further studies to explore these two alternative mechanisms of regulating viral 
protein synthesis are clearly needed. 
 
Our results indicate that the wild-type C proteins regulate viral RNA synthesis to prevent 
the production of dsRNA that would otherwise activate MDA5 and PKR which, in turn, 
would activate IRF3 and NF-κB, result in the induction of IFNβ, and inhibit protein 
synthesis.  We propose that the following series of events occur during infection with 
P(C-) HPIV1 (summarized in Table 1).  dsRNA is generated early, within the first 24 h 
of infection, due to the combined rapid increase of mRNA, genomic RNA, and anti-
genomic RNA.  The dsRNA activates PKR and also induces IFNβ.  PKR activation and 
IFNβ induction decrease viral protein synthesis, thereby maintaining low levels of N 
protein.  IFNβ might also inhibit protein synthesis by the induction of inhibitors such as 
IFIT1 and IFIT2 (187).  In addition, apoptosis is activated early in P(C-)-infected cells, 
but the mechanism underlying this induction remains undefined (9).  The combined 
effects of PKR activation, IFNβ induction, and the initiation of apoptosis are likely 
responsible for the peak and subsequent decline in viral macromolecular synthesis 
observed between 24 and 48 h after infection with P(C-) HPIV1.  The events occurring 
during infection with the F170S mutant represent a delayed version of what is observed 
following infection with P(C-) HPIV1.  The more gradual increase in transcription and 
replication of viral RNA in F170S-infected cells delays the formation of dsRNA until 
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between 24 and 48 h, at which time PKR is activated and IFNβ is induced.  The PKR-
mediated loss of C protein accumulation in F170S-infected cells likely contributes to the 
increase of transcription seen at 48 h since C is an inhibitor of viral transcription.  A more 
detailed analysis of the kinetics of viral and host cell RNA and protein synthesis in WT 




In summary, our initial working hypothesis that the HPIV1 C proteins inhibit IFNβ 
induction via a direct inhibition of the RIG-I/MDA5 pathway was not confirmed. Instead, 
we found that the HPIV1 C proteins regulate viral RNA synthesis to prevent the 
formation of dsRNA that otherwise triggers host antiviral responses, such as PKR 
activation and IFNβ induction.  MDA5 was found to be a more important sensor than 
RIG-I for infection with these dsRNA-generating HPIV1 mutants.  The kinetics of 
dsRNA accumulation and decreased expression of mutant C proteins suggest that a race 
between the evasion of host antiviral responses and the elimination of viral antagonists of 






HPIV1 was first discovered by Robert Chanock in 1959, but, after over 50 years, it 
remains an uncontrolled respiratory pathogen that continues to plague infants, children 
and even adults, in particular the elderly, nursing home residents, and the 
immunocompromised (23, 29).  There are currently no antiviral agents with proven 
efficacy against HPIV1.  Instead, the management of croup and other more severe 
manifestations of lower respiratory disease caused by HPIV1 is merely supportive.  
Furthermore, although vaccine development began in the 1960s, there is currently no 
licensed vaccine against HPIV1 (24, 133).  To date, non-living inactivated and subunit 
vaccines have failed to confer protection against upper and lower respiratory disease in 
humans and none are currently in clinical trials (24, 43, 133).  However, two live-
attenuated vaccine candidates against HPIV1 are currently being tested in phase 1 clinical 
trials.  One candidate is an unmodified Sendai virus that is administered intrasnasally as a 
HPIV1 vaccine (171).  The only other vaccine candidate against HPIV1 (rHPIV1-
CR84G/Δ170 HNT553A LY942A) was developed by this lab using reverse genetics (7).  The 
polymerase mutation LY942A was first identified in HPIV3cp45 and confers a temperature-
sensitive phenotype so that virus replication is permissive in the cooler upper respiratory 
tract but restricted in the warmer lower respiratory tract (126).  This HPIV1 mutant virus 
was restricted in replication by ≥ 100-fold compared to WT HPIV1 when the temperature 
was increased from 32°C to 39°C, the viral shut-off temperature (7).  The other 
attenuating mutations, CR84G and CΔ170, each interfere with the virus’ ability to antagonize 
the host antiviral response (192).  Although the HPIV1 C proteins are non-essential for 
viral replication in vitro, complete ablation of C protein expression results in a virus that 
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barely replicates in non-human primates and is over-attenuated as a vaccine candidate 
(9).  However, the C proteins can be mutated by reverse genetics to incrementally 
attenuate HPIV1 in order to develop vaccine candidates that possess an acceptable 
balance between attenuation and immunogenicity (9).  The C proteins are important 
virulence factors that play a key role in modulating the host response to HPIV1 infection.  
In the studies described here, we sought to examine the mechanisms by which the wild-
type HPIV1 C proteins prevent a potent innate antiviral immune response and to 
investigate the mechanisms by which mutating or deleting the C proteins leads to 
attenuation.    
 
To address these questions, we first created by reverse genetics a virus named P(C-) 
HPIV1 in which expression of the C proteins was silenced.  We found that the complete 
lack of C protein expression significantly restricted viral replication and induced type I 
IFN production during infection.  Using microarray-based transcriptional profiling, we 
found that the C proteins controlled the transcription of a broad array of genes in human 
respiratory epithelial cells.  Additionally, we found that the global gene expression profile 
induced during infection with F170S HPIV1 was surprisingly similar to P(C-) HPIV1.  
We applied a bioinformatics analysis and identified a significant over-representation of 
IRF and NF-κB binding sites among many of the C protein-responsive genes.  We also 
determined that the main components of the type I interferon (IFN) response activated 
upon infection with the C mutant HPIV1 viruses indeed consisted of IRF3 and NF-κB.  
We initially hypothesized that the C proteins might interact with a host factor in the RIG-
I/MDA5 pathway to prevent IRF3 and NF-κB activation and IFNβ induction during 
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infection with WT HPIV1.  Numerous examples of viral proteins that antagonize IFNβ 
production by this very mechanism had previously been described.  For instance, the 
influenza NS1 protein inhibits RIG-I activation by binding to TRIM25 and the hepatitis C 
NS3/4A protease cleaves and inactivates MAVS (44, 116).  Thus, we attempted to search 
for a host factor in the RIG-I/MDA5 pathway that might also interact with the C proteins.   
However, we made two key observations that contradicted this initial hypothesis.  First, 
we were unable to immunoprecipitate the HPIV1 C proteins with any of the known 
members of the RIG-I/MDA5 pathway that we examined.  Additionally, the HPIV1 C 
proteins, supplied in trans, failed to block IFNβ induction by two heterologous inducers, 
RSV and poly I:C, which are known to signal through RIG-I and MDA5, respectively.  
The inability of the HPIV1 C proteins to prevent IFNβ induction in response to these 
heterologous inducers suggested that they do not antagonize the components of the IFN 
production pathway at or downstream of RIG-I and MDA5.  On the other hand, the 
ability of the C proteins to inhibit IFNβ induction in the context of an HPIV1 infection 
suggested that their effect was specific to HPIV1.   
 
Even though the C proteins did not appear to interfere with the signaling pathway leading 
from RIG-I/MDA5 activation to IFNβ induction, we sought to determine whether the 
IFNβ induced during infection with the HPIV1 C mutant viruses occurred through the 
RIG-I/MDA5 pathway.  With the use of knockout MEFs, we discovered that 
IFNβ induction by infection with the HPIV1 C mutant viruses relied mainly on MDA5.  
As a result, we began to suspect that HPIV1-induced IFNβ expression might also involve 
dsRNA, the substrate for MDA5 activation.  We decided to test for the presence of 
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dsRNA in cells infected with the HPIV1 C mutants, even though previous reports 
suggested that dsRNA was absent in cells infected with other negative sense RNA 
viruses, including influenza, La Crosse, Sendai, and Newcastle disease (199).  To our 
surprise, we discovered a striking accumulation of dsRNA in response to infection with 
the HPIV1 C mutants.  We then began to explore the mechanisms by which the C 
proteins of WT HPIV1 suppress the accumulation of dsRNA by examining viral RNA 
and protein synthesis.  We were surprised to find that infection with viruses in which C 
protein function was compromised led to increased levels of viral RNA species and 
decreased N protein levels, creating an imbalance between the N protein-to-genomic 
RNA ratio and thereby potentially permitting dsRNA accumulation.  The formation of 
dsRNA would then trigger MDA5 activation and IFNβ production and also PKR 
activation and an inhibition of further protein synthesis (Figure 1).  
 
Figure 1. Diagrammatic representation of the steps leading to dsRNA accumulation and 
activation of the MDA5 and PKR pathways during infection with P(C-) HPIV1 but not 
with WT HPIV1.  The red lines represent the negative sense viral genome and the blue 
lines represent the positive sense viral antigenome or viral mRNA.  On the left panel, WT 
HPIV1 attaches, enters, and introduces its negative sense genome into the cytoplasm of 
the infected cell.  The antigenome serves as a template for the production of more 
genome and mRNA.  The mRNAs are translated by the ribosome to produce viral 
proteins, including the C proteins and the N proteins.  Encapsidation by the N protein 
shields genomic and antigenomic RNAs from recognition by intracellular sensors of 
dsRNA.  As a result, the dsRNA binding proteins MDA5 and PKR which are present 
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constitutively at low levels in the cytoplasm remain latent, the transcription factors IRF3 
and NF-κB remain in the cytoplasm and do not induce IFNβ expression, and EIF2A does 
not inhibit translation.  On the right panel, the absence of C proteins during P(C-) HPIV1 
infection leads to dysregulated viral RNA synthesis, i.e. increased production of negative 
sense genome and positive sense antigenome and mRNA.  The formation of dsRNA webs 
(symbolized by a spider web) triggers MDA5 and PKR activation.  MDA5 activates the 
transcription factors IRF3 and NF-κB and induces IFNβ expression.  PKR activates 
EIF2A which inhibits the translation of viral mRNAs and may limit the amount of N 
protein available to encapsidate the genome and antigenome.  The increase in viral RNA 
levels in the context of decreased N protein levels would further amplify the formation of 






The N protein has long been thought to function as a highly stable and ribonuclease 
resistant nucleocapsid coat that protects the viral genome and antigenome from nuclease 
digestion (100).  In the present study, we also found an association between the amount 
of N protein present and the accumulation of dsRNA.  HPIV1 genome replication and 
mRNA transcription are normally tightly coupled to the amount of available N protein to 
allow sufficient encapsidation of the genome and antigenome, and this process may 
become dysregulated in the absence of the C proteins.  The exact molecular mechanisms 
by which the HPIV1 C proteins maintain a balance between N protein levels and viral 
RNA synthesis to prevent the formation of immunostimulatory dsRNA remain to be 
determined.  The C proteins of murine PIV1 (SeV) were found to inhibit viral mRNA 
transcription in an in vitro transcripton system in which the P and L proteins are 
combined with RNA templates (33, 97, 110).  Furthermore, the SeV C proteins 
suppressed viral RNA synthesis from defective-interfering genomes in a promoter-
specific manner (21).  In particular, ablation of C protein expression during SeV infection 
led to a disproportionate increase in positive sense antigenomic RNA compared to 
negative sense genomic RNA (81).  Thus, it was postulated that a ratio of genomic to 
antigenomic RNA skewed towards greater levels of positive sense antigenomic RNA was 
a potential catalyst for dsRNA formation (81).  However, we found that, for HPIV1, 
deletion of the C proteins increased viral RNA synthesis but did not alter the ratio of viral 
genomic to antigenomic RNA.  We also observed decreased levels of viral protein, 
including N protein, during infection with P(C-) HPIV1.  Importantly, an infection with 
HPIV1 that does not express the C proteins induces the formation of dsRNA which 
triggers PKR and EIF2A activation and inhibits protein synthesis.  This suggests that the 
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extremely rapid and high accumulation of viral RNA might outpace the synthesis of N 
protein thereby triggering and further amplifying dsRNA formation.  Notably, one report 
has suggested that the SeV C proteins suppress viral RNA synthesis via an interaction 
with the L polymerase (75).  We have found preliminary evidence that the C proteins co-
localize with the N protein but not the P protein in cells infected with WT HPIV1 (not 
shown).  Whether the HPIV1 C proteins interact with and alter the function of the viral 
replication complex or with an as yet unidentified host factor remains to be seen.  The 
proximity of the C proteins to the N and L proteins may serve an important role in 
coupling viral RNA synthesis with encapsidation.    
 
The study of the HPIV1 C proteins has yielded unexpected insights into how HPIV1 can 
cause disease in children.  A better understanding of the mechanisms by which the C 
proteins control the balance between RNA and protein synthesis and interfere with innate 
immunity will require further study.  In summary, the HPIV1 C proteins are clearly 
multifunctional and much work to define their functions remains to be done.  However, 
significant progress has been made in the understanding of HPIV1 pathogenesis and in 
the development of a safe and efficacious vaccine against HPIV1.      
 




Supplementary Information for Chapter 3 
Figure S1. Venn diagram comparison of the 2421 genes and the 1600 genes significantly 
differentially expressed compared to mock during CF170S infection or P(C-) infection, 
respectively. Table 1 shows the expression of 10 representative genes from this Venn 
diagram that were not shared between the two C mutant infections. The expression of the 










Figure S2. Principal component analysis of experimental conditions using all genes on 
the microarrays and mean centering to examine the level of similarity between each 
condition. Each point represents a specific condition (virus and time point post-infection). 
The distance between points indicates the level of similarity between the conditions based 
on the expression of all genes on the array.  All genes were included in this analysis so 
that this analysis is not biased by any specific fold change or statistical selection criteria. 
The axes are eigenvectors, and the first eigenvector (x-axis) passes through the mean, 
minimizes the sum squared error for each point, and describes the direction of maximum 
variance. The eigenvalues represent the level of variance for each eigenvector. Overall 
gene expression during P(C-) and CF170S infection was highly similar. Both C mutant 
viruses induced gene expression patterns that were significantly different compared to 





Figure S3. Hierarchical clustering and functional analysis of 28 genes that differed 
















Figure S4. Differential gene expression between CF170S and P(C-) infection of A549 
cells. An alternative analysis identified 18 genes by a two-way ANOVA with multiple 
testing correction (see Table S7) that were significantly different between the two C 
mutant viruses. Expression ratios between CF170S and P(C-) for these 18 genes were 
plotted on a log2 scale to give a visual representation of the kinetics and magnitude of any 
differences in the transcriptional response between the two C mutant viruses. A ratio of 0 
indicates that there is no difference, negative values indicate that the expression with 
CF170S is lower compared to P(C-), and positive values indicate that the expression with 
CF170S is higher compared to P(C-). The dotted lines denote a 4-fold difference. The 
majority of genes were only different by slightly greater than 4-fold. However, a kinetic 
shift in the transcriptional profile can be observed after 24 h p.i. Up to 24 h p.i., gene 
expression during CF170S infection is, in general, lower than that during P(C-) infection. 
These differences do not persist at 48 h p.i., and both viruses approach equivalent 
expression for this set of genes. However, a small but distinct set of genes appears at 48 h 
p.i. in which gene expression during CF170S infection is, in general, now greater than that 



















Figure S5. Replication of wt HPIV1, CF170S, and P(C-) in A549 cells. A549 cells were 
inoculated with sucrose purified viruses at a MOI of 5 TCID50/cell and supernatant was 
harvested for virus quantitation at 0, 6, 12, 24, and 48 h p.i. Photomicrographs taken at 48 
h p.i. show more extensive cytopathic effect in P(C-) infected A549 cells than in wt 












Figure S6. Gene expression profiles for all 14 transcription factors identified by 
bioinformatics analysis. The expression of 4 genes IRF1, ISGF3G, NF-κB1, and c-Rel 






Table S1. Genes differentially expressed by wt HPIV1 or IFNβ compared to mock infection*† 













A APOL1 apolipoprotein L1 isoform b precursor A_24_P87931 6.7 7.6 1.6 1.7 4.2 8.1 
  APOL4 apolipoprotein L4 isoform 1 A_23_P380857 6.2 7.9 1.4 1.7 5.1 7.2 
  APOL6 apolipoprotein L, 6 A_24_P941167 8.6 8.3 1.5 1.7 6.3 9 
  APOL6 apolipoprotein L6 A_23_P155052 13.5 7.2 0.9 1 2.2 6 
  APOL6 apolipoprotein L6 A_23_P155049 8.1 6.8 1.1 0.9 4.3 8.5 
  APOL6   A_24_P7594 7.3 10.3 0.9 1.5 6.8 11.3 
  B2M beta-2-microglobulin precursor A_23_P37441 1.7 5.5 0.7 0.7 1.4 4.6 
  BATF2 
basic leucine zipper transcription factor, 
ATF-like 2 A_23_P370682 8.8 14.8 0.9 1.1 3.3 8.3 
  BST2 bone marrow stromal cell antigen 2 A_23_P39465 8.2 21.5 1.3 2.6 3.5 10.6 
  BTC betacellulin A_23_P135722 2.3 5 1.5 1.4 1.4 2.7 
  C15orf48 hypothetical protein LOC84419 A_23_P26024 1.6 3.6 0.9 1.1 1.4 4.8 
  C1orf38 
basement membrane-induced gene 
isoform 1 A_23_P873 14.2 16.6 1.2 1.5 2.1 3.6 
  CASP1 caspase 1 isoform alpha precursor A_23_P202978 6.2 46.2 0.8 0.9 6.3 17.1 
  CD38 CD38 antigen A_23_P167328 1.4 6 0.8 1.1 1.3 5.4 
  CEACAM1 
carcinoembryonic antigen-related cell 
adhesion molecule 1 isoform 1 
precursor A_24_P382319 20.4 15.5 1.3 1.7 6.4 13.6 
  CEACAM1 
carcinoembryonic antigen-related cell 
adhesion molecule 1 isoform 2 
precursor A_23_P434118 2.8 4.6 0.9 1 3 7.9 
  CFB complement factor B preproprotein A_23_P156687 3 7.9 0.6 0.8 1.7 6.2 
  CTSS cathepsin S preproprotein A_23_P46141 2.1 4.4 0.9 1.1 1.4 3.3 
  DDX58 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide RIG-I A_23_P20814 28.7 32 1.3 1.6 4.1 27.3 
  DTX3L deltex 3-like A_24_P941912 6.1 7.1 0.8 1 2.7 4 
  DTX3L deltex 3-like A_23_P347040 9.8 8.6 0.9 1 2.1 4.1 
  EIF2AK2 
eukaryotic translation initiation factor 2-
alpha kinase 2 A_23_P142750 2.7 5.5 1.1 1.1 1.1 1.5 
  EMR1 
egf-like module containing, mucin-like, 
hormone receptor-like sequence 1 A_23_P27556 1.3 5.2 0.7 1.1 1.4 2.9 
  EXOC3L exocyst complex component 3-like A_23_P424734 1.3 4.5 0.9 1.3 1.8 4.9 
  GBP1 
guanylate binding protein 1, interferon-
inducible, 67kD A_23_P62890 57.4 82.6 1.1 1 14.3 64.2 
  GBP1 
guanylate binding protein 1, interferon-
inducible, 67kD A_32_P107372 48 41.4 1 1.3 18.1 70.7 
  GBP3 guanylate binding protein 3 A_24_P370702 8.4 11.1 1.2 1.1 6.2 14.4 
  GBP3 guanylate binding protein 3 A_23_P51487 10.8 17.2 0.6 0.7 8.4 17.6 
  GBP4 guanylate binding protein 4 A_24_P45446 7.2 20.1 0.7 1.3 3.4 32.7 
  HCP5   A_23_P111126 1 8.2 0.6 1.1 1.4 14.7 
  HERC5 hect domain and RLD 5 A_23_P110196 4.3 21.4 0.7 1.5 4.1 40 
  HLA-B 
major histocompatibility complex, class 
I, B A_23_P125107 1.5 5.2 0.8 0.9 1.2 4.2 
  HLA-B 
major histocompatibility complex, class 
I, B A_24_P113674 1.6 4.3 1 0.9 1.2 3.9 
  HLA-C 
major histocompatibility complex, class 
I, C precursor A_24_P298409 1.6 4.6 1.1 1.1 1.3 3.6 
  HLA-C MHC class I antigen A_23_P95917 1.5 4.6 0.9 0.9 1.3 3.5 
  HLA-C   A_23_P113716 1.5 4.3 1.1 1.1 1.3 3.5 
  HLA-E 
major histocompatibility complex, class 
I, E precursor A_32_P460973 2.5 4.3 1 1 1.4 2.5 
  HLA-E 
major histocompatibility complex, class 
I, E precursor A_24_P326082 2.2 4.2 0.8 0.8 1.1 2.8 
  HLA-F 
major histocompatibility complex, class 
I, F precursor A_23_P314024 1.6 5.2 0.9 1 1.3 5.7 
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  HRASLS2 HRAS-like suppressor 2 A_24_P364263 2 6.2 1.1 1.1 1.4 4.2 
  HRASLS2 HRAS-like suppressor 2 A_23_P105012 2.1 9.8 0.8 1.2 1.9 7.3 
  HSH2D hematopoietic SH2 domain containing A_23_P153372 6 10.6 1 1.2 1.5 3.7 
  IFI16 interferon, gamma-inducible protein 16 A_23_P160025 11.9 19.3 1 1 1.8 2.9 
  IFI16   A_23_P217866 11.3 16.7 1.2 1.1 1.6 2.6 
  IFI27 interferon, alpha-inducible protein 27 A_23_P48513 12.4 20.8 1.1 1.1 2.9 12.3 
  IFI27 interferon, alpha-inducible protein 27 A_24_P270460 9.8 12.5 1 1.3 2.4 11.3 
  IFI35 interferon-induced protein 35 A_23_P152782 2.4 7.8 0.8 0.8 1.5 2.1 
  IFI44 
interferon-induced, hepatitis C-
associated microtubular aggregate 
protein A_23_P23074 50.7 65.1 1 7 16.1 55.2 
  IFI44L histocompatibility 28 A_23_P45871 24.6 78.5 1 0.9 2.2 24.5 
  IFI6 
interferon, alpha-inducible protein 6 
isoform c A_23_P201459 14.3 45.5 1 1.4 2.7 10.4 
  IFIH1 
interferon induced with helicase C 
domain 1 A_23_P68155 16.7 30 1.2 3.3 8 53.8 
  IFIT1 
interferon-induced protein with 
tetratricopeptide repeats 1 isoform 2 A_23_P52266 32.1 35.9 4.8 14.5 11.2 33.2 
  IFIT3 
interferon-induced protein with 
tetratricopeptide repeats 3 A_23_P35412 81.5 108.1 0.8 4.1 15.8 73.4 
  IFIT5 
interferon-induced protein with 
tetratricopeptide repeats 5 A_24_P30194 6.1 6.4 1.1 1.1 1.5 4.3 
  IFIT5 
interferon-induced protein with 
tetratricopeptide repeats 5 A_23_P63668 5.4 5.5 1.3 1.3 1.5 3.8 
  IFITM1 
interferon induced transmembrane 
protein 1 (9-27) A_23_P72737 6.7 8 0.9 1.1 2.3 2.2 
  IL4I1 interleukin 4 induced 1 isoform 2 A_23_P502520 2.5 7.9 1.3 1 1.3 6.2 
  INDO indoleamine-pyrrole 2,3 dioxygenase A_23_P112026 10.6 39.4 1.1 1 21.3 71 
  IRF7 interferon regulatory factor 7 isoform d A_24_P378019 8.4 13.6 1 1.3 2 3.7 
  ISG15 
interferon, alpha-inducible protein 
(clone IFI-15K) A_23_P819 13.5 36.9 1.2 3.3 9.9 25.2 
  ISG20 interferon stimulated gene 20kDa A_23_P32404 2.2 6.5 0.9 0.9 1.8 8.2 
  ISGF3G 
interferon-stimulated transcription 
factor 3, gamma 48kDa A_23_P65442 14.1 11 1.4 1.9 6.9 6.2 
  LAMP3 
lysosomal-associated membrane 
protein 3 A_23_P29773 7.8 114.5 1.3 1.4 1.8 7.6 
  LAP3 leucine aminopeptidase 3 A_23_P18604 2.2 5.4 0.5 0.8 1 1.5 
  LGALS9 galectin 9 long isoform A_32_P452655 3.2 8.8 1.3 1.2 1.4 2.5 
  LMO2 LIM domain only 2 A_23_P53126 12.1 9.7 1 0.9 1.1 2.7 
  MX1 myxovirus resistance protein 1 A_23_P17663 22 30.4 1.3 2.2 7.8 14.4 
  MX2 myxovirus resistance protein 2 A_23_P6263 18.5 74.3 1.6 1.2 3 5.5 
  NMI N-myc and STAT interactor A_23_P154235 2.7 6.2 0.9 0.8 1.6 3.1 
  NT5C3 5'-nucleotidase, cytosolic III isoform 2 A_23_P59547 1.7 4.3 0.9 0.9 1.2 1.5 
  OAS1 
2',5'-oligoadenylate synthetase 1 
isoform 2 A_23_P64828 5.1 8.8 1 0.9 1.5 4.1 
  OAS2 
2'-5'-oligoadenylate synthetase 2 
isoform 1 A_23_P204087 10.5 30 0.7 0.8 1 3.7 
  OAS3 2'-5'oligoadenylate synthetase 3 A_23_P47955 3.9 17.6 1 1.1 1.7 5.1 
  OAS3 2'-5'oligoadenylate synthetase 3 A_24_P335305 2.9 10.3 0.8 0.9 1.4 3.5 
  OASL 
2'-5'-oligoadenylate synthetase-like 
isoform a A_23_P139786 40.8 49.6 2.4 24.5 33.3 58.9 
  PARP12 
zinc finger CCCH-type domain 
containing 1 A_23_P111804 4 9.4 1.1 1.1 2 3 
  PARP14 
poly (ADP-ribose) polymerase family, 
member 14 A_32_P56759 5.2 8 0.7 1.3 3.6 8 
  PARP14 
poly (ADP-ribose) polymerase family, 
member 14 A_24_P161018 6.5 12.5 1.5 1.3 2.7 7 
  PARP9 
poly (ADP-ribose) polymerase family, 
member 9 A_23_P69383 10.2 11.3 1.2 1.1 3.8 5.2 
  PLA1A phospholipase A1 member A A_24_P294408 1.9 8.7 0.9 1.2 2.2 5.7 
  PLA1A phospholipase A1 member A A_23_P29816 1.4 5.4 1.2 1.3 1.5 5.3 
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  PLEKHA4 
pleckstrin homology domain containing, 
family A (phosphoinositide binding 
specific) member 4 A_23_P67360 4.7 8.6 1 1.4 3.6 11.7 
  PLEKHA4 
pleckstrin homology domain containing, 
family A (phosphoinositide binding 
specific) member 4 A_24_P408047 3.9 8.9 1.3 1.7 3.9 16.7 
  PLSCR1 phospholipid scramblase 1 A_23_P69109 3.7 12.6 0.9 0.8 1.1 3.2 
  PML 
promyelocytic leukemia protein isoform 
1 A_24_P207139 4.5 5.7 1.3 1 2 1.5 
  PML 
promyelocytic leukemia protein isoform 
6 A_23_P306148 2.7 4.1 1 1.2 1.6 1.7 
  PML 
promyelocytic leukemia protein isoform 
6 A_24_P198598 2.7 4.5 1 1.2 1.7 1.6 
  PNPT1 hypothetical protein A_32_P76035 2.2 5.1 0.8 1.1 1.2 1.2 
  PNPT1 
polyribonucleotide 
nucleotidyltransferase 1 A_23_P154488 2.4 4.8 0.9 1.1 1.2 1.2 
  PPM1K 
protein phosphatase 1K (PP2C domain 
containing) A_24_P214598 2.5 5.7 0.7 0.9 1.4 6.7 
  PSMB10 proteasome beta 10 subunit proprotein A_23_P140807 1.5 4.6 1.2 1.2 2.1 4.9 
  PSMB8 
proteasome beta 8 subunit isoform E1 
proprotein A_23_P250629 2.4 6.9 0.8 1 2.1 3.5 
  PSMB9 
proteasome beta 9 subunit isoform 1 
proprotein A_23_P111000 3.1 12 0.6 0.9 3.8 8.8 
  RARRES3 
retinoic acid receptor responder 
(tazarotene induced) 3 A_23_P1962 2.1 6 1 1.3 4.4 6.9 
  RASGRP3 
RAS guanyl releasing protein 3 (calcium 
and DAG-regulated) A_24_P54390 9.8 15.2 0.9 0.8 3.7 3.8 
  REC8 REC8 homolog A_24_P344087 5.5 4.9 1.6 2.4 3.9 3.9 
  RGS22 regulator of G-protein signalling 22 A_32_P125771 2 12.6 1 0.9 1.3 3 
  SAMD9 sterile alpha motif domain containing 9 A_23_P355244 23 26.9 1 1.1 3.7 14.6 
  SAMD9 sterile alpha motif domain containing 9 A_24_P175187 42.2 25.2 0.9 1.1 3.5 13.4 
  SAMD9 sterile alpha motif domain containing 9 A_24_P175188 36.7 37 0.9 1.1 5 12.4 
  SAMD9L 
sterile alpha motif domain containing 9-
like A_23_P145874 35.7 31.7 1.5 1.6 14.5 22.3 
  SIDT1 SID1 transmembrane family, member 1 A_23_P132515 4.5 9 0.9 1.9 2.7 2.6 
  SLC15A3 solute carrier family 15, member 3 A_23_P75786 4.9 14.9 0.9 0.8 1.7 7.1 
  SP100 nuclear antigen Sp100 isoform 2 A_24_P385611 2.9 5 0.8 0.9 1.2 1.9 
  SP100 nuclear autoantigen A_24_P916816 5.8 7.1 1.8 1.2 1.9 3.4 
  SP110 SP110 nuclear body protein isoform b A_23_P120002 8.8 14.5 1 0.9 1.8 2.2 
  SP140 SP140 nuclear body protein isoform 1 A_24_P328504 3.7 6.8 1.6 1.1 2 3.4 
  STAT1 
signal transducer and activator of 
transcription 1 isoform alpha A_23_P56630 3 8.3 0.6 1 3.7 4.9 
  STAT1 
signal transducer and activator of 
transcription 1 isoform beta A_24_P274270 4.6 10.1 0.9 1.5 4.7 5.7 
  STAT2 
signal transducer and activator of 
transcription 2 A_23_P76090 4.9 3.8 0.9 1.1 2.1 2.5 
  TAP1 
transporter 1, ATP-binding cassette, 
sub-family B A_23_P59005 4.8 9.2 1 1.4 3.8 9.3 
  TGM2 transglutaminase 2 isoform a A_32_P86763 1.7 4.2 0.6 0.7 1.2 1.5 
  TLR3 toll-like receptor 3 A_23_P29922 11.9 16.1 0.9 1 5.7 12.7 
  TMEM140 hypothetical protein LOC55281 A_23_P31177 12.1 8.5 1.2 0.9 3.4 4.4 
  TMEM140 hypothetical protein LOC55281 A_24_P372134 4.1 3.4 1.2 1 1.2 1.7 
  TNFRSF14 
tumor necrosis factor receptor superfamily, 
member 14 precursor A_23_P126908 1.9 6.1 1 0.7 3.1 5.3 
  TNFSF10 
tumor necrosis factor (ligand) 
superfamily, member 10 A_23_P121253 23.5 20.1 1.2 1.1 2.2 6.9 
  TNFSF13B 
tumor necrosis factor (ligand) 
superfamily, member 13b A_23_P14174 6.2 13.1 1 1.2 2.8 4.3 
  TRIM14 
tripartite motif protein TRIM14 isoform 
alpha A_23_P425752 1.7 4.6 1 1.2 1.2 1.6 
  TRIM14 
tripartite motif protein TRIM14 isoform 
alpha A_23_P216655 2.1 7.3 0.7 1 1.5 2.6 
  TRIM14 
tripartite motif protein TRIM14 isoform 
alpha A_24_P197964 2.3 8.7 0.6 1 1.3 2.5 
  TRIM14 
tripartite motif protein TRIM14 isoform 
alpha A_23_P334083 1.7 4.6 0.6 0.7 1.2 1.9 
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  TRIM22 tripartite motif-containing 22 A_23_P203498 16.1 42 0.8 0.9 6.6 19.6 
  TRIM34 tripartite motif protein 34 isoform 1 A_24_P398323 2.1 4.1 0.8 0.8 1.5 1.4 
  TRIM69   A_24_P50543 4.1 3.8 1 0.7 1.6 2.9 
  UBD diubiquitin A_23_P81898 6 12.9 1 0.8 3 41.6 
  UBE1L ubiquitin-activating enzyme E1-like A_23_P21207 3.5 21.8 0.9 0.8 2.7 7.5 
  UBE2L6 
ubiquitin-conjugating enzyme E2L 6 
isoform 2 A_23_P75741 2.8 9.2 0.7 1.1 1.8 2.9 
  USP18 ubiquitin specific protease 18 A_32_P132206 5.3 9.2 1.2 1.3 1.7 4.2 
  USP18 ubiquitin specific protease 18 A_23_P132159 4.9 9.6 0.9 1 1.5 3.5 
  ZNFX1 zinc finger, NFX1-type containing 1 A_24_P23034 5.7 3.2 1 1.2 1.7 3.7 
    hypothetical protein A_32_P161292 2.9 5.4 1.1 1.1 2.8 4.2 
    hypothetical protein LOC55337 A_24_P236949 2.3 7.6 0.8 0.8 1.1 1.7 
    hypothetical protein LOC55337 A_23_P38894 3.8 9.8 1.4 1.2 1.6 2 
    hypothetical protein LOC55601 A_23_P41470 5.1 13.7 0.4 0.8 3 10.7 
    hypothetical protein LOC55601 A_24_P334361 5.8 18.1 0.4 0.8 3.9 16.4 
    hypothetical protein LOC79132 A_23_P38346 11.8 50.6 1.2 2 6 48.6 
    hypothetical protein LOC93349 A_23_P337753 2.8 4.3 0.9 1.1 2.6 3.2 
    
leukocyte-derived arginine 
aminopeptidase A_23_P30243 4.3 4.6 1.1 1.3 3.1 5.8 
    
promyelocytic leukemia protein isoform 
2 A_23_P358944 5.1 4.5 1.4 1.2 1.4 2.3 
    Unknown (protein for MGC:105145) A_24_P418044 1.7 5.4 1 1.1 1.4 4.2 
    XIAP associated factor-1 isoform 1 A_23_P4286 65.7 270 1.6 1.4 7.9 77.7 
    XIAP associated factor-1 isoform 1 A_23_P4283 52.8 95.9 1.4 0.9 5 38.6 
      A_23_P354547 11.5 8.7 1.5 3.1 5.1 5 
      A_32_P171793 6.2 12.8 0.9 1.3 4.2 10.5 
      A_24_P829156 5.5 4.7 1.5 1.2 3.1 5.1 
      A_24_P740662 11.5 8.7 1.6 1.9 7.2 10 
      A_24_P127641 5.6 8.3 1.4 1.3 2.9 7.9 
      A_23_P384355 63.7 88.6 0.8 1 2.8 24.8 
      A_32_P156746 8.1 6.2 1.3 1 2.5 3.5 
      A_24_P868905 4.2 12.9 0.9 1.1 1.4 2.3 
      A_32_P54553 3.4 5.9 0.6 1 1.3 2.4 
      A_23_P65174 2.3 4 1 1 1.5 1.8 
      A_23_P30069 4 17.2 0.9 1.2 2.5 4.6 
      A_24_P15702 2 4.3 0.5 0.9 1.1 1.4 
      A_24_P118892 6.3 11.9 0.7 1.5 1.1 1.9 
      A_32_P99533 5.5 10 1.8 2 6.1 21.4 
      A_32_P56249 10 18.8 0.9 1 6.2 32 
      A_32_P154726 2.6 3.4 0.9 0.9 1.5 4.3 
      A_23_P370707 1.7 5.3 0.8 0.9 1.5 6.3 
      A_24_P586264 3.3 6.3 0.9 1.2 1.6 8.3 
      A_23_P250353 4 11.1 0.9 1.1 2 8.5 
      A_24_P68079 4.6 9.3 1 1.1 2.9 7.7 
      A_32_P92415 4.1 10 1.3 1.2 2.9 7.9 
      A_23_P125109 1.5 5 0.9 1 1.2 4.7 
      A_23_P373126 1.8 6.6 0.8 0.9 1.3 6.2 
      A_24_P860781 1.5 4.6 0.9 1 1 3.2 
      A_32_P143980 2 4.3 1.3 1.1 1.4 3.7 
      A_23_P17837 5.3 10.7 1.1 1.8 3.4 7.9 
      A_23_P203629 1.5 4.8 1.4 1.1 1.3 2.9 
B APOL2 apolipoprotein L2 A_23_P211488 5.6 2.5 1 1.3 3.6 6 
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 APOL2 apolipoprotein L2 A_24_P48898 3.7 3.1 1.8 1.8 3.5 5.2 
 BTN3A3 
butyrophilin, subfamily 3, member A3 
isoform a A_24_P311917 3.7 4.2 1.1 1.2 4.4 5.4 
 C20orf141  A_32_P133182 6.2 2.4 1.1 1.1 4.1 13.9 
 CA13 carbonic anhydrase XIII A_23_P381714 5.4 2.3 1.1 1.3 4.5 3.7 
 CCL2 small inducible cytokine A2 precursor A_23_P89431 1.9 1.2 1 1 1.1 5 
 CD274 CD274 antigen A_23_P338479 3.6 2.7 0.8 1 2 8.2 
 CXorf43 hypothetical protein LOC139324 A_23_P386364 2.8 3.7 0.6 0.8 1.8 4.7 
 FAS 
tumor necrosis factor receptor superfamily, 
member 6 isoform 1 precursor A_23_P63896 1.7 1.5 0.6 0.9 1.3 4.4 
 GBP5 guanylate-binding protein 5 A_23_P74290 25.7 20.1 1 1.3 16.5 88.5 
 HOXB4 homeobox B4 A_24_P416370 2.9 2 1.2 0.9 2.1 5.8 
 ICAM1 
intercellular adhesion molecule 1 
precursor A_23_P153320 4 1.8 0.7 1 2.5 23.3 
 IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2 A_23_P24004 72.6 85.4 2.9 14.5 42.9 531 
 IL15RA interleukin 15 receptor, alpha isoform 2 A_23_P138680 3.5 2.7 1 1.2 2.8 4.1 
 IRF1 interferon regulatory factor 1 A_23_P41765 4.8 2.2 0.9 2 3.6 8.5 
 KLK10 
kallikrein-related peptidase 10 
preproprotein A_23_P107911 2.3 4.3 1 1.2 2.8 16.1 
 NLRC5 
nucleotide-binding oligomerization 
domains 27 A_23_P402892 8.9 4.9 0.9 1.1 10.3 7.6 
 NLRC5  A_23_P26583 15.7 6.8 1 1 10.8 11.9 
 PMAIP1 
phorbol-12-myristate-13-acetate-induced 
protein 1 A_23_P207999 2 1.4 0.7 1.1 1.8 5.3 
 SOCS1 suppressor of cytokine signaling 1 A_23_P420196 4.1 2.1 0.9 1.5 1.5 4.2 
 TNFAIP6 
tumor necrosis factor, alpha-induced 
protein 6 precursor A_23_P165624 1.5 1.2 0.5 0.6 0.7 7 
 ZC3HAV1 zinc finger antiviral protein isoform 2 A_24_P341938 4.1 1.7 1 1.1 1.9 10.5 
 ZC3HAV1 zinc finger antiviral protein isoform 2 A_23_P20122 4.3 2.9 1.1 1.1 2.1 15.8 
 ZNFX1 zinc finger, NFX1-type containing 1 A_23_P68462 5.8 2.9 0.7 1.2 1.4 3.8 
   A_23_P256487 3.3 3.6 0.8 0.9 2.1 12.9 
   A_32_P224888 1.8 1.5 1 0.9 2.5 6.3 
      A_24_P36898 7.2 2.5 0.9 0.7 2.4 3.6 
C AGT angiotensinogen preproprotein A_23_P115261 7.5 2.7 0.9 1 1 0.7 
  GLI3 GLI-Kruppel family member GLI3 A_23_P111531 1.3 4.2 1 0.9 1.2 1 
  GMPR guanosine monophosphate reductase A_24_P277657 1.4 6.6 0.9 1 1 0.8 
  IFITM2 
interferon induced transmembrane 
protein 2 (1-8D) A_24_P287043 1.8 5.4 1 1 0.8 0.7 
  IFITM3 
interferon-induced transmembrane 
protein 3 (1-8U) A_23_P87545 2.6 9.7 1 1 1 1.2 
  IFITM4P   A_24_P16124 2.2 11.5 1 0.9 0.8 0.9 
  LGALS9 galectin 9 long isoform A_23_P116557 1.7 9.3 1 1 1.4 1 
  RET ret proto-oncogene isoform c A_24_P343695 0.9 4.6 1 1 1 1 
  SP100 hypothetical protein A_23_P209712 2.5 6.4 2 1.4 1.6 1.7 
  TRIM34 tripartite motif protein 34 isoform 3 A_23_P124190 3.4 7 2.2 1.3 1.6 2 
    similar to galectin 9 short isoform A_23_P101025 1.4 7 1.6 1.4 1.1 1.2 
      A_24_P254933 2 8.1 1 1 0.9 0.9 
      A_32_P167592 2.2 7.4 1 1 0.9 0.9 
      A_24_P15502 1.6 4.4 1 1 0.9 0.8 
      A_24_P7040 2.8 10.4 1 0.9 0.9 1.2 
      A_23_P202245 2.2 13.4 1 0.6 0.7 1.4 
      A_32_P154321 1.9 4.4 1.3 1 1.8 1.7 
D ATP4A 
ATPase, H+/K+ exchanging, alpha 
polypeptide A_23_P430728 0.8 0.9 1 2.7 13.5 45.9 




chemokine (C-C motif) ligand 3-like 3 
precursor A_23_P321920 1 1.3 0.8 2 5.8 10.2 
 CCL3L3 
chemokine (C-C motif) ligand 3-like 3 
precursor A_24_P228130 0.8 0.7 0.9 2.6 4.8 6.3 
 CCL5 small inducible cytokine A5 precursor A_23_P152838 1.6 12 1.8 17.5 23 29.9 
 CXCL10 small inducible cytokine B10 precursor A_24_P303091 0.8 2.2 0.9 3.9 9.3 12.4 
 GPR109B G protein-coupled receptor 109B A_23_P64721 1.6 2.3 1.5 4.1 10.2 42.3 
 IFNB1 interferon, beta 1, fibroblast A_23_P71774 0.7 3 0.9 9.3 31.7 180.6 
 IL28A interleukin 28A A_23_P409438 1.3 6.3 2.1 14.8 21 32.2 
 IL28B interleukin 28B A_23_P373619 1 3.7 1 18 19.9 21.5 
 IL29 interleukin 29 A_23_P337800 0.8 3 1.1 6.2 8.7 11.3 
 TAC3 tachykinin 3 isoform 1 A_23_P2283 1.3 1.2 1.3 2.8 4.5 9.3 
E ACAN aggrecan isoform 2 precursor A_23_P307310 1 1.3 1.2 0.9 2.1 14.2 
  ATF3 activating transcription factor 3 isoform 2 A_23_P34915 1.6 1.1 1.1 1.3 1.7 5.7 
  BCL2A1 BCL2-related protein A1 A_23_P152002 1.2 1.4 0.9 1.1 1.3 5 
  BIRC3 baculoviral IAP repeat-containing protein 3 A_23_P98350 1.1 1.9 1 1 1.7 9.2 
  BTN3A1 butyrophilin, subfamily 3, member A1 A_24_P329065 1.7 3.7 1 1.4 2.7 6.4 
  C19orf30 hypothetical protein LOC284424 A_23_P353667 1.5 1.4 1 1.5 0.7 6.3 
  CCL17 small inducible cytokine A17 precursor A_23_P26325 1.1 1.3 1 1.3 2.5 9.3 
  CCL20 chemokine (C-C motif) ligand 20 A_23_P17065 0.7 0.7 0.8 0.9 0.9 27.4 
  CCL4 
chemokine C-C motif ligand 4 isoform 1 
precursor A_23_P207564 0.7 1.4 0.9 2.2 3.3 30.7 
  CCRN4L CCR4 carbon catabolite repression 4-like A_24_P213794 1.2 1.1 1.3 1.4 1.4 5.2 
  CENTD1 centaurin delta 1 isoform a A_32_P83784 1.4 1.9 1.3 1 1.3 4.5 
  CHEK2 protein kinase CHK2 isoform c A_23_P109452 1.1 0.9 1.1 1.1 1.2 4.1 
  CREB5 
cAMP responsive element binding protein 5 
isoform alpha A_23_P157117 0.8 1 0.8 1.2 1.4 14.5 
  CREB5 
cAMP responsive element binding protein 5 
isoform alpha A_24_P532232 0.7 1.6 0.9 1.4 1.7 12.3 
  CSAG1 
chondrosarcoma associated gene 1 
isoform b A_24_P11061 1.8 2.1 1 1.2 1.4 8 
  CSAG2 CSAG family, member 2 A_24_P567298 1.3 2.1 1.3 1.3 1.6 8.2 
  CSAG3A CSAG family, member 3A A_24_P79529 1.3 2.8 1.1 1.1 1.7 15.7 
  CX3CL1 chemokine (C-X3-C motif) ligand 1 A_23_P37727 1.7 2.4 1.4 1.6 2.2 19.7 
  CXCL1 chemokine (C-X-C motif) ligand 1 A_23_P7144 1 1.1 1.1 0.9 0.9 4.6 
  CXCL2 chemokine (C-X-C motif) ligand 2 A_23_P315364 1.8 1.5 1.4 1.4 1.8 5.2 
  CXCL3 chemokine (C-X-C motif) ligand 3 A_24_P251764 1.6 1.2 1.2 1.2 1.4 4.3 
  CXCL3 chemokine (C-X-C motif) ligand 3 A_24_P183150 1.7 1.3 1.1 1 1.3 6.1 
  CXCR4 
chemokine (C-X-C motif) receptor 4 
isoform a A_23_P102000 0.8 1 1.3 1.4 1.7 27.2 
  DNAJC15 DNAJ domain-containing A_23_P117190 2.2 1.8 1.2 2.3 2.2 6.3 
  EGR4 early growth response 4 A_23_P380318 0.9 1.1 1.2 1.2 2.5 23.8 
  EPHA4 ephrin receptor EphA4 A_23_P108501 0.8 0.9 1.4 1.1 1.1 4.1 
  EPHA4 ephrin receptor EphA4 A_24_P274219 1.1 1.1 0.9 1.2 1.8 7.5 
  FUT1 fucosyltransferase 1 A_23_P107963 0.6 1.2 1.1 1.6 1.4 5.1 
  FZD4 frizzled 4 A_23_P64617 0.9 1.3 1.1 0.9 1.4 14.3 
  GALNTL4   A_24_P924301 1.4 3 4.6 1.7 2 1.9 
  GP1BA   A_23_P152926 1 1.9 2.5 2.1 1.5 5.1 
  GPBAR1 G protein-coupled bile acid receptor 1 A_23_P400378 0.8 1 1 1 1.3 4.6 
  HCP5 HLA complex P5 A_32_P85500 0.9 2.3 1.3 0.7 1.3 5.1 
  HCP5 HLA complex P5 A_24_P17870 1.4 3.4 1.2 1.1 1.3 8.8 
  HIP1R huntingtin interacting protein-1-related A_24_P229164 0.9 0.9 1.1 1.2 1.4 4.8 
  HIP1R huntingtin interacting protein-1-related A_23_P398294 1.1 1.2 1.8 1.4 1.8 11 
  HTR3E 5-hydroxytryptamine receptor 3 subunit E A_24_P32139 0.8 1.6 1 1.1 1.1 5.7 
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  IGF2AS insulin-like growth factor 2 antisense A_23_P116435 1.2 0.9 1.3 1.3 1.2 5.3 
  IL3RA interleukin 3 receptor, alpha precursor A_32_P217750 1.2 1.9 1.4 1 1.3 6.2 
  IL6 interleukin 6 (interferon, beta 2) A_23_P71037 1.6 1.5 1 1.8 3.6 34 
  IL8 interleukin 8 precursor A_32_P87013 2.1 1.2 1.1 1.4 2.8 17.7 
  JAK2 Janus kinase 2 A_23_P123608 1.8 1.2 0.9 1 1.6 5.1 
  KCNV1 potassium channel, subfamily V, member 1 A_23_P146125 1.3 0.7 1.2 1.2 1.4 11.7 
  KLF4 Kruppel-like factor 4 (gut) A_23_P32233 1 0.8 0.8 1 2.3 9.2 
  KLHDC7B kelch domain containing 7B A_24_P117410 1.2 2.6 1.1 1.3 1.9 11.1 
  LRRN3 leucine rich repeat neuronal 3 A_23_P31376 1 1.7 0.9 1.5 7.3 81.3 
  LTB lymphotoxin-beta isoform a A_23_P93348 0.8 1.1 0.8 1 1.1 18.7 
  MBOAT4 FKSG89 A_24_P306824 1.1 1.3 1 0.9 1.8 7.8 
  MXD1 MAX dimerization protein 1 A_24_P379750 1.2 1.1 1 1.1 1.4 4.1 
  MXD1 MAX dimerization protein 1 A_23_P408094 1.1 1.2 1.2 1.2 1.3 4.6 
  NCF2 neutrophil cytosolic factor 2 A_23_P138194 1.1 1 1 1 1.5 5.9 
  NFKBIA 
nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha A_23_P106002 1.1 1.3 1 1.1 1.6 7.1 
  NOV nov precursor A_23_P82929 1 0.7 1.1 1.2 1.6 4.6 
  NPHS1 nephrin A_23_P5200 0.8 1 1 0.7 1.2 5.2 
  OTUD1   A_24_P374834 0.8 0.8 0.7 0.5 1 5.3 
  OTUD1   A_32_P60459 1.1 1 0.9 0.6 1.1 7.1 
  PLA2G4C phospholipase A2, group IVC A_23_P50508 1 1.1 0.9 1 1.3 8.3 
  PLCG2 phospholipase C, gamma 2 A_23_P106675 1.4 1.4 1.7 1.2 1.4 6.2 
  PPP1R15A 
protein phosphatase 1, regulatory subunit 
15A A_23_P90172 0.9 1 1 1.1 1.4 5.7 
  PRR15 proline rich 15 A_32_P154911 2.4 1.6 1.8 1.5 2.3 6.8 
  PTGER4 prostaglandin E receptor 4, subtype EP4 A_23_P148047 1.1 0.9 0.7 1.1 2.3 14.4 
  PTX3 
pentraxin-related gene, rapidly induced by 
IL-1 beta A_23_P121064 0.8 1.2 0.7 0.8 1.4 20.1 
  RELB 
reticuloendotheliosis viral oncogene 
homolog B A_23_P55706 0.9 1.5 1.1 1 0.9 4.4 
  RGS9 regulator of G-protein signalling 9 isoform 1 A_23_P66881 0.7 0.7 1.2 1 2 5.5 
  RHCG Rhesus blood group, C glycoprotein A_23_P151975 1 0.9 1.4 1.3 1.5 4.4 
  SLAMF7 SLAM family member 7 A_24_P353638 0.9 1.4 0.7 1.3 2.2 6.9 
  SLC12A7 
solute carrier family 12 (potassium/chloride 
transporters), member 7 A_23_P61688 1.6 1.6 1.5 1.3 1.5 5.1 
  SMPD3 
sphingomyelin phosphodiesterase 3, 
neutral membrane A_23_P163567 1.2 1.5 0.9 0.8 1.1 5.6 
  SNPH syntaphilin A_23_P102706 0.9 0.9 1.5 1.2 1.2 4.7 
  SOD2 SOD2 protein A_24_P935819 4 1.3 2 1.5 2.4 10.8 
  TMC8 FLJ00400 protein A_23_P346093 0.7 1.5 0.8 1.4 1.8 5.3 
  TNF tumor necrosis factor alpha A_23_P376488 0.7 1.2 1.1 1.1 1 5.9 
  TNFAIP2 
tumor necrosis factor, alpha-induced 
protein 2 A_23_P421423 0.9 1.1 1.8 1.4 1.3 5.3 
  TNFAIP3 
tumor necrosis factor, alpha-induced 
protein 3 A_24_P166527 1 0.7 0.9 1 1.5 6.6 
  TNFAIP3 
tumor necrosis factor, alpha-induced 
protein 3 A_24_P157926 1.4 1.5 1.2 1.2 1.9 13.8 
  TNFRSF9 
tumor necrosis factor receptor superfamily, 
member 9 precursor A_23_P51936 1.1 1.2 1 1.4 2.3 8.2 
  TTC9B   A_23_P332392 1 1 1 1.2 1.4 7.2 
  ULBP2 UL16 binding protein 2 A_23_P168259 1.1 1 0.7 1 1.4 4.1 
  UNC5B unc-5 homolog B A_23_P52336 1 1 0.7 1.2 1.2 6.3 
  WARS tryptophanyl-tRNA synthetase isoform a A_23_P65651 1.4 2.1 1 1.6 2.4 6.7 
  ZBTB32 testis zinc finger protein A_23_P131024 0.8 1.6 1.3 1.2 8.2 61 
  ZC3HAV1 zinc finger antiviral protein isoform 1 A_23_P425224 3.7 0.7 1.2 1.1 1.6 5.7 
  ZEB2 zinc finger homeobox 1b A_23_P142560 1.5 1.5 1.3 0.9 1 5.9 
      A_32_P75867 3.3 5.8 1.8 2 7.2 20.1 
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      A_24_P126282 1.5 2.9 1.3 1 2.6 5 
      A_23_P6535 0.9 3.9 1.1 1.4 2 12.6 
      A_32_P219135 1 1 1.6 1.8 1.8 8.6 
      A_24_P933828 0.8 0.7 1.2 1.4 1.4 6.2 
      A_32_P222684 1 1.2 1.2 1.5 1.5 6.3 
      A_32_P170664 1.1 1 0.8 1.2 1.3 4.3 
      A_23_P328740 1 1.7 0.9 1.1 1.5 8.6 
      A_32_P703 1 1.1 1.1 1 1.2 4.8 
      A_32_P147395 1.2 1.1 1 0.9 1.1 7.8 
      A_32_P158181 1.4 1.6 1.2 0.9 1.2 5.7 
      A_32_P68504 1.3 1.4 1.2 1.3 1.4 7 
      A_32_P217261 1.4 1.2 1 0.9 1.3 4.7 
      A_32_P45844 1.4 2.5 1.4 1.8 2.1 18.9 
      A_23_P11980 0.9 1.3 1.8 0.9 1.3 11.2 
      A_24_P652537 1.6 1.6 0.9 1.1 2.8 15.2 
      A_24_P101651 1.3 2 1.2 1.8 2.1 7.8 
      A_32_P104841 1.4 1.5 1.3 1.4 3.3 9.4 
      A_32_P52632 1 1.6 1.2 0.9 1.3 7.7 
      A_24_P255384 0.9 2.1 0.9 0.9 0.9 7.3 
      A_32_P168375 1.1 1.3 1.4 1.3 1.2 4.5 
      A_24_P174353 0.9 2.1 1.5 1.9 1.1 8.3 
      A_32_P91773 2.2 1.1 2.3 1.9 2 10.6 
      A_32_P210038 1.2 1.2 1.3 1.1 1.4 5.1 
      A_24_P937817 1.5 1.1 0.7 1.1 1.6 4 
      A_24_P47329 2.7 2 1.4 2.3 2.9 6.3 
      A_32_P3317 1 0.8 0.6 0.8 3.8 5.2 
      A_32_P42989 1.5 1.3 1.4 1.7 1.3 4 
      A_32_P117322 1.2 1.1 1.1 1.3 0.6 4.8 
      A_32_P118010 2.4 0.7 1.3 1.5 2.4 4.1 
      A_32_P55987 1.2 1.6 4.1 1.8 1.7 2.9 
      A_23_P320407 0.6 2.1 2.1 1.3 1.3 4.7 
      A_32_P184039 0.9 1.5 3.1 1.4 1.6 5.7 
      A_24_P930337 2.3 1.9 4.9 1.3 1.4 1.2 
‡Genes listed in each cluster correspond to the same genes hierarchically clustered in Figure 1.  
*Rows in bold correspond to the 190 IFN-induced genes. 1 expressed sequence tag A_23_P416305 was down-regulated by IFNβ treatment. 




Table S2. Genes differentially expressed by wt, CF170S, and P(C-) HPIV1 compared to mock infection and to each other*† 















P(C-) P(C-) P(C-) P(C-
) 
WT WT WT WT 
Clus
ter‡ 










6 hr 12 hr 24 hr 48 
hr 









0.9 0.7 0.5 0.7 0.8 5 0.5 0.8 1.6 3.2 0.6 0.8 0.9 1 




1.1 1.1 0.6 0.7 2.2 11.
8 
0.5 0.7 4.4 7.6 0.7 0.7 1.1 2.2 




1 1 1.1 1.1 1.3 6.5 1 1.1 3 5.7 1.1 1.1 1.2 1.5 
 ADAR adenosine deaminase, RNA-
specific isoform a 
A_23_P200
439 
1.8 2.5 0.9 1.3 3.8 12.
3 
0.9 1.3 5 7.6 0.9 1 1.6 2.2 
 AFF1 myeloid/lymphoid or mixed-




1.2 1.3 1.2 1.1 3.3 21.
6 
1.3 1.3 5.7 9.1 1.1 0.7 1.4 3.2 
 AFF1 myeloid/lymphoid or mixed-




1.3 1.8 0.9 1.1 3.5 16.
5 
1.1 1.1 5.9 8.2 1.1 0.8 1.4 3 
 AFF4 ALL1 fused gene from 5q31 A_23_P218
977 
1.1 1.3 0.9 0.9 2.1 14.
6 
0.8 1 3.2 11.5 0.8 0.9 1.3 1.9 
 AFF4 ALL1 fused gene from 5q31 A_24_P942
636 
1.3 1.2 0.7 0.6 2.3 36.
4 
0.7 0.8 4 29.7 0.7 0.8 1.4 3.3 
 AGL amylo-1, 6-glucosidase, 4-alpha-
glucanotransferase isoform 1 
A_23_P200
298 
1.2 1 0.9 1 1.4 7.4 0.8 0.9 2.7 4.2 0.9 1 1.3 1.7 




0.9 0.9 0.6 0.7 1.2 8.6 0.6 0.7 1.7 5.9 0.6 0.8 0.9 1.8 
 ANKS1A ankyrin repeat and sterile alpha 
motif domain containing 1 
A_23_P156
748 
1.1 1 1.2 1.1 2.4 17.
6 
1 1.1 8.8 9.8 1.1 1.1 1.3 2.1 
 ARFGEF2 ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 
A_23_P599
5 
0.8 0.9 0.9 0.9 1.1 7 0.8 0.9 1.8 5.1 0.9 0.9 1.1 1.3 
 ARHGAP
24 
Rho GTPase activating protein 
24 isoform 2 
A_23_P110
151 
1.1 0.9 0.8 0.7 1.6 8.7 0.7 0.9 2.5 7.8 0.9 0.7 1 1.4 
 ARHGAP
24 
Rho GTPase activating protein 
24 isoform 2 
A_24_P380
061 
1.2 1 0.8 0.9 1.7 8.9 1.2 1 2.8 6.8 1.3 0.7 1 1.5 
 ARHGAP
26 
GTPase regulator associated 




1.1 1.5 1.7 1.3 2.3 11.
8 
1.6 1.4 6.9 6.6 1.3 1.2 1.3 2.6 
 ARL14 ADP-ribosylation factor 7 A_23_P921
61 
0.9 1.4 0.9 0.8 2.4 19.
8 
0.7 0.9 7.6 17.9 0.7 0.6 1.1 1 
 ARL4A ADP-ribosylation factor-like 4A A_32_P806
841 
1.1 1.1 0.9 0.8 2.6 10.
5 
0.8 0.8 5.1 6.6 1 1 1.2 2.4 
 ARL4A ADP-ribosylation factor-like 4A A_23_P145
761 
1.1 1.1 1 0.8 2.3 9.3 0.9 0.9 5.3 6.1 1 1 1.1 2.1 
 ARL5B ADP-ribosylation factor-like 8 A_24_P943
997 
1.4 1.3 0.7 0.7 6.2 94.
9 
0.7 0.8 12.4 79.3 0.7 0.9 1.3 4.4 
 ARL5B ADP-ribosylation factor-like 8 A_23_P378
588 
1.3 1 0.7 0.8 6 50.
1 
0.6 1 16.3 38.9 0.7 0.8 1.3 2.7 
 ARNTL2 aryl hydrocarbon receptor 
nuclear translocator-like 2 
A_23_P533
45 
1.1 1.3 0.7 0.8 1.7 14.
8 
0.7 0.8 2.2 8.9 0.7 0.8 1.1 2.3 








1.1 1.9 19.5 58.4 1.1 1.3 1.7 5.7 
 BANK1 B-cell scaffold protein with 
ankyrin repeats 1 isoform 1 
A_23_P102
32 
1.2 1.5 0.9 0.9 1.2 11.
9 
0.8 0.7 2.1 5.2 0.9 1 1 1.5 
 BCL2A1 BCL2-related protein A1 A_23_P152
002 
1.2 1.4 0.9 0.8 1.8 29.
3 
1 0.9 3.9 13.9 0.9 1.1 1.3 5 
 BIK BCL2-interacting killer A_23_P404
667 
0.9 1.1 1.1 1 1.2 12.
2 
1.1 1 3.1 14.2 1.2 0.9 0.9 2.9 
 BNIP3 BCL2/adenovirus E1B 19kD-
interacting protein 3 
A_23_P138
635 
1.1 1.3 0.9 0.8 1.1 7.4 0.8 0.8 1.6 6.4 0.8 0.8 1.3 1.7 
 BSN bassoon protein A_23_P297
35 
1.4 1.2 1.1 1.3 1.6 7.2 1.1 1.3 2.8 7.5 0.8 0.9 1.1 1.4 
 BTG1 B-cell translocation protein 1 A_23_P875
60 
1.2 1 0.9 0.9 1.8 5.4 0.8 1 2 4.9 0.9 0.8 1 1.3 
 BTN2A2 butyrophilin, subfamily 2, 
member A2 isoform b 
A_24_P346
210 
1 1.4 1.4 1.4 2.4 8 1.4 1.5 5.2 5.9 1.4 1.2 1.2 1.9 
 BTN2A2 butyrophilin, subfamily 2, 
member A2 isoform b 
A_24_P337
592 
0.9 1.4 1.4 1.3 3.3 27.
3 
1.4 1.4 9 19 1.4 1.1 1.3 2.6 
 BTN2A2 butyrophilin, subfamily 2, 
member A2 isoform b 
A_24_P249
072 
1.1 1.4 1.2 1.1 2.8 14.
3 
1.1 1.2 5.7 10.5 1.1 1 1.2 2 
 BTN2A2 butyrophilin, subfamily 2, 
member A2 isoform b 
A_23_P122
439 
0.8 1.4 1.2 1.1 3.1 20.
8 
1 1.1 7.4 15.2 1.2 1 1.1 2.3 
 C10orf118 CTCL tumor antigen L14-2 A_24_P942
694 
0.9 0.8 0.7 0.8 1.4 7.4 0.7 0.8 1.9 6.9 0.8 0.6 1.2 1.6 
 C18orf19 hypothetical protein LOC125228 A_23_P380
978 
1.1 1.1 0.6 0.7 1.4 11.
9 
0.6 0.8 4.7 16.9 0.6 0.8 1.2 1.6 




1.6 1.2 0.9 0.9 1.6 7 0.8 0.9 2.4 5.2 0.9 1 1.2 1.6 




1.3 1 1 0.9 1.4 8.4 0.9 0.9 2.7 5.6 0.9 0.9 1 1.5 




1.1 1.1 0.7 0.9 1.2 8 0.8 0.9 3 7.8 0.9 0.7 0.7 2 
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 C3orf19 hypothetical protein LOC51244 A_23_P354
277 
0.9 1 1 1 1.6 6.3 1 0.9 2.2 5.1 1 1 1 1.4 
 C3orf33 hypothetical protein LOC285315 A_23_P301
476 
1.2 1 0.9 1 1.5 7.6 0.8 0.9 2.9 4.7 1 1.1 1.2 1.4 




1.1 1.1 0.7 0.9 1.6 6.1 0.8 0.9 1.5 3.7 0.7 1.1 1.3 1.5 
 C3orf59 hypothetical protein LOC151963 A_32_P117
464 
1.5 1.4 0.7 0.7 3.9 17.
3 
0.6 0.9 5.8 13.4 0.8 1 1 2.4 
 C8orf46 hypothetical protein LOC254778 A_23_P353
614 
0.7 1.4 1 0.8 3.2 16.
1 
0.8 1.1 4.7 12.2 0.7 1 0.7 1.8 
 CA8 carbonic anhydrase VIII A_23_P838
38 
0.9 1 0.7 1 1.7 10 0.9 0.9 3.3 8.7 0.8 1 0.9 2.1 




1 1 0.9 0.8 1.2 5.6 0.9 0.8 2.2 4.1 0.9 0.8 0.9 1.3 
 CCDC6  A_23_P127
117 
1.3 1.3 0.9 0.9 1.4 13 1 1 3.4 12.7 0.8 0.9 0.9 2.1 




1.2 1.1 1.4 1.2 9 68.
2 
1.4 1.6 20.5 49.6 1.3 1.4 1.4 5.2 




0.9 0.7 1.1 0.8 1.9 12.
4 
1 0.9 5.2 8.5 1.1 0.8 0.9 2 




1 1.1 1 1 1.8 9.7 0.9 0.9 2.4 10.8 1 1 1.1 2 
 CENTD1 centaurin delta 1 isoform a A_32_P837
84 
1.4 1.9 1.3 0.9 5.1 45.
9 
1 1 14.6 28.2 1.3 1 1.3 4.5 
 CHEK2 protein kinase CHK2 isoform c A_23_P109
452 
1.1 0.9 1.5 1.2 4.4 35.
2 
1.1 1.2 14.5 15.8 1.1 1.1 1.2 4.1 
 CITED2 Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
A_23_P214
969 
0.9 1 0.9 0.8 2.6 14.
8 
0.7 0.9 5.7 9.2 0.9 0.7 1 2.8 




1.2 0.9 0.8 0.8 2 9.6 0.7 0.8 3.2 7.5 0.8 1.1 1.1 1.7 
 CPEB3 cytoplasmic polyadenylation 
element binding protein 3 
A_23_P468
13 
1.3 1.1 1.2 1 7.2 21.
1 
1 1.3 17.2 22.7 0.9 1.1 1.4 3 
 CPEB3 cytoplasmic polyadenylation 
element binding protein 3 
A_23_P468
12 
3.2 2.6 1.9 1 5.3 22.
1 
1.9 1.9 10.1 16.3 2.4 1.5 1.4 3.3 
 CREB5 cAMP responsive element 
binding protein 5 isoform alpha 
A_24_P532
232 
0.7 1.6 0.8 1.3 5 153
.1 
0.9 0.7 21.8 176.
7 
0.9 1.4 1.7 12.3 
 CREB5 cAMP responsive element 
binding protein 5 isoform alpha 
A_23_P157
117 
0.8 1 0.9 1 9 347
.7 
0.9 1.1 42.4 280.
9 
0.8 1.2 1.4 14.5 
 CRYM crystallin, mu isoform 1 A_23_P777
31 
1.1 0.8 0.9 1 2 7.3 1 1.1 6 6.4 1 1 1.3 1.1 




1.1 1 0.7 0.8 0.9 5 0.9 0.9 1.4 4.1 0.8 0.9 1 0.9 
 CYLD ubiquitin carboxyl-terminal 
hydrolase CYLD isoform 1 
A_24_P480
78 
1.2 1.2 0.8 0.9 2.6 23.
4 
0.9 0.9 5.5 18.2 1 0.9 1.1 2.8 
 CYLD ubiquitin carboxyl-terminal 
hydrolase CYLD isoform 1 
A_23_P659
96 
1.1 1 0.5 0.8 2.1 15.
8 
0.5 0.6 4 11.2 0.6 0.7 1.2 2.6 




1 1.1 1 0.8 2.1 8.2 1.1 1 3.5 6.3 1.3 0.8 0.8 1.6 
 DDEF1 development and differentiation 
enhancing factor 1 
A_23_P448
31 
1.2 1.2 1.1 1 1.9 11.
9 
1.1 1.1 4.2 8.2 1 1 1.3 1.9 
 DDEF1 development and differentiation 
enhancing factor 1 
A_23_P216
278 
1.1 1.2 1 1 1.7 20.
5 
1.1 1 5.2 14.8 1 0.9 1 2.1 
 DDEF2 development- and differentiation-
enhancing factor 2 
A_23_P400
88 
1.1 1 0.6 0.7 0.9 14 0.7 0.8 2.7 9.4 0.6 0.8 0.8 2 




0.9 1.2 0.8 1.3 3.3 8.6 0.9 2.1 6.3 8.7 0.8 1.3 1.3 1.8 
 DENND4
A 
c-myc promoter binding protein A_24_P409
265 
2 1 0.9 1 1.9 15.
1 





1.2 1.2 0.7 0.7 1.9 11.
2 





1.2 1.4 1.1 0.7 1.5 11.
3 
0.8 0.8 2.3 9.3 0.9 0.9 1.4 1.8 
 DICER1 dicer1 A_24_P221
63 
1.1 1.1 1.5 1.1 2.2 25.
7 
1.4 1.2 9.5 13.4 1.4 1 1.1 2.7 
 DNAJB4 DnaJ (Hsp40) homolog, 
subfamily B, member 4 
A_24_P393
958 
1 1 0.4 0.6 2.4 9 0.4 0.6 3.9 4.6 0.5 0.6 0.9 1.3 
 DNAJB4 DnaJ (Hsp40) homolog, 
subfamily B, member 4 
A_23_P513
39 
1 0.9 0.5 0.6 2.2 8.2 0.4 0.6 3.9 4.6 0.5 0.7 1 1.2 
 DNAJB5 DnaJ (Hsp40) homolog, 
subfamily B, member 5 
A_23_P112
241 
0.7 0.8 1.4 1.2 4.1 23.
3 
1.4 1.6 10.5 18.5 1.3 1.2 1.3 2.9 
 DOCK11 dedicator of cytokinesis 11 A_23_P148
584 
1.1 0.9 0.6 0.7 1.1 8.2 0.5 0.7 2.1 3.4 0.7 0.7 1 1.6 
 DSCR1 calcipressin 1 isoform a A_23_P166
248 
1.4 1 0.7 0.8 2.2 9.1 0.6 0.8 3.2 4.9 0.8 0.8 1 1.6 




1.3 1.3 1 1 1.4 9.9 1 0.9 3.5 4.6 1.1 0.8 0.9 1.5 




1.1 1.1 1.1 1 1.3 5.5 1 1.1 2.7 3.2 0.9 0.9 1 1 
 DUSP16 dual specificity phosphatase 16 A_24_P189
739 
1 1.1 0.8 0.9 1.9 5.6 0.6 0.9 2.2 3.2 0.8 1.2 1.1 1.2 
 DUSP8 dual specificity phosphatase 8 A_32_P982
98 
1 1.1 1 1.1 2.7 12.
5 
1.1 1 4 4.8 1 1 1 2.3 
 EBF4 KIAA1442 protein A_23_P109
122 
1.1 1.1 1.4 1.3 3.7 20.
3 
1.4 1.4 10.7 11.7 1.3 1.3 1.2 2.7 




1 1.1 0.7 0.7 2.6 28 0.7 1.2 6 48.3 0.7 1.6 1.7 4 
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 EFNB2 ephrin B2 A_24_P355
944 
1.2 0.8 0.8 0.9 3 29.
5 
0.8 0.9 6.8 19.3 1 1.3 1.2 2.4 




1.1 1.1 0.6 0.8 1.2 7.2 0.8 0.9 1.2 7.7 0.7 0.8 1.1 1.6 
 ELOVL7 ELOVL family member 7, 




1 1.7 0.6 0.7 3.2 41.
4 
0.5 0.7 8.3 18.9 0.5 0.9 1.4 4.5 
 EPHA4 ephrin receptor EphA4 A_24_P274
219 
1.1 1.1 0.8 0.9 3.9 98.
4 
1 0.8 12.1 52.1 0.9 1.2 1.8 7.5 
 EPHA4 ephrin receptor EphA4 A_23_P119
899 
1.1 1 0.7 1.5 3.3 48.
4 
1.3 1.2 10.5 50.1 0.6 2.2 1.2 3.8 
 EPRS glutamyl-prolyl tRNA synthetase A_23_P976
32 
0.9 0.7 0.6 0.8 1.1 10.
1 
0.6 0.7 1.4 5.6 0.7 1 1.1 1.3 
 ETS1 v-ets erythroblastosis virus E26 
oncogene homolog 1 
A_23_P127
525 
1.1 1 1.2 1.2 2.2 15.
4 
1.5 1.3 3.4 14.9 1.1 1 1 2.1 
 EXT1 exostosin 1 A_23_P432
73 
1.2 1.8 0.9 0.9 2 12.
6 
0.9 1 2.1 4.6 1 0.9 1.1 1.7 
 FAM126A down-regulated by Ctnnb1, a A_23_P858
2 
1.1 0.8 0.7 0.8 1.4 9.3 0.7 0.8 2.1 9.7 0.7 0.9 1.4 1.9 
 FAM62B family with sequence similarity 




1.1 1.2 1 1 1.5 13.
4 
0.9 1.1 2.5 8.8 1 1 1.2 2.4 
 FAS tumor necrosis factor receptor 




1.7 1.5 0.6 0.8 2.9 22.
7 
0.6 0.7 4.4 11.8 0.6 0.9 1.3 4.4 
 FGF2 fibroblast growth factor 2 A_23_P218
918 
1.1 1.1 1.1 1.1 2.4 13.
4 
1.2 1.2 5.3 12.3 1.1 1 1.2 3.5 
 FNDC3A fibronectin type III domain 
containing 3A isoform 2 
A_23_P255
03 
1.1 1.2 1 0.8 2.6 24.
8 
0.9 0.8 8 14.2 0.9 0.9 1.4 3.3 
 FNDC3A  A_24_P409
126 
1.1 1.8 1.2 1.1 2.5 47 0.9 1 7.4 60.8 1.2 1.3 1.3 3.9 
 FOLR2 folate receptor 2 precursor A_23_P477
09 
1.1 0.9 1 0.8 1.3 6.1 0.7 1 2.5 3 0.8 0.9 0.9 1.3 
 FRMD6 FERM domain containing 6 A_24_P330
303 
0.9 1 0.6 0.7 1.9 5.4 0.6 0.8 2.1 6.2 0.6 0.8 1.1 1.2 




1 0.9 1.1 1.1 3.2 17.
4 
1.1 1.1 9.4 11 1 1.1 1 2.8 
 FZD4 frizzled 4 A_24_P278
621 
1.4 1.4 1.3 1.3 3.3 50.
4 




protein like 1 
A_24_P481
6 




protein like 1 
A_23_P162
640 
0.9 1 0.8 0.9 1.8 9 0.8 0.9 2.6 5.7 0.8 0.8 0.9 1.7 




0.9 1.1 0.9 0.9 2.4 8.6 0.9 1 2.9 9.9 0.9 1.2 1.1 1.7 
 GATA6 GATA binding protein 6 A_23_P304
450 
1.8 1.6 1.6 1.2 5.7 17.
3 
1.1 1.3 6.6 14.8 1.7 1.3 1.4 2.6 




1.4 1.2 1.1 1 2.1 18.
4 
0.9 1 4.9 8.1 1.2 1 1 1.7 
 GLCCI1  A_23_P336
198 
1.1 0.9 0.7 0.9 2.3 14.
4 
0.8 0.9 7.2 7.6 0.8 0.8 1.2 2.6 
 GMFG glia maturation factor, gamma A_23_P208
866 
1.1 1 0.8 0.8 1 6.4 0.9 0.8 2.1 5.8 0.8 0.9 0.8 1.3 
 GPBP1 vasculin A_23_P364
465 





1.1 1 0.9 1.1 2.3 12.
8 
1 1 4 7.5 0.8 1.1 1.4 2.3 
 GRB10 growth factor receptor-bound 
protein 10 isoform c 
A_23_P122
863 
2.5 0.9 1.2 0.9 2.5 19.
1 
1.1 1 7.6 15.3 1 0.9 1.4 3.1 




1.1 1.1 0.7 0.9 3 20.
1 
0.7 1 6.2 13.3 0.7 1 1.6 3.4 
 HOXB3 homeobox B3 A_23_P316
511 
1 1.2 1.4 1.2 2.1 7.6 1.1 1.3 3.5 4.7 1.1 1.1 1.2 1.7 
 HOXB9 homeobox B9 A_23_P270
13 
0.9 1 1.1 1.2 2.4 10.
9 
1.2 1.2 4.8 8.1 1 1.1 1.1 1.9 
 HSCB J-type co-chaperone HSC20 A_23_P405
88 
1.2 1.2 0.7 0.9 2 11.
4 
0.8 0.9 4.3 9.8 0.7 0.9 0.9 1.6 




0.9 0.8 0.6 0.8 1.4 4.9 0.8 1.1 2 4.7 0.7 0.9 1.1 0.9 
 HSPB8 heat shock 27kDa protein 8 A_23_P162
579 
1.1 0.8 0.6 0.8 1.5 10.
5 
0.4 0.8 3.5 7.5 0.7 0.9 1.4 1.3 
 IGF2 insulin-like growth factor 2 A_23_P150
609 
1.1 0.8 1.5 1.3 4.5 37.
5 
1.2 1.4 21.1 25.9 1.3 1.1 0.8 3.9 




1.2 0.9 1.1 1.2 6.4 42.
9 
1.3 1.3 20.4 25.9 1.3 1.3 1.2 5.3 
 ING3 inhibitor of growth family, 
member 3 isoform 1 
A_23_P111
811 
1.3 1.3 1.2 1.2 1.7 9 1.2 1.2 3.2 7.9 1.2 1.1 1.1 1.7 
 INHBA inhibin beta A precursor A_23_P122
924 
1 1.7 1.3 1.3 2.6 18.
2 
1.1 1.5 5.6 9.1 1.2 1.2 1.2 3 




1.2 1.3 0.9 0.9 1.8 5.5 1 0.9 2.2 4.2 0.9 1.1 0.9 1.4 
 ITGA5 integrin alpha 5 precursor A_23_P365
62 
0.9 0.8 0.7 0.8 1.9 5.8 0.8 0.8 2.6 4.4 0.7 1 1.3 1.3 
 JAZF1 JAZF zinc finger 1 A_32_P366
94 
1.3 1.2 0.9 0.9 3 33.
3 
0.9 0.9 8.3 29 1 1.1 1.5 3.4 
 KCNG3 potassium voltage-gated 




1.1 1.1 1 0.9 2 52.
8 
0.9 0.9 6.2 30 0.9 1 1.1 4.5 




1.3 0.7 1 1.1 9.7 101
.6 
1 1.3 25.3 120.
8 
1.2 1.2 1.4 11.7 
 KLF6 Kruppel-like factor 6 A_24_P696
54 
1.4 1 0.9 1 2.9 7.2 1 1.6 3.8 3.9 0.8 0.8 0.8 1.3 
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 KLF6 Kruppel-like factor 6 A_23_P637
98 
1.5 1.1 1 1.1 3.5 9.7 1.1 1.7 5.3 5 0.9 0.9 0.8 1.4 
 KLF7 Kruppel-like factor 7 (ubiquitous) A_23_P679
80 
1 1 0.9 0.9 1.9 7.4 0.9 1.1 3.8 7 1 0.9 1 1.4 
 KTN1 kinectin 1 isoform a A_23_P106
131 
1 0.9 0.6 0.8 1.1 5.2 0.7 0.8 2.1 3.7 0.7 0.7 1 1.3 
 LRIG3 leucine-rich repeats and 
immunoglobulin-like domains 3 
A_23_P478
85 
1.1 1 0.9 0.9 1.9 10.
6 
0.7 0.9 2.2 3.2 0.9 0.8 1 1.3 




1.2 1.3 1 1.2 2.3 17.
3 
1.2 1.2 9.5 14.4 1.1 1.2 1.5 2.8 
 MAFB transcription factor MAFB A_23_P173
45 
1.1 1.1 0.9 1.1 5 17.
8 
1.2 1.2 7.3 9.2 1 1.5 1.1 3.2 
 MAFF transcription factor MAFF A_23_P103
110 
1 1.1 0.9 0.9 2.3 8.2 0.9 0.9 3.7 6.5 0.9 0.7 0.9 1.6 
 MAL2 MAL2 proteolipid protein A_23_P601
30 
1.1 1.3 1 1.7 2.3 80.
1 
0.8 0.7 7.3 79.1 1.2 1.4 1.6 6.2 
 MAOA monoamine oxidase A A_23_P838
57 
0.9 0.7 0.8 0.8 1.1 6.5 0.8 0.9 1.9 5.8 0.8 0.8 0.9 1 
 MAP4K4 mitogen-activated protein kinase 
kinase kinase kinase 4 isoform 2 
A_23_P108
604 
1 0.9 0.9 0.9 1.8 13.
2 
0.9 0.9 4 8.8 0.9 0.9 1.1 2.2 
 MAP4K4 mitogen-activated protein kinase 
kinase kinase kinase 4 isoform 2 
A_23_P102
192 
0.8 0.7 0.7 0.7 1.6 9.2 0.7 0.8 3.6 5.9 0.6 0.7 0.9 1.7 
 MCL1 myeloid cell leukemia sequence 
1 isoform 1 
A_24_P319
635 
1.4 1.4 0.6 0.9 3.8 9.2 0.7 1 5.1 8.4 0.7 0.9 1.1 1.6 
 MLL3 hypothetical protein A_23_P168
419 
0.9 0.9 1 0.9 1.5 6.6 0.9 0.9 3.4 4 1 0.9 1 1.4 
 NAV2 neuron navigator 2 isoform 1 A_23_P527
27 
0.8 0.9 1 0.8 1.6 12 0.9 0.9 4.7 7.4 0.9 0.7 1 2.2 
 NAV2 neuron navigator 2 isoform 1 A_23_P354
791 
0.7 0.7 0.7 0.4 1.3 8.8 0.8 0.4 3.8 8.5 0.6 0.5 0.9 1.5 
 NAV3 neuron navigator 3 A_24_P318
160 
0.9 1.1 0.7 0.9 2.3 40.
1 
0.8 0.8 7.8 31.2 0.6 0.9 1.9 3.2 
 NAV3 neuron navigator 3 A_23_P137
40 
0.9 1 0.9 1 1.7 12.
9 
0.9 0.8 3.8 8.4 0.8 0.9 1.7 2.2 
 NCALD neurocalcin delta A_23_P215
883 
0.8 0.6 0.9 1 3.8 16.
8 
0.9 0.7 5.8 14.7 1.3 1.2 1.1 2.3 
 NCF2 neutrophil cytosolic factor 2 A_23_P138
194 
1.1 1 1 1.1 3.1 31.
8 
1 1 5.3 25.4 1 1 1.5 5.9 




0.9 0.8 0.9 0.9 2.5 8.5 1.6 1.1 1.9 9.6 0.8 0.9 1 1.9 




1.5 1.2 1 1 3.1 6.2 0.9 1 3.1 6.3 1 1.1 1.2 1.5 
 NFKB1 nuclear factor kappa-B, subunit 1 A_23_P300
24 
0.9 1.1 1 1 2.3 10.
6 
0.9 1 4.4 7.2 1 1 1 2.5 
 NFKB2 nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 2 isoform b 
A_23_P202
156 
0.8 1.4 1.2 1.1 1.9 9.1 1.2 1.1 3.7 7.3 1.1 1.3 0.9 2.9 
 NLRP3 NLR family, pyrin domain 
containing 3 isoform a 
A_23_P988
3 
1.5 1 0.7 1.1 6.8 74.
6 
1.4 1 18.6 33.2 1.1 1 0.9 7.4 




1 1.1 1.3 1.3 2.8 17.
6 
1.2 1.3 5.3 14.5 1.1 1.3 1.2 1.4 
 NTN4 netrin 4 A_23_P204
630 
1 1 0.8 0.8 1.4 14 0.6 0.7 3.4 4.6 0.8 0.7 0.7 2.1 
 OR1F1 olfactory receptor, family 1, 
subfamily F, member 1 
A_23_P318
890 
1.2 1.3 1.6 1.4 2.7 13.
3 
1.4 1.3 7.1 6.7 1.1 1.1 1.1 3 
 OTUD1  A_32_P604
59 
1.1 1 0.8 0.9 7.2 150
.9 
0.7 1.1 29.3 102.
4 
0.9 0.6 1.1 7.1 
 OTUD1  A_24_P374
834 
0.8 0.8 0.6 0.6 6.8 85 0.5 0.7 24.1 55.8 0.7 0.5 1 5.3 





0.8 0.7 0.7 0.9 2.3 20.
9 
0.6 0.7 6.7 16 0.7 1.3 1.8 3 
 PAM peptidylglycine alpha-amidating 




1.1 1.1 1.2 1.1 1.3 5.9 1.1 1 1.9 3.2 1.1 1.1 1.2 1.4 




1 1.2 1 0.9 1.8 5.6 0.8 1 3.1 4.5 0.9 1.1 1.2 1.4 
 PELI1 pellino protein A_23_P120
345 
1.4 1.1 1.1 1.3 2.5 13.
8 
1.2 1 5.3 8.6 1.1 1.1 1.2 3.5 
 PHLDB2 pleckstrin homology-like domain, 
family B, member 2 
A_24_P240
166 
1.5 1.4 0.9 0.9 2.7 9.6 0.7 0.9 5 5.1 0.9 0.8 1.3 1.7 
 PLAG1 pleiomorphic adenoma gene 1 A_23_P411
723 
0.9 1 1 1.1 1.2 5.4 0.9 1 2.2 6 1 0.8 0.9 1.3 




0.9 1.2 1.3 1.7 3.6 22.
5 
1.5 1.7 16 23.9 1.1 1.2 1.2 1.9 
 PLCG2 phospholipase C, gamma 2 A_23_P106
675 
1.4 1.4 1.6 1.4 3.5 50.
2 
1.4 1.4 11.7 32.6 1.7 1.2 1.4 6.2 
 PLXNA1 plexin A1 A_23_P690
68 
0.9 0.7 0.6 0.7 1.4 6.5 0.9 0.9 3.2 4.2 0.8 1.3 1.3 1.6 
 PPID peptidylprolyl isomerase D A_23_P386
411 
1 0.9 0.8 0.8 1.1 4.4 0.8 0.9 1.5 4 0.7 0.9 1.1 1.1 
 PPM1K hypothetical protein A_24_P162
532 
1.9 0.7 1 1.1 4.7 8.9 1 1 3.5 7.3 1.1 1 0.9 2.7 
 PRKD1 protein kinase D1 A_23_P106
016 
1.2 1 0.9 0.9 1.3 5.3 0.9 0.9 2 3.5 1.1 0.9 1 1.2 
 PRRG4 proline rich Gla (G-




1.8 1.6 1.3 1.4 3.3 16.
5 
1.5 1.2 4.9 6.8 1.4 1.1 1.7 3.3 




1 1 1.1 1 1.2 7.5 1.1 1 2.3 6 1 0.9 1 1.5 




1.4 1.4 1 1 1.9 10.
1 
0.9 1 2.6 5.6 1.2 1 1.1 2.2 
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1 1 0.8 0.8 1.3 5.6 0.7 0.8 1.8 4.7 0.9 0.8 0.9 1.3 
 RAPH1 Ras association and pleckstrin 
homology domains 1 isoform 1 
A_24_P929
570 
0.9 0.9 0.5 0.7 2.9 22.
2 
0.6 0.7 6.6 19.3 0.7 0.9 1.3 2 
 RASGRP
1 
RAS guanyl releasing protein 1 A_23_P124
642 
1.1 1.2 1.2 0.9 1.3 21.
5 
0.7 0.8 2.7 11.7 1.2 1.1 1.1 2.4 
 RASSF5 Ras association (RalGDS/AF-6) 
domain family 5 isoform C 
A_24_P171
268 
1.1 1 0.7 0.8 1.6 19.
8 
0.6 0.6 1.6 7.8 1.4 1.3 1.3 2.1 
 RCOR1  A_23_P205
247 
1.2 0.8 0.8 0.8 2.5 12 0.7 0.8 4.1 9.4 0.6 0.5 0.7 1.5 
 RELB reticuloendotheliosis viral 
oncogene homolog B 
A_23_P557
06 
0.9 1.5 1.2 1.1 2.4 25.
7 
1.1 1 6.2 22.2 1.1 1 0.9 4.4 
 REV3L REV3-like, catalytic subunit of 
DNA polymerase zeta 
A_23_P214
139 
1 1.1 1 1.1 1.9 10.
7 
1.2 1.1 4.6 5.4 1 1 1.1 1.9 




1 0.8 0.6 0.8 5 200
.9 
0.9 0.9 57.8 105.
4 
1 0.6 1.1 15.4 
 RGMB RGM domain family, member B 
isoform 2 precursor 
A_24_P363
100 
1.1 1.2 1.2 1.2 1.9 7.3 1.1 1.3 3.2 5.8 1.1 1.3 1.2 1.7 
 RGS20 regulator of G-protein signalling 
20 isoform a 
A_23_P730
97 
1 1.2 0.8 0.9 1.4 9.4 0.8 1 2.7 7.6 0.8 1 1.2 1.2 
 RIPK1 receptor (TNFRSF)-interacting 
serine-threonine kinase 1 
A_23_P370
005 
1.4 1.2 1.1 1 3 8.1 1.1 1.1 5.3 5.6 1 1 1 1.7 
 RNF144 ring finger protein 144 A_23_P131
566 
1.3 1.3 1.2 0.9 2 12.
3 
1 1.2 2.2 9.7 1 1 1.1 2.1 




0.9 1 0.6 0.7 1.2 6.6 0.6 0.7 2.1 7.7 0.7 0.8 0.9 1.1 
 RP2 XRP2 protein A_23_P224
33 
1.2 1.2 1.1 1 2.3 7.3 1.1 1 4 4.3 1 0.8 1 1.7 
 RPS6KA6 ribosomal protein S6 kinase, 
90kDa, polypeptide 6 
A_23_P125
596 
0.8 0.8 0.7 0.9 1.3 5.9 0.7 0.8 2.4 5.7 0.7 0.8 1 1.4 
 RPS6KC1 ribosomal protein S6 kinase, 
52kDa, polypeptide 1 
A_23_P104
109 
1.3 1.4 1.1 1 2.4 28.
6 
1.1 1 7 18.4 1.2 1 1.1 2.6 




1.1 1.2 0.9 1 1.8 8.2 1 1.1 3.7 8.2 1.2 1.1 1.1 1.4 
 SALL1 sal-like 1 A_23_P328
074 
0.8 0.8 1 1.1 1.5 35.
3 
1 1 4.5 15.4 1.6 0.8 0.9 3.2 
 SAMD4A KIAA1053 protein A_23_P335
661 
1.1 1.2 1.1 1.1 2.7 14.
2 
1.1 1.2 7.4 9.1 1 1 1.2 2.2 




1.1 1.2 0.8 1.1 4.5 31.
1 
1.1 1.2 11 23.3 0.9 1.1 1.2 3.2 




1.2 1.2 0.7 0.9 1.6 7.4 0.7 0.9 1.6 6.9 0.9 0.9 1.3 1.4 
 SAR1A SAR1a gene homolog 1 A_24_P158
421 
1.1 1.1 0.9 0.9 2.1 15.
2 
0.9 0.9 3.8 9 0.9 1 1.2 3.2 
 SAR1A SAR1a gene homolog 1 A_23_P127
175 
1 1.2 1.1 1 1.7 29.
3 
1.1 1.1 4.5 28.2 1 1 1.1 2.9 
 SATB2 SATB family member 2 A_32_P174
365 
1.2 1.2 1 1 1.2 6.1 1 0.9 2.4 3.1 1 0.9 0.9 1.3 
 SCN3A sodium channel, voltage-gated, 
type III, alpha isoform 1 
A_23_P678
96 
1.8 1.5 1.1 1.3 2.9 130
.8 
1.6 1.3 11.4 45.4 1.4 1.1 1.3 1.7 
 SCYL1BP
1 
NTKL-binding protein 1 A_23_P368
145 
1.1 1.3 1 1 1.6 7.3 1 1.1 3.3 8.1 1 0.9 1.1 1.7 
 SDK1 FLJ00148 protein A_23_P937
22 
1 1 1.1 1 2.2 14.
3 
1.3 1.3 4.9 11.1 1 1.3 1.3 1.6 
 SEPSECS Sep (O-phosphoserine) 
tRNA:Sec (selenocysteine) tRNA 
synthase isoform 1 
A_23_P167
201 
1.1 1.1 0.8 0.8 1.9 7.5 0.7 0.8 2.2 7.9 0.8 0.6 0.7 1.5 
 SERTAD1 SERTA domain containing 1 A_23_P218
463 
1.2 1.1 1.2 1.1 2.1 6.6 1 1.1 3.6 5.4 1.1 1.3 0.9 1.1 
 SLA Src-like-adaptor A_23_P216
340 
1.3 1.3 1.5 0.7 2.1 25 0.6 0.9 5.4 9.3 1.2 1.3 1 2 
 SLC12A7 solute carrier family 12 
(potassium/chloride 
transporters), member 7 
A_24_P606
34 
1 1 1 0.8 2.4 20.
4 
0.8 1.1 11.8 17.7 0.9 1.2 1.3 3.1 
 SLC12A7 solute carrier family 12 
(potassium/chloride 
transporters), member 7 
A_23_P251
855 
1 0.8 0.7 0.9 2.4 23.
8 
0.7 0.9 14.6 16 0.7 0.8 1 3.4 
 SLC12A7 solute carrier family 12 
(potassium/chloride 
transporters), member 7 
A_23_P616
88 
1.6 1.6 1.7 1.3 3.6 50.
1 
1.5 1.5 26.5 45.1 1.5 1.3 1.5 5.1 
 SLC25A2
5 
solute carrier family 25, member 
25 isoform b 
A_24_P355
267 
1.1 1.1 1 1 2.4 6.7 0.9 1.1 3 5.8 1 1.1 1 1.4 
 SLC2A13 solute carrier family 2 (facilitated 
glucose transporter), member 13 
A_32_P199
801 
1 1 0.9 1 2.5 31.
3 
1 1.2 7.8 21.8 0.9 0.9 1.1 3.2 
 SLC2A13 solute carrier family 2 (facilitated 
glucose transporter), member 13 
A_23_P102
11 
1.2 0.9 1.1 1 1.5 14 0.9 0.9 3.5 11.3 1.2 0.9 1.4 2.8 
 SLC30A7 zinc transporter like 2 A_23_P229
15 
1.1 1.1 0.8 0.9 1.3 5.3 0.9 1 2.2 4.6 0.8 0.9 1.7 1.3 
 SLC31A2 solute carrier family 31 (copper 
transporters), member 2 
A_23_P217
109 
1 0.8 0.7 0.8 1 9.4 0.6 0.7 2 8.1 0.7 0.7 0.9 1.1 
 SLC33A1 acetyl-coenzyme A transporter A_23_P144
188 
1.3 1.2 0.9 0.9 2.6 12.
1 
0.8 1 4.8 8.3 1 1 1.7 2.5 




1 1.1 0.9 0.9 2.5 19.
2 
0.7 0.8 4.7 15 1 0.9 1.1 2.8 
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 SLC6A12 solute carrier family 6 
(neurotransmitter transporter, 
betaine/GABA), member 12 
A_23_P763
86 
1.2 1.3 1.1 1.2 3.2 40.
5 
0.7 0.7 8.8 11.1 1.1 1.1 0.6 4.4 
 SLCO5A1 organic anion transporter 
polypeptide-related protein 4 
A_23_P135
669 
0.7 1.4 0.7 0.9 2.3 38.
3 
0.9 0.8 8.4 17 0.9 1.2 1 2.6 
 SMPD3 sphingomyelin 




1.2 1.5 0.8 1.1 3.4 50.
6 
1 1.2 4.3 20.6 0.9 0.8 1.1 5.6 
 SNAPC1 small nuclear RNA activating 
complex, polypeptide 1, 43kDa 
A_23_P372
44 
1.4 1.3 1.1 1 2 6.3 0.9 0.9 2.8 8.9 1 1.1 1 1.7 
 SNPH syntaphilin A_23_P102
706 
0.9 0.9 1.4 1.2 5.2 34.
9 
1.3 1.5 24.9 24.5 1.5 1.2 1.2 4.7 
 SOD2 manganese superoxide 
dismutase isoform A precursor 
A_23_P134
176 
2.1 1.9 1 1.1 1.9 11.
4 
0.8 0.9 3.1 9.1 1.1 1.1 1.2 2.5 
 SPAG9 SPAG9 protein A_23_P207
476 
1 1.2 0.9 1 2.4 15.
4 
1 1.3 6.2 8.2 0.9 1.1 1.2 2.3 
 SPAG9 sperm associated antigen 9 A_24_P365
025 
1 1 0.8 0.9 1.4 8.8 0.8 0.9 3.2 6.5 0.8 0.9 1.2 1.8 
 SPRY2 sprouty 2 A_23_P128
698 
0.8 1.1 0.7 0.8 2.8 20.
1 
0.8 1 7.3 14 0.7 0.8 0.7 1.8 
 SRPK2 SFRS protein kinase 2 isoform b A_23_P406
438 
1 1 0.8 0.8 1.5 11.
4 
0.7 0.7 2.7 7.8 0.8 0.9 1.1 2.1 
 SRPK2 SFRS protein kinase 2 isoform b A_23_P215
599 
1 0.9 0.9 0.9 1.7 10.
8 
0.8 0.9 3.1 7.7 0.9 0.9 1.2 1.9 




1.1 1.1 0.6 0.8 2.9 9.3 0.8 1 4.3 7.8 0.7 0.6 0.9 1.3 




1 0.7 0.7 0.7 2.3 6.5 0.8 0.8 4.1 5.9 0.8 0.6 1 0.8 
 STK38L serine/threonine kinase 38 like A_23_P647
43 
1.3 1.2 1 1.1 2.5 15.
3 
1 1.1 4.1 13.4 1.1 1.1 1.3 2.5 
 STX11 syntaxin 11 A_23_P156
788 
0.9 0.8 0.7 0.8 2.4 11 0.7 0.8 3.4 9.5 0.8 1 1.1 2.3 
 SYDE1 synapse defective 1, Rho 
GTPase, homolog 1 
A_23_P101
796 
0.9 0.9 0.6 0.8 1.4 8.8 0.9 0.9 2.5 5.5 0.8 0.9 0.8 1.3 




1 0.8 0.9 1.3 2 23.
9 
1 1.3 6.4 13.2 0.9 1.5 1.8 2.2 
 TEP1 telomerase-associated protein 1 A_23_P654
81 
1.2 1.4 1.3 1.4 3.9 16.
5 
1.2 1.2 8.8 10.9 1.2 1.1 1.2 2.1 
 TESK2 testis-specific protein kinase 2 A_23_P987
5 
1 0.9 1.1 1.3 3 16.
2 
1.5 1 5.3 8.3 1.3 1 1 3 
 THRAP1 mediator of RNA polymerase II 




1.2 1 0.9 0.9 2.1 7 0.8 0.9 4.1 5.4 0.9 1 1.2 1.7 
 TMEM38B transmembrane protein 38B A_23_P602
59 
1.1 1 0.7 0.8 1.1 10 0.7 0.8 1.6 7.1 0.7 0.9 1.2 1.7 
 TMEM38B transmembrane protein 38B A_24_P278
156 
1 1 0.6 0.8 1 6.4 0.6 0.7 1.2 5.6 0.7 0.9 1.2 1.2 




1.1 1.1 0.3 0.8 2.2 65.
6 
0.3 0.5 3.3 44 0.6 1 1.9 3.6 
 TNFAIP6 tumor necrosis factor, alpha-
induced protein 6 precursor 
A_23_P165
624 
1.5 1.2 0.5 0.5 1 50.
9 
0.9 1 4.3 26.5 0.5 0.6 0.7 7 
 TNFRSF1
0B 
tumor necrosis factor receptor 
superfamily, member 10b 
isoform 1 precursor 
A_23_P169
030 
1 1.2 0.9 1 2.3 11.
5 
1.1 1 4.8 8.9 0.9 1 1.2 2.5 
 TRAF1 TNF receptor-associated factor 1 A_23_P216
970 
0.7 1.1 1.2 1.2 4.6 25.
8 
1.1 1.3 12.8 18.2 1.5 1.4 1.4 2.7 
 TRAF6 TNF receptor-associated factor 6 A_23_P759
21 





1.1 1.1 0.6 0.9 1.3 5.6 0.7 1 2.6 6.8 0.6 0.9 1 1.6 
 TRIM26 tripartite motif-containing 26 A_24_P898
583 
1.6 1.4 1.2 1.2 3.8 12.
1 
1.2 1.3 6.2 8.4 1.2 1.3 1.3 2.3 
 TRIM26 tripartite motif-containing 26 A_23_P214
587 
1.3 1.2 0.8 0.8 2.4 6.9 0.7 0.9 4 5 0.8 0.9 1 1.5 




1.3 1.4 1.3 1.1 1.8 7.9 1.3 1.2 2.3 3.5 1.2 1.2 1.2 1.6 
 TRPC4 transient receptor potential 4 A_23_P105
873 
0.6 0.4 0.7 0.8 3 107
.7 
0.7 0.7 30.2 98.8 0.5 0.5 0.7 4.5 




1 0.8 0.6 0.9 1.1 5.4 0.6 1 1.8 3.3 0.7 0.8 0.9 1 
 TTC28 KIAA1043 protein A_23_P291
85 
1.2 1.2 1.2 0.9 1.3 6 1 1 2.5 4.5 1.2 0.9 1 1.4 




1 1.1 1 1 1.8 10.
4 
1 1.1 3.1 7.8 1 1 1 1.7 




1 1 0.9 0.9 1.7 10.
5 
0.9 0.9 2.6 9 0.9 0.9 1 1.7 
 UTX ubiquitously transcribed 




1 1.1 0.8 0.8 2.4 26.
3 
0.8 0.9 6 15.1 0.8 0.7 1 2.3 
 WDR48 WD repeat domain 48 A_23_P804
09 
1.1 1.2 1 1 1.3 5.4 0.9 1 2.1 5.5 0.9 0.9 1 1.2 
 WHDC1  A_24_P307
827 
1.5 1.4 1.3 1.2 4.1 15.
3 
1.2 1.3 5.8 10 1.2 1 1.2 1.9 
 WNK1 WNK1 protein A_24_P511
27 
1 1 0.6 0.8 1.4 10.
3 
0.5 0.7 1.7 6.3 0.7 0.7 0.8 1.3 
 WTAP Wilms' tumour 1-associating 
protein isoform 1 
A_23_P371
155 
1.5 1.3 1.5 1.3 1.8 11.
1 
1.5 1.4 4 9.2 1.4 1.2 1.1 2 
 WTAP Wilms' tumour 1-associating 
protein isoform 2 
A_23_P215
037 
1 0.8 0.4 0.6 0.9 6.4 0.4 0.6 1.1 4.3 0.5 0.7 0.9 1.4 
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 XPA xeroderma pigmentosum, 
complementation group A 
A_23_P602
83 
1.1 1.1 0.8 0.8 1.2 7.2 0.7 0.8 2.2 8 0.8 0.8 0.8 1.2 




1.1 0.9 0.6 0.7 1.8 19.
3 
0.6 0.7 3.4 15.9 0.6 0.8 1 1.8 
 ZBTB43  A_24_P149
713 
1 1 0.8 0.8 1.6 4.7 0.9 1.1 2.2 4.3 0.8 1 1 1.1 




3.7 0.7 1.2 1.2 7.1 88.
4 
1 1.5 24.1 40 1.2 1.1 1.6 5.7 
 ZEB2 zinc finger homeobox 1b A_23_P142
560 
1.5 1.5 1.1 1.1 6.1 90.
6 
1 1.1 19.2 62.2 1.3 0.9 1 5.9 
 ZFY zinc finger protein, Y-linked A_24_P942
743 
1 0.9 0.8 0.7 1.5 10.
1 
0.6 0.7 2.4 8.5 0.8 0.8 0.9 2.1 
 ZFY zinc finger protein, Y-linked A_23_P624
65 
1.2 1.1 0.8 0.9 1.4 5.4 1 1 2 4.7 0.9 1 1.1 1.2 
 ZHX2 zinc fingers and homeoboxes 2 A_23_P168
951 
1 0.9 0.8 0.9 1.3 11 0.8 0.9 2.1 8.5 0.9 1.2 1.1 2 
 ZNF134 zinc finger protein 134 A_23_P141
866 
1 1.1 0.7 0.9 1.5 4.8 0.8 1 2 5.7 0.7 0.9 1 1.3 
 ZNF134 zinc finger protein 134 A_23_P325
661 
1 1.1 0.8 0.9 1.6 6.2 0.8 1 2.2 6.2 0.9 1 0.9 1.3 
 ZNF14 zinc finger protein 14 A_23_P101
811 
1 1.1 1 1 1.7 6.2 0.9 1 3.9 5.7 0.9 0.9 0.9 1.4 
 ZNF200 zinc finger protein 200 isoform 1 A_23_P152
356 
1.1 1 0.7 0.8 1.5 9.7 0.6 0.7 3.1 7.3 0.8 0.8 0.9 1.4 
 ZNF24 zinc finger protein 24 (KOX 17) A_24_P339
450 
1.2 1 0.8 0.7 1.9 9.1 0.6 0.8 1.9 10.1 0.8 0.9 1.2 1.7 
 ZNF323 zinc finger protein 323 isoform 1 A_24_P137
713 
1 1 0.8 0.9 1.8 5 0.7 0.9 2.5 6 0.8 0.9 0.9 1.4 
 ZNF416 zinc finger protein 416 A_23_P556
88 
0.9 1 0.8 0.9 1.6 3.6 0.9 1.1 2 4.9 0.9 0.9 0.9 1.2 
 ZNF529 zinc finger protein 529 A_23_P433
676 
1.1 1.3 1.2 1.1 1.5 8.2 1 1.2 2.4 8.2 1.1 1 1.1 1.6 
 ZNF567 zinc finger protein 567 A_23_P354
894 
1.1 1.2 1.1 1.1 1.2 9 1 1.1 3 6.2 1.1 1 1 1.3 
 ZNF597 zinc finger protein 597 A_23_P375
3 
1.4 1.2 0.9 1 2.4 7.9 1.2 1.5 3.5 6.5 1 1.2 1.1 1.4 
 ZNF638 zinc finger protein 638 A_24_P419
177 
0.9 1.1 1 1 2 4.7 1 1 2.8 4.6 0.9 1.1 1 1.1 
 ZNF670 zinc finger protein 670 A_23_P749
81 
1.1 1.1 0.8 1 1.7 7.1 0.7 0.9 2.8 6.5 0.8 1 1.1 1.5 
 ZNF671 zinc finger protein 671 A_23_P502
17 
0.7 1 0.8 0.6 1.2 5.1 0.7 0.8 2.7 6.2 0.8 0.7 0.8 1 
 ZNF697  A_32_P197
16 
1 0.9 0.8 0.7 2.8 21.
1 
0.5 0.9 5.9 21.4 0.9 0.9 1 2.6 
 ZNF711 zinc finger protein 711 A_23_P217
297 
1 1.1 0.8 0.9 1.8 7.5 0.6 0.8 2 11.3 0.9 1 1 1.8 
 ZNF79 zinc finger protein 79 (pT7) A_24_P128
312 
1.1 1.2 0.9 1 2 5.7 1 1.2 2.5 6.3 1 1.2 1 1.4 
 ZNF79 zinc finger protein 79 (pT7) A_23_P303
763 
1.2 1.3 1 1 2.1 6.3 1.1 1.2 2.1 7.2 1 1.3 1 1.5 




0.9 1.1 0.6 0.7 1.4 4 0.8 0.9 2 4.1 0.7 0.8 0.9 1 
  adenosylhomocysteinase 3 A_24_P725
18 
1.1 1 0.9 0.9 1 7.7 0.7 0.8 1.2 3.8 0.9 1 1 1.5 
  adenosylhomocysteinase 3 A_23_P252
075 
1.2 1.3 1 1.2 2.1 20.
9 
1.1 1.3 3.8 13.3 0.9 1 1.1 2.5 
  hypothetical protein A_23_P389
250 
1.4 1.7 1 1.6 3 15.
5 
1.2 1.3 6 10.5 1 1.2 1.6 2.4 
  hypothetical protein A_32_P828
63 
1.2 1.2 0.7 0.9 1.7 7.5 0.8 0.8 1.8 13 0.7 1.1 0.9 1.9 
  hypothetical protein LOC152641 A_24_P354
496 
0.9 1.2 0.7 1 1.6 6.8 0.9 1.1 2.8 6.7 0.9 0.8 0.8 1 
  hypothetical protein LOC79912 A_23_P204
187 
1 0.9 0.7 0.8 1.4 5.9 0.6 0.8 1.7 6.6 0.7 0.9 1 1.4 
  hypothetical protein LOC79912 A_24_P221
407 
0.9 0.9 0.7 0.7 2.8 8.1 0.7 0.8 1.6 5.9 0.5 0.8 0.9 1.6 




2 1.4 1.1 1.4 1.9 6.1 1 1.2 6.4 6 1.2 1.3 1 1.3 




1 1.1 1 0.9 2.2 12.
5 
1 1 4.2 7.5 1 0.6 0.8 2.1 
  KIAA2002 protein A_23_P658
51 
1 1.1 0.7 1 1.4 5.3 0.9 1 2.6 8.1 0.9 1 1.1 1.5 
  niban protein isoform 2 A_23_P217
832 
1 0.8 0.8 0.9 2.1 18.
6 
0.8 0.7 2.2 19.9 0.8 1 1.2 2.7 
  PALM2-AKAP2 protein isoform 1 A_23_P359
043 
1.2 0.8 0.5 0.6 1.5 7.6 0.5 0.6 1.8 4.5 0.6 0.7 1.1 1.6 




1.1 1.1 1 1 1.4 9 0.8 1 2.6 10.4 1.1 1 1 2.3 
   A_32_P998
04 
1.7 1.5 1.3 1.3 4.6 29.
7 
1.5 1.7 14.2 22.6 1.3 1 1.2 3.6 
   A_32_P889
05 
1.2 1.1 1.2 1.2 2.6 14.
9 
1.2 1.3 8.4 8.7 1.2 1 1 2.4 
   A_24_P682
22 
1.1 1.1 1.4 1.2 4.2 32.
6 
1.3 1.5 13.5 22 1.3 1.1 1.1 3.6 
   A_32_P165
407 
0.7 1 1.1 1 2.9 19.
9 
0.9 1 8.3 8.4 0.9 0.9 1 1.9 
   A_32_P192
389 
1.1 1.3 1.3 1 3.5 31.
8 
1 1.1 8.4 23.6 1.1 0.9 1 2.7 
   A_32_P117
322 
1.2 1.1 1 0.9 6.7 171
.2 
1 1.2 24 98.1 1.1 1.3 0.6 4.8 
   A_32_P137
604 
0.7 1.1 1.2 1.1 2.5 17.
7 
1.2 1.1 6.8 9.4 1.1 0.8 0.9 2.7 
   A_32_P685
04 
1.3 1.4 1.3 1.5 5.4 86.
3 
1.3 1.4 26.8 46.3 1.2 1.3 1.4 7 
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   A_24_P823
011 
1 1 0.7 0.8 1.8 7.6 0.6 0.9 4.5 4.9 0.9 0.9 1 1.9 
   A_32_P731
43 




0.8 0.9 18.3 58.8 1 1.9 1.8 5.3 
   A_24_P675
74 
1.6 1.4 1.8 1.3 3.8 12.
9 
1.7 1.1 7.9 9.9 1.1 1.5 1.9 2.7 
   A_24_P915
784 
1.3 1.2 0.9 0.9 2.2 40.
2 
0.8 0.9 5.2 27.6 0.8 1.1 1.3 2.9 
   A_24_P201
39 
1.2 1.3 0.7 0.8 2.7 22.
5 
0.7 1 5.7 19.1 0.8 0.9 1.1 2.5 
   A_23_P368
909 
1.2 1.1 0.9 1.1 2 27.
6 
0.8 0.8 4.4 17.2 0.7 0.9 1 1.7 
   A_23_P356
041 
0.8 0.7 0.5 0.6 1.4 6.7 0.5 0.7 2.3 4.6 0.5 0.7 1.1 1.4 
   A_32_P621
96 
1 1.3 1.2 1 2.1 16.
9 
1.2 1.1 5 12.2 1 1.5 2 2.2 
   A_32_P104
841 
1.4 1.5 1.4 0.9 3.4 64.
6 
0.8 1.2 14.4 45.3 1.3 1.4 3.3 9.4 
   A_32_P531
83 
0.8 0.9 0.9 0.9 2.1 11.
2 
0.8 1.2 4.4 9.7 0.8 1 1.1 1.4 
   A_23_P649
62 
1.1 0.7 0.9 1 3.6 39.
5 
1.5 1.2 7.1 19.9 1.1 1.5 1.2 2.5 
   A_24_P845
4 
0.8 0.8 0.8 0.9 1.8 8.2 0.9 1.2 3.8 5.5 0.8 1 1.2 1.8 
   A_32_P883
49 
1.1 1.8 1.3 1.2 2.7 10.
8 
1.4 1.3 5.4 11.2 1.3 1.1 1.1 2.7 
   A_24_P255
384 
0.9 2.1 0.9 1 1.8 52.
3 
0.8 1.3 13.5 31 0.9 0.9 0.9 7.3 
   A_23_P497
25 
0.8 2 1.2 1.1 2.4 35.
6 
1.6 1.2 8.3 17.4 1.4 0.5 0.7 3.7 
   A_32_P669
08 




0.9 0.9 17 44.2 1.1 0.9 1.2 2.8 
   A_24_P389
612 
1.2 1.2 0.8 0.8 3.6 18.
2 
0.7 0.9 8.2 14 0.8 0.8 1.2 2.1 
   A_32_P118
847 
1.2 1.1 0.9 1 2.6 11.
3 
0.9 0.9 6 7.5 0.9 0.9 1.1 1.5 
   A_24_P535
256 
1 2.1 0.8 0.6 3.6 14.
8 
0.6 1 6.7 7.1 0.6 1.2 1.7 2.5 
   A_32_P362
80 
1.1 1.3 0.9 0.8 2.4 9.5 1.3 1.2 4 8.5 0.8 0.6 0.9 1.6 
   A_23_P435
029 
1.1 1.3 1 0.8 1.8 5.8 1.4 1.2 4.3 4.4 1.2 0.7 0.9 1.4 
   A_24_P364
066 
1.3 0.9 1 1 2 7.7 0.9 1 4 3.6 1 1 1.2 1.8 
   A_32_P617
2 
1 0.9 0.8 0.8 1.5 15.
2 
0.9 1 5.4 10.1 0.8 0.9 1 1.7 
   A_24_P814
096 
1 1 0.8 0.9 1.5 5.2 0.8 0.9 2.2 3.8 0.8 0.7 0.8 1.2 
   A_24_P523
061 
1 1 1 1 1.5 5.5 1 1.1 2.6 4 1 0.8 0.9 1.3 
   A_32_P393
84 
1.2 1 0.9 0.9 1.4 7.7 0.8 0.8 2.7 7.6 1 0.8 0.7 1.5 
   A_32_P148
407 
0.9 0.9 1.3 1 1.3 15.
9 
1 0.9 3.1 10 1 1.1 1.4 2.5 
   A_24_P929
835 
1 1.5 0.8 1 2 5.9 1.1 1.3 4.2 5.9 0.9 0.9 1.1 1.4 
   A_24_P222
591 
1 1.1 0.7 0.9 1.7 5.5 0.8 1 2.1 6.4 0.8 0.9 1.2 1.3 
   A_32_P174
110 
1.2 1.1 0.9 1.8 1.8 7.9 0.8 1.2 2.8 6 1.2 1 1.3 1.4 
   A_23_P317
654 
1.2 1 0.7 0.9 1.6 5.5 0.8 0.9 2.3 3.2 0.7 0.9 1.1 1.1 
   A_24_P887
092 
2 0.9 0.9 1 1.9 18.
2 
0.9 1.1 2.6 12.2 0.9 1 0.7 4.5 
   A_24_P473
29 
2.7 2 1.7 1.4 4.2 39.
6 
0.9 1.1 7.5 12 1.4 2.3 2.9 6.3 
   A_24_P307
395 
0.9 0.8 0.5 0.5 1 7.3 0.5 0.6 1.7 3.4 0.5 0.8 0.9 1.5 
   A_23_P143
02 
1.1 1 1.2 1.1 1.9 10.
6 
1.3 1.3 2.2 4.8 1.2 1.1 1.5 2.6 
   A_32_P222
571 
1.9 1.5 1.7 1.6 3.7 9.3 1.7 1.9 5.6 7.1 1.4 1.3 1.3 2 
   A_32_P207
767 
1.1 1.2 1 0.8 2 8.2 0.8 0.9 2.9 6.9 0.6 0.8 1 1 
   A_23_P418
031 
1.4 1.5 1.5 1.3 2.5 6.1 1.5 1.4 3.9 4.8 1.5 1.6 1.3 1.4 
   A_23_P143
016 
1.3 1.2 1.1 1.1 2.8 6.5 1.3 1.2 3.6 4.4 1 1.3 0.9 1.2 
   A_32_P108
567 
0.7 0.8 1.2 1 3.9 11.
1 
1.2 0.8 3.8 7.3 1.1 0.5 1.1 1.9 
B ACAN aggrecan isoform 2 precursor A_23_P307
310 




1.4 1.2 19.6 20.3 1.2 0.9 2.1 14.2 
 ACTN2 actinin, alpha 2 A_23_P115
021 




1 1 185.3 235.
8 
1.1 0.9 1.4 40.8 




1.4 0.8 0.5 0.6 7.1 21.
1 
0.4 1.4 11.1 19.3 0.5 0.8 1.5 3.4 
 BAMBI BMP and activin membrane-
bound inhibitor precursor 
A_23_P522
07 
0.9 0.7 1.2 1 4.6 18.
9 
0.8 1 11.6 9.8 1.3 1.1 1.3 3 




1.1 1.9 1 0.9 6.5 40.
8 
0.7 0.9 11.6 34.9 1 1 1.7 9.2 
 C17orf66 hypothetical protein LOC256957 A_23_P430
792 




1 1.7 100.1 79.3 0.9 1.3 3.3 40.4 
 C17orf76 hypothetical protein LOC388341 A_23_P368
484 
0.8 1.2 1.2 1.1 2.9 12 1.1 1.2 5.8 7.5 1.2 1.1 0.9 2.6 
 C19orf30 hypothetical protein LOC284424 A_23_P353
667 
1.5 1.4 1.1 1.3 3.7 19.
6 
1.9 1.1 10.3 12.8 1 1.5 0.7 6.3 
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 C20orf141  A_32_P133
182 




0.8 3.4 237.7 99.4 1.1 1.1 4.1 13.9 
 C3orf59 hypothetical protein LOC151963 A_23_P326
963 
1.3 1.5 0.9 0.5 4.5 9 0.8 0.8 4 12.9 0.6 1 1.4 1.4 
 CASP3 caspase 3 preproprotein A_23_P924
10 
1.1 1.1 0.9 1 2.3 6.3 1 1 6.5 4.1 1 1 1.1 2.5 
 CCL20 chemokine (C-C motif) ligand 20 A_23_P170
65 
0.7 0.7 1 1.1 4.2 115
.8 
0.6 1.8 36.2 69.1 0.8 0.9 0.9 27.4 
 CCL4 chemokine C-C motif ligand 4 
isoform 1 precursor 
A_23_P207
564 




1.1 4.3 69.3 81.1 0.9 2.2 3.3 30.7 
 CSAG1 chondrosarcoma associated 
gene 1 isoform b 
A_24_P110
61 
1.8 2.1 1.2 1.2 6.7 33.
9 
1 1 18.6 21.3 1 1.2 1.4 8 
 CSAG2 CSAG family, member 2 A_24_P567
298 
1.3 2.1 1.1 1.2 7.4 43.
6 
1.1 1.5 23.5 30.2 1.3 1.3 1.6 8.2 
 CSAG3A CSAG family, member 3A A_24_P795
29 




1 1.2 40.8 45.9 1.1 1.1 1.7 15.7 




1 1.1 1.1 1 1.9 10.
4 
0.7 1.3 4.1 7.2 1.1 0.9 0.9 4.6 




1.5 1.2 1.3 1.2 3.5 7.5 1.1 1.8 5.5 5.3 1.2 1.2 1.3 3.9 




1.6 1.2 1.3 1.2 3.6 8.4 1.1 1.8 5.7 6.1 1.2 1.2 1.4 4.3 




1.7 1.3 1.2 1 4.4 16.
3 
0.9 1.9 10.1 11.5 1.1 1 1.3 6.1 
 CXCR4 chemokine (C-X-C motif) 
receptor 4 isoform a 
A_23_P102
000 




1 1.3 81.9 72.2 1.3 1.4 1.7 27.2 
 DCHS1 dachsous 1 precursor A_23_P986
45 
0.8 1.4 1.4 1.1 7.4 14.
9 





2.1 0.9 0.7 1.3 1.6 8.7 0.5 0.5 3.6 6 0.6 1.1 1 1.3 
 DNAJC15 DNAJ domain-containing A_23_P117
190 




0.8 1.8 22.7 17 1.2 2.3 2.2 6.3 
 EGR4 early growth response 4 A_23_P380
318 
0.9 1.1 1.5 1.3 33.
3 
84 1.4 4.4 56.3 46.2 1.2 1.2 2.5 23.8 
 FUT1 fucosyltransferase 1 A_23_P107
963 
0.6 1.2 1.3 1.3 5 25.
6 
1.4 0.9 8.8 17.7 1.1 1.6 1.4 5.1 
 FZD4 frizzled 4 A_23_P646
17 
0.9 1.3 1.1 1.1 7.5 75.
2 
1.2 1.4 22.8 49.5 1.1 0.9 1.4 14.3 




1.2 2.1 1 0.9 3.6 6.9 0.7 1 3.2 7.9 1.2 1 0.8 1.8 
 HES4 hairy and enhancer of split 4 A_23_P149
448 
1.3 2.5 1.4 1.3 4.2 10.
9 
1.4 1.5 7.7 7.6 1.3 1.4 1.3 3 




0.9 0.9 1.1 1.2 5.9 14.
7 
1.2 1.5 11.1 9.6 1.1 1.2 1.4 4.8 








1.8 2.2 43.5 48.3 1.8 1.4 1.8 11 
 HOXB4 homeobox B4 A_24_P416
370 




1.2 1.7 44 32.1 1.2 0.9 2.1 5.8 




0.8 1.6 1.1 1.1 3.8 39.
6 
0.8 1 21.8 23.4 1 1.1 1.1 5.7 




4 1.8 0.9 1 14.
2 
75 0.8 1 39.2 57.2 0.7 1 2.5 23.3 




1.2 1.9 1.9 1.1 3.9 15.
2 
1.9 1.5 6.9 10 1.4 1 1.3 6.2 
 IL8 interleukin 8 precursor A_32_P870
13 




0.7 2.2 42.3 43.2 1.1 1.4 2.8 17.7 
 JAK2 Janus kinase 2 A_23_P123
608 
1.8 1.2 1 1 9.1 22.
5 
0.9 1.1 14.8 13.2 0.9 1 1.6 5.1 
 KCNN1 potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 1 
A_23_P119
573 




1 1.3 32.6 27.4 1 1 1.7 9.3 
 KLF2 Kruppel-like factor A_23_P119
196 
0.8 0.8 1.1 1.1 5.6 25.
4 
1.2 1.4 16.4 11.8 1 0.9 1 3.1 
 KLF4 Kruppel-like factor 4 (gut) A_23_P322
33 




0.6 1.1 24.8 34.7 0.8 1 2.3 9.2 
 KLHDC7B kelch domain containing 7B A_24_P117
410 




1.3 1.3 17 27.1 1.1 1.3 1.9 11.1 
 LRRN3 leucine rich repeat neuronal 3 A_23_P313
76 




0.9 1.8 192.9 193.
2 
0.9 1.5 7.3 81.3 
 LTB lymphotoxin-beta isoform a A_23_P933
48 
0.8 1.1 0.9 1.3 3.3 34.
4 
1.6 1.5 9.8 28.6 0.8 1 1.1 18.7 
 MED12L mediator of RNA polymerase II 
transcription, subunit 12 
homolog (S. cerevisiae)-like 
A_32_P701
268 
0.8 0.7 1.9 1.2 4.1 46.
7 
1.6 1.2 18.3 23.7 1.4 2.4 1.3 6.6 
 MXD1 MAX dimerization protein 1 A_23_P408
094 
1.1 1.2 1.3 1.2 5 21.
7 
1.5 1.5 9.8 10.4 1.2 1.2 1.3 4.6 
 NFKBIA nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, alpha 
A_23_P106
002 
1.1 1.3 1 1.1 9.7 59 0.8 2 34.7 24.5 1 1.1 1.6 7.1 
 NFKBIE nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, epsilon 
A_23_P306
55 
0.8 1.2 1.2 1.2 3.9 20.
3 
1.1 1.1 7.5 12.4 1.2 1.3 1.1 3.7 
 PIWIL4 piwi-like 4 A_23_P427
760 
1 1.5 1.5 1.6 3.4 8.8 1.3 1.3 7.7 6 1.1 1.3 1.4 3.3 
 PLA2G4C phospholipase A2, group IVC A_23_P505
08 
1 1.1 0.7 1 7.5 60.
9 
0.7 1.2 21.1 28.1 0.9 1 1.3 8.3 
 PMAIP1 phorbol-12-myristate-13-acetate-
induced protein 1 
A_23_P207
999 




0.7 2 24.5 21.1 0.7 1.1 1.8 5.3 
 PPP1R15
A 
protein phosphatase 1, 
regulatory subunit 15A 
A_23_P901
72 




1.2 2.4 20.4 19.2 1 1.1 1.4 5.7 
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 PRDM1 PR domain containing 1, with 
ZNF domain isoform 1 
A_23_P350
451 
1 1.5 1 1 6.9 7.9 0.9 1.1 5.3 6.2 1 0.9 1 2.9 
 PRR15 proline rich 15 A_32_P154
911 
2.4 1.6 1.6 1.6 9 12.
4 
1 1.5 12.2 9.1 1.8 1.5 2.3 6.8 




1.1 0.9 0.6 0.9 20.
5 
146 0.5 2 41.7 72.9 0.7 1.1 2.3 14.4 
 PTX3 pentraxin-related gene, rapidly 
induced by IL-1 beta 
A_23_P121
064 




0.6 1 67.2 89.1 0.7 0.8 1.4 20.1 




1.1 1.1 0.7 1 4.2 15.
9 
1 1.4 7.8 12.4 0.8 0.8 1.1 3.9 
 SEMA3D semaphorin 3D A_32_P291
18 




1 1.3 73.8 127.
7 
1 1 2.2 21 
 SLC1A3 solute carrier family 1 (glial high 








1.5 1.4 125.4 105.
4 
1.4 0.9 1.8 17.1 
 TMC8 FLJ00400 protein A_23_P346
093 
0.7 1.5 1 1.6 5 21.
8 
1.7 1.9 11.7 15.4 0.8 1.4 1.8 5.3 
 TNFAIP2 tumor necrosis factor, alpha-
induced protein 2 
A_23_P421
423 
0.9 1.1 2 1.6 2.9 19.
5 
1.5 1.5 9.6 13.4 1.8 1.4 1.3 5.3 
 TNFAIP3 tumor necrosis factor, alpha-
induced protein 3 
A_24_P166
527 




1 2.5 29 23 0.9 1 1.5 6.6 
 TNFAIP3 tumor necrosis factor, alpha-
induced protein 3 
A_24_P157
926 
1.4 1.5 1.1 1.5 17.
1 
78 0.8 2.7 34.1 37.5 1.2 1.2 1.9 13.8 
 TNFRSF9 tumor necrosis factor receptor 
superfamily, member 9 precursor 
A_23_P519
36 
1.1 1.2 1.1 1.1 4.2 28 1.4 1.1 12.4 19.1 1 1.4 2.3 8.2 
 TRAF1 TNF receptor-associated factor 1 A_24_P898
91 
0.7 1.7 1.4 1.3 5.6 21.
8 
1.1 1.4 14.8 14.5 1.1 1.4 1.4 3.6 
 TTC9B  A_23_P332
392 
1 1 1 1 8 25.
1 
1.2 1.3 15.3 16 1 1.2 1.4 7.2 
 ULBP2 UL16 binding protein 2 A_23_P168
259 
1.1 1 0.7 1 8 26.
5 
0.6 1.4 16.2 16.8 0.7 1 1.4 4.1 
 ULBP2 UL16 binding protein 2 A_24_P149
314 
1.2 1 0.6 0.7 6.5 13.
7 
0.7 1.1 13.1 8.9 0.9 1.1 1.5 2.8 
 ULBP2 UL16 binding protein 2 A_23_P145
485 
1.1 0.9 0.6 0.8 6.4 16.
6 
0.8 1.3 13.4 10.7 0.8 1.1 1.3 3 
 WISP1 WNT1 inducible signaling 








1.1 1.4 38.8 18.7 1.2 0.9 1.1 9.1 




1 1 0.8 0.9 5.1 12.
9 
0.7 1 7.4 12.7 0.8 1 1.7 2.3 








0.6 1.6 26 74 1 1.1 1.9 10.5 








1.1 2 33.6 77.2 1.1 1.1 2.1 15.8 
  hypothetical protein A_24_P119
678 




1.4 1.2 21.4 18.9 1.6 0.9 1.4 9.9 
   A_32_P957
66 
0.8 0.7 0.9 1.1 16 125
.9 
1 1 84.6 88.1 1 1 1 25.5 
   A_24_P931
804 
0.8 0.7 0.9 1.1 16.
9 
91 1 1.5 54 42.6 1 0.8 1.1 10 
   A_32_P219
135 
1 1 1.7 1.6 9.7 26.
6 
1.5 1.8 19.2 18.8 1.6 1.8 1.8 8.6 
   A_24_P933
828 
0.8 0.7 1.3 1.1 5.9 27.
4 
1.1 1.5 16.4 19.1 1.2 1.4 1.4 6.2 
   A_23_P506
46 




1.2 2 23.2 25.3 1.6 1.4 2 9.1 
   A_23_P119
80 




1 1.9 34.3 40.5 1.8 0.9 1.3 11.2 




1.4 2.4 33.9 32.2 1.1 1 1.2 4.8 
   A_32_P221
437 
1.1 1.1 1.2 1.2 4 13.
3 
1.4 1.3 8.8 7.2 1.2 1 1.2 2.9 
   A_32_P308
98 
1.1 1.2 1.1 1.4 4.1 18.
8 
1.3 1.5 8.2 9 1 1.1 1.6 3.9 
   A_32_P222
684 
1 1.2 1.3 1.4 9.1 46 1.1 1.4 40.7 26.8 1.2 1.5 1.5 6.3 
   A_24_P401
830 
0.9 1.2 1.4 1.5 6.7 18.
2 
1.4 1.7 17.8 10.4 1.1 1.2 1.2 3.8 
   A_32_P170
664 
1.1 1 0.9 1.2 5.4 19.
7 
1.1 1.4 16.8 8.8 0.8 1.2 1.3 4.3 
   A_24_P652
537 
1.6 1.6 1.4 1.2 30.
8 
95 1.4 1.3 55.5 52.1 0.9 1.1 2.8 15.2 
   A_23_P328
740 
1 1.7 0.9 1.3 8.9 36.
8 
1.1 1.9 17.7 35.7 0.9 1.1 1.5 8.6 
   A_32_P224
888 




1.1 1.5 44.9 36.2 1 0.9 2.5 6.3 
   A_32_P122
494 
1.2 1 1.6 1.3 4.6 14.
9 
1.2 1.3 9.9 8.8 1.7 1.2 2.1 3.3 
   A_32_P217
261 
1.4 1.2 1 1.1 4.5 32.
4 
0.9 1 8 17.7 1 0.9 1.3 4.7 
   A_24_P849
245 
1.2 1.1 0.8 1 3.1 10.
2 
0.8 0.9 4.5 7 0.8 1 1.1 3.4 
   A_24_P101
651 
1.3 2 1.3 1 8.1 32.
3 
1.1 1.3 18.9 21.2 1.2 1.8 2.1 7.8 
   A_23_P285
82 
0.7 1 0.7 0.7 2.2 14 0.9 0.8 5.8 7.7 0.8 0.7 0.8 3.9 
   A_32_P458
44 
1.4 2.5 1.2 1.3 29 77.
3 
0.9 1.8 32.1 23.6 1.4 1.8 2.1 18.9 
   A_24_P734
406 




1 1.6 14.2 16.4 1.2 1.1 1.8 7.5 
   A_32_P169
550 
0.9 1.3 1.2 0.9 6.2 9.2 0.9 1.4 5.6 6.4 1.1 0.9 0.9 2.9 
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   A_23_P157
766 
1 1.2 1.3 1 4.9 8 0.8 0.9 5.7 5.1 1.4 1.1 0.9 3.1 
   A_23_P320
407 
0.6 2.1 2.1 2.1 4.1 25.
6 
2.8 1.7 10.8 11.4 2.1 1.3 1.3 4.7 
   A_24_P174
353 
0.9 2.1 1.6 1.1 3.9 14.
9 
1.5 1.4 9 15 1.5 1.9 1.1 8.3 
   A_24_P231
483 
1.6 3.8 1.3 1.1 8.9 26.
5 
0.8 1.3 18.7 17.9 1 1.2 1.2 2.1 
   A_32_P535
24 
1 0.9 0.7 1.3 1.7 9.7 0.9 0.5 4 4 0.9 1.3 1.1 1.9 
   A_23_P207
774 
1 0.9 1.2 1.2 2.7 9.7 0.6 0.6 4.6 4.6 0.8 1 0.7 2.1 
C ABCA5 ATP-binding cassette, sub-family 
A , member 5 
A_24_P670
96 
1 1 1.8 1.5 1.8 9.1 1.6 1.5 4.4 4.3 1.5 1.1 1.2 1.4 
 ABCA5 ATP-binding cassette, sub-family 
A , member 5 
A_23_P780
18 
1.1 1 1.5 1.4 1.7 7.7 1.5 1.5 3.8 3.5 1.3 1 1.1 1.4 
 ABL2 v-abl Abelson murine leukemia 




1.1 1 1.8 1 3.2 10.
6 
1.1 1.2 5.6 7.6 1.6 1.1 1.3 1.6 




1.1 0.8 1.1 1.1 1.1 7 1 1.1 2.7 3.7 1.1 1.1 1.1 1.2 
 ALDH1L2 hypothetical protein A_23_P879
41 





0.9 1.1 1.9 1.3 1.6 3.9 1.3 1.5 2.6 4.3 1.4 1.1 1.3 1.1 




1.1 1 1 1.1 2 7.6 0.9 1.1 5.4 4.2 1.1 1 1.1 1.6 
 ANKRD1 cardiac ankyrin repeat protein A_23_P161
218 
0.9 0.9 1.1 1.2 1.3 5.6 0.9 1.1 1.3 4.4 0.8 0.7 0.5 0.9 
 AP3B2 adaptor-related protein complex 
3, beta 2 subunit 
A_23_P773
04 
1.7 1.4 1.4 1.4 1.2 10.
5 
1.2 1.2 1.7 6.5 0.9 1.2 1.4 1.1 
 AQP9 aquaporin 9 A_23_P106
362 
0.8 0.8 0.9 1 0.7 22.
8 
1 0.9 1.8 26 0.9 0.9 1 1 
 ARHGAP
9 




1.6 1.6 1.1 1.1 2.2 12.
8 
1 2.8 5.6 14 1.3 1.6 1.1 2.8 




1 0.9 1 1 1.4 4.9 1.3 1.1 3.4 3.2 1 1 0.9 1.1 
 AVIL  A_23_P532
57 
1 1.3 1.6 1.4 2.6 6.8 1.9 1.6 7.8 2.8 1 0.8 0.6 1 
 AXUD1 AXIN1 up-regulated 1 A_23_P121
011 
1.1 0.8 0.7 0.9 4.3 3.8 0.7 1.1 4.6 2.9 0.7 1.2 0.9 1.1 




0.8 0.9 1.5 0.9 2.2 13.
8 
1.6 1 4.2 8.7 1.1 1.5 0.8 1.4 
 BBC3 BCL2 binding component 3 A_24_P305
312 
0.8 0.7 0.6 0.8 3.1 6 0.8 1.3 5.6 2.5 0.7 0.9 0.8 1.6 
 BBC3 BCL2 binding component 3 A_23_P382
775 
1.4 1.2 1.5 2 9.8 35.
1 
1.9 3.5 28.5 10.3 1.2 1.4 1.2 3.9 
 BCL6 B-cell lymphoma 6 protein A_23_P578
56 
1.7 1 1.3 1.2 4.1 9.3 1.1 1.2 7.8 5.2 1.1 0.8 1.2 1.8 
 BEXL1  A_24_P405
51 
1 0.9 0.9 1 1.1 5.4 0.8 0.9 1.3 5.1 0.9 1 0.8 1.1 




1.1 0.9 1.1 1 1.1 7.4 0.9 0.9 1.1 3.3 1 1.1 1 1.1 
 BOC brother of CDO A_23_P257
763 
0.8 0.7 1.3 0.9 1.2 5 1.3 1.3 2.4 2.8 1 0.8 0.8 0.9 
 C10orf10 fasting induced gene A_23_P355
97 
0.8 1.3 0.9 0.8 1.4 8.9 0.9 1.2 2.7 4.5 0.7 0.5 0.3 1 
 C10orf10 fasting induced gene A_24_P329
795 
2.4 1.9 1 1.1 1.3 12.
2 
0.9 1.2 2.7 6.1 0.9 0.6 0.3 1.2 




1 0.9 1.2 1.1 4 6.3 1.1 1.6 7.5 3.9 1.2 1 0.9 1.7 
 C12orf28 hypothetical protein LOC196446 A_32_P424
761 
0.9 0.6 0.9 1.1 1 10 1 1.1 4.7 7.4 1.3 1 1 1.4 
 C12orf34 hypothetical protein LOC84915 A_23_P128
375 
1 1 1.2 1.2 1.4 8 1.1 1.2 2 6 1.1 1.3 1.2 1.6 
 C14orf81  A_24_P153
558 
0.8 1 1.5 1.3 1.2 8.6 1.4 1.1 3.9 4.1 1.3 1.1 0.8 1.2 
 C17orf55 hypothetical protein LOC284185 A_23_P426
565 
1.1 1 1.4 1.2 2.7 4.9 1.1 1.2 7.7 2.9 1.3 0.9 1.1 2 




0.8 1.7 0.8 0.9 1.9 11.
1 
1 1.1 2.2 9 0.8 0.9 1.1 2.7 
 C19orf47 hypothetical protein LOC126526 A_32_P505
133 
0.9 0.9 1 0.8 1.1 3.6 1 0.9 1.6 5 0.8 0.8 0.8 1.1 
 C1orf102 oxidored-nitro domain-containing 
protein isoform 1 
A_23_P103
433 
1.1 0.9 1.2 1.1 1.3 4.3 1.3 1.2 2.1 4.5 1.1 1 0.9 1.1 
 C1orf79  A_23_P745
81 
1.1 1.3 1.5 1.4 2 6.5 1.3 1.3 2.4 6.2 1.3 1.3 1.1 1.6 
 C2orf49 hypothetical protein LOC79074 A_23_P165
698 
1.1 1.1 0.9 0.9 1.3 5.8 0.9 1 1.6 6.1 0.9 1 0.9 1.4 
 C3orf19 hypothetical protein LOC51244 A_24_P144
481 
1.1 1.3 1.3 1.2 2 8.5 1.4 1.2 4 8 1.2 1.1 1 1.6 




1.1 1.3 1.3 1.2 2.7 6.6 1.6 1.6 2.9 5.6 1.3 1.2 1.4 1.4 
 CAMK1G calcium/calmodulin-dependent 
protein kinase IG 
A_23_P974
02 
1.2 0.6 1 1.1 3.1 22.
7 
0.8 0.8 7.3 23 1 1.1 0.5 3.1 
 CCDC65 coiled-coil domain containing 65 A_23_P479
04 
1.4 0.7 0.7 1.2 1 9.3 0.7 1.4 1.8 11.3 0.7 1.4 0.6 1.3 
 CCL23 small inducible cytokine A23 
isoform CKbeta8-1 precursor 
A_24_P319
088 
0.3 0.9 1 1.2 1.2 9.6 1.1 1.1 2.9 2.9 1.1 1 0.9 1 
 CD163L1 scavenger receptor cysteine-rich 
type 1 protein M160 precursor 
A_23_P614
66 
1.2 1.3 0.7 1.1 1.6 5.7 1.3 0.6 2.3 5.2 1 0.8 1.2 1 
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 CD70 tumor necrosis factor ligand 
superfamily, member 7 
A_23_P119
202 
1.1 1 1.7 1.4 1.3 10.
4 
1.6 1.4 3.3 7.8 1.5 1.5 1.2 2 
 CD83 CD83 antigen isoform a A_23_P706
70 
0.8 0.9 0.9 0.9 1.7 10.
9 
0.8 0.8 4 7.5 1.1 1 0.8 2 




1.5 0.9 1.2 1.3 4.6 7.7 1.3 1.5 9.6 5.9 1.1 1.2 1.2 2.1 




1.3 0.9 0.9 1 2.6 3.3 1 1.2 4.4 2.6 0.9 1 1 1.5 




1.5 0.8 1 1.1 3.3 4.3 1.1 1.2 5.8 3.2 1 1 1 1.7 
 CHGA chromogranin A precursor A_32_P270
46 
1 1 1.3 1.1 1.2 5.2 1.3 1.2 1.7 3.9 1.2 1.1 1.1 1.2 
 CLEC4M C-type lectin domain family 4, 
member M isoform 3 
A_23_P208
482 
1 1.1 1.6 1 1.1 7.1 1.5 1.3 2.7 6.4 1 1.1 0.9 1.2 
 CLK4 CDC-like kinase 4 A_23_P616
74 
0.9 1.1 1.4 1.2 1.6 6.3 1.3 1.4 3.9 4.3 1.2 1.1 1 1.4 
 CLK4 CDC-like kinase 4 A_24_P123
521 
1 1 1.2 1.2 1.4 4.7 1.2 1.3 2.8 2.7 1 1.2 1 0.9 




1 1.2 1.6 1.3 2.4 40.
4 
1.2 1.3 9 14.8 1.4 1 0.8 2.7 




0.9 1.1 1.1 0.9 2 24.
9 
1.5 1.2 6.3 12.9 1 1.4 0.8 2.3 
 CXXC4 CXXC finger 4 A_23_P121
676 
1.1 1 1.2 0.7 2.2 35.
4 
1.1 1 11.2 30.5 1.8 1.1 1.1 2.8 
 DENND4
A 
c-myc promoter binding protein A_24_P136
497 
1.5 1 1.7 1.4 2.9 11.
9 
1.5 1.3 6.6 4.9 1.3 1 1.1 1.6 
 DHRS2 dehydrogenase/reductase (SDR 
family) member 2 isoform 1 
A_23_P485
70 
1 0.9 1.5 1.5 1.6 8.6 1.1 1.1 2.5 7.5 1.4 1.3 1 2.2 
 DICER1 dicer1 A_23_P371
11 
1.1 1.1 1.8 1.4 2.5 21.
8 
1.8 1.5 11.3 7.7 1.6 1.2 1.2 2.6 




1 1.1 1.3 1.2 1.5 5.9 1 1.1 2.4 4.4 1.1 1.1 1.1 1.4 
 DND1 dead end homolog 1 A_32_P420
54 
0.9 1.1 1.6 1.3 2 57.
1 
1.7 1.4 8.1 19.2 1.4 1 1 1.3 
 DPYSL4 dihydropyrimidinase-like 4 A_23_P331
049 
1.1 1.1 1.2 1 1.5 6.1 1.3 1 3.9 3.8 1.1 1.1 1.2 1.3 
 DUSP8 dual specificity phosphatase 8 A_24_P322
867 
1.1 1.4 1.8 2 2.7 10 1.7 1.8 7.4 5.2 1.8 1.8 1.1 1.9 
 DUSP8 dual specificity phosphatase 8 A_23_P390
528 
1.1 1.4 2.3 2.1 2.7 10.
6 
2.1 2.1 7.9 5.1 2 1.7 1.2 1.8 




1.1 1.1 1.1 1.2 1.1 11.
9 
1.3 1.1 1.9 10.4 1 1.1 1.1 2.1 
 EFNA1 ephrin A1 isoform a precursor A_23_P254
512 
1.2 1.3 1.5 1.5 4.9 6 1.1 2.1 10 3.6 1.4 1.2 1 3.3 
 EFNA1 ephrin A1 isoform a precursor A_23_P113
005 
1.1 1.1 1.1 1.2 3.3 3.2 1 1.6 5.5 2.4 1.1 1 0.9 2.4 
 EGR1 early growth response 1 A_23_P214
080 
0.7 1 1.4 1.4 4.4 9.1 1.2 2.4 13.7 4.4 1.4 1.3 1.1 1.3 
 EGR3 early growth response 3 A_23_P216
225 




1.2 1.9 39.9 7.3 1 0.9 1 5.6 




1 1.1 1.1 1 1.4 4.7 1 1 1.7 5 1 0.9 0.9 1.1 
 EPHA4 ephrin receptor EphA4 A_23_P108
501 
0.8 0.9 1.3 1.2 2.6 40.
2 
0.9 1 8.5 29.4 1.4 1.1 1.1 4.1 
 ETV3 ets variant gene 3 A_23_P400
945 
1.1 1.1 1.6 1.7 5.1 3.9 1.7 2.5 6.6 2.1 1.5 1.4 1.5 3.1 
 EZH2 enhancer of zeste 2 isoform a A_23_P259
641 
1.1 1 1.2 1.1 1.2 8.2 1.2 1.3 3.5 4.2 1.2 0.9 1 1.1 
 FAM110A hypothetical protein LOC83541 A_23_P386
241 
0.9 0.8 1.1 0.9 1.1 5.3 1.2 1.1 2.3 6 1 0.9 0.8 1.4 
 FAM90A1 hypothetical protein LOC55138 A_24_P643
028 





1 0.9 1.2 1.3 1.2 5.7 1.3 1.2 1.8 4.9 1.1 1.2 1 1.3 




1 1 0.8 1 1.7 3.2 0.9 0.6 1.6 6.2 1.3 0.9 1.3 1.6 
 GABPB2 GA binding protein transcription 




1.2 1.3 1.3 1.2 1.4 8.2 1.2 1.1 2 8.5 1.3 1.2 1.9 1.8 
 GBA3 cytosolic beta-glucosidase A_23_P186
72 
1 0.7 1 1.2 1 118
.2 
1 1.1 5 113.
2 
1 1.4 0.8 2.7 




1.2 1.1 1.3 1.4 3 15.
3 
1.5 1.3 9.3 8.1 1.2 1.1 1.3 2.7 
 GLI3 GLI-Kruppel family member GLI3 A_23_P111
531 
1.3 4.2 0.9 1.4 5.5 9.7 1 1.5 5.9 5.1 1 0.9 1.2 1 
 GOT1 aspartate aminotransferase 1 A_23_P638
25 
1.1 1 1.1 1.1 1.4 4.1 1.2 1.2 1.4 6.3 1 1.2 1.3 1.5 
 GP1BA  A_23_P152
926 
1 1.9 1.9 1.7 3.7 85.
4 
1.5 1.4 17.2 112.
9 
2.5 2.1 1.5 5.1 
 GRIP2 FLJ00218 protein A_24_P930
868 
2.5 2.2 1.7 2.4 9.2 19.
9 
2.2 1.6 12.3 6.1 1.5 1.8 1.2 4.8 
 HARS histidyl-tRNA synthetase A_24_P892
84 
0.8 0.8 1.2 0.9 0.9 20.
1 
1 0.9 1.3 8.2 0.9 1 0.9 0.9 
 HARS histidyl-tRNA synthetase A_23_P133
227 
1 1 1.1 1 1.1 33.
5 
1.2 1 1.8 13 1 1.1 1 1 
 HBG1 A-gamma globin A_23_P531
37 
1 0.8 1 0.9 1.2 6.8 1 1 3.3 9.5 1 0.9 1.2 1.4 
 HCFC2 host cell factor C2 A_23_P254
03 
1.3 1.3 1.3 1.1 1.5 5.4 1.1 1.1 2 5 1.3 1.1 1 1.2 




1 1.1 1.7 1.3 3.3 18.
8 
1.7 1.6 9.8 15.1 1.4 1 0.9 2.2 
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 HCP5 HLA complex P5 A_24_P178
70 
1.4 3.4 1.4 1.6 1.5 40 1.5 1.6 4.1 18.1 1.2 1.1 1.3 8.8 
 HCP5  A_23_P111
126 
1 8.2 0.8 0.8 3 72.
6 
0.8 1.6 3.7 40.2 0.6 1.1 1.4 14.7 
 HIVEP2 human immunodeficiency virus 
type I enhancer binding protein 2 
A_23_P214
766 
1.2 1 1.5 1.3 2.1 14.
2 
1.5 1.2 5.1 9.1 1.4 1 0.9 1.9 
 HOXA4 homeobox A4 A_23_P253
982 
0.9 0.9 1.1 0.9 1.3 4.3 1.1 1 2.1 6.2 1 1 1 1 
 HOXD10 homeobox D10 A_23_P381
368 
0.9 0.9 1.3 1.1 2.8 4.6 1.3 1.2 5 2.9 1.2 1.1 1.1 2.2 
 HRK harakiri A_23_P251
94 
1 1.4 1.7 1.5 2.1 7.1 1.6 1.4 2.6 7.9 1.4 1.4 1.1 1.2 





1.4 1.3 1.6 1.4 2.2 8.3 1.3 1.4 5.2 3.8 1.6 1.3 1.2 1.9 
 IFNA4 interferon, alpha 4 A_24_P403
459 
1.4 0.9 1.5 1.5 7.5 191
.3 
1.4 1.8 4.5 38.8 1.2 1.4 1.2 2.2 
 IFNA8 interferon, alpha 8 A_23_P146
539 
0.8 0.7 0.9 1 2.7 67 0.9 0.6 1.8 15.7 1.2 0.9 0.9 0.9 
 IGF2 insulin-like growth factor 2 A_23_P421
379 
1 1.2 1.5 0.7 1.6 23.
7 
1.5 1.2 9.1 14 0.8 0.9 1 1.3 
 IGF2  A_32_P566
61 
1.3 0.9 1.2 1.8 2.7 26.
7 
1.1 0.9 7.6 15.4 1.8 1.4 1.2 1.8 




0.7 1 1.1 1.2 1.7 11.
4 
1.1 1.3 4.9 12.8 0.9 0.9 1 1.7 
 INTU PDZ domain containing 6 A_32_P118
372 
1 0.9 1.9 1.3 2.6 17.
4 
1.5 1.3 7.9 9.9 1.6 1.3 1 2.1 
 ITGAM integrin alpha M precursor A_23_P124
108 
1.3 1.4 1.2 1.8 2 15 1.3 1.6 5.9 13.5 1.4 1.3 1.2 2.7 
 JPH2 junctophilin 2 isoform 1 A_23_P394
395 
1 1.1 1 1 1.4 7.2 1.2 1 1.9 6.9 1 1 0.9 0.8 
 JUN jun oncogene A_23_P201
538 
1 1.1 1.8 1.7 7.7 18.
8 
1.5 2.5 22.9 8.5 1.7 1.8 1.2 2.9 
 JUNB jun B proto-oncogene A_23_P482
1 
1.2 1.4 1.3 1.5 3.5 6.3 1.2 1.7 6.3 3 1.2 1.3 1.2 1.7 
 KIAA1267 hypothetical protein LOC284058 A_23_P553
76 
1 1.2 1.5 1.2 1.3 5.1 1.5 1.2 2.5 3.4 1.4 0.9 0.9 1.1 
 KRT17 keratin 17 A_23_P961
58 
0.9 1.4 0.9 1.1 2.2 29.
4 
0.7 1.2 3.8 25.4 1.3 1.1 1.2 5 
 KRT34 keratin 34 A_23_P101
054 
1 1 0.7 1.3 1.4 14.
1 
1 1 1.8 13.8 0.8 1.3 1.4 1.5 




1 1.1 1.4 1.1 1.8 4.1 1.3 1.1 2.8 3.3 1.2 1 0.9 0.9 
 LCE1F late cornified envelope 1F A_23_P411
321 
1 1.1 1.4 1.6 1.5 6.5 1.5 1.4 2.3 3 1.3 1.4 1.3 1.6 
 LPA lipoprotein Lp(a) precursor A_23_P952
21 
0.8 1.1 0.8 1 1.1 23 0.9 1 1.5 15.5 1.1 0.8 1.1 2.2 
 LPXN leupaxin A_23_P871
50 
1 1.1 1.2 1.3 1.9 10 1.2 1.3 4.3 9.2 1.1 1 1 1.7 
 LRRC46 leucine rich repeat containing 46 A_23_P152
949 
0.9 1 1 0.9 1.1 3.7 1.2 1.2 1.9 4.2 1 1 0.8 0.9 
 LRRC48 leucine rich repeat containing 48 A_24_P270
971 
1.1 0.9 1.2 1.2 1.5 3.5 1.4 1.3 2.9 4.1 1.3 0.9 0.8 0.9 
 LRRC49 leucine rich repeat containing 49 A_23_P129
174 
1.1 0.8 1.1 1 1.2 7.6 1.1 1.1 2.2 7.3 1.1 1 1 1.5 




1 0.8 1.3 1 1.8 22.
5 
1.1 1.3 7.8 15.5 1.1 1 0.8 2 




1.3 1.2 1.3 1 1.4 5.3 1.4 1.2 2 4 1.2 1.1 0.9 0.9 
 MAP3K10 mitogen-activated protein kinase 
kinase kinase 10 
A_24_P284
523 
1 1 1.9 1.6 2 10.
2 
1.9 1.4 4.3 7.3 1.5 1.2 1.1 1.5 
 MAP3K7I
P3 
mitogen-activated protein kinase 




1.2 1.4 1.2 1.2 1.4 8.1 1.5 1.2 1.9 7 1.2 1.1 1.1 1.5 




0.9 1.1 0.9 0.9 1.1 11.
3 
1.3 1.1 1.8 14.7 0.7 0.9 0.9 1.6 
 MARK1 MAP/microtubule affinity-
regulating kinase 1 
A_23_P424 0.8 0.8 0.7 1.3 1.6 4.2 0.8 0.7 1 7.9 0.9 0.9 1 0.8 
 MDM4 mouse double minute 4 homolog A_23_P103
503 
1 1.4 1.5 1.3 1.9 10.
7 
1.5 1.6 3.6 7.6 1.3 1.1 1.1 1.9 
 MEG3  A_24_P272
993 
0.9 1.1 2.2 1.7 1.6 7.7 1.9 1.6 2.6 3.8 1.9 1.3 1.3 1.7 
 MLL3 myeloid/lymphoid or mixed-
lineage leukemia 3 isoform 2 
A_24_P840
688 
1.2 1.3 1.4 1.3 1.6 10.
4 
1.6 1.4 5.1 6.6 1.2 1.3 1.2 1.9 
 NAV2 steerin2 protein A_24_P933
458 
0.9 1 1.9 1.5 2.9 14.
3 
2.1 1.8 8.3 7.3 1.4 0.9 1 2 
 NFKBIZ nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells inhibitor, zeta isoform a 
A_23_P212
089 
1.1 1.2 1.9 1.3 2.4 8.3 1.7 1.9 4.2 3.5 1.5 0.8 0.9 2.2 
 NLGN3 neuroligin 3 A_23_P622
98 
1.1 1.8 1.3 1.3 2.1 5.5 1.9 1.3 2.6 3.5 1.7 0.9 1.1 0.9 
 NR2F1 nuclear receptor subfamily 2, 
group F, member 1 
A_23_P348
737 
1 1.1 2.1 1.3 6.8 37.
5 
1.9 1.6 29 17.7 1.7 1.1 1.2 2.8 




1.2 1.2 1.8 1.2 2.4 27.
9 
2 1.5 8.7 31.6 1.5 1 1 1.9 




1.2 1.1 1.4 1.4 2.1 11.
3 
1.6 1.2 2.9 6.5 1.2 1.3 1.1 1.7 
 OLFM3 olfactomedin 3 A_24_P402
444 
0.8 0.6 1 1.5 1 18.
5 
1 1 2 19.1 1.7 0.9 1 1 




0.7 0.7 1.1 1.3 1.2 15.
9 
0.9 0.9 2.4 13.4 0.8 1 0.8 1.1 
 
180 




1 1 1.2 1.2 1.5 3.8 1.6 1.4 2 4.9 1.1 1.2 1.1 1.1 
 PHLDB2 PHLDB2 protein A_24_P178
065 
1.4 1 1.3 1.1 3 8 1 1.6 6.5 3.1 1.1 1 1.3 1.3 
 PHLDB2 pleckstrin homology-like domain, 
family B, member 2 
A_24_P260
122 
1.4 1.4 1.3 1.3 3.8 6.4 1.1 1.1 6.1 3.4 1.2 1.1 1.3 1.3 
 PLA2G4C phospholipase A2, group IVC A_24_P316
439 




0.7 0.8 19 16.5 0.6 1 0.6 5.6 




0.7 0.6 1 1 1 7.5 1 1 1.2 17.5 1.1 1.1 1 1 
 PPP1R10 protein phosphatase 1, 
regulatory subunit 10 
A_23_P156
667 





1.1 0.9 1.2 1 2.1 8.6 0.8 1.1 2.8 5.9 1.2 1.2 0.9 1.4 
 PRR8 PRR8 protein A_23_P417
113 
1.3 1.5 1.3 1.2 1.3 6.3 1.4 1.3 1.5 5 1.2 1.1 1 1.5 
 PSCD3 pleckstrin homology, Sec7 and 
coiled/coil domains 3 
A_23_P111
593 










1.3 1.6 1.1 1.2 2.1 5.2 1.4 1.4 3.9 3 1.1 1.1 2.1 1.2 
 PTPN14 protein tyrosine phosphatase, 
non-receptor type 14 
A_23_P149
111 
0.9 1 1.2 1 1.8 6.9 1.2 1.2 2.7 6.3 1.1 1 0.9 1.3 
 PTPN21 protein tyrosine phosphatase, 
non-receptor type 21 
A_23_P770
31 
1 1.1 1.4 1.2 1.7 7.2 1.2 1.2 2.8 5.9 1.2 1 1 1.2 
 RAI2 retinoic acid induced 2 A_23_P254
165 
1.2 1.2 1.1 1.2 1.3 7.1 1.3 0.9 1.9 6.2 1.5 1.2 1.1 1.1 
 RANBP3L RAN binding protein 3-like A_23_P391
207 
0.8 0.7 0.8 1.1 1.9 21.
5 
1 0.9 3 10.4 1 0.9 0.6 1.5 
 RAPH1 Ras association and pleckstrin 
homology domains 1 isoform 1 
A_24_P924
862 
1 1 1.3 1.1 1.8 8 1.2 1.1 4.4 8.4 1.2 1.1 1.1 1.4 
 RAPH1 Ras association and pleckstrin 
homology domains 1 isoform 2 
A_23_P409
966 
1.6 1.2 1.8 1.4 3.9 19.
4 
1.6 1.4 14.5 9.1 2.3 1.9 1.3 1.7 




1 1 1.2 1.1 1.4 6.1 1.1 1.2 4.4 3.6 1.1 1.2 1 1.2 
 RBMS3 RNA binding motif, single 




0.9 1 1.6 1.4 2.9 5.6 1.6 1 5.4 2.9 1.3 0.8 0.9 1.4 
 RND1 GTP-binding protein RHO6 A_23_P533
70 
0.9 0.9 0.7 1 3.2 3.7 0.8 1.8 5.4 2.5 0.8 0.8 1 1.8 
 RNF180 ring finger protein 180 A_23_P377
996 
1 1.2 1.2 1.5 1.3 6.5 1.1 1.1 2.2 5.4 1.2 1.4 1.3 1.4 




1.1 1.1 1.4 1.3 1.9 12.
5 
1.3 1.3 4.5 10.5 1.2 1.1 1.2 1.6 
 RUNX1 AML1a protein A_24_P341
55 
1.2 1 1.5 1.6 2.5 12.
6 
1.2 1.2 6.3 5.8 1.5 1.4 1.1 1.7 
 SIPA1L2 signal-induced proliferation-
associated 1 like 2 
A_23_P137
470 
1 0.8 1.4 1.2 1.7 7.7 1.1 1.2 3.8 3.7 1.3 1.1 0.9 1.8 
 SLC2A6 solute carrier family 2 (facilitated 
glucose transporter), member 6 
A_23_P169
249 
0.9 1 1.2 1.2 1.6 8.2 1.2 1.2 3.5 4.5 1.2 1.2 1.5 1.9 
 SLC39A9 solute carrier family 39 (zinc 
transporter), member 9 
A_23_P380
326 
1 0.9 0.8 0.9 0.9 3.7 0.8 0.8 1 5.4 0.8 0.8 0.9 1.1 
 SLC6A13 SLC6A13 protein A_24_P923
483 
1.3 1.3 2 2.4 2.3 11.
7 
2 1.6 9.7 3.9 1.7 1.7 1.6 1.7 
 SNX19 sorting nexin 19 A_24_P816
91 
0.9 1.1 1.2 1.1 1.5 4.5 1 1.1 2.6 3.9 1 1 0.9 1.1 




2.1 1.2 1.4 1.2 5.6 3.2 1.4 1.3 4.3 2.4 1.3 1.5 1.2 1.3 
 SOD2 SOD2 protein A_24_P935
819 




2.3 6.7 45.3 20.5 2 1.5 2.4 10.8 
 SPACA3 sperm acrosome associated 3 A_23_P317
244 
1.1 1.2 1.3 0.9 1 15.
3 
1.5 1.4 1.8 12.1 1.3 1.8 1.1 1.9 
 SPHK1 sphingosine kinase 1 isoform 1 A_23_P381
06 
1.1 1.2 1.1 1.1 1.5 5.5 1 1.1 2 5.3 1 1.2 1 1.2 




1.5 1.1 1.3 1.4 1.6 12 0.9 0.9 1.5 5.7 0.8 0.8 0.7 1.2 
 SPRR2C small proline-rich protein A_23_P126
089 
0.6 1.4 1.1 1 0.9 18.
3 
1.3 1.1 1.5 26.2 1.1 1.2 1 1.3 
 SPRR2D small proline-rich protein 2D A_23_P116
44 
1.4 1.1 0.8 1.4 1.3 16.
7 
1.2 1.2 1.8 24.3 0.8 1.5 0.9 1.7 




0.9 0.9 1.1 1.1 2.8 10.
6 
1.1 1.2 6.4 4.2 1 1 1 1.8 
 STMN4 stathmin-like-protein RB3 A_23_P317
39 
1.6 1.1 1.3 1.1 1.6 12.
7 
0.9 1.1 1.2 14.7 1.2 1 0.7 2.1 




1.8 1 0.9 1.3 1.5 9.7 0.7 0.8 1 11.1 1.1 0.8 1.1 1.1 
 THAP2 THAP domain containing, 
apoptosis associated protein 2 
A_23_P105
382 
1.1 1 0.9 0.8 0.8 4.8 0.6 0.7 1.1 3.9 1.1 0.8 0.8 0.9 
 THRAP1 mediator of RNA polymerase II 




1.2 1.3 1.5 1.3 2 8 1.5 1.4 3.8 5.7 1.3 1.3 1.3 1.7 
 TKTL1 transketolase-like 1 A_23_P259
901 
0.9 0.9 0.8 1 1.1 3.6 1.4 0.9 1.7 7.3 0.9 1 0.9 1.7 
 TMEM135 hypothetical protein LOC65084 A_24_P127
075 
0.8 0.9 0.8 0.8 1 5.1 0.7 0.6 1.8 4.8 0.6 0.6 1.5 1 
 TMEM27 transmembrane protein 27 A_23_P339
84 
1.4 2.2 0.9 0.9 1.6 8.9 0.8 0.8 3.1 7.8 0.9 0.8 0.7 1.6 
 TNC tenascin C (hexabrachion) A_23_P157
865 









0.9 1.1 1.2 1.2 1.6 11.
1 
1.4 1.3 2.5 11.3 1.1 1.2 1.2 1.4 
 TSC22D2 TSC22 domain family 2 A_23_P922
30 
1.1 1 1 0.8 1 4.8 0.8 0.8 1.7 3.5 1 1 0.8 1.1 
 TSPAN10 tetraspanin 10 A_24_P213
643 
1.1 1 1.2 1.1 2.5 7.1 1.3 1.3 3.7 3.6 1.2 1.1 1.1 1.5 




1 0.8 0.7 0.9 0.9 5.7 0.9 0.7 1.5 6.1 0.8 0.8 0.8 0.8 
 TUFT1 tuftelin 1 A_23_P371
824 
0.8 0.9 1.2 1.1 2 4.5 0.9 1 2.3 5 1.2 1 0.9 1.1 




1 1.2 1.8 1.4 1.7 9 1.6 1.7 5 4.2 1.5 1.3 1.1 1.4 
 VIP vasoactive intestinal peptide 
isoform 1 preproprotein 
A_23_P196
50 
0.8 0.7 0.9 1.4 1.8 19.
7 
0.9 1.2 1.6 27.2 1 0.9 1 1.6 
 VNN1 vanin 1 precursor A_23_P255
345 
1.2 1.1 1 1.3 0.9 14.
1 
0.7 1.2 2.4 12.1 1.4 0.7 0.5 3.7 




1 0.9 1 1.1 1.5 5.4 1.1 1.2 3.9 3.3 1 1.1 1 1.1 
 WBSCR1
9 
hypothetical protein LOC285955 A_32_P180
435 
1.4 1.2 1.6 1.9 2 9.8 1.4 1.5 4.4 5.9 1.1 1.4 1.1 1.7 
 WBSCR1
9 
hypothetical protein LOC285955 A_32_P177
040 
1.4 1.2 1.5 1.7 1.5 9.3 1.3 1.9 3.4 5.9 1.2 1.3 1.4 1.8 
 WDR42A WDR42A protein A_24_P767
25 
1 1.3 1 1 1.1 5.9 1 1 1.5 5 0.9 0.9 1 1 
 WDR42A  A_24_P886
960 
0.9 1.1 1.2 1.1 1.7 10.
1 
1 1.1 5.8 7 1.1 0.9 0.9 1.3 
 WDR66 WD repeat domain 66 A_24_P179
504 
0.8 0.7 0.9 1 1.2 5.4 1 1 1.2 6.5 0.9 1.2 1.2 1.1 
 WNT4 wingless-type MMTV integration 
site family, member 4 precursor 
A_23_P382
607 
1 1 1.2 1.2 1.9 8.7 1.2 1.1 3.4 3.2 1.3 1.2 1.1 1.5 
 XRN1 5'-3' exoribonuclease 1 isoform a A_23_P132
822 
1.1 1.4 0.6 1.2 3.3 9.9 0.7 0.8 3.5 6.5 2.7 0.9 0.8 1.3 




1.2 1.1 1.3 1.4 6.4 12 1.2 2.4 15 4.1 1.1 1.2 1.3 2.2 
 ZFP36L2 butyrate response factor 2 A_23_P101
960 
1.3 1.4 2.3 1.5 4.9 17.
6 
2.1 2 19.4 10.6 1.8 1.3 1.1 2.3 
 ZNF121 zinc finger protein 121 A_24_P935
782 
1 1.5 0.7 0.7 1.1 4.6 0.9 0.7 1.7 4.7 0.7 1.1 0.8 0.7 
 ZNF222 zinc finger protein 222 A_24_P165
082 
0.9 1.1 0.8 0.9 1.1 4.5 0.8 0.9 1.6 5.6 0.9 0.9 0.9 1.1 
 ZNF222 zinc finger protein 222 A_23_P218
517 
0.9 1.2 0.8 0.9 1.1 5 0.8 0.9 1.6 5.4 0.9 0.9 0.9 1.1 
 ZNF222 zinc finger protein 222 A_23_P125
042 
0.9 1.1 0.7 0.4 1 4.2 0.6 0.7 1.2 4.9 0.6 0.8 0.8 1 
 ZNF256 zinc finger protein 256 A_23_P160
22 
0.9 1.2 1 1 1.4 5 1.2 1.1 2.1 6 0.9 0.9 0.9 1.2 
 ZNF461 gonadotropin inducible 
transcription repressor 1 
A_23_P674
24 
1.1 1 1.3 1.2 1.5 5.7 1.2 1.2 2.9 4.7 1.1 1.1 1.1 1.2 
 ZNF462 zinc finger protein 462 A_23_P604
99 
1.1 1.3 1.7 1.2 1.9 15.
7 
1.3 1.3 3.5 9.7 1.3 1.1 1.1 1.6 
 ZNF503 zinc finger protein 503 A_23_P202
484 
1.2 1.4 1.8 1.5 3.4 11.
4 
1.8 1.5 8.2 5.5 1.5 1.5 1.2 2 
 ZNF585A zinc finger protein 585A A_23_P902
20 
1 1.1 1 1.1 1.4 4.1 1 1 1.7 5.2 0.9 0.9 1 1.2 
 ZNF585A  A_24_P849
467 
1 2.9 0.9 0.9 1.9 11.
6 
0.9 0.8 1.6 11.3 0.8 1 0.9 2.4 
 ZNF697 ZNF697 protein A_23_P322
076 
0.9 1 1.9 1.9 1.9 8.2 1.4 1.3 2.5 6.1 1.5 1.2 1.5 1.4 
 ZNF704  A_24_P505
790 
1 1 2.1 1.6 1.9 10.
3 
1.7 1.5 4.6 5.5 1.6 1.4 1 1.9 
 ZNF8 zinc finger protein 8 A_23_P130
466 
1.1 1.2 1.3 1.2 1.6 6.1 1.2 1.3 2.7 5.9 1.2 1 1.1 1.4 
 ZSCAN29 zinc finger protein 690 A_23_P100
092 
1.1 1.4 1.6 1.3 1.6 6.5 1.5 1.4 2.7 4.8 1.4 1.3 1.2 1.5 




0.9 0.9 1.5 1.4 2.3 22.
3 
1.4 1.3 7.7 14 1.3 1.3 1.3 2.7 




0.9 0.9 1.5 1.4 2.2 16.
1 
1.4 1.3 5.6 10.5 1.4 1.4 1.3 2.3 
  FLJ00291 protein A_24_P932
648 
1.1 1.2 1.2 1.3 1.6 7.6 1.3 1.7 3.5 7.3 1 1.1 1.2 1.8 




1 1.1 1 1 0.9 6.6 1.1 0.9 1.1 6 1 0.8 0.8 1.5 
  golgin-like protein A_23_P106
371 
1.3 1.2 1.7 1.3 1.6 9.7 1.7 1.3 4.1 5.7 1.5 1.1 1.2 1.1 
  HSPC080 A_24_P917
418 
1.1 1 1.5 1 2.1 9.3 1.3 1.2 4.5 5.1 1.2 1.2 1 1.6 
  hypothetical protein LOC147744 A_23_P107
775 
0.9 1.1 1.6 1.3 1.4 7.8 1.8 1.5 3.8 4.6 1.4 1 1 1.4 
  hypothetical protein LOC205860 A_23_P350
005 
1 0.9 1.9 1.8 2 11 1.7 1.5 3.7 8.3 1.6 1.7 1.9 1.9 
  hypothetical protein LOC286006 A_24_P380
679 
1.2 1.1 2.3 1.6 2.2 6.4 1.7 1.4 3.9 5.1 1.7 1.7 1.4 1.6 
  hypothetical protein LOC440321 A_24_P264
166 
0.9 1.3 1.7 1.4 2 10.
1 
1.3 1.5 4.1 6.6 1.3 1.1 1.2 1.2 
  hypothetical protein LOC54891 A_23_P142
756 
1 1.3 1.3 1.1 1.7 9.2 1.4 1 4 9.2 1.2 0.8 0.8 2.1 
  hypothetical protein LOC80154 A_23_P129
103 
0.9 0.9 1.4 1.4 1.8 8.2 1.3 1.2 3.8 5.8 1.2 1.2 1.2 1.9 
  KIAA1267 protein A_24_P316
381 
1.2 1.4 1.9 1.4 1.8 5.8 1.9 1.7 4 4 1.3 1.3 1.2 1.2 
  KIAA1267 protein A_32_P210
106 
1.1 1.3 1.8 1.9 2 6 1.8 1.8 3.9 4 1.3 1.3 1.4 1.2 
  KIAA1466 protein A_24_P324
581 
1.8 2.1 2 1.3 6.3 8.8 1.7 1.3 6.5 3 1.5 1.4 1.6 1.4 
 
182 
  KIAA1466 protein A_24_P324
577 
1.6 1.9 2.2 1.6 4.6 7.2 2.1 1.6 5.5 3.2 1.9 1.4 1.4 1.5 
  LOC727751 protein A_23_P320
478 
0.9 0.9 1.1 1.2 1.8 7.8 1.1 1.2 4 5.2 1.2 1.3 1.2 2 
  MGC26597 protein A_23_P389
426 
0.7 1.3 0.9 1.2 2.1 5.9 1.1 1.1 2.8 4.7 1.1 1.2 0.7 1.2 
  Nedd4 binding protein 3 A_23_P587
47 
0.7 1.2 1.4 1.4 1.8 14 1.6 1.4 5 13.3 1.2 1.3 1.1 2.5 
  PRO1995 A_24_P927
090 
0.8 1 1.4 1.8 3.6 20.
3 
1.7 1.7 9.6 7 1.4 1.6 1.3 2.8 
  RBP1-like protein A_24_P196
499 
1.1 1.9 1 1.1 1.2 10.
1 
0.9 1.2 3.1 11.7 1 0.9 1.1 1.4 




0.9 1.1 1 1.1 0.9 6.5 1.3 1.2 1.8 5.1 1.1 1 0.9 1.3 
  T-complex protein 1 A_23_P291
10 
0.8 0.7 1 1.1 1.1 10.
8 
1 1 3.5 5.5 1 0.9 0.8 1.1 




5 1.2 1.1 0.9 1.2 8.2 1.2 1 2.4 6.5 1.4 1.5 1.2 1 
   A_32_P871
91 
1.4 0.7 1.6 1.3 1.2 8.8 1.2 1.1 4 7.9 1.6 0.8 0.6 1.3 
   A_32_P802
95 
1.5 1.3 1.5 1.4 2.1 12.
6 
1.4 1.4 5.2 8 1.5 1.3 1.2 2.2 
   A_24_P399
220 
1.3 1.5 1.8 1.6 2.3 11.
3 
1.5 1.5 4.8 6.1 1.6 1.2 1.3 1.9 
   A_32_P356
4 
1.2 1.3 1.4 1.5 2.6 7.2 1.6 1.6 3.5 5.1 1.5 1.3 1.2 1.7 
   A_24_P264
664 
1.1 1.3 1.6 1.3 2.2 7 1.5 1.3 3.8 5.5 1.4 1.1 1.2 1.6 
   A_32_P226
205 
1.2 1.6 2.1 1.3 3.2 31.
6 
1.3 1.3 15.7 24.2 1.6 1.1 1 2 
   A_32_P106
925 
1 1.3 1.7 1.6 2 11.
4 
1.6 1.5 6.8 8.4 1.6 1.4 1.1 1.6 
   A_32_P614
39 
1.3 1.3 1.5 1.2 1.4 12.
1 
1.4 1.3 2.9 6.4 1.3 1.1 1.1 1.7 
   A_32_P209
250 
1 1.1 1.2 1 1.3 5.6 1.1 1.1 1.9 4.3 1.1 1 0.9 1.3 
   A_23_P215
819 
1 1 1.1 1.1 1.6 7.8 1.1 1.1 3.3 6 1.1 1 1 1.3 
   A_32_P126
647 
1 1 1.3 1.2 1.3 6.3 1.5 1.2 3.1 5.2 1.1 1 0.9 1.2 
   A_32_P429
89 
1.5 1.3 1.8 2.5 2.5 35.
4 
1.4 1.5 8.7 20.2 1.4 1.7 1.3 4 
   A_32_P744
09 
1 1 1.4 1.2 3.8 39.
1 
1.1 1.5 6.8 28 1.4 1.4 1.5 4 
   A_32_P141
184 
0.9 0.9 1.3 0.8 2 4.8 1 1 2.2 6 1.3 1 1 1.3 
   A_32_P592
77 
0.9 1.4 2.9 1.9 4 46.
6 
2.3 1.7 8.9 13.3 2.2 1.5 1.4 1.8 
   A_23_P381
979 
0.9 1.2 2.2 1.4 1.8 10.
8 
1.9 1.3 3.9 5.1 1.8 1.1 1.1 1.7 
   A_32_P239
2 
1.1 1.5 2.3 1.8 2 8.4 2.1 1.7 4.5 5.9 1.9 1.4 1.4 1.3 
   A_32_P213
948 
1.1 1.1 1.8 1.4 1.5 6.1 1.7 1.4 2.5 3.3 1.6 1.2 1.2 1.1 
   A_24_P272
225 
1.1 1.2 1.3 1.1 1.5 5.1 1.3 1.3 2.4 3.2 1.2 1 1.1 1.2 
   A_24_P510
502 
1 1.1 1.6 1.4 1.4 9.1 1.4 1.5 3.3 5.3 1.4 1.2 1.2 1.2 
   A_32_P199
923 
1.1 1.1 1.7 1.1 1.4 9.9 2 1.3 4.5 4.4 1.7 1.3 1 1.5 
   A_32_P276
6 
0.9 1.2 1.6 1.3 1.6 9.6 1.6 1.5 4.8 4.1 1.2 1 0.9 1.1 
   A_24_P110
141 
1 0.9 1.4 1.2 1.5 4.7 1.1 1.4 2.9 3.7 1.1 1 1 1.1 
   A_23_P209
360 
0.9 1.3 1.2 1.2 1.5 4.9 1.2 1.2 2.6 3 1.2 1.1 0.9 1.1 
   A_32_P234
853 
1 1 0.9 1.1 0.9 4.5 1.2 1 2.4 4.4 0.9 1.1 0.9 1 
   A_24_P399
28 
0.9 0.9 1.3 1.1 0.9 6.5 0.9 1.1 2 3.1 0.8 1.1 0.9 1.1 
   A_32_P128
209 
1.1 1.1 1.1 1.2 1.1 6.9 1.1 1.1 2 4 1 1 1.1 1 
   A_24_P885
873 
1 1 0.7 0.9 1.1 9.2 1.1 1.5 3.2 3.6 1 1 1 0.9 
   A_24_P914
043 
0.9 1.1 1 1.4 1.2 19.
8 
1 1.4 5 14.6 1.2 1.5 2.1 2.9 
   A_32_P113
472 
0.9 1.1 1.1 1 1.7 6.1 1.1 1.1 2.3 3.8 1.1 0.8 0.7 1.3 
   A_24_P924
697 
1 1.1 1.2 1 1.7 6.6 1.1 1 1.9 4 1.3 0.8 0.7 1.4 
   A_24_P919
150 
0.9 0.7 1.2 1.4 2 10.
5 
1.7 1.6 4.3 4.2 1.3 0.9 1.2 1.3 
   A_24_P718
503 
1 1 1.5 1.4 1.7 14.
6 
1.6 1.4 3.7 4.4 1.6 1.3 1.1 1.3 
   A_32_P138
977 
1 1.3 1.3 1.6 1.1 9.8 0.9 1 4.8 4.7 1.2 1.2 0.6 1.5 
   A_32_P644
2 
0.9 1 1.6 1.2 2.6 10 1.6 1.5 7.2 3.3 1.4 1.2 1.2 2.4 
   A_32_P207
802 
1 1.2 3.1 2.4 4.8 17.
4 
2.6 2 14 5.5 2.1 1.6 1.7 2.5 
   A_32_P232
883 
1 1 1.3 1.4 2.6 10.
5 
1.2 1.1 5.2 5.3 1.2 1.2 1.5 1.5 
   A_32_P224
345 




1 1 56.1 31.3 1 0.9 1 4.2 
   A_32_P135
65 
1 1 1.2 1.1 3.1 9.5 1.3 1.1 7.3 4.7 1.4 1.2 1.2 1.9 
 
183 
   A_32_P132
928 
1.2 1 2.3 1.5 3.7 23.
5 
2.1 1.6 13.2 8 1.9 1.2 1.6 3 
   A_24_P332
081 
1 1.2 2 1.7 3.2 18.
9 
1.8 1.7 10.5 8.2 1.7 1.4 1.5 2.4 
   A_24_P788
878 
1 1.4 1.4 1.3 3 15.
4 
1.1 1.2 9.2 6.7 1.2 1.1 0.8 2.1 
   A_23_P812
98 
0.8 1 1.1 1 1.8 4.2 1.1 1 3.7 2.6 1 0.8 0.7 1.6 
   A_24_P323
522 
0.8 1 2 1.7 3.9 19.
6 
2 1.7 17.3 7.9 1.4 1.2 1.1 2.4 
   A_23_P335
398 
0.9 0.9 1.3 1.1 2 18.
2 
0.9 1 6.8 8.5 0.9 0.6 1.3 1.4 
   A_32_P387
82 
1 1.2 2.2 1.3 2.9 12.
4 
1.6 1.6 7.9 5.5 1.9 1.4 1.2 1.8 
   A_23_P984
83 
0.9 1.3 1.5 1.2 1.8 6.2 1.3 1.4 4.1 3.1 1.4 1.1 1.1 1.5 
   A_24_P585
428 
0.8 1.3 1.3 1 1.8 5.2 1.2 1.3 5.1 2.7 1.3 0.9 1 1.2 
   A_32_P127
501 
1.1 1.5 2.8 1.9 3 21.
5 
2.5 2 12.9 10.4 2.1 1.3 1.2 1.7 
   A_32_P110
016 
0.9 0.9 1.3 1.2 1.4 4.7 1.2 1.4 3.7 2.4 1.3 0.9 0.7 1 
   A_32_P221
641 
1 2.6 2.7 2.3 5.1 29 2.9 1.7 10.9 9 4.5 1.7 1.8 2.6 
   A_24_P767
972 
1.2 1.3 1.1 1.5 3.1 14.
4 
1.7 1.3 8 4.6 1.7 1.4 1 1.4 
   A_32_P184
039 




2.9 4 33.1 17.6 3.1 1.4 1.6 5.7 
   A_24_P102
283 
1.3 1.5 2.7 1.8 6.2 18.
1 
3.5 3 13.4 10 2.5 0.9 1.2 3.8 
   A_32_P165
823 
1.3 1.1 1.8 1.3 2.9 5.9 2.1 1.9 6 5.6 1.3 1.3 1.4 2.1 
   A_32_P173
955 
1.2 1.5 1.4 1.2 2 7.7 2.1 1.7 4.7 3 1.3 1 1.2 1.8 
   A_32_P463
538 
1 0.8 1.1 1.1 1.5 8 0.9 1.2 3.2 3.1 0.8 1.1 1.9 1.3 
   A_24_P147
76 
1.8 0.7 1 1.2 1.6 10.
3 
1 1.5 4.3 7.6 1.2 0.9 2.6 1.5 
   A_32_P677
8 
2 1.3 1.2 1.4 2.3 5.2 1.1 1.3 3.7 5.5 1.9 1 2 1.1 
   A_32_P125
803 
1.6 1.6 1.1 0.9 1.3 6 1 1.3 2.7 4.1 1.6 1 1 1.2 
   A_32_P104
448 
1.5 1.3 0.7 0.8 1.4 5.9 0.8 1.2 3.1 6.1 1 0.9 0.9 0.9 
   A_32_P739
91 
0.8 0.7 1.2 1.1 0.8 12.
4 
1.4 0.7 1.2 18.3 0.8 1 0.9 1.4 
   A_32_P220
463 
1.1 1.3 1.3 1.4 1.6 6.2 1.5 1.6 1.9 7.2 1.1 1.5 1.2 1.5 
   A_32_P216
015 
0.8 0.7 1 1.1 1.2 5.8 1 1 1.7 7.4 1.1 1 1 1.1 
   A_32_P593
02 
1.3 1.7 1.3 1 1.4 9.4 1.4 1.1 2.2 6.6 1.1 1.1 1.1 1 
   A_32_P150
81 
1.2 1.4 1.1 1 1.3 13.
2 
1 1.2 2.2 9.5 1.1 1.2 1 1.5 
   A_23_P218
1 
1 1 1 1 1.1 5.7 0.9 0.9 1.9 5.2 1 1.1 0.9 1 
   A_32_P518
55 
0.9 1.2 1 1 0.9 9.3 1 1.2 2.2 5.7 1.1 0.9 0.8 1.2 
   A_32_P308
91 
1.4 1.1 1.3 1.7 1.5 15.
5 
1.8 1.8 3.1 10.9 1.4 2 1.2 1.4 
   A_32_P206
208 
0.9 0.9 1.3 1.1 0.9 6.7 1.3 1.2 1.8 5.1 1.1 1.3 1 1 
   A_24_P811
397 
0.8 0.7 1 1.1 1 35.
8 
1 0.9 3 19.9 1.1 0.9 0.9 1.1 
   A_24_P892
464 
0.9 1.1 1.1 1.1 1.6 17.
6 
1.5 1.3 3.5 17.5 1.4 1.3 1.2 1.8 
   A_23_P546
4 
1.1 1.1 1.1 1.1 1.3 7.9 1.2 1.2 2.1 6.9 1.1 1.1 1.2 1.5 
   A_32_P107
6 
0.8 0.7 0.8 0.9 1.4 8.2 0.8 0.9 2.2 8.7 1.1 0.7 1 0.9 
   A_23_P427
68 
0.9 1 0.9 1.4 1.5 6.7 1.1 1 1.6 6.7 1.1 1 1.1 1.1 
   A_32_P170
454 
0.9 1.2 1.4 1.4 2.3 7.4 1.3 1.3 2.5 8.3 1.2 1.2 1 1.2 
   A_32_P156
786 
1 1.2 1.2 1.3 2.3 5.7 1.1 1.1 2.2 6 1.2 1.2 1.1 1 
   A_24_P941
279 
0.7 1.1 1.1 1.1 1.7 5.6 1.4 1.1 2.4 5.7 1 1.2 1 1.4 
   A_24_P882
959 
1.3 1.1 0.7 1 1.2 7.8 0.9 1.3 1.3 12 0.7 1 0.7 1.1 
   A_24_P337
143 
1 0.9 0.8 0.8 1.4 6.2 0.7 1.2 1.4 9.5 0.6 0.6 1 1.2 
   A_32_P147
21 
1.7 1.4 1.2 1.8 2 13.
4 
1.9 1.4 1.6 9.8 1.3 2.3 1.4 1.4 
   A_24_P526
190 
2.2 1.1 1 1.4 1.2 24.
5 
1.2 0.9 3.4 17 1.3 0.9 1.6 2.3 
   A_23_P413
268 
1.3 1 1.1 0.8 1.2 6.5 1.2 1 2.1 3.9 1 1.2 1.6 1.2 
   A_24_P823
514 
1.7 1 1.4 1.2 1.8 4.5 1.2 1.1 2 4 1.3 1.1 0.9 1.1 
   A_24_P950
70 
1 1.4 0.9 1 0.9 5.2 0.7 0.7 1.1 3.1 1 0.8 0.6 1.3 
   A_32_P174
285 
0.9 1.6 1.3 0.9 0.9 8.4 0.9 0.9 3.6 9.5 0.9 1 1 1.6 
   A_32_P192
354 
0.9 1 1.2 1.1 1.7 3.6 1.5 0.8 2.5 4.9 1.2 1.3 1.1 1.2 
   A_32_P116
957 
1.2 1.1 1 1.1 1.1 5 1 1 2.6 10.5 1 1.1 1.1 1.9 
 
184 
   A_23_P355
46 
0.7 0.7 0.9 1.2 1.4 13.
1 
1 1 6.1 18.5 0.8 0.8 0.8 2.1 
   A_24_P772
488 
0.7 0.6 0.9 1 1 4.4 1.1 0.9 2.8 6.9 1 0.8 1 1 
   A_23_P356
965 
0.9 1.7 1.6 1.1 1.3 4.5 1.4 1.2 2.2 4.7 1.3 1 1 0.9 
   A_24_P212
875 
0.8 1.2 0.7 0.8 1.8 4.4 0.8 1.2 1.3 4.8 0.8 0.6 0.9 0.7 
   A_32_P882
5 
1.4 0.9 0.9 1.4 3.6 10.
6 
1.2 1.2 9.6 7.2 1.3 1.2 0.7 2.9 
   A_32_P213
002 
2.1 2.6 2.3 1.9 7 13.
7 
2.3 2.1 13.4 5.9 1.8 1.1 1.5 2.6 
   A_32_P102
979 
1.3 1.2 1.4 1.3 4 5.7 1.5 1.6 9.1 3 1.4 1 1.1 1.4 
   A_32_P210
038 




1.7 1.7 16.3 9.5 1.3 1.1 1.4 5.1 
   A_32_P143
637 
1.1 1.1 1.8 1.7 6.5 22.
7 
1.3 1.1 11.7 5.4 1.2 0.8 1.2 2.6 
   A_24_P367
454 
0.9 1.6 1.7 2.2 6.4 25.
9 
0.9 2.3 22.6 12.9 1.4 0.9 1 4.5 
   A_32_P111
919 
0.7 1.2 1.3 1.6 3.4 10.
9 
1.4 1.8 10.3 4.2 1.1 1.4 2.3 2.2 
   A_32_P201
976 
1.4 1 2.3 1.8 3.9 7.8 2.3 2.5 5.8 4.3 1.3 1.2 0.8 1.3 
   A_24_P252
739 
1.3 1 1.5 1.3 3.3 8.3 1.6 2.1 6 4.8 1 1 0.9 1.2 
   A_32_P139
815 
1.2 1 1.5 1.2 1.9 4.1 1.2 2 2.8 2.1 1.1 1.1 1 0.7 
   A_24_P230
972 
1 1.6 1.4 1.2 3.7 4.8 1.3 1.7 7 2 1.7 0.9 1.3 2.7 
   A_32_P233
405 
1.5 2 1.5 1.1 2.6 5.1 1.2 1.5 4.7 3.1 1 1 1.1 1.2 
   A_24_P924
010 




1.6 2.2 15.6 9.3 1.3 1.6 1.2 1.3 
   A_32_P226
556 
1.2 2.8 1.9 1.6 2.3 9.5 1.5 1.3 6.9 3.2 1.7 1.4 0.9 1.8 
   A_23_P653
5 
0.9 3.9 1.2 1.6 6.4 20.
8 
1.2 0.7 18.8 14.4 1.1 1.4 2 12.6 
   A_24_P126
406 
0.4 0.5 0.9 1.1 18.
2 
5.7 0.8 0.8 1.4 7 0.9 1.4 1.4 0.9 








1.9 13.4 86.6 88 1 2.7 13.5 45.9 




1.9 1.2 0.9 1 5.7 3.5 0.9 1.4 6.5 4.3 1 1 1.1 5 










5.3 21.8 55.5 90.3 1.8 17.5 23 29.9 
 CH25H cholesterol 25-hydroxylase A_23_P864
70 








1.4 5 31.7 813.
7 








0.7 2.9 18.8 10.1 1.4 1.6 2.2 19.7 
 GPR109B G protein-coupled receptor 109B A_23_P647
21 




1.3 3.1 37.2 70.3 1.5 4.1 10.2 42.3 
 IFNB1 interferon, beta 1, fibroblast A_23_P717
74 






1 66.2 353.3 321.
6 
0.9 9.3 31.7 180.
6 
 IL28A interleukin 28A A_23_P409
438 






6.1 25.5 73.6 65 2.1 14.8 21 32.2 
 IL6 interleukin 6 (interferon, beta 2) A_23_P710
37 




0.8 12.5 71.9 90.7 1 1.8 3.6 34 




1.2 0.9 1.4 1.5 1 14.
3 
1.3 1.4 1.6 2.4 1.3 1.1 1.2 1.4 




0.9 0.8 0.7 1 1.3 4.5 0.6 0.8 0.9 5.2 0.7 1.2 1.4 0.9 
 COL11A2 collagen, type XI, alpha 2 
isoform 1 preproprotein 
A_23_P423
22 
1.1 1.1 4 1.7 1.1 14 1.7 1.5 2.4 13.3 1.6 1.3 1.1 1.3 
 DACT2 dapper, antagonist of beta-
catenin, homolog 2 
A_24_P289
260 
0.9 1.1 0.7 0.5 0.8 2.3 0.8 0.7 2.3 4.6 0.7 1.1 0.8 0.7 
 FEZ1 zygin 1 isoform 1 A_23_P202
881 
1.5 0.9 0.8 0.8 0.9 5.6 0.6 0.8 1.2 4.1 0.8 1.7 1.4 1.3 




1.6 1.7 1.3 1.8 1.4 5.5 0.8 1.9 1.6 9.7 1.1 1.8 1.8 0.6 




0.9 1 1 1.1 0.8 3.6 1.2 1.1 1 5 1 1 0.8 0.9 




0.8 1 1.3 1.1 0.8 4.1 1.3 1.1 1.3 4.8 1.1 1 0.8 0.9 
 OXTR oxytocin receptor A_23_P132
619 
0.8 0.8 1.5 1.2 0.8 3.4 1.3 1.2 1 5 1.5 1.1 0.7 0.9 




1.4 1.4 1 1.1 0.8 1.2 0.7 1.1 1.2 5.6 0.9 0.9 0.8 1.6 




1 0.6 1.3 0.7 0.9 9.8 0.8 1.1 0.7 2.3 1.3 1.4 1 0.7 
 SIRT4 sirtuin 4 A_23_P992
26 
0.8 0.8 1 0.8 0.8 3.2 0.5 0.8 0.9 4.6 0.6 0.9 1 0.9 
 SLC22A1 solute carrier family 22 member 
1 isoform b 
A_23_P145
569 
1 0.9 0.9 1.1 0.8 1.7 1.3 1 0.9 4.1 0.8 1.1 1.2 1 




0.9 1 1 1.8 1.7 6.4 0.6 1.8 1.3 5.5 1.2 1.6 1.6 0.7 
 TMEM16F transmembrane protein 16F A_23_P536
41 
1.1 1.1 0.8 0.9 1.1 4.1 0.7 1 0.8 5.5 0.6 1 1.1 0.8 
 UPK2 uroplakin 2 A_23_P642
38 
1.4 0.9 1.1 1.1 1.2 6.1 1.2 1 1.7 2.3 1.3 1.1 1 1.1 
 ZNF396 zinc finger protein A_24_P393
565 
1.2 1.3 1.1 0.9 1.8 5.3 0.8 1.3 2.3 4.2 0.8 1.6 1.7 1.2 
 
185 
 ZNF545 zinc finger protein 545 A_23_P416
813 
1.1 1.3 0.7 0.5 1.1 1.8 0.9 0.6 1.3 5.3 0.7 1.2 1.2 0.9 
   A_32_P834
726 
0.8 1.2 1.3 1.7 1.1 8.7 0.7 1.5 1.4 3.9 1.5 2.3 0.9 0.9 
   A_23_P931
09 
0.7 0.7 1 0.9 0.5 4.4 0.9 0.9 0.5 6 1.4 1 0.9 0.8 
   A_23_P247 1.6 0.9 0.9 1.1 0.7 7.3 1 0.7 0.6 19.3 0.9 0.7 1.1 0.9 
   A_24_P570
583 
1 1 1 0.9 1.2 2.2 1 1 1.3 4.9 1 0.9 0.9 0.9 
   A_23_P637
36 
0.9 0.9 1 0.9 0.9 2.4 0.7 1.1 1.2 6.9 0.8 1 1.2 0.8 
   A_32_P523
86 
0.9 1.4 1.5 2.7 1.5 5.8 2.1 1.4 2.3 3.4 1.5 2 1.9 1.1 
   A_32_P158
019 
1.4 2.3 1.1 0.9 2.1 2 1 0.8 1.5 6.3 1 0.9 0.6 0.8 




6.7 7.6 1.8 1.7 19.
9 
38 1.6 2.3 31.5 28.2 1.6 1.7 4.2 8.1 
 APOL2 apolipoprotein L2 A_23_P211
488 




1 1.8 20.6 16.8 1 1.3 3.6 6 
 APOL4 apolipoprotein L4 isoform 1 A_23_P380
857 




1.5 2.5 18.2 15 1.4 1.7 5.1 7.2 
 APOL6 apolipoprotein L, 6 A_24_P941
167 
8.6 8.3 1.5 1.9 14.
2 
9.8 1.4 2.6 16.7 8.5 1.5 1.7 6.3 9 
 APOL6 apolipoprotein L6 A_23_P155
049 
8.1 6.8 1.2 1.6 11.
8 
8.3 0.9 1.2 9.5 8.5 1.1 0.9 4.3 8.5 
 APOL6  A_24_P759
4 




0.6 6.3 17.4 6.9 0.9 1.5 6.8 11.3 




1.7 5.5 0.6 0.8 2.8 12.
6 
0.6 0.9 3.6 12.7 0.7 0.7 1.4 4.6 
 BATF2 basic leucine zipper transcription 
factor, ATF-like 2 
A_23_P370
682 




1.2 1.7 20.3 9 0.9 1.1 3.3 8.3 








1.5 2.5 18 20.9 1.3 2.6 3.5 10.6 
 BTC betacellulin A_23_P135
722 
2.3 5 1.7 1.5 3.5 1.9 1.4 1.5 3.8 2.2 1.5 1.4 1.4 2.7 
 C1orf38 basement membrane-induced 
gene isoform 1 
A_24_P857
75 
14 14.8 0.7 1.3 27.
2 
7.8 1.5 1.3 16.8 7.3 0.9 0.7 1.5 2.7 
 C1orf38 basement membrane-induced 
gene isoform 1 




1.5 3.4 27.7 10.2 1.2 1.5 2.1 3.6 
 CA13 carbonic anhydrase XIII A_23_P381
714 
5.4 2.3 1 1.2 10.
5 
22 1.2 0.9 7.9 15.7 1.1 1.3 4.5 3.7 




6.2 46.2 0.9 1.1 27.
6 
7.8 0.8 1.1 17.8 23 0.8 0.9 6.3 17.1 
 CD274 CD274 antigen A_23_P338
479 




0.9 1.1 17 12.6 0.8 1 2 8.2 
 CD38 CD38 antigen A_23_P167
328 
1.4 6 0.8 0.9 4.7 13.
5 




related cell adhesion molecule 1 
isoform 1 precursor 
A_24_P382
319 








related cell adhesion molecule 
1 isoform 2 precursor 
A_23_P434
118 
2.8 4.6 1.4 1.1 8.9 15.
5 
0.7 1 10 7.5 0.9 1 3 7.9 








0.8 1.8 42.5 15.6 0.6 0.8 1.7 6.2 
 CTSS cathepsin S preproprotein A_23_P461
41 
2.1 4.4 0.9 1 2.7 3.7 0.9 0.9 1.9 3.4 0.9 1.1 1.4 3.3 








1 9.4 321.1 284.
5 
1.1 2.4 10.1 96 
 CXorf43 hypothetical protein LOC139324 A_23_P386
364 
2.8 3.7 0.5 0.6 10 33.
1 
0.3 0.6 8.3 22.3 0.6 0.8 1.8 4.7 
 DDX58 DEAD/H (Asp-Glu-Ala-Asp/His) 
box polypeptide RIG-I 
A_23_P208
14 




1.6 5.7 195 315.
1 
1.3 1.6 4.1 27.3 




2 1.8 0.7 1.7 7.7 2.9 1 1.6 4.2 1.9 0.9 0.7 0.7 0.9 
 DTX3L deltex 3-like A_24_P941
912 
6.1 7.1 0.9 1.5 7 9.4 0.7 1.7 7.6 6.3 0.8 1 2.7 4 
 DTX3L deltex 3-like A_23_P347
040 




0.8 1.3 9.1 15 0.9 1 2.1 4.1 
 EIF2AK2 eukaryotic translation 




2.7 5.5 1.3 1.2 4.4 5.5 1.4 1.5 4.6 3.5 1.1 1.1 1.1 1.5 
 EMR1 egf-like module containing, 
mucin-like, hormone receptor-
like sequence 1 
A_23_P275
56 
1.3 5.2 0.6 0.7 2.8 2.5 0.8 0.9 1.9 3.3 0.7 1.1 1.4 2.9 




1.3 4.5 1.2 1.3 9.7 11.
1 
1.1 1.2 8.1 5.8 0.9 1.3 1.8 4.9 
 FAM46A hypothetical protein LOC55603 A_23_P706
60 
3 2.4 1.5 1.5 8.8 13.
8 
1.2 1.6 14.4 10.2 1.4 1.5 1.9 2.7 








1.5 1.7 136 90.2 1 1.3 18.1 70.7 








1 2.7 122.2 140.
5 
1.1 1 14.3 64.2 
 GBP3 guanylate binding protein 3 A_24_P370
702 




1.2 1.6 17.9 10 1.2 1.1 6.2 14.4 
 GBP3 guanylate binding protein 3 A_23_P514
87 
10.8 17.2 0.4 0.9 23.
4 
13 0.6 0.8 19.1 10.7 0.6 0.7 8.4 17.6 
 GBP4 guanylate binding protein 4 A_24_P454
46 
7.2 20.1 1 1.2 39.
5 
147 1.2 1.6 45.4 73.6 0.7 1.3 3.4 32.7 
 
186 








1 4.5 260.1 197.
8 
1.4 1 17.9 187.
6 
 GBP5 guanylate-binding protein 5 A_23_P742
90 




1.4 3.4 140.5 160 1 1.3 16.5 88.5 




1.4 6.6 1.1 0.5 3.7 1.3 0.8 0.7 2.5 2.6 0.9 1 1 0.8 
 HERC5 hect domain and RLD 5 A_23_P110
196 




0.8 3.5 147.3 261 0.7 1.5 4.1 40 
 HLA-B major histocompatibility complex, 
class I, B 
A_23_P125
107 
1.5 5.2 0.7 0.8 4.1 18.
4 
0.7 0.9 5.1 10.7 0.8 0.9 1.2 4.2 
 HLA-B major histocompatibility complex, 
class I, B 
A_24_P113
674 
1.6 4.3 0.8 0.9 4 16.
2 
0.8 1 5.2 10.4 1 0.9 1.2 3.9 
 HLA-C major histocompatibility complex, 
class I, C precursor 
A_24_P298
409 
1.6 4.6 1.1 1.1 3.3 15.
2 
1 1.2 5 11 1.1 1.1 1.3 3.6 
 HLA-C MHC class I antigen A_23_P959
17 
1.5 4.6 0.8 0.9 3.7 13.
9 
0.7 0.9 4.4 8.8 0.9 0.9 1.3 3.5 
 HLA-C  A_23_P113
716 
1.5 4.3 1.1 1.1 3.5 16 1 1.2 5 11.5 1.1 1.1 1.3 3.5 
 HLA-E major histocompatibility 
complex, class I, E precursor 
A_24_P326
082 
2.2 4.2 0.8 0.8 3.4 11.
1 
0.8 0.9 3.4 6.7 0.8 0.8 1.1 2.8 
 HLA-E major histocompatibility 
complex, class I, E precursor 
A_32_P460
973 
2.5 4.3 1 1 3.7 5.1 1 1.1 3.4 4.5 1 1 1.4 2.5 
 HLA-F major histocompatibility complex, 
class I, F precursor 
A_23_P314
024 
1.6 5.2 0.9 0.9 5.9 28.
2 
0.9 1 7 14 0.9 1 1.3 5.7 
 HRASLS2 HRAS-like suppressor 2 A_23_P105
012 




1.1 1.4 9.7 11.1 0.8 1.2 1.9 7.3 
 HRASLS2 HRAS-like suppressor 2 A_24_P364
263 
2 6.2 0.9 1 4.3 6.6 1.1 1.1 3.6 6.2 1.1 1.1 1.4 4.2 




6 10.6 1 1.9 20 33.
8 
1 1.6 23.1 11.3 1 1.2 1.5 3.7 
 IBRDC3 IBR domain containing 3 A_23_P321
388 
1.6 1.8 1.5 1.5 4.8 2.2 1.6 1.4 4 2 1.1 1.1 1 2.2 








1 2 12.4 9.4 1 1 1.8 2.9 
 IFI16  A_23_P217
866 




1.1 1.8 12.2 9.2 1.2 1.1 1.6 2.6 








1.3 4.3 22.6 21.1 1 1.3 2.4 11.3 








1.5 3.1 34 34.8 1.1 1.1 2.9 12.3 
 IFI35 interferon-induced protein 35 A_23_P152
782 
2.4 7.8 0.7 0.9 6.3 3.7 0.8 1.1 5.7 3.3 0.8 0.8 1.5 2.1 











1.4 21 128.9 111.
9 
1 7 16.1 55.2 
 IFI44L histocompatibility 28 A_23_P458
71 




1.1 3 127.3 95.2 1 0.9 2.2 24.5 
 IFI6 interferon, alpha-inducible 
protein 6 isoform c 
A_23_P201
459 




1.7 4.8 43.3 43.7 1 1.4 2.7 10.4 
 IFIH1 interferon induced with helicase 
C domain 1 
A_23_P681
55 




2 8.7 150.9 191.
8 
1.2 3.3 8 53.8 
 IFIT1 interferon-induced protein with 








16.2 35.2 94.6 76.7 4.8 14.5 11.2 33.2 
 IFIT2 interferon-induced protein with 
tetratricopeptide repeats 2 
A_23_P240
04 










2.9 14.5 42.9 531 
 IFIT2 interferon-induced protein with 











3.4 46.5 411.3 548.
7 
1.4 14.9 27.5 327 
 IFIT3 interferon-induced protein with 









2.2 21.2 353.2 224.
7 
0.8 4.1 15.8 73.4 
 IFIT5 interferon-induced protein with 
tetratricopeptide repeats 5 
A_24_P301
94 
6.1 6.4 1.1 1.3 8.3 24.
6 
1.1 1.7 10.6 13.5 1.1 1.1 1.5 4.3 
 IFIT5 interferon-induced protein with 
tetratricopeptide repeats 5 
A_23_P636
68 
5.4 5.5 1.2 1.5 8.3 26 1.2 1.8 12.2 14.8 1.3 1.3 1.5 3.8 
 IFITM1 interferon induced 
transmembrane protein 1 (9-27) 
A_23_P727
37 
6.7 8 0.8 2.3 10 9.8 1.3 3.6 13.4 9.9 0.9 1.1 2.3 2.2 
 IFITM2 interferon induced 
transmembrane protein 2 (1-8D) 
A_24_P287
043 
1.8 5.4 1.1 1 3.6 1.9 1.2 1.1 4 2.6 1 1 0.8 0.7 
 IFITM3 interferon-induced 
transmembrane protein 3 (1-8U) 
A_23_P875
45 
2.6 9.7 1.1 1.1 6.4 5.9 1.3 1.4 8.1 6.8 1 1 1 1.2 
 IFITM4P  A_24_P161
24 
2.2 11.5 0.9 0.9 4.4 2.5 1.1 1.1 4.9 4.1 1 0.9 0.8 0.9 
 IL4I1 interleukin 4 induced 1 isoform 2 A_23_P502
520 
2.5 7.9 1.4 1.3 5.9 16.
5 
1.1 1.4 7 11.2 1.3 1 1.3 6.2 




10.6 39.4 0.9 1.1 87 110
.2 
1 1.6 93.1 89.3 1.1 1 21.3 71 
 IRF1 interferon regulatory factor 1 A_23_P417
65 




0.9 2.2 18.3 16.7 0.9 2 3.6 8.5 








1.3 4.9 22.2 13.9 1 1.3 2 3.7 
 ISG15 interferon, alpha-inducible 
protein (clone IFI-15K) 
A_23_P819 13.5 36.9 1.2 5.2 35.
2 
94 2 10.2 58.8 76.7 1.2 3.3 9.9 25.2 




2.2 6.5 1 1 9.4 38.
6 
1 1.3 20.4 30.4 0.9 0.9 1.8 8.2 
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 ISGF3G interferon-stimulated 








3.2 5.2 15.3 11.4 1.4 1.9 6.9 6.2 
 KIAA1618 hypothetical protein LOC57714 A_24_P350
124 
1.7 3.5 1.6 1.5 4.6 2.9 1.6 1.7 5.6 2.2 1.5 1.2 1.3 1.6 








0.9 1.8 14.7 16.4 1 1.2 2.8 16.1 








83 0.8 0.8 10 84.9 1.3 1.4 1.8 7.6 
 LAP3 leucine aminopeptidase 3 A_23_P186
04 
2.2 5.4 0.5 0.8 4.2 2.6 0.6 0.9 2.8 2.5 0.5 0.8 1 1.5 
 LGALS9 galectin 9 long isoform A_32_P452
655 
3.2 8.8 1.3 1.5 6.8 8.2 1.3 1.5 7.8 7.6 1.3 1.2 1.4 2.5 
 LGALS9 galectin 9 long isoform A_23_P116
557 
1.7 9.3 1.1 0.9 4.2 2.2 1.1 1.4 2.7 2.6 1 1 1.4 1 
 LMO2 LIM domain only 2 A_23_P531
26 
12.1 9.7 1 1.2 25 9.3 0.8 1.1 15.8 5.2 1 0.9 1.1 2.7 
 MX1 myxovirus resistance protein 1 A_23_P176
63 






1.9 17.2 41.2 32 1.3 2.2 7.8 14.4 
 MX2 myxovirus resistance protein 2 A_23_P626
3 




1.3 3.4 82.9 41.8 1.6 1.2 3 5.5 
 MYD88 myeloid differentiation primary 
response gene (88) 
A_23_P362
659 
2.7 3.5 1 1 4.3 1.2 0.9 1.2 3.3 1.3 1.1 1 1.1 1.2 
 NCOA7 nuclear receptor coactivator 7 A_24_P124
35 
2.9 1.9 1 1.2 6.6 14.
8 
0.8 1.5 9.2 7.1 1.1 1.1 1.2 3.1 
 NCOA7 nuclear receptor coactivator 7 A_23_P156
957 
3.4 2.4 1 1.2 7.7 15.
9 
1 3.2 12.2 7.2 1 1.1 1.2 2.7 
 NLRC5 nucleotide-binding 
oligomerization domains 27 
A_23_P402
892 
8.9 4.9 1 1.1 16.
2 
3.7 0.9 1.7 17.5 3.2 0.9 1.1 10.3 7.6 
 NLRC5  A_23_P265
83 
15.7 6.8 1.1 1.3 18.
5 
7.2 0.9 1.6 22.3 3.6 1 1 10.8 11.9 
 NMI N-myc and STAT interactor A_23_P154
235 
2.7 6.2 0.8 0.9 4.2 21 0.7 0.8 4.6 10.6 0.9 0.8 1.6 3.1 




1.7 4.3 0.9 1 3.7 2.9 0.9 1 2.8 2.4 0.9 0.9 1.2 1.5 




5.1 8.8 0.9 1.3 7.3 10.
6 
0.9 1.8 6.9 7.5 1 0.9 1.5 4.1 








0.9 1.1 20 23.4 1 1.1 1.2 7.5 
 OAS2 2'-5'-oligoadenylate 
synthetase 2 isoform 1 
A_23_P204
087 




1 0.7 8.2 12 0.7 0.8 1 3.7 
 OAS3 2'-5'oligoadenylate synthetase 3 A_24_P335
305 
2.9 10.3 0.8 1.4 8.1 12.
5 
0.9 1.9 8 9.6 0.8 0.9 1.4 3.5 
 OAS3 2'-5'oligoadenylate synthetase 3 A_23_P479
55 
3.9 17.6 0.9 1.5 9.3 18.
2 
1.2 2.1 10.3 15.2 1 1.1 1.7 5.1 
 OASL 2'-5'-oligoadenylate synthetase-
like isoform a 
A_23_P139
786 




11.5 41.5 114.8 135.
5 
2.4 24.5 33.3 58.9 








1 1.7 12.9 6.2 1.1 1.1 2 3 
 PARP14 poly (ADP-ribose) polymerase 
family, member 14 
A_24_P161
018 




1.5 2.4 29.6 36.8 1.5 1.3 2.7 7 
 PARP14 poly (ADP-ribose) polymerase 
family, member 14 
A_32_P567
59 
5.2 8 1.1 1.3 16.
8 
62 0.7 2 30.2 27.4 0.7 1.3 3.6 8 
 PARP9 poly (ADP-ribose) polymerase 
family, member 9 
A_23_P693
83 




1 3.4 14.5 7.4 1.2 1.1 3.8 5.2 
 PLA1A phospholipase A1 member A A_24_P294
408 
1.9 8.7 1 1.1 9.9 22.
3 
0.9 0.8 7.1 10.7 0.9 1.2 2.2 5.7 
 PLA1A phospholipase A1 member A A_23_P298
16 
1.4 5.4 1.9 1.4 9.9 24.
7 
1.5 1.6 5.4 9 1.2 1.3 1.5 5.3 
 PLEKHA4 pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
A_24_P408
047 




1.8 4.1 43.2 46.7 1.3 1.7 3.9 16.7 
 PLEKHA4 pleckstrin homology domain 
containing, family A 
(phosphoinositide binding 
specific) member 4 
A_23_P673
60 




0.9 2.1 21.9 20.1 1 1.4 3.6 11.7 
 PLSCR1 phospholipid scramblase 1 A_23_P691
09 
3.7 12.6 0.9 1.4 8.9 14.
5 
0.8 1.8 8.7 8.2 0.9 0.8 1.1 3.2 
 PML promyelocytic leukemia 
protein isoform 1 
A_24_P207
139 
4.5 5.7 1.3 1 6.6 4.5 0.8 1.5 6.3 3.1 1.3 1 2 1.5 
 PML promyelocytic leukemia 
protein isoform 6 
A_24_P198
598 
2.7 4.5 1 1.1 4.8 3.6 1 1.3 3.9 2.9 1 1.2 1.7 1.6 
 PML promyelocytic leukemia 
protein isoform 6 
A_23_P306
148 
2.7 4.1 1 1.1 5 3.8 1 1.4 4.2 2.9 1 1.2 1.6 1.7 
 PNPT1 hypothetical protein A_32_P760
35 
2.2 5.1 0.8 1 4.5 2.8 0.9 1 3.4 1.9 0.8 1.1 1.2 1.2 




2.4 4.8 1 1 5.2 7.8 1 1.1 5.1 3.1 0.9 1.1 1.2 1.2 








1 1.3 28.7 27.7 0.7 0.9 1.4 6.7 




1.5 4.6 1.3 1.2 3 2.4 1.4 1.1 3.1 3.3 1.2 1.2 2.1 4.9 
 PSMB8 proteasome beta 8 subunit 
isoform E1 proprotein 
A_23_P250
629 
2.4 6.9 0.7 0.9 4.6 1.8 0.7 0.9 3.1 2.2 0.8 1 2.1 3.5 
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 PSMB9 proteasome beta 9 subunit 
isoform 1 proprotein 
A_23_P111
000 
3.1 12 0.5 0.8 9.4 3.6 0.8 1.1 6.1 4.9 0.6 0.9 3.8 8.8 
 RARRES
3 





2.1 6 1.2 1.3 7.4 10.
4 
1.3 1.5 8 8.3 1 1.3 4.4 6.9 
 RASGRP
3 
RAS guanyl releasing protein 3 
(calcium and DAG-regulated) 
A_24_P543
90 




0.6 1.8 14.7 7.3 0.9 0.8 3.7 3.8 
 REC8 REC8 homolog A_24_P344
087 
5.5 4.9 2.1 4.3 6.6 8.3 3.6 4.7 9.3 5.2 1.6 2.4 3.9 3.9 




2 12.6 0.8 0.7 3.9 2.1 1.2 1.5 2.1 4.4 1 0.9 1.3 3 




1.9 3.5 1.7 1.6 5.4 2.1 1.5 1.3 5.9 2.2 1.7 1.4 1.3 1.5 
 RSAD2 radical S-adenosyl methionine 
domain containing 2 
A_24_P316
965 




1 2.9 194.4 302.
7 
1 1.2 6.1 61.4 




36.7 37 0.8 1.9 49.
1 
50 0.8 3.2 35.6 34.8 0.9 1.1 5 12.4 








0.8 3.4 34.1 37.7 0.9 1.1 3.5 13.4 








0.9 3.2 41.2 53.3 1 1.1 3.7 14.6 








1.4 5.9 82.9 37.6 1.5 1.6 14.5 22.3 




1.3 1 0.6 0.9 3.5 4.3 0.6 0.9 4.9 2.8 0.6 0.8 1.2 1.8 




1.4 1.2 0.7 1 4 5.3 0.7 1 6.3 3.4 0.7 1 1.2 2 




4.5 9 1 1.1 15.
1 
2.9 1.3 1.8 9.1 1.2 0.9 1.9 2.7 2.6 




4.9 14.9 1 0.4 15.
2 
33 0.7 0.7 12.9 17.5 0.9 0.8 1.7 7.1 








1.3 1.9 13.8 6.3 0.9 1.5 1.5 4.2 
 SP100 hypothetical protein A_23_P209
712 
2.5 6.4 2.8 1.8 3.5 4.5 2.5 1.9 4.2 2.6 2 1.4 1.6 1.7 




2.9 5 0.9 1 4.4 5.1 0.8 1.1 3.8 3.2 0.8 0.9 1.2 1.9 
 SP100 nuclear autoantigen A_24_P916
816 




2.6 3.7 11.8 5.6 1.8 1.2 1.9 3.4 




8.8 14.5 0.9 1.2 15.
3 
10 0.9 1.8 10.9 5.8 1 0.9 1.8 2.2 




3.7 6.8 1.3 1.5 5.9 5.5 0.9 1.2 4.9 3.5 1.6 1.1 2 3.4 
 STAT1 signal transducer and 




3 8.3 0.5 1 11 13.
1 
0.5 1.1 6.8 7.7 0.6 1 3.7 4.9 
 STAT1 signal transducer and 








0.9 2.9 15.3 7.6 0.9 1.5 4.7 5.7 
 STAT2 signal transducer and activator 
of transcription 2 
A_23_P760
90 
4.9 3.8 1.3 1.3 8.6 4.2 1 1.6 8.3 2.4 0.9 1.1 2.1 2.5 
 TAP1 transporter 1, ATP-binding 
cassette, sub-family B 
A_23_P590
05 




1.1 1.4 11.5 9.5 1 1.4 3.8 9.3 
 TAPBPL TAP binding protein-like A_23_P367
00 
1.3 2.7 0.7 0.7 3.4 15.
7 
0.6 0.9 7.6 11.1 0.7 0.8 1.5 3.4 
 TDRD7 tudor domain containing 7 A_23_P123
672 
2.7 3.1 0.9 1 5.8 20.
3 
0.8 1.3 9.4 12.3 1 0.8 1 2.1 
 TGM2 transglutaminase 2 isoform a A_32_P867
63 
1.7 4.2 0.6 0.6 2.2 1.2 0.5 0.7 1.4 1.2 0.6 0.7 1.2 1.5 
 TLR3 toll-like receptor 3 A_23_P299
22 
11.9 16.1 1.3 1.3 29.
3 
6.6 0.9 1.8 12 16.1 0.9 1 5.7 12.7 




4.1 3.4 1.1 1 4.3 4.1 1 0.9 2.3 3.4 1.2 1 1.2 1.7 
 TMEM140 hypothetical protein LOC55281 A_23_P311
77 
12.1 8.5 0.9 1.1 23.
9 
14 1.1 1.6 14.1 10.7 1.2 0.9 3.4 4.4 
 TNFSF10 tumor necrosis factor (ligand) 
superfamily, member 10 
A_23_P121
253 




1.1 1.6 26.1 11.5 1.2 1.1 2.2 6.9 
 TNFSF13
B 
tumor necrosis factor (ligand) 
superfamily, member 13b 
A_23_P141
74 




1.2 1 14.5 14.1 1 1.2 2.8 4.3 




2.3 8.7 0.5 1 6.4 9.4 0.7 1.2 5.6 6.5 0.6 1 1.3 2.5 




2.1 7.3 0.6 1.1 7 8.6 0.8 1.5 6.3 5.6 0.7 1 1.5 2.6 




1.7 4.6 1 1.2 4.9 4.9 1.1 1.3 5 3.5 1 1.2 1.2 1.6 
 TRIM22 tripartite motif-containing 22 A_23_P203
498 




1 1.3 63.1 36.6 0.8 0.9 6.6 19.6 
 TRIM25 tripartite motif-containing 25 A_23_P153
26 
2.5 2.2 1.1 1.1 4.5 11 1.2 1.2 4.8 8.3 1.1 1 1.2 1.8 
 TRIM25 tripartite motif-containing 25 A_24_P936
767 
3.5 2.9 0.7 1.1 7.5 5.9 0.7 1.3 5.2 4.3 0.7 0.9 1.2 1.8 




2.1 4.1 0.9 0.9 4 1.4 0.8 0.9 2.3 1.5 0.8 0.8 1.5 1.4 




3.4 7 2.4 1.8 5.2 2 1.6 1.6 5.1 1.8 2.2 1.3 1.6 2 
 TRIM38 tripartite motif-containing 38 A_24_P294
851 
3.6 3.3 0.7 1.2 6.4 2.3 0.9 1.3 6 1.9 0.7 1.1 1.4 1.8 
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 TRIM69  A_24_P505
43 
4.1 3.8 0.9 0.9 5.1 4.4 0.7 1 3.1 3 1 0.7 1.6 2.9 
 UBD diubiquitin A_23_P818
98 
6 12.9 1 1.2 7.7 20.
3 
0.8 1.1 5.5 19.2 1 0.8 3 41.6 




3.5 21.8 1 0.8 19 8.4 0.9 0.8 24.4 8.9 0.9 0.8 2.7 7.5 
 UBE2L6 ubiquitin-conjugating enzyme 
E2L 6 isoform 2 
A_23_P757
41 
2.8 9.2 0.6 0.8 4.8 2 0.6 0.9 3.4 2.6 0.7 1.1 1.8 2.9 
 USP18 ubiquitin specific protease 18 A_32_P132
206 




1.1 1.8 18.7 18 1.2 1.3 1.7 4.2 
 USP18 ubiquitin specific protease 18 A_23_P132
159 




0.8 1.6 22.2 21.1 0.9 1 1.5 3.5 




5.7 3.2 1 1.3 7.1 15.
3 
0.9 1.6 9.9 11.4 1 1.2 1.7 3.7 








0.6 1.6 9.8 9.7 0.7 1.2 1.4 3.8 
  hypothetical protein A_32_P161
292 




1 1.5 14.5 17.8 1.1 1.1 2.8 4.2 
  hypothetical protein A_32_P662
8 
1.6 3.5 1.1 1 4.4 3 1 1.1 4.7 1.7 1 1 1 1.1 
  hypothetical protein LOC55337 A_23_P388
94 
3.8 9.8 1.6 1.6 12.
7 
9.7 1.3 1.9 11.9 5 1.4 1.2 1.6 2 
  hypothetical protein LOC55337 A_24_P236
949 
2.3 7.6 0.7 0.9 6 8.3 1 1.4 6.9 4.7 0.8 0.8 1.1 1.7 
  hypothetical protein LOC55601 A_24_P334
361 




0.4 1.5 50.4 75.9 0.4 0.8 3.9 16.4 
  hypothetical protein LOC55601 A_23_P414
70 




0.4 1.4 38.5 51.5 0.4 0.8 3 10.7 
  hypothetical protein LOC79132 A_23_P383
46 




1.4 5.5 146.3 183.
8 
1.2 2 6 48.6 




2.8 4.3 1.2 1.1 6.1 2.7 0.8 0.8 4.3 2.8 0.9 1.1 2.6 3.2 




4.3 4.6 1.1 1.4 8.3 11.
6 
1.2 1.6 8.8 11.9 1.1 1.3 3.1 5.8 




5.1 4.5 1.6 1.7 9.5 7.6 1.6 1.9 9.8 4.4 1.4 1.2 1.4 2.3 




1.4 7 1.4 1.2 3.4 3 1.7 1.4 2.7 2.5 1.6 1.4 1.1 1.2 




1.7 5.4 0.9 1 4.2 17.
9 
0.8 1 5.2 11.4 1 1.1 1.4 4.2 








1.2 3.7 225.6 209.
2 
1.6 1.4 7.9 77.7 








1.1 2.7 143.6 90.8 1.4 0.9 5 38.6 
   A_32_P995
33 




1.5 6.7 42.5 36.9 1.8 2 6.1 21.4 
   A_24_P927
166 




1 6.9 126.8 103.
5 
1.6 1.4 6.5 28.9 
   A_32_P924
15 




1.2 2.1 33.9 42.8 1.3 1.2 2.9 7.9 
   A_24_P586
264 




1.1 1.7 34.9 33.3 0.9 1.2 1.6 8.3 
   A_32_P154
726 
2.6 3.4 0.8 0.9 7.5 20.
4 
0.7 1 9.2 12.6 0.9 0.9 1.5 4.3 
   A_24_P127
641 




1.3 2 20 16.6 1.4 1.3 2.9 7.9 
   A_24_P680
79 




1 2 16.5 12.9 1 1.1 2.9 7.7 
   A_23_P250
353 
4 11.1 0.7 1.2 12.
2 
26 0.8 1.8 16.8 22 0.9 1.1 2 8.5 
   A_32_P114
831 
2.3 4.1 1.2 1.8 7 10.
5 
1.7 1.4 8 12.7 1 1.3 1.6 4.3 
   A_32_P220
897 
2.8 2.4 1 1.1 3.6 6.8 0.8 1.5 5.4 5 1.1 0.8 1.1 2 
   A_24_P829
156 




1.5 2.4 13.7 7.3 1.5 1.2 3.1 5.1 
   A_23_P256
487 




0.9 1.3 20.9 27.3 0.8 0.9 2.1 12.9 
   A_32_P758
67 




1.2 3.1 19.3 13.6 1.8 2 7.2 20.1 
   A_32_P143
980 
2 4.3 1.2 1.3 4 11.
1 
1.3 1.3 4.6 8.1 1.3 1.1 1.4 3.7 
   A_23_P338
113 
1.2 3.3 0.7 0.8 3.2 14.
1 
0.7 0.8 3.9 8.2 0.8 0.8 0.9 3.4 
   A_23_P125
109 
1.5 5 0.8 0.9 4.3 22.
9 
0.8 0.9 5.7 13.9 0.9 1 1.2 4.7 
   A_23_P373
126 
1.8 6.6 0.8 0.9 6.9 27 0.8 1 7.8 14.7 0.8 0.9 1.3 6.2 
   A_23_P370
707 
1.7 5.3 0.8 0.9 7 23 0.8 1 7.4 12.9 0.8 0.9 1.5 6.3 
   A_24_P860
781 
1.5 4.6 0.9 1 2.5 12.
2 
0.9 0.9 3.4 8.4 0.9 1 1 3.2 
   A_23_P350
295 
1.1 2.3 0.9 0.9 2 10.
2 
0.8 0.9 2.9 7.1 0.9 0.9 1 2.5 
   A_32_P545
53 
3.4 5.9 0.7 0.9 8.8 14.
6 
0.6 1.4 9.5 9.9 0.6 1 1.3 2.4 
   A_23_P300
69 




1 2.2 34.5 22.3 0.9 1.2 2.5 4.6 
   A_23_P651
74 
2.3 4 1 1.1 4.8 6.5 1.1 1.3 4.5 3.7 1 1 1.5 1.8 
   A_23_P178
37 




1.8 2.9 24.5 18.4 1.1 1.8 3.4 7.9 
   A_23_P384
355 




0.6 4.5 81.5 170.
7 
0.8 1 2.8 24.8 
   A_24_P368
98 
7.2 2.5 0.8 1 6.1 12.
8 
0.9 0.7 5.9 5.8 0.9 0.7 2.4 3.6 
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   A_24_P740
662 
11.5 8.7 2.2 4.9 19.
6 
26 2.1 8.1 28.9 15.7 1.6 1.9 7.2 10 
   A_24_P118
892 




0.7 1.9 9.6 9.4 0.7 1.5 1.1 1.9 
   A_24_P868
905 
4.2 12.9 1 1.4 9.5 10.
3 
1.4 1.6 12.2 9.7 0.9 1.1 1.4 2.3 
   A_32_P167
592 
2.2 7.4 1.1 1.2 4.6 3.4 1.3 1.3 5.6 4.1 1 1 0.9 0.9 
   A_24_P704
0 
2.8 10.4 1 1 6.5 5.4 1.2 1.4 8.5 6.6 1 0.9 0.9 1.2 
   A_23_P202
245 
2.2 13.4 1 1.2 8.8 8.6 1.1 1.1 6.3 10.2 1 0.6 0.7 1.4 
   A_32_P156
746 
8.1 6.2 1.1 2.3 16.
2 
4.8 1.3 2.9 15.9 3.1 1.3 1 2.5 3.5 
   A_24_P236
680 
3.8 3.1 1.1 1.5 7.4 3.3 1.3 1.9 5.4 2.8 1 1.2 1.5 1.7 
   A_24_P157
02 
2 4.3 0.5 0.9 3.8 1.8 0.5 1 1.8 2.3 0.5 0.9 1.1 1.4 
   A_32_P562
49 




0.7 0.8 28.2 16.1 0.9 1 6.2 32 
   A_32_P171
793 
6.2 12.8 0.9 1.7 18.
1 
7.8 0.8 1.2 12.6 8.1 0.9 1.3 4.2 10.5 
   A_23_P203
629 
1.5 4.8 1.6 1.1 2.9 3.8 1.7 1.2 2.8 3.7 1.4 1.1 1.3 2.9 
   A_23_P354
547 




3.8 7.5 16.2 5.1 1.5 3.1 5.1 5 
   A_32_P154
321 
1.9 4.4 1.3 1.1 2.6 1.5 1.3 1.3 2.9 2.3 1.3 1 1.8 1.7 
   A_24_P155
02 
1.6 4.4 1 1 2.6 1.8 1.2 1.2 3.1 2.3 1 1 0.9 0.8 
   A_24_P254
933 
2 8.1 1 1 3.6 2.6 1.2 1.3 4.4 3.8 1 1 0.9 0.9 
   A_24_P306
810 
3.1 3.2 1.8 2.1 8.1 2.2 1.9 2.1 7.3 1.6 1.5 1 1.7 1.8 
G AVIL advillin A_24_P419
087 
1.3 1.6 1.8 2.7 3.1 5.2 2.4 3 5.2 3.1 2.1 0.9 1 1.2 
 CDH15 cadherin 15 preproprotein A_32_P253
57 
1.7 1.1 1 1.3 6.8 3.3 1.2 1.1 1.6 2.5 1.2 1.3 3.2 1.6 




2.7 1.3 2 1.5 3.7 1.9 1.6 1.5 5.2 1.4 1.7 1 0.8 1 
 CHRNA10 cholinergic receptor, nicotinic, 
alpha polypeptide 10 
A_23_P411
188 
0.8 1 1.8 1.6 1.7 7.5 1.8 1.5 4.9 4.3 1.5 1.4 1.1 1.2 
 DDEF1IT1 HSPC054 A_23_P146
325 
1.3 1.5 4.5 2.3 2.8 7.6 3.5 2.3 7.9 2.9 3.2 1.5 1.3 1.6 
 FEV FEV (ETS oncogene family) A_23_P546
0 
1.2 1.2 1.6 1.5 2.4 10.
9 
1.7 1.2 1 1 1.2 2 1.5 2.5 
 IL1B interleukin 1, beta proprotein A_23_P795
18 
1.2 1 0.8 1 1.8 4.3 0.8 1 1.6 0.8 0.9 1.1 1 3.5 
 ITGB1BP
2 
integrin beta 1 binding protein 2 A_23_P454
24 
0.9 1 2.8 1.8 2.1 3.8 1.9 1.7 4.7 2 1.8 1.2 1 1.3 
 MLL3 myeloid/lymphoid or mixed-
lineage leukemia 3 isoform 2 
A_32_P209
472 
0.9 1.1 2.5 2.6 2.1 11.
4 
2.5 2 7.6 4.4 1.5 1.5 1.2 1.8 
 SATB2  A_24_P928
408 
1.7 1.7 3.9 3.1 2.4 7.9 3.2 2 7.1 2.6 2.4 1.4 1.5 1.2 




2.4 1.2 1.4 1.4 4.8 1.3 1.6 1.8 4.1 0.9 1.2 1 0.8 0.7 
 SSH2 hSSH-2 A_23_P395
954 
1.2 2 2.8 1.7 1.7 4.5 1.4 2.1 2.7 1.4 1.8 1.3 1.3 1.1 
 SYNPO2  A_23_P310
094 
1.2 1.7 0.6 1.2 2.7 9.7 0.5 0.9 2.1 1.6 0.8 1.6 2.3 2.7 




2.2 1 3 1.5 1.6 7.9 1.3 2.2 4.4 4.4 2.6 1.1 0.9 1.1 
 ZBTB20  A_32_P179
526 
1.2 1.6 4.2 2.4 2.8 2.6 3.8 2.5 4.8 1.3 3.2 1.2 1.2 1.2 
  hypothetical protein A_24_P273
647 
0.8 1.1 1.6 1.4 1 5.2 1.3 1 2.2 2.4 1.5 1.4 0.9 0.9 
  interferon epsilon 1 A_23_P302
060 
1.1 1.2 1.6 2.2 2 6 2.2 1.8 2.6 2 1.5 1 1.5 1.1 
  KIAA1541 protein A_24_P940
218 
1.1 1.1 2.6 2.1 1.9 6.4 1.9 1.7 3.7 3.9 2.2 1.8 1.5 1.5 
   A_32_P989
40 
1.1 1.4 4.7 2.7 4.9 30.
3 
3.3 2.2 15.5 11.5 3.9 1.8 1.6 3.3 
   A_32_P208
039 
1 1.2 3.9 2.2 3.3 20.
3 
2.7 1.8 10.3 8 2.9 1.6 1.3 2.4 
   A_32_P559
87 
1.2 1.6 5.3 3 4.1 25.
3 
4.4 2.5 13.6 8.9 4.1 1.8 1.7 2.9 
   A_32_P220
567 
1 1.1 2.4 1.7 2.2 9.4 2.1 1.9 6.2 4.1 2 1.2 1.1 1.8 
   A_32_P216
122 
0.8 1.6 4.2 2.5 3.1 16.
4 
3.2 1.8 8 10.6 3.2 1.5 1.4 2.3 
   A_32_P214
054 
0.8 1.4 3.8 2.8 2.7 11.
8 
3.3 2.1 5.7 6.1 3 1.7 1.3 2.1 
   A_32_P158
74 
1 1.1 2.2 1.9 1.6 6.3 2.4 2.1 4 3.8 1.7 1.3 1.3 1.4 
   A_24_P145
333 
0.9 1.1 2.2 1.9 1.7 4.8 1.7 1.5 4.2 2.5 2.5 1.1 1 1.3 
   A_23_P242
75 
1.2 1.1 2.4 2.2 1.4 6.7 2.1 1.7 3.4 3.2 1.8 1.8 1.4 1.1 
   A_32_P449
32 
1 1.2 1.9 1.6 1.3 4.8 1.9 1.6 2.4 4.7 1.6 1 1.1 1.2 
   A_32_P101
33 
0.8 2.2 3.9 2.6 2 10.
5 
3.4 2.4 4.2 6 3.1 1.3 1.3 2 
   A_32_P406
73 
1 1.5 2.1 2.3 1.5 5.1 2.5 2.1 4.1 4.4 2.5 1.2 1.1 1 
   A_32_P921
01 
1 1.5 2.4 1.8 2 3.2 2.5 2.1 5.1 2.8 1.9 1.9 0.7 1.8 
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   A_32_P839
73 
1 1.5 4.3 2.1 2.2 6.3 3.3 2.2 5.6 2.2 2.3 1.4 1.3 1.6 
   A_32_P191
074 
1.2 1.6 4.1 2.8 3.9 10.
9 
3.1 2.8 11 3.9 3.1 1.9 1.6 2 
   A_24_P162
128 
1 1.5 4 2.1 2.8 5 2.7 2.3 6.1 2.6 2.5 1.4 1.3 1.4 
   A_32_P751
6 
1.1 1.6 2.5 1.9 2.8 4.3 2.5 2 5.2 2 1.9 1.2 1.2 1.2 
   A_23_P399
292 
1.1 1.6 2.6 2 3 5 2.7 2 6 2.3 1.9 1.2 1.2 1.2 
   A_32_P198
282 
2.4 1.7 4.4 3.1 2 9.7 3.9 3 7.9 3.5 2.9 1.4 1.4 2.1 
   A_32_P118
220 
1.1 1.3 5.2 2.5 2 9.3 4.3 2.1 5.2 4.1 2.3 1.6 1.4 1.6 
   A_24_P932
388 
1 1.8 5.9 1.6 4 10.
8 
2.4 2.7 8 3.8 2.4 1.4 1.4 3.5 
   A_32_P110
485 
1.1 1.6 2.6 2.7 3.5 8.9 1.7 3.7 4.5 2.8 1.7 1.5 1.2 1 
   A_24_P204
374 
0.7 1 1 1.3 1.7 5.6 1.4 1.4 3 2.2 1.2 1.1 1.1 0.8 
   A_32_P211
048 
1 3.1 5.5 2.6 1.9 9 4.7 2.5 4.1 2.8 4.7 1.7 1.6 1.3 
   A_32_P129
310 
1.2 1.7 3.4 2 1.5 5.2 2.7 2.3 3.2 1.4 2.6 1.5 1.4 1.1 
   A_32_P539
76 
1.5 1.7 6.3 3.3 3.3 5.4 6.8 3.3 6.4 2.1 3.1 1.7 1.5 1.7 
   A_32_P198
791 
1.1 1.8 4.2 2.4 6.5 5.2 5.1 2.8 7.2 2.3 2.7 1.7 1.6 3 
   A_23_P156
408 
0.8 1.3 1.5 0.8 0.8 4.3 1.2 0.9 1.1 3 2.4 0.6 0.6 1 
   A_32_P158
181 
1.4 1.6 1.1 1.2 3.8 1.4 1.6 1.6 1.9 1.1 1.2 0.9 1.2 5.7 
   A_32_P331
7 
1 0.8 0.6 0.7 2 2 0.5 0.8 0.7 0.6 0.6 0.8 3.8 5.2 
H ABCB6 ATP-binding cassette, sub-family 
B, member 6 
A_24_P197
196 
1 0.9 1.3 1.1 1 0.2 1.4 1.2 0.7 0.4 1.1 1.1 1.2 1 
 ABCB6 ATP-binding cassette, sub-family 
B, member 6 
A_23_P544
1 
0.9 0.8 1.2 1.1 0.9 0.2 1.3 1.2 0.7 0.3 1.1 1 1.1 0.8 
 ABCC4 ATP-binding cassette, sub-family 
C, member 4 
A_24_P169
13 
1.1 0.9 0.8 0.8 0.8 0.1 0.8 0.8 0.5 0.3 1 0.9 0.8 0.7 
 ABCC6 ATP-binding cassette, sub-family 
C (CFTR/MRP), member 6 
A_23_P152
72 
1.3 1.4 1.6 1.3 0.9 0.2 1.3 1.1 0.7 0.3 1.5 1.4 1.1 0.8 
 ABHD6 abhydrolase domain containing 6 A_23_P211
850 
1.1 1.3 1.4 1.2 0.9 0.2 1.2 1.1 0.7 0.5 1.4 1.4 1.4 1.1 
 ACSM3 SA hypertension-associated 
homolog isoform 2 
A_23_P317
756 
1.1 0.9 0.8 0.9 0.8 0.1 0.7 0.8 0.4 0.2 0.9 0.9 1 1 
 ADORA2
B 
adenosine A2b receptor A_23_P554
77 
0.9 0.9 0.9 1 0.6 0.1 0.8 0.9 0.4 0.3 0.9 1.2 0.9 0.7 
 AGR2 anterior gradient 2 homolog A_23_P314
07 
1.2 1.2 1.2 1.2 1.6 0.2 0.8 0.8 0.5 0.3 1.2 1.3 1.9 1.9 




7.5 2.7 0.8 0.8 1.7 0.4 1 0.8 0.8 0.3 0.9 1 1 0.7 




1 0.8 1.1 1.2 1 0.1 1 1 0.7 0.2 1.1 1.2 1.2 0.8 




1.1 0.8 0.9 0.9 1 0.1 0.8 0.8 0.6 0.3 0.9 1.1 1.2 0.7 
 AKR1C1 aldo-keto reductase family 1, 
member C1 (dihydrodiol 





1 0.9 0.9 1 0.8 0.2 0.8 0.8 0.6 0.2 1 1.1 1 0.8 




1.1 0.7 0.8 0.9 0.7 0.1 0.7 0.8 0.5 0.2 0.8 1.1 1 0.7 
 ALDH3A1 aldehyde dehydrogenase 3 
family, member A1 
A_23_P207
213 
0.7 0.5 0.5 0.5 0.6 0.1 0.6 0.6 0.5 0.2 0.5 0.7 0.7 0.6 




0.9 0.7 0.9 1 0.8 0.2 0.8 1 0.6 0.2 0.9 1.2 1.1 0.9 
 ANXA13 annexin A13 isoform b A_23_P600
09 
1.1 0.6 0.7 0.7 0.6 0.1 0.8 0.7 0.3 0.1 0.6 0.8 1.1 0.7 
 ANXA13 annexin A13 isoform b A_23_P600
06 
1.3 0.7 0.8 0.8 0.6 0.1 0.7 0.7 0.2 0.1 0.8 0.7 1 0.6 
 APBA2 amyloid beta A4 precursor 




1 0.7 1.1 0.9 0.6 0.1 0.9 0.9 0.6 0.2 1 1.1 0.8 0.6 
 APOBEC3
C 





0.9 0.9 0.7 0.8 0.8 0.2 0.7 0.7 0.6 0.3 0.7 1 0.9 0.8 
 APOH apolipoprotein H precursor A_23_P382
44 
1.1 0.8 0.8 0.8 0.5 0 1 0.9 0.4 0.1 0.9 0.8 0.9 0.7 
 ARL6IP5 ADP-ribosylation-like factor 6 
interacting protein 5 
A_23_P166
640 
1.3 1 0.8 0.8 0.7 0.2 0.6 0.7 0.4 0.4 0.8 1 1.1 1.2 




1.3 0.8 0.9 0.6 0.7 0 1 0.7 0.1 0 1 0.9 1.1 0.4 
 AYTL1 hypothetical protein A_24_P364
807 
1.4 1 0.8 0.8 0.9 0.2 0.9 0.9 0.4 0.3 1 1.4 1.1 1.2 





1 1 1 0.8 0.6 0.1 0.8 1 0.4 0.3 1.1 1 0.8 0.6 





1.1 1.1 1.3 1 1 0.2 1.1 1.1 0.6 0.3 1.3 1 1.2 1 
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 C12orf27  A_24_P314
515 
0.9 1.2 1.5 1.3 1 0.1 1.7 1.5 0.8 0.2 1.4 1.1 1.2 0.8 




1.2 1.1 0.8 0.9 0.7 0.2 0.8 0.8 0.5 0.4 0.9 1 1 1 
 C18orf56 hypothetical protein LOC494514 A_24_P238
499 
1.1 1 0.6 0.7 0.6 0.1 0.6 0.6 0.4 0.3 0.7 0.7 0.8 0.8 




1.3 0.9 0.8 0.8 0.7 0.1 0.7 0.8 0.5 0.3 0.8 0.9 0.9 0.8 
 C4BPA complement component 4 




1.3 1.2 0.7 0.8 0.6 0.2 0.9 0.8 0.5 0.4 0.8 0.9 0.9 0.9 
 CA12  A_23_P163
338 
1.3 1.1 2 1.8 0.8 0.2 1.5 1 0.4 0.2 1.6 1.5 1.6 1.1 
 CA12  A_23_P163
336 
1.1 1.1 2.8 1.9 1.1 0.2 2.2 1.5 0.9 0.3 2.3 1.7 1.6 1.1 




1 0.8 0.9 1 0.7 0.2 0.8 0.8 0.4 0.3 0.9 1.1 1 0.7 
 CD302 CD302 antigen A_24_P396
702 
1.2 0.9 0.9 0.9 0.9 0.2 0.9 0.9 0.5 0.2 0.9 1 1.1 1 
 CDH1 cadherin 1, type 1 preproprotein A_23_P206
359 
1.2 1.7 1.2 1 0.9 0.2 0.9 0.8 0.7 0.3 1.3 1 0.8 0.8 




0.9 0.7 1 0.9 0.6 0.2 0.9 0.9 0.3 0.2 1 1 1 0.8 




0.9 0.8 0.7 0.7 0.7 0.2 0.7 0.8 0.4 0.2 0.7 0.9 0.9 0.7 
 CIT citron A_23_P420
551 
0.9 0.8 0.9 0.9 0.7 0.2 1.1 1.2 0.8 0.4 0.9 0.8 0.8 0.9 









1 0.9 0.8 0.8 0.7 0.1 0.7 0.7 0.4 0.2 1 1 0.9 0.8 
 CNTN1 contactin 1 isoform 1 precursor A_23_P390
700 
1.1 0.7 0.6 0.7 0.9 0.2 0.5 0.7 0.4 0.1 0.6 1 1.4 1 




2.4 0.8 0.7 0.9 0.8 0.2 0.7 0.9 0.8 0.1 1 0.7 1.5 0.8 
 CORO2A coronin, actin binding protein, 2A A_23_P135
061 
1.1 1 0.9 0.9 1.1 0.2 1 1 0.8 0.3 0.9 0.9 0.9 0.9 
 CPLX2 complexin 2 A_24_P391
868 
0.7 0.6 0.9 0.9 1 0.2 1 1 0.9 0.2 0.8 1 1 0.8 
 CRYZ crystallin, zeta A_23_P114
662 
0.9 0.8 0.7 0.7 0.5 0.1 0.6 0.6 0.4 0.2 0.7 0.7 0.7 0.6 
 CRYZ  A_24_P548
453 
0.9 0.7 0.5 0.6 0.5 0.1 0.5 0.6 0.3 0.2 0.6 0.7 0.7 0.5 
 CTTNBP2 cortactin binding protein 2 A_23_P215
744 
1 0.8 1.5 0.9 0.3 0 1.1 0.8 0.2 0.2 1 0.7 0.4 0.4 




0.9 1 0.6 0.7 0.7 0.2 0.5 0.7 0.4 0.4 0.7 0.7 1 0.9 




1 1.1 0.5 0.7 0.8 0.2 0.4 0.6 0.4 0.1 0.5 0.7 1 0.6 
 CYBRD1 cytochrome b reductase 1 A_23_P209
564 
1.1 1.1 0.8 0.8 0.7 0.2 0.6 0.7 0.5 0.3 0.9 0.8 0.9 1 




0.9 1 1.5 0.9 0.8 0.2 1.2 1.1 0.9 0.4 1.4 0.7 0.8 0.9 




1 1 1.6 1 0.8 0.2 1.3 1.1 1 0.4 1.5 0.7 0.9 0.9 




0.9 0.8 1.1 0.8 0.8 0.1 0.8 0.8 0.3 0.3 1 1.2 1.2 0.6 
 DPYSL2 dihydropyrimidinase-like 2 A_24_P383
47 
1.1 0.9 0.8 0.8 0.8 0.2 0.7 0.7 0.5 0.3 0.9 0.9 1 1 
 DSCR1L2 Down syndrome critical region 
gene 1-like 2 
A_23_P391
275 
1.1 1.1 1.2 1 0.8 0.2 1.2 1 0.6 0.3 1.1 1 0.9 0.9 




0.9 0.8 0.7 0.8 0.8 0.2 0.7 0.8 0.5 0.3 0.8 1 1 0.7 
 ELL3 elongation factor RNA 
polymerase II-like 3 
A_24_P479
88 
1.2 1 1.2 0.8 0.7 0.2 1.2 0.9 0.5 0.4 1.1 0.9 1 1.1 




1 0.8 0.9 0.9 0.8 0.2 0.8 0.9 0.6 0.2 0.9 1.1 1 0.7 




0.8 1 0.5 0.5 0.7 0.2 0.4 0.6 0.3 0.3 0.5 0.6 1 1.2 
 FAM64A hypothetical protein LOC54478 A_23_P498
78 
0.8 0.7 0.6 0.6 0.7 0.1 0.7 0.8 0.5 0.3 0.6 0.6 0.7 0.7 
 FGL1 fibrinogen-like 1 precursor A_23_P204
84 
1.4 1.2 0.6 0.7 0.7 0.1 0.6 0.6 0.5 0.2 0.7 0.7 0.8 0.7 




1.1 0.8 0.7 0.9 0.7 0.1 0.9 1.1 0.4 0.2 0.8 0.9 0.9 0.8 
 FOXQ1 forkhead box Q1 A_32_P164
246 







1.2 1.2 0.8 0.8 0.7 0.2 0.6 0.8 0.3 0.3 1.1 0.9 1.1 1.3 




1.1 0.8 0.9 0.9 0.9 0.2 1 0.8 0.9 0.3 1 1 1.1 1 




1 0.9 1.6 1.3 0.9 0.2 1.4 1.3 0.8 0.3 1.4 1.2 1.3 0.9 
 GSTM3 glutathione S-transferase M3 A_24_P914
434 
1 0.8 0.8 0.9 0.7 0.2 0.8 0.8 0.5 0.3 0.9 1 0.9 0.7 
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1.1 1.2 0.8 0.9 1 0.2 0.8 0.8 0.6 0.3 0.8 0.9 1 0.8 




1 1.2 0.7 0.8 1 0.2 0.7 0.8 0.5 0.4 0.8 0.9 1 0.8 




1 1.1 0.8 0.7 0.8 0.2 0.7 0.7 0.6 0.4 0.8 0.8 0.9 0.8 
 HLA-DMB major histocompatibility complex, 
class II, DM beta precursor 
A_32_P351
968 
1 0.5 0.6 0.7 0.6 0.1 0.7 0.8 0.4 0.1 0.6 0.7 0.8 0.6 




1.1 1.2 0.9 0.9 0.7 0.2 0.9 1 0.5 0.3 1 0.9 0.9 0.9 
 HTRA1 HtrA serine peptidase 1 A_23_P979
90 
0.9 0.6 1.1 0.9 0.7 0.1 0.9 0.9 0.6 0.2 1.1 0.9 0.8 0.7 




1.2 1 1 1 0.7 0.1 1.2 1.1 0.5 0.2 0.9 0.9 1.1 0.8 
 INHBB inhibin beta B subunit precursor A_23_P153
964 
0.8 0.8 1.3 1.1 0.8 0.2 1 1 0.7 0.4 1.3 1.1 1 0.9 




1.4 1.3 0.9 0.9 1.3 0.2 0.7 1 0.4 0.4 1 1.2 1.3 1 





0.9 1 0.6 0.8 0.6 0.2 0.7 0.8 0.5 0.3 0.8 1 0.8 0.7 
 KIAA1815 hypothetical protein LOC79956 A_23_P169
154 





1.1 1 1.6 1.3 1.4 0.2 1.2 1.2 0.8 0.2 1.5 1.3 1.4 0.8 




1.1 0.8 0.9 0.9 0.6 0.2 0.6 0.7 0.4 0.3 1 0.9 0.8 0.8 
 MALAT1  A_24_P497
244 
0.9 1.2 2.1 1.5 0.9 0.2 1.8 1.6 0.9 0.3 1.8 1.3 1.3 0.9 




0.7 0.5 0.5 0.6 0.6 0.2 0.5 0.6 0.3 0.2 0.5 0.7 0.9 0.8 
 MANEA mannosidase, endo-alpha A_23_P255
663 
1.2 1 0.7 0.7 0.8 0.2 0.6 0.7 0.6 0.4 0.8 0.8 1.1 1 
 MANSC1 MANSC domain containing 1 A_23_P162
211 
1 1 0.7 0.7 0.6 0.2 0.6 0.5 0.4 0.3 0.8 0.9 1 1 
 MATN2 matrilin 2 isoform b precursor A_23_P713
28 
1 0.7 0.8 0.8 0.8 0.1 0.7 0.8 0.5 0.2 0.8 0.9 1 0.9 
 MATN3 matrilin 3 precursor A_23_P102
058 
1.1 1.2 0.6 0.7 0.7 0.2 0.6 0.6 0.4 0.4 0.7 0.8 0.9 0.9 
 METTL7A methyltransferase like 7A A_23_P415
021 
1.4 0.7 1.5 1.2 0.8 0.1 1.1 0.9 0.5 0.1 1.8 0.9 0.8 0.6 
 METTL7B methyltransferase like 7B A_24_P646
53 
0.9 0.8 0.6 0.7 0.6 0.2 0.7 0.7 0.4 0.3 0.8 0.8 0.9 0.7 
 MGAT3  A_24_P245
838 
1.2 1 1.5 1.2 0.8 0.1 1 1.2 0.7 0.3 1.3 1.2 0.9 0.6 




1.3 1.3 1.1 1 0.8 0.2 0.9 0.9 0.6 0.4 1.1 0.9 0.8 0.7 
 MOSC1 MOCO sulphurase C-terminal 
domain containing 1 
A_24_P233
995 
0.9 0.8 1.3 1.2 0.6 0.1 1 1.2 0.6 0.3 1.2 1.1 0.9 0.6 
 NMU neuromedin U A_23_P695
37 
1.2 0.9 0.8 0.8 0.8 0.1 0.9 0.8 0.5 0.2 0.9 1 0.8 0.8 
 NQO1 NAD(P)H menadione 
oxidoreductase 1, dioxin-
inducible isoform a 
A_23_P206
661 
1 0.9 0.7 0.8 0.8 0.2 0.7 0.8 0.5 0.3 0.8 0.9 1 0.8 
 NT5E 5' nucleotidase, ecto A_24_P316
430 
1.2 1.7 0.4 0.6 0.9 0.2 0.7 0.8 0.9 0.7 0.5 0.6 0.7 1.1 




1.2 1.1 1.1 0.9 0.8 0.1 0.9 0.9 0.4 0.2 1.2 1.1 1 0.8 
 OLFML2A olfactomedin-like 2A A_24_P220
485 
0.9 0.6 1.1 1 0.8 0.2 1.1 1 0.7 0.3 1.1 1 0.9 0.9 
 PCYOX1L prenylcysteine oxidase 1 like A_23_P302
75 
1.2 1 1.2 1.1 0.8 0.2 1.2 1.1 0.8 0.4 1.2 1.1 0.9 1 
 PDGFD platelet derived growth factor D 
isoform 1 precursor 
A_24_P124
349 
1.2 1.1 0.8 1 0.7 0.1 0.7 0.8 0.5 0.2 0.9 1 1 0.6 




1 0.8 0.7 0.8 0.7 0.2 0.8 0.9 0.4 0.3 0.8 0.8 1 0.9 




1.4 1.3 1.1 1 0.8 0.1 1 1 0.5 0.3 1.2 0.8 1.1 1 




1.2 1 0.7 0.9 0.6 0.2 0.9 1 0.4 0.2 0.9 1 1 0.7 
 PF4 platelet factor 4 (chemokine (C-
X-C motif) ligand 4) 
A_24_P794
03 
1.4 0.9 1.1 1.1 0.7 0.1 1 1 0.6 0.3 1.1 1.1 1.1 0.9 




1.1 1 1.4 1.3 0.9 0.3 0.8 1.1 0.5 0.2 1.2 0.7 2.1 1.1 
 PRDM13 PR domain containing 13 A_23_P256
581 
1 1 1 1 0.7 0.2 0.7 0.7 0.5 0.3 1.1 1.1 0.9 0.9 
 PRKACB cAMP-dependent protein kinase 
catalytic subunit beta isoform 3 
A_23_P371
410 
1.3 1.1 0.7 0.9 1 0.2 1 0.9 0.5 0.2 0.8 1 1.1 0.9 
 PRKX protein kinase, X-linked A_23_P217
339 
1 0.8 1 0.9 0.7 0.2 1 0.8 0.6 0.3 1 0.9 0.9 0.9 
 PRPS2 phosphoribosyl pyrophosphate 
synthetase 2 isoform 2 
A_23_P966
41 
1.1 0.9 0.6 0.6 0.6 0.2 0.6 0.6 0.4 0.4 0.6 0.7 0.9 0.7 
 RAB11FIP
4 
RAB11 family interacting protein 
4 (class II) 
A_24_P164
549 
1.2 0.8 2 1.1 0.9 0.1 1.3 1.1 0.4 0.2 1.8 1.1 1 0.6 
 RAB37 RAB37, member RAS oncogene 
family isoform 3 
A_23_P414
654 
1.1 0.8 1.5 1.1 1 0.2 1 1 0.6 0.2 1.5 1.1 0.9 1.1 
 RALGPS1 Ral GEF with PH domain and 
SH3 binding motif 1 
A_23_P390
148 
1.3 0.9 1.3 1.7 1.2 0.2 1 1.1 0.8 0.2 1.5 1.5 1.6 1.2 
 
194 




0.9 1 1.2 1.1 0.9 0.1 1.1 1 0.6 0.2 1.1 0.9 1 0.9 




1.5 0.9 0.8 0.9 1.1 0.2 0.6 0.8 0.5 0.2 1 1 1.1 0.9 
 RNF128 ring finger protein 128 isoform 1 A_23_P148
345 
1.1 1 0.5 0.6 0.8 0.2 0.3 0.4 0.3 0.2 0.7 0.6 1.3 0.8 
 RNF157 ring finger protein 157 A_32_P578
10 
0.9 0.8 0.9 0.9 0.7 0.2 0.8 0.8 0.5 0.3 0.9 1 0.8 0.6 
 SAMD13 dnaj-like protein A_32_P130
788 
0.9 0.8 0.6 0.6 0.3 0.2 0.5 0.5 0.2 0.2 0.7 0.6 0.6 0.8 
 SCARA5 scavenger receptor class A, 
member 5 (putative) 
A_23_P941
03 
1.1 0.9 1.3 1 1 0.2 0.9 1 0.5 0.3 1.4 1.3 1.2 1.2 
 SCD5 acyl-CoA-desaturase A_24_P385
134 
1.3 1 1.2 1 0.6 0.2 0.9 0.8 0.4 0.3 1.4 0.9 1 0.8 
 SGCD delta-sarcoglycan isoform 1 A_23_P147
647 
1.2 1.3 1 0.9 1.2 0.2 1.2 1 0.8 0.7 1.1 0.9 1.1 0.8 




1 1 0.9 0.9 0.9 0.1 0.8 0.9 0.6 0.2 1 0.9 1 0.8 




1.1 0.8 0.8 1 0.7 0.2 0.8 1 0.6 0.2 0.9 0.9 1.2 0.8 
 SLC23A1 solute carrier family 23 
(nucleobase transporters), 
member 1 isoform b 
A_23_P219
90 
1.2 1 0.4 0.5 0.9 0.1 0.6 0.6 0.6 0.2 0.5 0.6 1 0.7 
 SLC24A1 solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 1 
A_23_P205
913 
1.1 1 0.7 0.7 0.7 0.2 0.4 0.7 0.5 0.4 0.7 0.7 0.7 1 
 SLC40A1 solute carrier family 40 (iron-
regulated transporter), member 1 
A_23_P102
391 
1.2 1.2 1.1 1.1 0.4 0.1 0.8 0.8 0.3 0.2 1.2 1.1 0.8 0.6 
 SOX2 sex-determining region Y-box 2 A_23_P401
055 
1.1 1.2 1 0.9 0.8 0.2 1 0.9 0.5 0.3 1.1 1.1 1 1.1 
 SPC25 spindle pole body component 25 A_23_P510
85 
1.1 0.9 0.8 0.7 0.6 0.2 1.2 0.9 0.5 0.4 0.8 0.7 0.9 0.7 




1.2 1.1 1.1 1 0.9 0.2 0.7 0.8 0.5 0.2 1.1 1.1 1.3 0.9 
 SRI sorcin isoform a A_23_P597
18 
1.2 0.9 0.7 0.9 0.6 0.2 0.7 0.8 0.5 0.4 0.7 0.9 0.8 0.8 
 ST3GAL5 ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 isoform 1 
A_23_P311
869 
0.8 0.9 0.8 0.6 0.5 0.2 0.8 0.8 0.5 0.5 0.7 0.7 0.7 1.1 
 ST6GAL2 KIAA1877 protein A_32_P126
157 
0.9 0.7 0.8 0.7 0.7 0.2 0.7 0.7 0.4 0.2 0.8 0.6 1.3 1.3 
 ST8SIA4 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 4 isoform a 
A_23_P361
984 
4.1 1.6 0.9 1.2 3 1.4 0.9 1 1.3 0.6 1.7 0.8 2.6 1.6 
 SULF2 sulfatase 2 isoform a precursor A_23_P154
605 
1.2 0.9 1.8 1.6 1.1 0.2 1.3 1.1 0.7 0.2 1.8 1.6 1.3 0.9 
 TACSTD1 tumor-associated calcium signal 
transducer 1 precursor 
A_23_P910
81 
1.3 0.9 0.9 0.9 0.8 0.1 0.8 0.8 0.5 0.2 0.9 0.9 1 0.8 




1.4 1 1.1 0.9 0.9 0.1 0.9 0.9 0.8 0.4 1.1 1.1 1 0.7 




1.2 1.1 1.2 1.2 1 0.2 1.3 1.2 0.9 0.3 1.2 1.1 0.8 0.9 




1 0.9 0.7 0.7 0.7 0.2 0.7 0.8 0.5 0.3 0.7 0.7 0.8 0.7 




1.1 0.7 0.6 0.7 0.5 0.1 0.7 0.8 0.4 0.2 0.7 0.6 0.7 0.5 
 TRIM2 tripartite motif-containing 2 A_23_P213
141 
1.3 0.8 1.3 1.2 1.1 0.2 1.2 1.1 0.7 0.4 1.4 1.2 1.2 1.2 




0.9 1.1 0.7 0.8 0.7 0.2 0.6 0.7 0.5 0.3 0.7 0.8 0.8 0.8 
 UGT1A6 UDP glycosyltransferase 1 




1 0.7 0.7 0.7 0.5 0.1 0.5 0.7 0.3 0.2 0.7 1 1.1 0.6 
 UGT1A6 UDP glycosyltransferase 1 




1.2 1.1 1.2 1.2 0.7 0.2 1 1 0.6 0.4 1.3 1.2 1.2 0.9 
 UGT2B11 UDP glycosyltransferase 2 
family, polypeptide B11 
A_23_P212
968 
1.1 0.5 0.6 0.8 0.8 0.2 0.7 0.8 0.9 0.2 0.7 1.1 1.1 0.7 
 UPK1B uroplakin 1B A_24_P200
219 
1 0.7 0.3 0.6 0.5 0.3 0.5 0.6 0.5 0.2 0.6 0.7 0.9 0.8 
 USH1C  A_23_P127
818 
0.9 1.2 1.7 1.1 1.6 0.2 1.9 1.8 1 0.3 1 0.8 1.1 0.9 
 VAV3 vav 3 oncogene isoform 1 A_23_P201
551 
1.1 0.9 1.2 1 1 0.1 1 1 0.5 0.1 1.4 0.9 1.4 0.7 
  hypothetical protein LOC134145 A_23_P133
279 
1.1 0.5 0.8 0.8 0.6 0.2 0.8 0.8 0.4 0.3 0.9 0.9 0.9 0.9 
  hypothetical protein LOC25854 A_23_P416
965 
1.2 0.8 0.9 0.9 0.9 0.2 0.9 0.8 0.6 0.3 0.9 1 0.9 0.8 
  hypothetical protein LOC54842 A_23_P285
30 
1.1 1 0.7 0.7 0.7 0.2 0.6 0.6 0.4 0.3 0.8 0.8 0.8 1.1 
  OK/SW-CL.92 A_24_P919
683 
1.2 0.9 1.8 1.5 0.8 0.1 1.4 1.3 0.6 0.3 1.3 1 1.1 0.8 





0.9 0.8 0.6 0.8 0.8 0.2 0.7 0.8 0.6 0.3 0.8 0.9 0.9 0.7 
   A_32_P992
4 
1 1 1 1.1 0.9 0.2 0.9 1 0.6 0.3 1 1 1.1 0.9 
   A_23_P464
47 
1 0.8 1 1 0.8 0.2 0.8 1 0.6 0.2 1 1.1 1 0.9 
   A_32_P218
707 
1.1 0.9 1.3 1.1 1.1 0.2 1.2 1 0.8 0.4 1.2 1.2 1.3 1.3 
   A_24_P451
992 
0.9 0.7 0.7 0.7 0.7 0.1 0.6 0.8 0.5 0.2 0.7 0.9 0.8 0.6 
 
195 
   A_24_P918
762 
1.1 0.9 1 0.9 0.9 0.2 0.8 0.8 0.5 0.3 1 1 1.1 0.9 
   A_24_P354
488 
1.1 0.9 0.9 0.9 0.7 0.2 0.7 0.8 0.5 0.3 0.9 1 1 0.9 
   A_24_P307
306 
1 0.8 0.7 0.8 0.7 0.2 0.7 0.8 0.4 0.3 0.8 1 0.8 0.8 
   A_24_P161
725 
0.9 0.9 0.8 0.9 0.9 0.2 0.7 0.9 0.5 0.3 0.8 0.8 1.2 0.9 
   A_24_P152
845 
1.1 0.8 0.6 0.7 0.9 0.2 0.6 0.7 0.5 0.3 0.7 0.9 1.2 0.8 
   A_32_P959
73 
1.1 1 1 1.1 0.9 0.2 0.9 1.1 0.5 0.3 1.1 1.3 1.3 1 
   A_32_P145
502 
1.1 1.2 1.1 1.2 1.1 0.2 1.1 1 0.8 0.5 1.4 1.4 1.2 1 
   A_32_P161
755 
0.8 0.7 0.9 1 0.8 0.2 0.8 0.9 0.5 0.3 0.9 1 1 0.7 
   A_24_P920
388 
0.9 0.9 1.1 1.5 0.9 0.2 0.9 0.9 0.5 0.3 1 1 1 0.8 
   A_24_P128
524 
1.2 1 1.1 1.1 0.8 0.1 0.9 0.9 0.7 0.4 1 1.2 1 0.9 
   A_23_P796
22 
1.3 1.1 1.1 1 0.8 0.2 1 0.9 0.6 0.3 1.1 1.1 0.9 0.9 
   A_24_P680
548 
0.9 0.8 0.8 0.8 0.6 0.1 0.8 0.8 0.6 0.3 0.8 0.8 0.8 0.7 
   A_24_P647
163 
1.1 0.9 0.8 0.8 0.6 0.1 0.8 0.8 0.5 0.2 0.9 0.8 0.8 0.7 
   A_24_P159
06 
1.2 1.1 0.9 0.9 0.6 0.1 1 1 0.5 0.3 0.9 0.9 0.9 0.7 
   A_24_P108
281 
1.1 0.7 0.9 0.9 0.6 0.2 1 0.8 0.5 0.4 0.8 1 0.9 0.8 
   A_32_P925
36 
1.3 1 1.4 1.2 0.8 0.2 1.2 0.9 0.6 0.3 1.3 1 1.2 1 
   A_32_P130
522 
1.2 1 1.1 1.1 0.9 0.2 1 0.9 0.6 0.4 1.2 1 1 1.3 
   A_32_P717
44 
1.1 0.9 1.2 1 0.9 0.2 1 1 0.6 0.3 1.2 0.9 1.2 1.1 
   A_24_P706
752 
1.2 0.8 1 0.9 0.8 0.2 0.9 0.9 0.6 0.3 1 1.1 1.1 1.1 
   A_24_P303
145 
1.1 0.7 1.3 1 0.7 0.2 0.9 0.9 0.5 0.2 1.1 1.1 1 0.9 
   A_23_P259
561 
1 0.6 0.8 0.8 0.8 0.1 0.8 1 0.4 0.2 1 0.9 1 0.7 
   A_24_P118
938 
1 1.1 0.8 1 0.7 0.2 1 0.8 0.6 0.3 1.4 1.1 1.1 0.8 
   A_32_P914
91 
1.2 1.2 0.8 0.8 0.8 0.1 0.9 1 0.6 0.3 0.8 0.9 1 1 
   A_32_P662
97 
1 0.9 0.8 1 0.7 0.2 0.8 0.9 0.5 0.4 0.7 0.9 1 0.8 
   A_32_P228
254 
1.1 1 0.7 0.7 0.5 0.2 0.7 0.7 0.4 0.4 0.9 0.7 0.8 0.7 
   A_23_P753
62 
1.1 0.9 0.9 0.8 0.9 0.2 0.8 0.9 0.6 0.4 0.8 1 1 0.9 
   A_24_P625
898 
0.9 1 0.5 0.6 0.5 0.2 0.5 0.6 0.4 0.4 0.6 0.7 0.7 0.8 
   A_23_P213
527 
1.3 1.3 1.2 1 1.3 0.2 0.8 0.8 0.9 0.4 1.2 1 0.9 0.9 
   A_32_P710
32 
0.9 0.5 0.7 0.8 0.4 0.1 0.7 0.9 0.4 0.1 0.8 0.8 0.9 0.7 
   A_32_P697
83 
1.1 0.6 1.4 1.2 0.8 0.2 1.1 1.1 0.5 0.1 1.2 1.2 1.3 1 
   A_24_P340
112 
1.3 0.4 1 0.9 0.6 0.2 0.9 0.7 0.3 0.1 0.9 1 0.9 1.1 
   A_24_P132
703 
1.3 1 1.1 1.1 0.8 0.2 1.1 0.7 0.4 0.3 1.5 1.1 1 1 
   A_32_P640
04 
0.8 1.1 0.9 1 0.8 0.1 1.1 1 0.6 0.3 0.9 0.8 0.9 0.9 
   A_32_P231
25 
1.1 1.2 1.5 1.4 1.2 0.2 1.4 1.1 0.8 0.3 1.5 1.1 0.9 1 
   A_24_P878
419 
1 1 1.3 1.1 0.8 0.1 1.2 1.1 0.7 0.3 1.3 1 0.8 0.7 
   A_24_P213
325 
1 1 1.3 1.2 0.9 0.1 1.3 1.2 0.8 0.3 1.4 1.1 0.9 0.8 
   A_24_P670
63 
1 0.9 1.3 1.2 0.9 0.1 1.2 1.2 0.8 0.3 1.2 1 0.8 0.7 
   A_24_P676
81 
1 1 1.2 1.1 0.9 0.1 1.2 1 0.8 0.3 1.2 1 0.8 0.7 
   A_23_P373
119 
1 1 1.3 1.1 0.9 0.1 1.2 1.1 0.7 0.2 1.3 1.1 0.9 0.8 
   A_24_P871
208 
1.5 1.3 1.6 1.5 1 0.2 1.5 1.3 0.7 0.3 1.6 1.4 1.1 1 
   A_24_P341
106 
1.1 1.1 1 1.1 0.8 0.1 1.1 1 0.6 0.2 1.3 1 0.8 0.7 
   A_24_P246
85 
1.1 1.1 1.2 1.2 0.8 0.1 1.2 1.1 0.6 0.3 1.2 1 0.8 0.7 
   A_24_P827
794 
1.3 1.1 1.2 1.2 0.8 0.2 1.1 1.2 0.7 0.4 1.3 1.1 0.8 0.7 
   A_24_P475
556 
1.1 1 1.1 1.1 0.8 0.2 1.3 1.1 0.8 0.3 1.1 1 1 0.9 
   A_24_P761
490 
1.1 1.2 1.4 1.1 0.8 0.2 1.5 1.3 0.9 0.4 1.3 1.1 0.9 0.8 
   A_24_P109
962 
1.1 1.1 1.4 1.2 0.8 0.2 1.5 1.3 0.9 0.4 1.2 1 0.9 0.8 
   A_23_P316
81 
1.1 1.1 1.2 1.3 0.8 0.2 1.3 1.3 1 0.4 1.1 0.9 0.9 0.9 
   A_24_P324
084 
1.2 1.1 1.3 1.3 0.9 0.2 1.5 1.4 1 0.5 1.2 1.4 1.2 1 
   A_24_P249
82 
1 1 1.1 1.2 0.8 0.2 1.3 1.2 0.9 0.5 1 1.3 1.1 0.8 
 
196 
   A_32_P233
049 
1.1 1 1.8 1.5 1 0.2 1.9 1.4 0.6 0.3 1.6 1.4 1.2 1.2 
   A_23_P327
370 
0.8 0.8 1.2 1 0.8 0.2 1.2 1.1 0.6 0.3 1.1 0.9 0.8 0.9 
   A_32_P198
731 
1 0.9 1.3 0.9 0.7 0.2 1.2 1.1 0.6 0.3 1.4 0.9 0.8 0.8 
   A_24_P150
466 
1 0.9 1.4 1.3 0.8 0.2 1.1 1 0.6 0.4 1.4 1.3 0.9 1 
   A_23_P153
958 
0.9 0.9 1.8 1.4 0.9 0.2 1.3 1.3 0.7 0.4 1.6 1.4 1.1 1 
   A_32_P223
504 
2.3 1.7 4.7 3.9 1.6 0.1 3.4 1.9 1 0.2 2.9 2 1.4 1 
   A_24_P419
017 
1.7 1.3 3.4 2.3 1.6 0.1 3.1 2.2 0.7 0.2 2.9 1.9 1.1 0.6 
   A_32_P213
509 
1 1.1 3.8 2.4 0.9 0.1 3.4 2.2 1.1 0.4 3 1.6 1.2 0.8 
   A_24_P268
474 
1 1 2.5 1.4 0.9 0.2 2.2 1.3 0.9 0.4 1.8 1.4 1 0.8 
   A_32_P133
37 
1.2 1.2 2.1 1.6 1 0.1 2.2 1.6 1 0.2 1.7 1.2 1 0.7 
   A_24_P163
009 
0.8 0.8 1.7 1.2 0.8 0.1 1.4 1.2 0.9 0.2 1.4 0.9 0.9 0.7 
   A_23_P480
80 
0.8 0.9 1.5 1.3 0.9 0.2 1.4 1.3 0.7 0.3 1.2 1.2 1 0.9 
   A_32_P195
346 
1.2 1.7 4 1.8 1.1 0.2 4.4 2.3 1 0.3 2.3 1.3 1.2 0.9 
   A_24_P163
78 
0.9 1 1.6 1.4 0.8 0.2 1.9 1.4 0.8 0.4 1.3 1 0.9 1.1 
   A_32_P546
28 
1.5 1.2 0.7 0.9 1.3 0.1 0.7 1.1 1.2 0.2 0.8 0.9 0.9 0.6 
   A_32_P174
874 
1 1.1 1.3 1 1.1 0.2 1 1.4 1 0.3 1.1 1 1.2 0.9 
   A_32_P378
3 
0.9 1.9 3.5 2.4 0.8 0.2 3.8 2.4 1 0.6 2.7 1.3 1.1 1.2 
   A_24_P665
185 
1.3 2 4.1 2.3 1.1 0.2 3.4 2.4 1.3 0.6 3.2 1.4 1.2 1.1 
   A_32_P977
39 
0.9 0.7 0.4 0.5 0.6 0.2 0.3 0.6 0.4 0.2 0.4 0.6 1.1 1 
   A_23_P316
487 
0.9 0.7 0.4 0.4 0.8 0.3 0.4 0.5 0.5 0.2 0.4 0.6 1.2 0.9 
   A_23_P305
245 
1.2 1.2 0.5 0.6 0.8 0.2 0.6 0.6 0.4 0.2 0.6 1 1.3 1.1 
   A_32_P442
10 
1.3 0.9 1.1 0.7 1.3 0.4 0.6 0.8 0.5 0.2 1.1 0.9 1.4 1.2 
   A_32_P873
23 
1.2 0.9 0.9 0.8 1 0.2 0.7 0.8 0.6 0.2 0.7 1.1 1.1 1 
   A_32_P131
998 
1 0.8 0.7 0.9 1 0.2 0.8 0.8 0.5 0.3 0.7 1 1.5 1.4 
   A_32_P452
29 
1.3 1.1 0.8 0.8 0.6 0.2 0.8 0.7 0.3 0.3 0.8 0.7 1 0.9 
   A_32_P448
31 
1.1 0.9 0.8 0.8 0.7 0.2 0.6 0.6 0.5 0.4 0.8 1 1.1 1.2 
   A_32_P116
70 
1.4 1 0.5 1.2 0.9 0.2 0.5 1.2 0.8 0.2 0.6 1 1 0.9 
   A_23_P156
996 
1.3 1.4 0.9 1.2 2.3 0.2 1.1 0.9 1.8 0.4 0.8 1.3 1.4 1.2 
   A_32_P203
688 
1.1 0.5 1 0.7 0.5 0.3 0.8 0.8 0.3 0.2 1.3 0.9 1.1 1.2 
   A_23_P416
305 
1 0.2 1.2 1 0.4 0.2 1.2 1.1 0.3 0.3 1 1.1 0.9 0.7 
   A_32_P214
503 
0.9 0.4 0.8 0.8 0.8 0.3 0.8 0.7 0.4 0.2 0.9 1 1.5 1.4 
   A_23_P204
541 
1 0.6 0.6 0.8 1 0.3 0.5 0.7 0.5 0.2 0.7 0.9 1.6 1.7 
‡Genes listed in each cluster correspond to the same genes hierarchically clustered in Figure 4.  
*Rows in bold correspond to 76 additional interferon induced genes from Table S1. 
†Rows in blue correspond to the 17 predominantly IFN-responsive but wt HPIV1 unresponsive genes from cluster C of figure 1. 14 of those genes are found in cluster F, 1 gene in cluster C, 1 gene 





Table S3.  
Table S3. Comparison of IFNB mRNA message by qPCR   
    IFNB Expression (Van Cleve et al. 2006) IFNB Expression with Taqman Assay 
Virus Time vs Mock Ratio CF170S:WT vs Mock Ratio CF170S:WT 


















Table S4.  
Symbol Product  Agilent 6 h 24 h 6 h 12 h 24 h 48 h 6 h 12 h 24 h 48 h 6 h 12 h 24 h 48 h 
AKT1 v-akt murine 
thymoma viral 
oncogene homolog 1 
A_23_P296
0 





















1.2 1.1 0.8 0.9 1 0.8 0.7 0.7 0.5 0.7 0.7 0.9 1 0.7 
BCL2 B-cell lymphoma 




1.2 1.3 0.9 0.9 0.9 0.6 0.8 0.8 0.5 0.9 1.1 1.2 0.9 1.1 
BCL2 B-cell lymphoma 


















1.2 1.4 0.9 0.8 1.8 29.3 1 0.9 3.9 13.9 0.9 1.1 1.3 5 
BCL2L
1 
BCL2-like 1 isoform 1 A_23_P210
886 
0.6 0.6 0.5 0.7 0.8 0.5 0.6 0.7 0.6 0.6 0.6 0.8 0.8 0.7 
BCL2L
1 
BCL2-like 1 isoform 2 A_24_P100
130 







1.5 1.1 1.9 1.4 1.1 1.2 1.4 1.2 0.9 1.4 1.6 1.5 1.4 0.8 
BCL2L
12 

























1.7 1.4 1 1 2.7 2.1 1 1 1.8 1.9 1 0.8 1 1.4 
BCL2L
2 
BCL2-like 2 protein A_23_P418
373 
1 1.1 1.1 1.1 1.2 1.6 1.1 1 1.1 1.4 1.1 1 1.1 1.2 
BFAR apoptosis regulator A_24_P184
931 
0.8 0.9 0.5 0.6 0.7 0.6 0.6 0.6 0.6 0.8 0.7 0.7 0.7 0.8 
BFAR apoptosis regulator A_23_P659
63 
0.9 0.9 0.8 0.9 0.9 0.9 0.8 0.9 0.8 0.9 0.8 0.9 0.9 1.1 





1 1.1 0.7 0.8 1.3 3 0.7 0.8 1.4 2.5 0.8 0.9 1.1 1.6 





1.1 1.9 1 0.9 6.5 40.8 0.7 0.9 11.6 34.9 1 1 1.7 9.2 





1.2 1.4 0.8 0.9 1.4 2.4 0.9 0.9 1.3 2.4 0.9 0.9 1 1.4 
BIRC5 baculoviral IAP 
repeat-containing 
protein 5 isoform 3 
A_23_P118
815 
0.9 0.8 0.7 0.7 0.9 0.5 0.9 0.9 0.8 0.8 0.7 0.7 0.9 1 




1.2 1 1 0.9 1 1.2 0.9 0.9 1.1 1 0.9 0.9 1.2 1.1 





0.8 0.7 1.3 1.1 0.9 0.6 1.3 1.3 1.3 0.6 1.1 0.9 0.7 0.7 




0.8 0.8 0.9 1 1 1.2 1 0.9 1.2 1 1 0.9 1 1 
BNIP1 BCL2/adenovirus 
E1B 19kD interacting 




0.9 0.9 1 1 1.2 1.9 1 1 1.2 2.2 1 1.2 1.1 1.2 
BNIP2 BCL2/adenovirus 




1.2 1.1 1 1.1 1.1 1.8 0.9 1 1.2 1.7 1 1 1.1 1.4 





1.1 1.1 0.9 1.1 1.1 3.6 1 1.1 1.7 2.8 0.9 1 1 1.3 





1 1.1 0.9 0.8 1.4 1.6 0.8 0.8 1.8 1.3 0.8 0.8 0.8 1.3 
CFLAR FLAME-1-delta A_23_P209
394 
0.9 1.1 0.6 0.7 1.2 3.2 0.7 0.8 1.4 2.9 0.6 0.8 0.8 1.5 
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0.8 0.7 0.8 1.1 1 1.1 1 1 1 1 1 0.8 1 0.9 






0.8 1 5.8 1.1 1 1.2 1 0.9 1.2 0.9 1 0.9 0.9 1 
GDNF HFK4-GDNF A_24_P376
451 
1.1 1.3 1.9 1.4 1.4 2.6 1.7 1.5 2.4 1.7 1.7 1.3 1 1.3 
IGF1R IGF1R protein A_23_P417
282 
1.2 0.9 1.4 1 0.9 0.4 1.2 1 0.8 0.5 1.3 1 0.9 0.8 
IGF1R insulin-like growth 




1 0.9 0.8 0.8 0.8 0.9 0.8 0.8 0.7 0.9 0.8 0.8 0.7 0.7 
IGF1R unknown protein A_23_P305
680 
1.2 0.7 1.3 0.7 1.1 1.3 1.1 0.8 1.5 1 1 1.1 0.8 0.8 
MCL1 myeloid cell leukemia 
sequence 1 isoform 1 
A_24_P336
759 
1.1 1.1 0.8 0.9 2.3 2.3 0.8 1 2.9 1.7 0.8 0.9 1 1.2 
MCL1 myeloid cell leukemia 
sequence 1 isoform 1 
A_24_P336
754 
1.2 1.2 1.1 1.1 3.3 4.6 1.1 1.3 4.6 3.7 1 1 1.2 1.5 
MCL1 myeloid cell leukemia 
sequence 1 isoform 1 
A_24_P319
635 
1.4 1.4 0.6 0.9 3.8 9.2 0.7 1 5.1 8.4 0.7 0.9 1.1 1.6 
NOL3 nucleolar protein 3 A_23_P206
371 





Table S5.  
Table S5. Expression of known intrinsic apoptosis 





















WT WT WT WT 
Symbol Product Agilent 6 h 24 h 6 h 12 h 24 h 48 h 6 h 12 h 24 h 48 h 6 h 12 h 24 h 48 h 
APAF1 apoptotic peptidase 









1.2 0.9 0.8 0.9 1.2 0.8 1 1 0.9 0.9 0.9 1 1 1 





0.8 0.7 0.9 1 0.9 0.5 0.9 1 0.9 0.6 0.9 1 0.9 0.9 
BID BH3 interacting 
domain death 
agonist isoform 1 
A_24_P1879
48 
1 1 0.9 1 0.9 0.6 0.9 1 0.8 0.8 0.9 0.9 1 1.2 
BID BH3 interacting 
domain death 
agonist isoform 1 
A_23_P1549
29 
1 1 0.8 0.9 0.7 0.5 0.8 0.9 0.6 0.7 0.9 0.9 1 1.2 




1 1 1.1 1 1 0.9 1.1 1.1 0.9 0.9 1 1 0.9 1 




1.1 1.2 1.3 1.2 1.2 1 1.3 1.2 1.1 1.1 1.3 1.2 1.1 1.2 
DIABL
O 


















Table S6.  
Table S6. Genes Differentially Expressed between CF170S and P(C-) infection by 2-Fold followed by P < 0.01 with MTC            
   F170S P(C-) Ratio F170S : P(C-)a 
Symbol Product Agilent 6 12 24 48 6 12 24 48 6 12 24 48 
ABHD6 
abhydrolase domain 








member A2 isoform 
b A_24_P337592 1.4 1.3 3.3 27.3 1.4 1.4 9 19 1 1 0.4 1.4 
CASP3 
caspase 3 
preproprotein A_23_P92410 0.9 1 2.3 6.3 1 1 6.5 4.1 1 1 0.3 1.6 
DUSP8b 
dual specificity 
phosphatase 8 A_24_P322867 1.8 2 2.7 10 1.7 1.8 7.4 5.2 1.1 1.1 0.4 1.9 
FAM64A 
hypothetical protein 




virus type I 
enhancer binding 









kinase kinase 8 A_23_P23947 1.4 1.4 4.1 6.6 1.2 1.8 4.7 2.9 1.1 0.8 0.9 2.3 
NAV2 steerin2 protein A_24_P933458 1.9 1.5 2.9 14.3 2.1 1.8 8.3 7.3 0.9 0.8 0.3 2 
NCOA7 
nuclear receptor 
coactivator 7 A_23_P156957 1 1.2 7.7 15.9 1 3.2 12.2 7.2 1 0.4 0.6 2.2 
PRIM1 
DNA primase small 





precursor A_24_P250922 0.8 0.9 5 12.3 0.6 1.2 7.6 4.4 1.4 0.8 0.7 2.8 
PTPRG PTPRG protein A_32_P93493 0.9 2.6 1.3 0.2 1.1 2.3 1.8 0.4 0.8 1.1 0.7 0.4 
RBM35A 
RNA binding motif 
protein 35A isoform 








associated 1 like 2 A_23_P137470 1.4 1.2 1.7 7.7 1.1 1.2 3.8 3.7 1.2 1.1 0.5 2.1 
SLC27A2 
solute carrier family 
27 (fatty acid 
transporter), 
member 2 A_23_P140450 0.8 0.9 0.7 0.2 0.7 0.8 0.5 0.5 1 1.1 1.3 0.4 
SLC2A13 














associated with the 
nucleus, X 
chromosome, family 
member A1 A_23_P96302 0.8 0.9 0.7 0.2 1.1 1 0.7 0.5 0.7 0.9 1 0.4 
STK19 
serine/threonine 






isoform 1 precursor A_23_P169030 0.9 1 2.3 11.5 1.1 1 4.8 8.9 0.9 1 0.5 1.3 
ZEB2b 
zinc finger 
homeobox 1b A_23_P142560 1.1 1.1 6.1 90.6 1 1.1 19.2 62.2 1.1 1 0.3 1.5 
  A_24_P127641 1.4 1.8 16.3 36.6 1.3 2 20 16.6 1.1 0.9 0.8 2.2 
  A_24_P696924 2.3 1.7 3.8 4 2 2.5 5.2 1.8 1.2 0.7 0.7 2.3 
  A_32_P207802 3.1 2.4 4.8 17.4 2.6 2 14 5.5 1.2 1.2 0.3 3.1 
    A_32_P51855 1 1 0.9 9.3 1 1.2 2.2 5.7 1.1 0.9 0.4 1.6 
aBoxes indicate times post-infection at which gene expression between CF170S and P(C-) infection differed by greater than 2=fold     







Table S7. Genes Differentially Expressed by 4-fold and an ANOVA P < 0.01 with MTCa 
between  CF170S  and P(C-) Infection          




) P(C-) P(C-) WT WT WT WT 
Symbol Product Agilent 6 hr 12 hr 24 hr 48 hr 6 hr 
12 





















isoform a A_23_P139786 2.1 29.7 77 187.9 11.5 41.5 114.8 135.5 2.4 24.5 33.3 58.9 
C20orf141  A_32_P133182 0.8 1.5 48.5 166.7 0.8 3.4 237.7 99.4 1.1 1.1 4.1 13.9 
CXXC4 CXXC finger 4 A_23_P121676 1.2 0.7 2.2 35.4 1.1 1 11.2 30.5 1.8 1.1 1.1 2.8 
DICER1 dicer1 A_24_P22163 1.5 1.1 2.2 25.7 1.4 1.2 9.5 13.4 1.4 1 1.1 2.7 
OTUD1  A_32_P60459 0.8 0.9 7.2 150.9 0.7 1.1 29.3 102.4 0.9 0.6 1.1 7.1 
PLCB4 
phospholipase C 
beta 4 isoform a A_23_P28898 1.3 1.7 3.6 22.5 1.5 1.7 16 23.9 1.1 1.2 1.2 1.9 
SLC12A7 




member 7 A_24_P60634 1 0.8 2.4 20.4 0.8 1.1 11.8 17.7 0.9 1.2 1.3 3.1 
SLC12A7 




member 7 A_23_P251855 0.7 0.9 2.4 23.8 0.7 0.9 14.6 16 0.7 0.8 1 3.4 
SLC12A7 




member 7 A_23_P61688 1.7 1.3 3.6 50.1 1.5 1.5 26.5 45.1 1.5 1.3 1.5 5.1 




induced protein 6 
precursor A_23_P165624 0.5 0.5 1 50.9 0.9 1 4.3 26.5 0.5 0.6 0.7 7 
  A_24_P255384 0.9 1 1.8 52.3 0.8 1.3 13.5 31 0.9 0.9 0.9 7.3 
  A_32_P95766 0.9 1.1 16 125.9 1 1 84.6 88.1 1 1 1 25.5 
  A_32_P226205 2.1 1.3 3.2 31.6 1.3 1.3 15.7 24.2 1.6 1.1 1 2 
FEV 
FEV (ETS 
oncogene family) A_23_P5460 1.6 1.5 2.4 10.9 1.7 1.2 1 1 1.2 2 1.5 2.5 
SYNPO2   A_23_P310094 0.6 1.2 2.7 9.7 0.5 0.9 2.1 1.6 0.8 1.6 2.3 2.7 
aBenjamini-Hochberg multiple 
testing correction (MTC)              
bBoxes indicate time at which gene expression differed by greater than 4-fold between CF170S and P(C-) infections.  All 18 genes identified as significantly differentially expressed 






Table S8. RT-qPCR Primers   
Gene 
Symbol Assay ID* TaqMan Probe Context Sequence 
IRF7 Hs00242190_g1 ACCGCGGTGCAAGAGCCCAGCCCAG 
IFNB1 Hs01077958_s1 TCTTCAACCAGCAGATGCTGTTTAA 
MX1 Hs00182073_m1 CCTATCACCAGGAGGCCAGCAAGCG 
NFKB1 Hs00231653_m1 CAAAGCAGCAGGAGCAGATCCCCTG 
TRAF1 Hs01090170_m1 GCCCTTCCGGAACAAGGTCACCTTC 
GAPDH Hs99999905_m1 TTGGGCGCCTGGTCACCAGGGCTGC 




Supplementary Information for Chapter 4 
Supplementary Figure 1. Activation of components of the IFNβ enhanceosome by 
HPIV1 infection.  Phosphorylated ATF2 (Thr 71), total ATF2, phosphorylated P38 (Thr 
180 / Tyr 182), and total P38 were detected by Western blot in A549 cells (A) infected 
with WT, F170S, or P(C-) HPIV1 at a MOI of 5 for 48 h or (B) treated with 10 µg/mL 




Supplementary Figure 2. Examination of C protein interaction with RIG-I pathway 
components.  293T cells were transfected with a Myc-tagged C expression plasmid along 
with (A) V5-tagged TRIM25 and/or Flag-tagged Riplet, (B) RIGI and/or MDA5, (C) 
IPS1 and/or TBK1, (D) TRAF3 and/or TRAF6, (E) BIRC2 and/or BIRC4, or (F) 
TRADD and/or FADD.  Myc-tagged TRADD and Flag-tagged TRAF3 was transfected 
together as a positive control.  Myc-tagged proteins were immuno-precipitated using 





Supplementary Figure 3. Levels of viral genomic versus anti-genomic RNA levels over 
time during infection with WT and mutant HPIV1.  HPIV1 genomic and anti-genomic 
RNA was distinguished using genome- and anti-genome-specific primers respectively for 
reverse transcription (RT) followed by real-time PCR.  (A) A549 cells were infected with 
WT, F170S, and P(C-) HPIV1 using a MOI of 5 for 12, 24, or 48 h and genomic (left 
axis, intact lines) and anti-genomic RNA (right axis, dotted lines) were measured by real-
time PCR, normalized to the level of WT HPIV1 anti-genome at 12 h.  (B) The ratio of 




Supplementary Figure 4. Relative levels of (A) IRF3 phosphorylation, (B) IκBβ 
degradation, (C), P38 phosphorylation, and (D) PKR knockdown were measured by 
densitometry of Figure 8a and normalized to mock-infected shCON levels and to 
GAPDH protein expression.  (E) Relative levels of C’ protein expression normalized to 
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